Avelino Fraga Ferreira

HYPOXIA BIOMARKERS IN PROSTATE CANCER: FROM GENETIC POLYMORPHISMS TO INTRATUMORAL PROTEIN EXPRESSION

Tese de candidatura ao grau de Doutor em Ciências Médicas, submetida ao Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto, ICBAS - UP

Orientador: Professor Doutor Rui Manuel de Medeiros Melo Silva
Categoria: Professor Associado Convidado com Agregação
Afiliação: ICBAS - UP

Co – Orientador: Professor Doutor Carlos Alberto da Silva Lopes
Categoria: Professor Catedrático Jubilado
Afiliação: ICBAS - UP

Dedico a:

À Mariana e à Inês. À Emília e ao Manuel. À Lurdinhas.

Ao Serviço Urologia, pelo prazer que tem sido estudar e trabalhar aqui.

A Paulo Cunha e Silva, meu colega de curso e meu amigo. Foi o ser humano mais fascinante e genial que conheci. Foi quem mais correspondeu ao lema das nossas "Biomédicas", *um médico que só sabe medicina, nem medicina sabe*.

DIRETIVAS LEGAIS

No cumprimento do disposto, declara-se que o autor desta dissertação, participou ativamente na execução do trabalho experimental que esteve na origem dos trabalhos apresentados, bem como na redação dos respetivos manuscritos. De acordo com o Artigo 34º do Decreto-Lei nº 115/2013, foram utilizados para esta tese resultados contidos nos seguintes trabalhos publicados ou a aguardar publicação:

Fraga A, Ribeiro R, Coelho A, Vizcaíno JR, Coutinho H, Lopes JM, Príncipe P, Lobato C, Lopes C, Medeiros R. Putative functional genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer. (*submitted*)

Fraga A, Ribeiro R, Principe P, Lopes C, Medeiros R. Hypoxia and prostate cancer aggressiveness: different tales with common ending. *Clin Genitourinary Cancer 2015; 13 (4): 295-301*.

Fraga A, Ribeiro R, Príncipe P, Lobato C, Pina F, Maurício J, Monteiro C, Sousa H, Calais da Silva F, Lopes C, Medeiros R. The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration. *Eur J Cancer 2014; 50: 359-65*.

Ribeiro R, Monteiro C, Azevedo A, Cunha V, Ramanakumar AV, **Fraga A**, Pina F, Lopes C, Medeiros R, Franco EL. Performance of an adipokine pathway-based multilocus genetic risk score for prostate cancer risk prediction. *PLoS ONE 2012; 7 (6): e39236*.

Fraga A, Ribeiro R, Medeiros R. Hipoxia tumoral. Papel del factor inductor de la hipoxia. *Actas Urol Esp* 2009; 33 (9): 941-951.

Ribeiro R., **Fraga A**, Monteiro C., Ramanakumar A, Guedes AF, Ferreira AL, Cunha V, Azevedo A, Maurício J, Lobo F, Pina F., Calais FE, Lopes C, Franco E.L., Medeiros R. Inherited variation in adipokine pathway genes may determine prognosis for prostate cancer patients receiving androgen-deprivation therapy. *(submitted)*

Teixeira AL, Ribeiro R, **Fraga A**, Pina F, Calais-da-Silva FE, Calais-da-Silva FA, Medeiros R. Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. *Pharmacogenom J* 2009; 9: 341-346.

AGRADECIMENTOS

Ao Prof. Rui Medeiros e Prof. Carlos Lopes, por terem aceitado orientar esta investigação e esta tese, mesmo sabendo que o doutorando teria múltiplos afazeres.

Ao Prof. Rui Medeiros e ao Grupo de Oncologia Molecular por me terem aceite entre vós, pelos contributos e por terem tornado evidente a utilidade de um clinico no laboratório e entre investigadores. Creio que o contacto com colegas tão jovens e tão sabedores me tornou também mais jovem. Hoje sinto-me um de vós: um investigador. Obrigado.

Ao Prof. Ricardo Ribeiro – meu Amigo e colega de doutoramento – pelo entusiasmo com que investiga e a todos contagia. É um prazer discutir hipóteses e construir projetos com o Ricardo. A sua solidez de conhecimentos, a capacidade de integração, são determinantes em qualquer grupo de investigação. Mas a sua ajuda, correções, sentido crítico e presença, foram fundamentais em todos os passos que demos ao longo destes anos. E estou certo que teremos muitos mais projetos para concretizar.

Aos meus colegas do Hospital Sto. António-CHP, do Hospital Militar e do IPATIMUP, muito obrigado pelos contributos e por sentir sempre que este projeto era também vosso.

Aos meus amigos que sei ficarem felizes com a minha felicidade e me perdoam as ausências.

À minha família, onde a fraga se alicerça em fraga e onde encontro sempre a força e o apoio para continuar.

CONTENTS

Figures Index 3
Tables Index 4
List of Abbreviations 5
ABSTRACT 7
RESUMO 9
THESIS PLANNING 13
CHAPTER 1 - GENERAL INTRODUCTION 17
1.1. Aims 19
CHAPTER 2 - REVIEW OF THE LITERATURE 23
2.1. Prostate cancer as a particular research model: from bedside-to-bench 23
2.1.1. Anatomy 24
2.1.2. Histopathology 24
2.1.3. Epidemiology 25
2.1.4. Molecular mechanisms 26
2.1.5. Diagnosis 26
2.1.6. Clinical and pathological staging 27
2.1.7. Treatments 28
2.2. Hypoxia and cancer 29
2.2.1. Molecular structure of HIF-1α 29
2.2.2. Molecular mechanisms of HIF and *HIF1A* activation 31
2.2.3. General functions of the *HIF1A* gene 33
2.2.4. Hypoxia, hypoxia inducible factor and cancer 34
2.3 Hypoxia and prostate cancer aggressiveness: from pathophysiology to clinical biomarkers 39
2.3.1. A common tumor hypoxia-driven mechanism (through HIF-1α), with many pathways and therapeutic implications 40
CHAPTER 3 – CLINICAL STUDIES 51
3.1. Clinical study 1 51
3.1.1. Summary 51
3.1.2. Overview and methods 51
3.1.3. Results 53
3.1.4. Discussion 56
3.2. Clinical study 2 60
3.2.1. Summary 60
3.2.2. Overview and methods 60
3.2.3. Results 62
3.2.4. Discussion 64
3.3. Clinical study 3 65
3.3.1. Summary 65
3.3.2. Overview and methods 65
3.3.3. Results 67
3.3.4. Discussion 69
3.4. Clinical study 4 71
3.4.1. Summary 71
3.4.2. Overview and methods 71
3.4.3. Results 74
3.4.4. Discussion 81
CHAPTER 4 – CONCLUSIONS AND FUTURE PERSPECTIVES 87
4.1 General conclusion 87
4.2 Future perspectives 89
REFERENCES 92
ANNEXES 115
Published papers 115

FIGURES INDEX

Figure 1 Molecular structure of HIF-1α

Figure 2 Stability and activity of the HIF

Figure 3 HIF-1α signaling and regulation pathways

Figure 4 Responses determined by the HIF

Figure 5 HIF-1α regulation

Figure 6 Integration of hypoxia with hif-1α associated mechanisms in prostate cancer, specifically downstream-activated LOX, VEGF, and CAIX pathways, and emergence of metastatic traits

Figure 7 Hypoxia-induced HIF-1α-driven modulation of key genes and resulting biological effect

Figure 8 Representative microscopy images of staining for hypoxia markers in prostate tissues

Figure 9 Frequency of patients with positive staining in benign and malignant epithelial cells

Figure 10 Comparison of LOX immunoreactivity score in prostate epithelial cells of benign and malignant patients

Figure 11 LOX immunoreactivity score by HIF-1α positivity in epithelial cells

Figure 12 Expression of VEGFR2 (H score) in prostate epithelial cells according to prostatic diseases

Figure 13 LOX protein expression (both for immunoreactivity score and staining intensity) according to *LOX* +473 G>A polymorphism

Figure 14 VEGFR2 protein expression (H score) according to *KDR* -604 T>C polymorphism

TABLES INDEX

Table 1 Examples of molecules regulated by HIF-1α and their pathophysiologic action

Table 2 Tumors that show overexpression of HIF assessed with immunohistochemistry

Table 3 *HIF1A* +1772 genotype distribution and risk for prostate cancer

Table 4 Genotype distribution in PCa subjects (n=754) according to clinicopathological characteristics

Table 5 Clinicopathological characteristics features of the group of patients under ADT (n=429)

Table 6 Association of *HIF1A* +1722 C>T polymorphism with resistance to ADT

Table 7 Risk for metastasis in patients receiving androgen deprivation therapy

Table 8 Characteristics of SNPs from the VEGF/KDR pathway included in this study

Table 9 Age-adjusted Odds Ratios and 95% CI of prostate cancer according to VEGF/KDR pathway polymorphisms

Table 10 VEGF/KDR pathway SNPs included in experimental study 3 and the rationale for combined analysis

Table 11 Association of SNPs in genes of adipokine pathways with resistance to ADT

Table 12 Association of SNPs in genes of adipokine pathways with all-cause mortality

Table 13 Descriptive clinicopathological data of participating patients

Table 14 Genotypic distribution of functional SNPs in genes of hypoxia pathways by disease status using additive and recessive models analyses

Table 15 Association of the genetic polymorphisms in *HIF1A* +1772 C>T and *CA9* +201 A>G with HIF-1α and CAIX immunoreactivity in prostatic epithelial cells

Table 16 Association of the *KDR-604 T>C* genetic polymorphism with VEGFR2 immunoreactivity in vessels and in prostatic epithelial cells

Table 17 Expression of proteins from hypoxia pathways in prostate cancer patients, by Gleason grade and PSA value

LIST OF ABBREVIATIONS

ADT, Androgen deprivation therapy
AKT, Protein kinase B
Ang2, Angiopoietin 2
AR, Androgen receptor
ARNT, Aryl hydrocarbon nuclear translocator
BPH, Benign prostate hyperplasia
CaP, Cancro prostata
CAIX, Carbonic anhydrase IX
COX-2, Cyclooxygenase 2
C-TAD, Transcription activation domain of the C-terminal
ECM, extracellular matrix
EGF, Epidermal growth factor
E-M-T, Epithelial-to-mesenchymal transition
EPO, erythropoietin
ERK 1/2, Extracellular signal-regulated kinases 1/2
GLUT-1, Glucose transporter 1
GLUT-3, Glucose transporter 3
GWAS, Genome-wide association study
HIF, hypoxia inducible factor
HIF-1α, hypoxia inducible factor – 1 alpha
HIF-1β, hypoxia inducible factor – 1 beta
HIF-2α, hypoxia inducible factor – 2 alpha
IGF-1, Insulin growth factor 1
IGF-2, Insulin growth factor 2
IGFBP, Insulin growth factor binding protein
IHC, immunohistochemistry
iNOS, inducible nitric oxide synthase
KDR, Kinase insert domain receptor (gene coding for VEGFR2)
LHRH, luteinizing hormone releasing hormone
LOX, Lysyl oxidase
LOXL2, Lysyl oxidase-like 2
LOX-PP, Lysyl oxidase pro-peptide
MRI, Magnetic resonance imaging
NF-KB, Nuclear transcription factor kappa B

NLS, Nuclear localization signals
ODD, Oxygen dependent domain
PCa, Prostate cancer
PH, Prolyl hydroxylase
PHD, Proline hydroxylation domain
PI3K, Phosphoinositide 3-kinase
PIA, Proliferative inflammatory atrophy
PIN, Prostate intraepithelial neoplasia
PSA, Prostate specific antigen
PTEN, Phosphatase and tensin homolog
RP, Radical prostatectomy
ROS, Reactive oxygen species
SNP, Single nucleotide polymorphism
TAD, Transactivation domain
TAM, Tumor-associated macrophage
TGF-α, transforming growth factor alpha
TNM, Tumor, Node and Metastasis, staging system
UICC, Union for International Cancer Control
VEGF, Vascular endothelial growth factor
VEGFR2, Vascular endothelial growth factor receptor 2
VHL, Von Hippel Lindau

ABSTRACT

Current advances in prostate cancer (PCa) steered an increased precision in diagnosis and treatment, even though this disease endures as a significant cause of death for men in Portugal, in Europe and worldwide. Diagnostic tools used today, e.g. PSA test, resulted in overdiagnosis and overtreatment, with significant morbidity and unclear clinical benefit for patients. Conversely, PCa prognosis is established in the clinical setting through tumor and clinical variables, although its precision is far from optimal. Increasing concern has been devoted to uncover novel molecular markers to increase precision for stratifying patients to therapies and the extent of surveillance required either before or after initial treatment.

Here, we studied the relevance of germline genetic variants in genes involved in tumor hypoxia in the determination of PCa aggressiveness profile. Several single nucleotide polymorphisms (SNPs) in *HIF1A* (*HIF1A* +1772 C>T, rs11549465) and in genes of downstream pathways *VEGF/KDR (VEGF* +405 G>C, rs2010963; *VEGF* +936 C>T, rs3025039; *VEGF* -460 C>T, rs833061; *KDR* -604 T>C, rs2071559), *LOX* (*LOX* +473 G>A, rs1800449) and *CA9* (*CA9* +201 A>G, rs2071676) were genotyped, using DNA from approximately 1500 male subjects (754 PCa and 736 cancer-free controls) included in case-control studies. A nested group of over 480 PCa patients eligible for androgen deprivation therapy (ADT) was followed-up using as endpoints: resistance to ADT (primary), all-cause overall survival (secondary) and development of *de novo* bone metastasis while under ADT (tertiary). In addition, representative areas of prostate carcinoma (n=51) and of nodular prostate hyperplasia (BPH) (n=20) were analysed for hypoxia-inducible factor 1 alpha (HIF-1α), carbonic anhydrase IX (CAIX), lysyl oxidase (LOX) and vascular endothelial growth factor receptor 2 (VEGFR2) immunohistochemical protein expression using a tissue microarray, and correlated with putative functional polymorphisms at the corresponding genes (*HIF1A* +1772 C>T; *CA9* +201 A>G; *LOX* +473 G>A; *KDR* -604 T>C).

Findings from molecular epidemiology studies showed that SNPs on both the *HIF1A* (*HIF1A* +1772 C>T) and *VEGF* (*VEGF* +405 G>C, *VEGF* +936 C>T, *VEGF* -460 C>T)/*KDR* (*KDR* -604 T>C) genes were not associated with increased risk for being diagnosed with PCa or high-grade PCa, even on univariate analyses.

Concerning the follow-up study on patients under ADT, results demonstrated an independent effect of *HIF1A* +1772 T-carriers for developing distant metastasis and resistance to ADT (HR, 2.0; 95%CI, 1.1-3.9 and HR, 6.0; 95%CI, 2.2-16.8,

respectively), albeit no association was found with the secondary endpoint (overall survival). Conversely, the VEGF/KDR SNPs were neither individually nor in combination significantly associated with the primary and tertiary endpoints in patients under ADT. Only the VEGF/KDR SNPs combined into the high/intermediate profile of VEGF-VEGFR2 pathway activation were associated with higher risk for all-cause mortality (HR, 1.6; 95%CI, 1.1-2.4) in univariate analysis.
The genotype-phenotype analyses showed higher LOX staining intensity for carriers of the homozygous *LOX +473* G-allele (P=0.011), and that *KDR* -604 T-allele carriers were more prone to have higher VEGFR2 expression in prostate epithelial cells (P<0.006). Immunohistochemistry disclosed predominance of positive CAIX and VEGFR2 expression in epithelial cells of prostate carcinomas compared to BPH (P=0.043 and P=0.035, respectively). In addition, the VEGFR2 expression score in prostate epithelial cells was higher in organ-confined and extra prostatic carcinoma compared to BPH (P=0.031 and P=0.004, respectively). Notably, for LOX protein the immune reactivity score was significantly higher in organ-confined carcinomas compare to BPH (P=0.015).
The expression on prostate epithelial cells of target molecules in hypoxia pathways analysed here (VEGFR2, CAIX and LOX) allowed differentiating malignant from benign prostate disease. Two of the genetic polymorphisms (*LOX* +473 G>A and *KDR* – 604 T>C) accounted for a potential gene-environment effect in the activation of hypoxia-driven pathways in prostate carcinoma. Nevertheless, genetic polymorphism-protein expression relationship in molecules analysed here were not concordant, suggesting that increased complexity might explain the genotype-phenotype association. Upcoming results in LOX and CAIX SNPs from molecular epidemiology studies might add to the comprehension of this association, allowing the development of genetic risk scores combining genetic hypoxia markers and clinicopathological variables. Further research in larger series is warranted to clarify and expand present findings. Ultimately, a different set of genetic variants is likely to influence prognosis, including genetic polymorphisms involved in steroid metabolism, metastasis and drug metabolism.

RESUMO

Os últimos avanços no cancro da próstata (CaP) conduziram a uma maior precisão no diagnóstico e tratamento, embora esta doença permaneça uma importante causa de morte nos homens em Portugal, na Europa e no mundo. Algumas ferramentas de diagnóstico usadas, por exemplo o teste PSA, resultaram em excesso de diagnósticos e tratamento excessivo, com significativa morbilidade e benefício clínico pouco evidente. Por outro lado, o prognóstico do CaP é estabelecido na clínica através da combinação de variáveis clinicopatológicas em nomogramas, embora a sua precisão esteja longe de ser ideal. Uma preocupação crescente tem sido dedicada à descoberta de novos marcadores moleculares com o intuito de aumentar a precisão para estratificar os doentes com CaP para tratamento e em relação à extensão de vigilância necessária, antes e após o tratamento inicial.

Nesta tese estudou-se a relevância das variantes genéticas da linha germinativa em genes envolvidos na hipóxia tumoral na determinação do perfil de agressividade do CaP. Vários polimorfismos genéticos, no *HIF1A* (*HIF1A* 1772 C> T, rs11549465) e em genes de vias relevantes a jusante: *VEGF* / *KDR* (*VEGF* 405 G> C, rs2010963; *VEGF* 936 C> T, rs3025039; *VEGF* -460 C> T, rs833061 ; *KDR* -604 T> C, rs2071559), *LOX* (*LOX* 473 G> A, rs1800449) e *CA9* (*CA9* 201 A> G, rs2071676), foram genotipados, usando o DNA de cerca de 1500 indivíduos do sexo masculino (754 CaP e 736 controlos) incluídos em estudos caso-controlo. De entre os doentes com CaP, um grupo de mais de 480 CaP elegíveis para terapêutica de privação de androgeneos, foi seguido durante vários anos. A resistência à terapêutica de privação de androgeneos, sobrevida global e o desenvolvimento de novo de metástases ósseas, foram respetivamente considerados como *endpoint* primário, secundário e terciário. Para além do estudo genético, num subgrupo de doentes e controlos mais reduzido, áreas representativas de carcinoma da próstata (n = 51) e de hiperplasia nodular da próstata (HBP) (n = 20) foram analisadas por imuno-histoquímica (IHC) utilizando um *microarray* de tecido. A abundância de fator indutível por hipóxia (HIF-1α), anidrase carbónica IX (CAIX), lisil oxidase (LOX) e a expressão da proteína recetor 2 do fator de crescimento vascular endothelial (VEGFR2) foi correlacionada com os polimorfismos estudados dos genes correspondentes (*HIF1A* 1772 C> T; *CA9* 201 A> G; *LOX* 473 G> A; *KDR* - 604 T>C). Achados dos estudos de epidemiologia molecular mostraram que os SNPs nos genes *HIF1A* (*HIF1A* 1772 C> T), *VEGF* (*VEGF* 405 G> C, *VEGF* 936 C> T, *VEGF* -460

C> T) e *KDR* (*KDR* -604 T> C) não estavam associados a maior risco de ser diagnosticado com CaP ou CaP de alto grau em análises uni ou multivariadas.

Em relação ao estudo de follow-up em pacientes em terapêutica de privação androgénica (TPA), os resultados demonstraram um efeito independente do *HIF1A* 1772 portadores alelo T para o desenvolvimento de metástases e resistência à terapêutica privação androgénica (TPA) (HR, 2.0; 95% CI, 1.1-3.9 e HR, 6.0; 95% CI, 2.2-16.8, respetivamente), não tendo sido observada associação com o *endpoint* secundário (sobrevida global). Por outro lado, os polimorfismos nos genes *VEGF e KDR* não estavam individualmente nem em combinação significativamente associados com os endpoints primário e terciário. Apenas a combinação de polimorfismos no *VEGF* e *KDR* como perfil de ativação alta/intermédia da via VEGF-VEGFR2 estava associada a maior risco de mortalidade na análise univariada (HR, 1.6; 95% CI, 1.1-2.4).

As análises genótipo-fenótipo mostraram maior expressão de proteína nas células epiteliais da próstata nos portadores homozigóticos para o alelo G do *LOX* 473 (P = 0.011) e nos portadores do alelo T do *KDR* -604 (P <0.006). Adicionalmente, a análise por imuno-histoquímica evidenciou uma maior frequência de células epiteliais positivas para o CAIX e VEGFR2 em CaP comparativamente com adenomas (P=0.043 e P=0.035, respetivamente). Além disso, o *score* de expressão de VEGFR2 nas células epiteliais da próstata foi mais elevado quer no CaP confinado ao órgão quer no extra-prostárico comparados com os adenomas (P = 0.031 e P = 0.004, respetivamente). Para a proteína LOX o *score* de imunorreatividade foi significativamente maior no CaP confinado ao órgão comparado com os adenomas (P = 0.015).

A expressão de moléculas-alvo por células epiteliais da próstata em vias de hipóxia aqui analisadas (VEGFR-2, CAIX e LOX) permitiu diferenciar a doença prostática maligna da benigna. Dois dos polimorfismos genéticos (*LOX* 473 G>A e *KDR* - 604 T>C) poderão ser responsáveis por um potencial efeito gene-ambiente na ativação de vias induzidas por hipóxia no CaP. No entanto, a relação entre expressão proteica-polimorfismo genético-risco de CaP agressivo nos marcadores aqui analisados não foram concordantes, sugerindo que apenas uma complexidade acrescida poderá explicar a associação genótipo-fenótipo-risco. Os resultados dos estudos de epidemiologia molecular a decorrer com os polimorfismos do *LOX* e *CAIX* poderão acrescentar à compreensão desta associação, permitindo o desenvolvimento de *scores* de risco genético que combinam vários marcadores genéticos e proteicos de hipóxia com variáveis clinicopatológicas. É evidente a

necessidade de estudos em séries maiores para clarificar e expandir os resultados aqui apresentados. De facto, o conhecimento de um conjunto de variantes genéticas maior e mais alargado, é suscetível de influenciar o prognóstico, nomeadamente o conhecimento de polimorfismos genéticos envolvidos no metabolismo de esteróides, metástases e metabolismo de fármacos.

THESIS PLANNING

The present thesis is organized into four different Chapters. In ***Chapter 1***, a short general introduction to review cancer cell singularities and propel Prostate Cancer (PCa) research questions is presented. Then, the literature is reviewed throughout ***Chapter 2***, despite an introductory note revealing our personal clinically-driven approach, focusing on PCa particularities as a research model that took questions from the clinical setting (bedside) towards the bench of basic and translational experimental investigation. These personal thoughts emerged within the frame of classical knowledgeable epidemiology, carcinogenesis and clinicopathology of PCa. Moreover, this chapter included a wide literature review attentive to hypoxia and cancer as a whole, with particular attention to the role of hypoxia-inducible factor – 1 alpha (HIF-1α), which was deepened to focus on PCa and disease aggressiveness through the interplay with key downstream pathways. The *Chapter 2* was upheld on candidate strong clinical background and on two published reviews [*Clin Genitourinary Cancer 2015; 13 (4): 295-301; Actas Urol Esp 2009; 33 (9): 941-951*].

For the sake of clarity, we decided to include experimental works that resulted in scientific publication on a separate ***Chapter 3***. Here, each separate study from a total of four, congruent with literature review and questions identified in clinical practice, was independently described and presented through a short overview, results and discussion, followed by the respective printed paper in appendix. Therefore, in this chapter the most relevant results and specific discussion are concisely depicted, grounded on published papers *[Eur J Cancer 2014; 50: 359-65; PLoS ONE 2012; 7 (6):e39236]* and submitted manuscripts *("Putative functional genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer"*, and *"Inherited variation in adipokine pathway genes may determine prognosis for prostate cancer patients receiving androgen-deprivation therapy"*). An integrative but concise overall conclusion, followed by emerging specific conclusions and prospective investigative remarks were depicted in ***Chapter 4***. We believe this outline will fit the purpose of showing all the major scientific achievements and discoveries made throughout the PhD track, while making it less burdensome to readers.

Hypoxia Biomarkers in Prostate Cancer:
From genetic polymorphisms to intratumoral protein expression

CAP 1 – GENERAL INTRODUCTION AND AIMS

CAP 2 – REVIEW OF LITERATURE	Hypoxia and Cancer Hypoxia and prostate câncer aggressiveness: from pathophysiology to clinical biomarkers	Anexo 1 Anexo 2
CAP 3 – CLINICAL STUDIES.	Clinical studies #1, #2, #3 and #4: Overview and methods. Results. Discussion.	Anexo 3 Anexo 4 Anexo 5 Anexo 6

CAP 4 – CONCLUSIONS AND FUTURE PERSPECTIVES

Anexo 1 - *Papel del factor inductor de la hipoxia. Actas Urol Esp 2009; 33(9): 941-951*

Anexo 2 – *Hypoxia and prostate cancer aggressiveness: different tales with common ending. Clin Genitourinary Cancer 2015; 13(4): 295-301.*

Anexo 3 – *The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration. Eur J Cancer 2014; 50: 359-65.*

Anexo 4 – *Performance of an Adipokine pathway based multilocus genetic risk score for prostate cancer risk prediction. PLoS ONE 2012; 7(6): e39236.*

Anexo 5 – *Inherited variation in adipokine pathway genes may determine prognosis for prostate cancer patients receiving androgen deprivation therapy. Submitted.*

Anexo 6 – *Putative functional genetic polymorphisms in key hypoxia regulated downstream molecules and phenotypic correlation in prostate cancer. Submitted.*

1. GENERAL INTRODUCTION

Advances in cancer biology research have led to a better understanding of this disease and have shown that it is an extremely complex and dynamic biological phenomenon, characterized by a great capacity for adaptation to evolving environments along its natural history. At the outset, the cancer cell is doomed to failure to die, due to the surrounding environment and because it is against the life cycle, even though if ultimately successful it will result in patient's death. Hence, it is not surprising that throughout cancer development, different biological singularities are happening that will facilitate cancer cell's survival and tumor progression.

Tumor promotion, proliferation, cell instability, deregulation of energy mechanisms, mutations, resistance to apoptosis, invasiveness and metastasis, angiogenesis, the ability to resist and adapt to hypoxia phenomena are all characteristic hallmarks of cancer cells that will lead to its immortality and progression [1]. These singularities are characteristic phenotypic findings that are superimposed on the genetic background and environmental exposure's driving forces, which ultimately determine the diversity among cancers and the different responses of patients even to the same type of cancer and therapies.

Prostate Cancer (PCa) is a very heterogeneous disease with great clinical variability, varying considerably in their genetic profile and biological behavior, making it difficult and complex to decide the best therapeutic approach. Therefore, it is vital to advance our ability to detect the most aggressive cancers. For that reason, it seems imperious to uncover and understand the mechanisms of PCa development, particularly in relation to hypoxia. At our research Group we recognized that raising further the understanding of cancer hypoxia mechanisms and its impact on angiogenesis and tumor microenvironment of PCa will add relevant information to current knowledge and potentially impact clinical reasoning. In fact, although tumor hypoxia is common in urological oncology, particularly in relation to PCa aggressiveness, further research in environmental factors and germline genetic variants as modulators of hypoxia in PCa will foster comprehensive development of predictive and prognostic biomarkers to improve PCa management.

Neoplastic tissues in the prostate gland are highly hypoxic, where the degree of microenvironmental hypoxia largely determines the response to subsequent resistance to treatment and tumor progression, as reflected in the local response evaluated through immunohistochemistry [2].

Several studies have shown a relevant role for hypoxia in androgen dependent PCa, which is supported by the observed clinical impact of anti-androgens involving the downregulation of hypoxia-inducible factor 1 alpha (HIF-1α) transcription and decreased angiogenic potential [3-5]. Studies involving genetic variants, including the *HIF1A* gene, in susceptibility to PCa and hypoxia mechanisms are scarce and often controversial [4-7], thereby fostering further research. Even though some biomarkers are central in hypoxia, we should consider a panel of markers since individually they are unlikely to be assertive enough to be clinically relevant [8,9]. In fact, underlying tumor hypoxia we should notice the existence of a regulatory circuit between molecules (such as vascular endothelial growth factor, VEGF, lysyl oxidase, LOX, carbonic anhydrase, CAIX) and pathways controlled by HIF-1α, which synergistically model the tumor microenvironment and regulate PCa aggressiveness.

During the process of fitting with hypoxia, the microenvironment changes and cells adapt to withstand the hostile environment, where well documented neoangiogenesis regulated by VEGF and its receptors allows new architecture and microcirculation, glycolytic pathways change to avoid cellular acidosis with altered expression of glucose transporters -1 and -3 (GLUT-1 and GLUT-3), changes in pH regulation through carbonic anhydrase IX, and altered lysyl oxidase to modulate extracellular matrix to allow tumor expansion and metastasis. A recent study identified HIF-1α, VEGF and angiogenesis as hypoxia markers that were associated with risk of biochemical failure in patients with localized PCa [2], whereas others showed LOX and CAIX overexpression in PCa compared with BPH and correlation with Gleason grade [10], although additional studies are required to confirm these proteins as useful hypoxia markers in PCa.

Underlying the intricate resulting phenotype of hypoxia microenvironment in prostate tumors, uncovering germline variations in locus of genes coding for molecules in hypoxia pathways likely to play a role in tumor progression and aggressiveness may reveal new potential biomarkers.

The identification of better hypoxia biomarkers can help personalize which patients might benefit more from regulatory hypoxia therapies. Ultimately, being capable of predicting the correlation of local hypoxic phenotypic changes with prognosis, can lead to the application of focal therapy directed to hypoxic areas guided by magnetic resonance imaging or using hypoxia-targeted nanotools [11,12].

This thesis is focused on hypoxia-driven prostate tumor aggressiveness and disease progression. Here we attempt to disclose genetic and phenotypic

characteristics from molecules involved in hypoxia pathways that better define malignancy and discriminate aggressive disease. The ultimate purpose is to congregate enough data from genetic and protein markers (from pathways directly regulated by HIF-1α: CAIX, LOX, VEGFR2) in order to develop a predictive/prognostic model for stratification by risk groups according to the molecular profile. Analysis of genetic variants that may influence the production and action of these molecules, may add new insights into the functional molecular profile of susceptibility to cancer and understanding of its pathophysiology. Accordingly, we expect to study the functional effect of single nucleotide polymorphisms (SNPs) through the verification of protein expression directly in prostatic tissue by immunohistochemistry (IHC). We expect that results presented may help clarify the mechanism of hypoxia in PCa development and will prove to be a step in the need to continue and deepen this line of investigation.

1.1. Aims

- To study the protein expression directly in prostatic tissue corresponding to the functional effect of SNPs in the respective genes, revealing genotype-phenotype relationships.
- To analyze genetic variants in genes coding for molecules that may influence hypoxia downstream effects, therefore adding new insights into the functional molecular profile of susceptibility to prostate cancer and understanding of its pathophysiology.
- To uncover genetic and phenotypic characteristics from molecules involved in hypoxia pathways that better define malignancy and discriminate aggressive disease.
- To identify better hypoxia biomarkers and add to knowledge on stratification of patients who might benefit more from regulatory hypoxia therapies.
- Contribute to the development of new risk scores using molecular markers capable of predicting local hypoxic phenotypic changes, which can lead to the application of focal therapy directed to hypoxic areas.

REVIEW OF THE LITERATURE

2.1 Prostate cancer as a particular research model: from bedside-to-bench

Prostate cancer is one of the most frequent and controversial pathologies of modern medicine. In recent years we have witnessed on the one hand an increased demand for care in this area and on the other hand the development of scientific advances accompanied by great technological progress.

The pronounced progress and new perspectives of cure obtained with the use of prostate specific antigen (PSA) [13] enabled earlier diagnosis of the disease. The technology has progressed immensely allowing easier, faster and more accurate diagnosis, and more comfortable treatments with less sequelae. However, current ultimate treatments have been developed for over fifty years. Indeed, radical prostatectomy (RP) remains the paramount therapeutic opportunity for local disease, and androgen deprivation therapy the everyday treatment for advanced disease.

Prostate cancer is now considered a heterogeneous disease, where efforts should be emphasized towards detecting, identifying and targeting the most aggressive tumors. Existing prognostic algorithms that include clinicopathological variables such as the Gleason grade, PSA, imaging and histological features are limited to crude estimates of disease progression.

Knowledge of the mechanisms of carcinogenesis and tumor biology, including genetic changes associated with tumor initiation and progression, has been an opportunity to add genetic markers to the predictive and prognostic panel, to improve clinical reasoning and aid therapeutic decisions.

For several years it was recognized that a genetic component underlies PCa development and aggressiveness, and approximately 42% higher risk cancer can be ascribed to genetic factors [14]. Only a small proportion of cancers can be attributed to monogenic, high penetrance genes, whereas most have multifactorial etiology, combining environmental and genetic factors. Low penetrance genetic variants, alone or combined as a genetic risk score have been studied, although still inconclusive [15-17].

The identification of susceptibility genes for PCa and its biochemical and metabolic relationship will add to our knowledge contributions in the field of molecular cancer pathophysiology, allowing the closer identification of risk groups and to establish relations with drug response. Notably, several current therapies

(androgen deprivation therapy, chemotherapy, and radiotherapy) may be influenced by genetic variations with functional features in genes coding for regulatory molecules in tissue hypoxia.

2.1.1. Anatomy

Prostate is an exocrine organ measuring approximately 25cc. It is characterized by the presence of tubuloalveolar glands that secrete fluid through ducts that empty into the prostatic urethra. The prostate is located deep in the pelvis below the pubis, above rectum and between bladder and external urinary sphincter. The prostate is involved by a capsule and is divided into a peripheral zone, where most cancers arise, a transition zone where approximately 15% of neoplasias occur, and a central zone with rare malignant transformation [18].

2.1.2. Histopathology

Normal prostatic epithelium contains a heterogeneous group of cells representing several distinct levels of differentiation. Secretory cells are well differentiated epithelial cells that are PSA-producers and androgen receptor (AR) positive. The secretory cells are derived from basal cells through an intermediate proliferating group of cells that are variable in AR and PSA expression. The PSA producing secretory cells are terminally differentiated and incapable of proliferation [19]. Rare neuroendocrine cells are also present in normal prostatic epithelium.

More than 95% of PCa are adenocarcinomas that arise in acinar and proximal ductal epithelium. The typical adenocarcinoma of prostate can be distinguished from others neoplasms using PSA immunohistochemistry. Intraductal proliferation, termed prostatic intraepithelial neoplasia (PIN) is considered a histologic precursor of malignancy; however, an atrophic but highly proliferative condition associated with chronic inflammation, proliferative inflammatory atrophy (PIA), may in fact be the first histologic step in the carcinogenic process [20]. PIN is defined by the presence of cytological atypical epithelial cells within architecturally benign appearing acini and is subdivided into low and high grade; only high grade PIN is considered a precursor of invasive carcinomas and it may precede the development of cancer by 10 years or more [21]. Prostatic adenocarcinomas are often multifocal and heterogeneous, a factor that complicates both prognostication and attempts to develop focal therapies. Patients not only have multifocal tumors but also an average of 2.7 different grades of cancer in each specimen; only 10% of cancers

from RP specimens are comprised of a single histologic grade. The majority of RP specimens contain more than one prostate malignancy focus and type. Genetic studies indicated that multifocality is typically a function of separately arising tumors rather than intraprostatic tumor spread [22]. Adding to the picture, several studies indicate a critical role for stroma cells in supporting the growth of malignant prostate epithelial cells, thereby remaining an area of active investigation [23].

2.1.3. Epidemiology

Considerable changes have occurred in the epidemiology of PCa since the widespread availability of PSA in the early 1990s. In fact, dramatic changes in its incidence have taken place since the PSA became commercially available, as prostate tissue has been increasingly biopsied with better quality in men without symptoms.

Prostate cancer is an important public health issue, being the most frequent non cutaneous male malignancy and the second most common cause of cancer death in men [24]. It was estimated that during the year 2012 in the United States, PCa became the most common cancer in men over 60 years, with about 214 740 new cases and 28 170 deaths [25], accounting for approximately 29% of new malignant cases and 9% of the causes of death by cancer in males. Concurringly in Europe, PCa is the leading cause of death in males, whereas incidence is highest in Northern and Western Europe (> 200 per 100 000) with continuously increasing rates in Eastern and Southern Europe [26]. During the last decade, the five-year relative survival for PCa steadily increased from 73.4% in 1999-2001 to 83,5% in 2005-2007, with an estimated total economic burden of PCa in Europe exceeding 8.43 billion euros [26]. In Portugal, the number of estimated new cases of PCa in 2008 has been 5140 [27,28]. It is the most common malignancy in men after colorectal cancer. The estimated risk for a Portuguese man, below 75 years old, to develop any cancer type is 25.9%, while the risk for PCa is 3.2% and the risk of dying from PCa 3.0 % [29].

There are large differences in incidence of PCa between countries, ethnic backgrounds and populations. Genetic, environmental and social characteristics (access to medical care for example) are likely factors that might influence the development and progression of the disease, despite the persistent clinically-established risk factors, age, race and family history of PCa [30]. Environmental factors have been suggested to influence the risk of progression from so called

latent PCa to clinical PCa, including fat and alcohol consumption, exposure to ultraviolet radiation, chronic inflammation, obesity and metabolic syndrome, but further research is warranted to confirm association.

2.1.4. Molecular mechanisms

Prostate cancer has elevated morbidity, even though its pathogenesis remains unclear. Several putative risk factors and mechanisms have been implicated, but current evidence remains inconclusive.

Normal epithelial cells acquire somatic mutations in critical regions of the genome that result in increased cell proliferation and confer the ability to invade and metastasize; their normal function is modified due to alterations in multiple cellular signaling pathways. Actually, the progression of PCa is known to be caused by deregulation of intracellular signaling pathways such as the AR pathway, PI3K-Akt, NF-kB, Wnt and Notch. It is known that PCa is an endocrine-related cancer driven by androgens, and the mutations at that level are thought to be determinant [31].

A genetic polymorphism has been defined as a commonly occurring (>1%) genetic variation, at the nucleotide level, in the general population. Compared to mutations, SNPs have been perceived as functionally insignificant, albeit current evidence emphasizes that a considerable fraction affects protein intrinsic properties and function to a variable degree. Low penetrance susceptibility alleles are defined as polymorphic genes with specific alleles that associate with altered susceptibility for disease. Usually, variants in these genes are common in the normal population. Therefore, although each variant may be associated with a relatively small attributable fraction risk for prostate cancer, the impact of combining relevant genetic polymorphisms, may add significance to their use as molecular markers and determinants of PCa diagnosis and aggressiveness prediction. Several reports have demonstrated the importance of genetic polymorphisms in the phenotype of several cellular mechanisms. If these genetic variants are combined to induce interactions at gene and protein level, they are likely to influence cancer mechanisms at the cell, with repercussion in the microenvironment and with perception of external environment.

2.1.5. Diagnosis

Screening for Pca is a highly controversial topic. There is no level 1 evidence that PSA screening reduces mortality due to PCa. In the Cochrane review published in 2013, screening was associated with increased diagnosis of PCa (RR, 1.3; 95%CI,

1.02-1.7), with more localized disease (RR, 1.8; 95%CI, 1.2-2.7) and less advanced PCa (T3-4, N1, M1) (RR, 0.8; 95%CI, 0.7-0.9). The early detection of PCa seems to be important because it allows the diagnosis of localized and potentially curable disease, even at the expenses of increased iatrogeny in patients with indolent tumors [32,33]. Nevertheless, controversy exists concerning the cost-effective profile of using PSA widely [34] and the impact on the patient's overall quality of life is still unclear.

A critical issue emerging from the debatable PSA-associated overdiagnosis and overtreatment is the previously unmet need for additional molecular markers that can improve the discrimination of PCa aggressiveness. The patient with advanced disease may receive only palliative treatment.

The diagnosis of PCa is based on PSA values and/or suspicious digital rectal examination, which refer, when adequate, for prostate biopsy. Usually, men with PSA values ≥ 4.0 ng/ml or PSA velocity > 0,75ng/ml/year, are candidates for prostate biopsy. Nevertheless, these PSA cut-offs remain controversial and often lead to false positives and negatives.

Diagnosis of PCa relies on prostate biopsy with subsequent histopathological identification. The accuracy and lower morbidity of prostate biopsy procedure should be taken into account, and are known to influence diagnosis precision.

Currently, the prostate biopsy protocols are increasingly standardized, together with better echography and fusion images obtained from MRI, which have allowed significant advances in diagnosis accuracy and therapeutic guidance (mainly surgical precision and the possibility of focal treatments).

Histopathologically determined Gleason grade and PSA levels are commonly used in nomograms for clinical assessment of the prognosis.

2.1.6. Clinical and pathological staging

Classification of disease staging, either local or regional or systemic, is crucial, since it informs about its progression and extent. Ordinarily, we use the Union for International Cancer Control (UICC) classification of the tumor, node and metastasis (TNM), including the following features: digital rectal examination, multiparametric magnetic resonance imaging (MRI), histopathological findings and PSA values.

The most precise staging is provided when patients are submitted to RP. In this setting the RP specimen, seminal vesicles and locoregional lymph nodes are analyzed together, providing more precise information to better assess risk of

recurrence and necessity of adjuvant treatment. Nevertheless, PCa has a great clinical variability. In cases, PCa patients apparently remain asymptomatic, often without a diagnosis and die of other causes. Frequently, this slow-growing, indolent disease may never elapse as clinically important, and patients are likely to die from another cause [35,36]. This may be due to old age at the time of diagnosis, slow growth seen in many tumors or to therapeutic response. However, sometimes tumors are very aggressive from the start and rapidly progress after a variable period of latency.

Thus, given the elevated prevalence of this disease, its morbidity and mortality, as well as the economic and social repercussions, additional efforts should be undertaken to understand and establish the biological, genetic and environmental mechanisms underlying PCa natural history [37].

2.1.7. Treatments

Therapeutic options in PCa should be reasoned taking into account disease stage (TNM), tumor Gleason grade, PSA level, and patient's age, life expectancy, expected quality of life, in order to modify its natural history, influencing the risk of disease progression and mortality [38]. When such factors are evaluated, diverse treatments are available including active surveillance, surgery, focal therapy, radiotherapy, brachytherapy, hormonal therapy and chemotherapy, according to the moment in the disease natural history.

The development of novel biomarkers for PCa that fit within clinical needs, will certainly improve prognosis and clinical decision-making capacity. In this setting, it is necessary to foster research in this field to upgrade knowledge and accurately provide guidance for different therapeutic options. In recent years, active surveillance and focal treatments in PCa, have emerged as novel therapeutic modalities with strong evidence to take into account. Knowledge of biomarkers and PCa features can help make the right choices for our patients.

2. 2. Hypoxia and cancer

[Fraga A et al. Tumor hypoxia. The role of HIF. Actas Urol Esp 2009; 33 (9): 941-51]

Solid tumors usually occur and progress in a hypoxic environment, suggesting that hypoxia modulates tumor cell resistance to apoptosis and influences neoangiogenesis, making them more aggressive, with invasive capacity and resistant to treatment.

The genetic and biological mechanisms underlying this phenomenon are incompletely clear, even though many studies suggest a role of HIF in this process. Under hypoxic conditions, the alpha subunit is not destroyed, and will activate transcription of a set of genes that ultimately contributes to tumor aggressiveness. Its expression is associated to an increased metastatic potential that has been shown in both animal studies and human tumors.

Hypoxia-inducible factor (HIF) is a transcription factor that regulates cells' response to hypoxia and acts as a regulator of oxygen homeostasis [39-41]. The transcription factor activates genes that codify proteins that increase the availability of oxygen and permit metabolic adaptation in the absence of oxygen; it controls the expression of several genes and proteins involved in angiogenesis, erythropoiesis, glycolysis, invasion, apoptosis, vascular tone, pH regulation, epithelial homeostasis, and drug resistance. More than 60 target genes induced by HIF have been identified [40]; others are suppressed [42]; many functions are HIF-dependent [42].

Tumor hypoxia has emerged as a key factor in tumor progression and is associated to a poor prognosis in urological oncology, particularly kidney and prostate cancer. The purpose of this study was to review the significance of hypoxia in carcinogenesis and tumor progression by reviewing the current knowledge on the subject and the mechanisms of action and activation of hypoxia-inducible factor 1 alpha (HIF-1α).

2.2.1. Molecular structure of HIF-1α

The *HIF1A* gene, which codifies HIF-1α, is located in the 14q21-q24 locus [43], which contains 15 exons [44]. It is a heterodimer composed of alpha chains (regulated by O_2) and beta chains, arranged in a helix-loop-helix (bHLH); it belongs to a family of transcription factors consisting of three alpha subunits (HIF-1α, HIF-2α, HIF-3α) and one beta subunit (HIF-1β), also known as aryl hydrocarbon nuclear translocator (ARNT) [45-47].

There are two nuclear localization signals (NLS), located on the C-terminal (aminoacids 718-721) and on the N-terminal (aminoacids 17-33), but only the C-terminal is responsible for the nuclear accumulation of HIF-1α [48]. It is also known that HIF contains two transactivation domains (TAD) in the C-terminal (aminoacids 531-575 and 786-826), separated by a sequence of aminoacids (575-786) that inhibit transactivation [49] (Figure 1).



Figure 1. Molecular structure of HIF-1α. Adapted from [45].

The N-terminal of the molecule (aminoacid 1-390) contains the bHLH-PAS domain, necessary for dimerization and binding to DNA [50]. The interaction between the bHLH domains of the two subunits regulates their dimerization [51].
The C-terminal domain's function is to signal the translocation of HIF-1α for the nucleus, protein stabilization, and interaction with coactivator p300 [49]. In the oxygen-dependent domain (ODD) of HIF-1α, proline residues in positions 402 and 564 have an important effect on the stability of the protein in normoxic conditions, as they permit, when hydroxylated, recognition by the von Hippel-Lindau protein (pVHL) and subsequent activation of the ubiquitin degradation pathway [52-57]. The hydroxylation of proline residues in the ODD domain of HIF-1α is the critical point that regulates the protein's stability [58,59] (Figure 2). The transcription activity of *HIF1A* gene is thus regulated by the cellular oxygen tension.



Figure 2. Stability and activity of the HIF. Adapted from [60].

2.2.2. Molecular mechanisms of HIF and of *HIF1A* activation

In the presence of O2, the proline hydroxylation domains (PHD1, 2, 3) provoke specific hydroxylation in two proline residues (P402 and P564) in the HIF-1α ODD, which allows pVHL to recognize HIF-1α; the E3-ubiquitin complex is formed, which will transform HIF-1α into a degradation target [61-64]. Jaakkola et al [63] showed that the interaction between pVHL and the specific HIF-1α domain is regulated by the hydroxylation of the proline residue (HIF-1α P564) by an enzyme called HIF-1α prolyl hydroxylase (HIF-PH), which requires iron and oxygen.

Another O_2 sensor is the factor inhibiting HIF-1 (FIH-1), which hydroxylates HIF-1α in the presence of O_2, at the asparagine residue 803 in the transcription activation domain of the C-terminal (C-TAD), and is inactive in hypoxia, which permits interaction with co-activators CBP/p300 [65,66] (Figure 2).

In hypoxic conditions, molecular O_2 is not available, and thus the enzymes are inactive, which implies elevated levels of HIF-1α [5]. HIF-1α is not hydroxylated, and therefore not degraded; this causes it to accumulate in heterodimerized form with the beta subunit (HIF-β). This heterodimer migrates toward the nucleus, where it binds to the specific DNA sequences, and activates genes involved in the adaptation to hypoxia, cell survival, angiogenesis, and metastasis, such as, for instance, vascular endothelial growth factor (VEGF), transforming growth factor alpha (TGF-

α), glucose transporter 1 (GLUT-1), and carbonic anhydrase IX (CAIX), among many others known to be involved in tumor development and aggressiveness [67,68].
Therefore, the main regulator of HIF is oxygen [54,69]. The second in order of importance are oncogenes, which may contribute to stabilize or degrade protein. For example, protein p53, the product of the tumor suppressor gene *TP53*, inhibits the activity of HIF-1α and becomes a target for proteasomal degradation [70]. However, *TP53* deletions or mutations may facilitate the accumulation of HIF-1α in conditions of hypoxia, increasing the expression of VEGF in tumor cells.
The product of the tumor suppressor gene VHL also regulates the stability of HIF-1α [71], since in the presence of oxygen pVHL can bind to the HIF-1α subunit and become a target for prolyl-hydroxylation [57-59]. Additionally, other oncogenes (v-Src or RasV12) inhibit prolyl-hydroxylation, which implies stabilization of HIF-1α [69-72].
We also know that the expression of the *HIF1A* gene can be regulated through other pathways, mainly those of intracellular signaling, such as protein-kinase B (Akt) and phosphatidylinositol 3'-kinase (PI3K), although their role in these regulation pathways is not yet clear.
Other *HIF1A*-regulating molecules have been described, such as the reactive oxygen species (ROS) involved in carcinogenesis, or cytokines like the tumor necrosis factor alpha (TNF-α) and angiotensin [73-77], which signal pathways such as RAS/RAF1/MEK1/ERK1/2 and/or p53/JNK, activated as a response to oncogenes, growth factors, or hypoxia (Figure 3).



Figure 3. HIF-1α signaling and regulation pathways. Adapted from [78].

2.2.3. General functions of the *HIF1A* gene

Hypoxia is a diminished oxygen tension, defined in clinical terms as a reduction of the availability of oxygen to critical levels (tension under 7%) [77].

HIF-1α is involved in the response to hypoxia, in oxygen homeostasis, and in myocardial, brain and retinal ischemia, pulmonary hypertension, preeclampsia, intrauterine growth retardation, and cancer. It plays a crucial role in physiological homeostatic and etiopathological mechanisms. It acts on target genes because its function is regulated by growth factors and genetic abnormalities involved in tumor progression [79,80].

Aberrant blood vessels can disappear at any time, but they can sometimes be reutilized, causing local reoxygenation, stimulating sudden changes of hypoxia and reoxygenation as a result of local angiogenesis [81-84].

The tumor's environment is well characterized; it is understood as a fluctuation between hypoxia and nutrient deprivation that leads to genetic and epigenetic adaptation of cell clones, which increases its invasion and metastatic capacity.

Additionally, these adaptations to hypoxia make tumors more difficult to treat and more resistant to therapies. An important part of this process is the adaptation of gene products as a response to hypoxia, and the fact that many of these hypoxia-regulated genes are mediated by *HIF1A* [85]; approximately 1% of the genome is estimated to be regulated by hypoxia.

Tumor hypoxia by itself is an important epigenetic factor in the regulation of the HIF-1α protein. In addition to inhibiting PSDs and HIF-1α, hypoxia generates oxygen free radicals capable of stabilizing the HIF-1α protein and of inducing the *HIF* and *VEGF* genes [86,87].

When hypoxia is established, there is a cell response to prevent apoptosis [63], and the HIF-1α transcription factor is activated, which generates a heterodimer with HIF-1β (ARNT) in the hypoxia response element (HRE), which leads to a multiple cell response and the activation of oncogenes [88], increased vascularization with the production of VEGF, increased glucose transport (GLUT1), increased activity of carbonic anhydrase (CAIX), and even the induction of several apoptotic genes [89-91]. HIF is known to act on genes that codify erythropoietin, transferrin, endothelin-1, inducible nitric oxide synthase (iNOS), hemoxygenase 1, insulin growth factor-2 (IGF-2), insulin-like growth factor binding proteins 1, 2 and 3 (IGFBP 1, 2, 3), glucose transporters (GLUT), and glycolytic enzymes [50,92,93] (Figure 4). This promotes metabolic adaptation to hypoxia, and is also regulated by O_2 tension,

depending on the expression of the HIF-1α subunit [94]. Malignant cells' ability to adapt to hypoxia is fundamental for tumor growth (Table 1).



Figure 4. Responses determined by the HIF. Adapted from [95].

Table 1. Examples of molecules regulated by HIF-1α and their pathophysiologic action

Molecule	Function	References
VEGF	Angiogenesis	[5-7] [16] [37,38] [66] [68] [71-78]
Erythropoietin	Erythropoiesis	[5-7][16][66][68][77,78]
GLUT-1	Glycolysis	[5-7][16][37,38][66][68] [77,78]
TGF-α	Invasion and metastasis	[5-7][37,38][78]
Transferrin	Apoptosis	[5-7][16][68][77,78]
Endothelin	Vascular tone	[5-7][16][68][77,78]
CAIX	pH regulator	[5-7][37,38][66][77,78]
iNOS	Drug resistance	[5-7][16][68][77,78]
IGFBP-1, 2, 3	Homeostasis	[5-7][16][68][77,78]

2.2.4. Hypoxia, hypoxia inducible factor, and cancer

Hypoxia is significantly less in tumors in which the average O_2 tension exceeds 1.5% [77,96,97]. In order to survive, tumor cells must adapt to a low pO_2; many genomic products are involved in tumor neoangiogenesis. These adaptations contribute to phenotypic survival and clinical aggressiveness [98]. Tumor hypoxia has been associated with poor prognosis in many kinds of cancer [99].

Tumor cell clones can adapt to hypoxic microenvironments in both primary and metastatic sites. The genetic and epigenetic mechanisms of adaptation to hypoxia (genetic instability, aerobic glycolysis, loss of control of the cell cycle, loss of apoptosis signalling) are characteristic of malignancy [85] (Figure 5).



Figure 5. HIF-1α regulation

There is evidence that hypoxia may control and maintain genetic instability. This genetic instability may reduce DNA repair and increase the rate of mutation [90]. Intratumor hypoxia is a factor of poor prognosis observed in prostate, breast, musculoskeletal, head and neck, and cervical cancer [100-102]; it is associated with a higher rate of failure of radiotherapy, chemotherapy, and with increased metastasis [90].
We know that the activation of aerobic glycolysis represents an initial event in the process of neoplastic transformation, probably as a response to increased cell proliferation [103], since rapidly proliferating cells consume more oxygen. Tumors have increased glycolysis, and we know that the concentration of glucose and of components of the glycolytic pathway have an effect on HIF [104,105]. The tumor pH is more acidic due to an increased production of lactate and CO_2. In order to survive, cells must maintain a balance between the intracellular and the extracellular pH; this is achieved thanks to several transporters. Carbonic anhydrase IX plays a fundamental role in this balance; several studies have shown a correlation between hypoxia, angiogenesis, HIF-1α, and CAIX [106].

Therefore, HIF levels are adapted for cells to maintain a high rate of proliferation; on the other hand, the increased cell proliferation may induce an increased expression of HIF [92]. In conditions of hypoxia, where the action of growth factors leads to an increased cell proliferation and thus to an increased oxygen requirement, HIF-1α is more expressed and activated, inducing the expression of genes that codify the pro-angiogenic molecules that permit metabolic adaptation to hypoxia; this is the most powerful activator of genes that codify glycolytic enzymes and pro-angiogenic growth factors [92,107-109,95], since tumors cannot thrive without angiogenesis that allows the diffusion of oxygen, glucose, and other nutrients [110,111].

Angiogenesis is the development of new blood vessels from the pre-existing vessel network, and plays a preponderant role in various pathophysiologic mechanisms, both benign (cicatrization, wounds, ischemia, diabetic retinopathy) and malignant (tumor growth and metastasis); VEGF plays a fundamental role in angiogenesis, and is regulated by HIF [60,112,113].

Currently, there is evidence that tumor blood vessels are disorganized and lack an adequate structure for circulation, which often leads to collapse. Since tumor development requires oxygen, nutrients, and an adequate metabolic function, it is necessary to promote angiogenesis factors in order to inhibit the apoptosis of tumor cells triggered by hypoxia. Therefore, angiogenesis as a response to tumor hypoxia is mediated by HIF-1α [114].

HIF-1α has been considered a key factor in the regulation of VEGF and its receptor (VEGRF), as well as of other angiogenic factors. Several immunohistochemical studies conducted on various tumor models [115] show that the expression of HIF-1α is associated with an increase in VEGF and of vascularization and metastasis, which imply a worse prognosis [116,117]. There seems to be a direct relationship between angiogenesis and metastasis in several kinds of tumors, such as melanoma, glioma, lung, breast, ovary, bladder and prostate cancers [118,119]. It has been proven that HIF-1α target proteins are implicated in the proliferation, survival, adhesion, and mobility of cancer cells.

On the other hand, an increased expression of HIF-1α, in combination with inactivated mutations in suppressor genes such as *VHL*, *p53*, *PTEN* or the amplification of the oncogenes *Akt*, *RAS*, *ERK1/2*, has often been observed in cancer patients; these abnormalities are associated with tumor growth, invasion, and metastasis.

Zhong et al. [120] have demonstrated an increased expression of HIF-1α in approximately 53% of tumors, including cancer of colon, stomach, pancreas, lung, ovary, prostate, kidney, melanoma, and glioblastoma. The increased expression of HIF-1α is associated with a shorter survival in breast and uterine cancer, and with poor response to treatment in nasopharyngeal cancer, highlighting the role of tumor hypoxia in prognosis [116,121-125] (Table 2).

Table 2. Tumors that show overexpression of HIF assessed with immunohistochemistry

	References				
Organ	[99]	[83-85]	[97,98]	[72][100-104]	[48][60][105-108]
Colon	X				
Stomach	X				
Pancreas	X				
Lung	X		X		
Ovary	X		X		
Uterus		X		X	
Prostate	X	X	X		X
Kidney	X				
Glioma	X		X		
Breast		X	X	X	
Head and neck		X			
Melanoma	X		X		

In prostate cancer, it is expressed in the initial stages of carcinogenesis, and this expression is associated with diagnostic and prognostic indicators of early relapse and metastasis; HIF-1α may be a potential poor prognosis biomarker. Its importance in tumor progression becomes a potential target in chemoprevention strategies and in the ability to inhibit angiogenesis [85]. Experimental studies with mice prostate cancer cells show that an overexpression of HIF-1α is associated with more growth and metastatic potential [126]. Similarly, a greater expression of HIF-1α has been found in human prostate tumors [120,127]. The *VEGF* gene, induced mainly by HIF-1α, has been frequently found to be overexpressed in prostate cancer, especially in patients with metastatic or hormone-resistant cancer; this suggests a central action of this molecule in this process [128,129].
The activation of oncogenes and growth factors can induce the HIF system in non-hypoxic cells, or amplify the response to hypoxia. In fact, several growth factors

and cytokines of the stroma and parenchyma also act as regulators and are capable of inducing the expression of HIF-1α, its binding and transactivation capacity, such as the epidermal growth factor (EGF) [130], TGFα [109,131], factors IGF-1 and IGF-2 [132], and interleukin 1beta [83, 133]. Additionally, recent studies show that HIF may play an important role in resistance to treatment [83,134,135].
The HIF system acts as the main regulator of the response to hypoxia, triggering the cascade of mechanisms that permit the tumor to adapt to a hostile environment, and emerges as an important transcription factor in the biology of cancer.

2.3. Hypoxia and prostate cancer aggressiveness: from pathophysiology to clinical biomarkers

[Fraga A et al. Hypoxia and Prostate Cancer Aggressiveness: A Tale With Many Endings. Clin Genitourinary Cancer 2015; 13 (4): 295-301]

Tumors have been reported to possess extensive regions of hypoxia relative to the corresponding normal tissue [96,97]. At least partially, this is due to the rapid proliferation of tumor mass that distances cells from the oxygen carrying vasculature, but is also the consequence of distorted and irregular characteristics of newly formed vessels, ultimately leading to inefficient oxygen transport. It is well established that solid tumors, like prostate cancer, exist under fluctuating oxygen tensions and are exposed to both acute and chronic hypoxia [136-138].

The hypoxic tumor microenvironment correlates with increased tumor invasiveness, metastasis, and resistance to radiotherapy and chemotherapy [97,139-141]. Hypoxia has a detrimental effect on the efficacy of treatment and consequently in the clinical outcomes of patients with prostate cancer, being an independent poor prognostic indicator for patients with prostate and other cancers [97,136].

Over 1% of the genome is transcriptionally responsive to hypoxia, although this varies according to cell type [142]. A large number of endogenous markers of hypoxia which are up-regulated under hypoxic conditions include the vascular endothelial growth factor A (VEGF-A), prolyl hydroxylase 2 (PHD2), inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX-2), carbonic anhydrase IX (CAIX), lysyl oxidase (LOX), hypoxia inducible factor 1a (HIF-1a), hypoxia inducible factor 2a (HIF-2a), glucose transporter 1 (GLUT-1), erythropoietin (EPO), E-cadherin, and angiopoietin 2 (Ang2), among others [60,143,144].

Most of these genes have previously been shown to be upregulated by hypoxia in vitro and in vivo tumor models, resulting in a more aggressive, treatment-resistant phenotype [145-148]. Nonetheless, of all these hypoxia biomarkers, none could adequately predict tumor hypoxia [96], even though a biomarker that could reliably and easily identify a man’s prostate cancer oxygen status would be useful for personalized medicine. Current knowledge suggests that rather than considering individual genes, a panel of genes may provide a more accurate reflection of tumor hypoxia [8,9].

Here, we demonstrate linkage with HIF-1α as a tentative explanatory mechanism of prostate cancer aggressiveness. Hypoxia drives a tale where HIF-1α-dependent

effects lead to many influences in distinct key cancer biology features, rendering targeted therapies the endings less efficient. The most appropriate approach would be to inhibit the upstream common driver (HIF-1α) activity. Additional translational and clinical research initiatives in prostate cancer are required to prove its usefulness.

2.3.1. A common tumor hypoxia-driven mechanism (through HIF-1α), with many pathways and therapeutic implications

The hypoxia-inducible factor induces the transcription of numerous genes involved in multiple functions on hypoxia conditions [138,149,150]. HIF-1α is a heterodimeric transcription factor that is the prototypical hypoxia-associated molecule [40]. It is the master key regulator in the hypoxic response of cells by the activity of prolyl hydroxylase domain and orchestrates the hypoxic response (Figure 6). Usually HIF-1α has a cytoplasmic localization, but under hypoxic conditions it is detected and localized in the nucleus, where it binds to HIF-1β and induces transcription causing up-regulation of effector genes by binding to the hypoxia response element within their promoter regions (Figure 6) [151,152].



Figure 6. Integration of hypoxia with HIF-1α-associated mechanisms in prostate cancer. specifically downstream-activated LOX, VEGF, and CAIX pathways, and emergence of metastatic traits. The hypoxic environment at the growing prostate tumor primary site conducts HIF-1a toward phosphorylation and translocation to the nucleus instead of the usual proteosomal degradation in normoxia. Here, both the stimulus to increase HIF-1a availability and the suppression of PHD activity concur to hamper HIF-1a degradation. Within the nucleus of the malignant cell, this transcription factor initiates the expression of genes (eg, *VEGF*, *LOX*, *CA9*) notable for their role in driving prostate cancer progression and metastasis. Taken together, these molecules are responsible for modulating the tumor microenvironment through recruitment of tumor-associated macrophages (TAMs), promoting angiogenesis (neoangiogenesis with loss of pericytes, contributing to tortuous and permeable vessels), inducing epithelial-to-mesenchymal transition (E-M-T) and metastasis, thus promoting prostate cancer aggressiveness. Abbreviations: CA9, carbonic anhydrase IX; E-M-T, epithelial-to-mesenchymal transition; HIF-1α, hypoxia inducible factor subunit 1 alpha; HIF-1β, hypoxia inducible factor subunit 1 beta; LOX, lysyl oxidase; MAPK, mitogen activated protein kinase; PHD, prolyl hydrolases; PI3K, phosphoinositol-3-kinase; TAM, tumor-associated macrophages; VEGF, vascular endothelial growth factor; VHL, von Hippel-Lindau.

Under hypoxic conditions, HIF-1α induces expression of pro-angiogenic factors and endothelial cell mitogens, eg, vascular endothelial growth factor A (VEGF-A), thus inducing proliferation, sprouting and tube formation of endothelial cells and sustained angiogenesis [153]. Unlike HIF-1α, HIF-2α protein is expressed only in some cell types, can escape degradation, and is transcriptionally active at near-normoxic conditions [154,155]. Still, HIF-2α contributes as HIF-1α to the development of tumor aggressiveness [155,156]. In the prostate, focal HIF-2α expression has been detected in benign neuroendocrinelike and malignant cells [157], being more pronounced in larger prostate tumors [5]. Thus, the role of HIF-2α in hypoxia-associated tumors, particularly prostate cancer, warrants further investigation.

HIF-1α protein has been shown to be increased in prostate cancer tissue sections compared to BPH and to be associated with higher risk for biochemical failure [151,2]. One study reported a trend for higher HIF-1α mRNA expression in prostate cancer versus BPH samples [10]. However, this finding agrees with previous studies showing that HIF-1α is decisively regulated at the posttranslational level [5,158]. Additionally, a direct link between androgen receptors and pro-angiogenic factors may exist, as HIF-1α expression is increased with androgens [5] and decreased in prostatectomy specimen treated with preoperative androgen deprivation therapy [159,2].

Neovascularization is essential for physiologic processes, including in the cancer pathophysiology. In fact, it is well established that tumor growth is associated with increased vascularity [146,160,161]. Mounting evidence from in vitro and in vivo models indicates VEGF is a key regulator of angiogenesis through an effect in endothelial cell growth and proliferation [161]. VEGF binds 2 highly related receptor tyrosine kinases, VEGFR-1 and VEGFR-2. VEGFR-1 expression is upregulated by hypoxia via an HIF-1α dependent mechanism, thereby favouring the activation of VEGF/VEGFR-1 and -2 signalling pathways due to increased availability of both ligand and receptors [162].

It is known that oxygen tension plays a key role in regulating the expression of VEGF [163], whereas VEGF inhibition suppresses pathologic angiogenesis in a wide variety of preclinical models. More specifically, hypoxia may trigger vascular endothelial growth factor (VEGF) expression via the transcription complex of hypoxia-inducible factor HIF-1α (Figure 7). Hypoxia and the consequential

angiogenesis may play a major role in prostate cancer progression [164], as VEGF and HIF-1α is increased in prostate cancer compared to BPH [165,151].

Tumor cells usually have a high rate of glucose uptake accompanied by elevated glucose consumption through the preferential activation of the glycolytic pathway [104]. Several genes involved in glucose uptake and glycolysis (eg, GLUT-1 and most genes coding for enzymes in the glycolytic pathway) have been shown to be targets of HIF-1α [47]. Additionally, HIF-1α activation inhibits mitochondrial metabolism by promoting the expression of pyruvate dehydrogenase kinase 1 to inhibit pyruvate dehydrogenase activity [166], thereby diverting pyruvate to lactate. Noteworthy, despite the decreased flux of glucose-derived pyruvate into the mitochondria, in place of oxidative metabolism, cancers rely on reductive reactions from glutamine carbon [167]. Enhanced lactate production and the production of CO_2 induced by anaerobic conditions contribute to the major acid load in tumor environment. The production of CO_2 induced by anaerobic conditions further contributes to the major acid load in the tumor environment. One of the striking features of cancer cells is their ability to acidify their environment, and the orientation of CAIX suggests that it may serve as one of the mechanisms by which cancer cells regulate extracellular pH and induce cytoplasmic alkalization, playing a role in the adaptation of tumors to hypoxic conditions by regulating the pH of the intracellular and extracellular compartment (Figure 7) [168,169].



Figure 7. Hypoxia-Induced HIF-1α-Driven Modulation of Key Genes and Resulting Biological Effect. During tumor growth, the unavoidable low availability of oxygen in some areas triggers oxygen-sensing mechanisms, notably prolyl hydrolases (PHDs), which regulate HIF-1α activity (if downregulated, or alternatively proteasomal degradation). In addition, mitochondria-mediated use of oxygen produces reactive oxygen species that suppress PHD2 activity, further stabilizing HIF-1α. Alternative hypoxia-independent or -dependent pathways for HIF-1α up-regulation include binding of growth factors (IGF, EGF, TGF) to tyrosine kinase receptors that signal HIF1A transcription through MAPK and PI3K/Akt/mTOR pathways (by up-regulating the transcription factor eIF-4E). Stabilized and active HIF-1α protein enters the nucleus and binds to HIF-1β to form a complex that regulates the expression of key genes that code for proteins with relevant functions in prostate cancer development and progression. Regulation of genes encoding proteins responsible for metabolic reprograming (eg, GLUT1, ALDOA, PGK1, LDH, PDK1, HK1, and HK2 that switch tumor cell toward glycogenolysis as the main source of energy); genes responsible for pH regulation (eg, MCT1, MCT4, and CA9 that alkalinize the intracellular environment); genes involved in tumor cell apoptosis and survival (eg, IGF2, TGFA, BNIP3, CCND1, TP53, and VEGFA, which down-regulate apoptosis while inducing survival);

genes accounting for neoangiogenesis (eg, VEGF, PDGF, ANGPT2, and SERPINE1 that up-regulate sprouting of new tumor vessel; and genes coding for modulators of invasion and metastasis (eg, the proteolytic CTSD, MMP2, and PLAUR, migration inducers TGFA, MET, and LOX, and adhesion molecules E-cadherin and vimentin). Abbreviations: ALDOA, aldolase A gene; ANGPT2, angiopoietin 2 gene; BNIP3, bcl2/adenovirus e1b 19 kDa protein-interacting protein 3 gene; CA9, carbonic anhydrase 9 gene; CAIX, carbonic anhydrase IX; CathpsD, cathepsin D gene; CCND1, cyclin D1 gene; CTSD, cathepsin D gene; ECM, extracellular matrix; EGF, epidermal growth factor; eIF-4E, eukaryotic translation initiation factor 4E; GLUT1, solute carrier family 2 (facilitated glucose transporter) member 1 or SLC2A1 gene; HIF-1α, hypoxia-inducible factor 1 alpha; HIF-1β, hypoxia-inducible factor 1 beta; HK1, hexokinase 1 gene; HK2, hexokinase 2 gene; IGF, insulin growth factor; IGF2, insulin growth factor 2 gene; LDH, lactate dehydrogenase A gene; LOX, lysyl oxidase; LOX, lysyl oxidase gene; MAPK, mitogen activated protein kinase pathway; MCT1, solute carrier family 16 (monocarboxylic acid transporter) member 1 or SLC16A1 gene; MCT4, solute carrier family 16 (monocarboxylic acid transporter) member 1 or SLC16A3 gene; MET, met protooncogene gene; MMP2, matrix metalloproteinase 2 gene; O_2, molecular oxygen; PDGF, platelet-derived growth factor gene; PDHA, pyruvate dehydrogenase A; PDK1, pyruvate dehydrogenase kinase isoenzyme 1 gene; PGK1, phosphoglycerate kinase 1 gene; PHD2, prolyl hydrolase 2; PI3K/mTOR, phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway; PLAUR, plasminogen activator receptor urokinase-type gene; ROS, reactive oxygen species; SERPINE1, serpin peptidase inhibitor member 1 or plasminogen activator inhibitor type 1 gene; TCA, tricarboxylic acid cycle; TGF, transforming growth factor; TGFA, transforming growth factor alpha gene; TP53, tumor protein p53 gene; VEGFA, vascular endothelial growth factor A gene.

The membrane-bound enzyme CAIX catalyzes the reversible conversion of CO_2 to carbonic acid, contributing to the modulation of pH in tumor cells [170]. The CAIX is HIF-dependent and has been shown to be up-regulated in multiple human cancers [170]. A correlation between hypoxia, angiogenesis, HIF-1α, and CAIX in tumors and metastasis has been reported [106], although the involvement of cancer-associated antigen in prostate tumor progression and metastasis through the modulation of pH remains elusive.

Despite being normally expressed in normal tissues, CAIX becomes highly expressed when tumor cell hypoxia occurs in malignancies [171]. CAIX is up-regulated by hypoxia [172], and its gene is a target of HIF-1α (Figure 7) [173]. Interestingly, the degree of CAIX expression was found to be a prognostic factor of poor survival in many cancer types [174-179]. Prostate cancer cell lines can express CAIX during severe hypoxia [180], which is a good marker of hypoxia particularly for androgen-independent cell lines, with reliable increases in *CA9* mRNA expression after hypoxia exposure [10]. Even though initial findings showed an absence of CAIX expression in primary prostate cancers [180,181], others have observed moderate expression in both BPH and malignant prostatic tissue [10]. Thus, the clinical usefulness of CAIX as a diagnostic tool with implications for therapy and patient outcome remains to be elucidated.

The clinical and pathologic heterogeneity found in cancers highly depends on reciprocal interactions between malignant cells and their dynamic microenvironment [1]. The cross-talk between cells and with extracellular matrix (ECM) in tumor microenvironment seems to be critical in many aspects of cancer

development, including maintenance of cancer cell dormancy, cancer progression and metastasis, and drug resistance [1]. The ECM of solid tumors is composed of a complex meshwork of fibrillar collagens, glycoproteins, and proteoglycans [182,183], which affect metastasis, proliferation, angiogenesis, adhesion, migration, invasion, and drug delivery [184,185].

Hypoxia is an important microenvironment factor in the development of cancer, and while HIF-1α has been shown to be the key regulator of the cellular response to hypoxia [1,186], the relationship between tumor hypoxia and components of ECM is far less known. The role of ECM components and remodeling in cancer has only been a focus of research during the last years. Recent findings suggest that hypoxia mediates collagen 1 fiber remodeling in the ECM of tumors, which may impact delivery of macromolecular agents and the dissemination of cells [184,187-189]. Collagen type I is the major structural ECM component in prostate tumors, with cancer cell invasion occurring radially along its fibers [187]. Moreover, cells of myofibroblast phenotype in the reactive stroma of Gleason 3 scored prostate cancers exhibited elevated collagen type 1 synthesis, which was first observed in activated periacinar fibroblasts adjacent to prostatic intraepithelial neoplasia [184]. In a previously described hypoxia gene signature [190], LOX was shown to be directly regulated by HIF-1α and essential for hypoxia-induced metastasis in several cancer models [191,192]. In agreement with this finding, hypoxia-induced cancer cell invasion was severely impaired through inhibition of LOX expression [193,194]. Cancer cell proliferation was stimulated by LOX in a HIF-1α-dependent manner both in vitro and in vivo [194]. Thus, the regulatory circuit between LOX and HIF-1α act in synergy to foster tumor formation in the adaptation of tumor cells to hypoxia (Figure 7).

The LOX family of oxidases oxidizes lysine residues in collagens and elastin, resulting in the covalent cross-linking and stabilization of these ECM structural components, thus providing collagen and elastic fibers with most of their tensile strength and structural integrity [195]. The accurately regulated expression and activity of the LOX family of oxidases are a prerequisite for them to exert critical functions in connective tissue homeostasis. *LOX* mRNA level is highly up-regulated under hypoxic conditions mediated by HIF-1α at the transcriptional level [183]. In addition to the well-documented roles in connective tissue homeostasis, the LOX family of oxidases participates in other critical biological functions, including cell migration, cell polarity, epithelial-to-mesenchymal transition (EMT), and angiogenesis [196-200].

LOX is synthesized as a pro-enzyme (Pro-LOX) from stromal cells, from normal epithelial cells, or from tumor cells under hypoxic conditions, and is secreted where it undergoes extracellular proteolytic processing by pro-collagen C-proteinases to a functional enzyme and a pro-peptide (LOX-PP) [201,202]. Levels of Pro-LOX production in prostate cancer epithelium are decreased as a function of prostate cancer progression [203]. A recent study proposed that Pro-LOX, but not LOX-PP, is a tumor suppressor [204]. Further studies showed that LOX-PP is an active inhibitor of prostate cancer and other tumor cells growth and of RAS-dependent signalling [194,205,206].

Although LOX was initially implicated as a tumor suppressor, now it is accepted as a poor prognosis marker, particularly in promoting metastasis in breast, lung, prostatic, head and neck, and bronchogenic carcinomas [207,208,203,186,191,149]. Cancer invasion is facilitated by stromal collagen reorganization, and this behavior is significantly increased in collagen-dense tissues (Figure 7) [209]. Many ECM modifying enzymes, including matrix metalloproteinases and LOX family oxidases, are aberrantly expressed during malignant transformation, progression, and metastasis of cancers [186].

Lysyl oxidase-like 2 (LOXL2), a LOX oxidase family member, accumulates in the endothelial ECM and regulates sprouting angiogenesis through assembling type IV collagen in the endothelial basement membrane [210]. Therefore, oxidases of the LOX family play roles in cancer progression and metastasis, promoting not only cancer cell migration and invasion but also angiogenesis in concert with pro-angiogenic factors under hypoxia. Furthermore, inhibition of LOXL2 resulted in a marked reduction in activated fibroblasts and endothelial cells, as well as decreased production of growth factors and cytokines [211]. In agreement, a recent report in advanced renal cell carcinoma patients receiving therapy with angiogenesis inhibitors (pazopanib and sunitinib) disclosed an association of a LOXL2 intronic single nucleotide polymorphism (rs4872122) with overall survival, suggesting its potential role as a predictive biomarker for antiangiogenic drugs and as a therapeutic target in cancer [212].

LOX is a potent chemokine inducing directional migration of varied cell types; when it is present, it strongly induces directional migration of cells [186], and it regulates cell polarity and the E-M-T process (Figure 7) [186,194]. Hypoxia represses E-cadherin expression and promotes E-M-T [198,200]. HIF-1α enhanced E-M-T in vitro and induced epithelial cell migration through up-regulation of LOX [198-200,213]. The up-regulated expression of LOX and LOXL2 under hypoxia is required and

sufficient for hypoxic repression of E-cadherin, possibly through stabilization of the SNAIL transcription factor [198,199]. Further studies are warranted to investigate the contribution of individual LOX family members to the induction of E-M-T in the context of dynamic microenvironment during cancer cell invasion and metastasis.

3.1. Clinical study 1

[Fraga A et al. The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration. Eur J Cancer 2014; 50: 359-65]

3.1.1. Summary

The hypoxia inducible factor 1 alpha (HIF1α) is a key regulator of tumour cell response to hypoxia, orchestrating mechanisms known to be involved in cancer aggressiveness and metastatic behaviour.

In this study we sought to evaluate the association of a functional genetic polymorphism in *HIF1A* with overall and metastatic prostate cancer (PCa) risk and with response to androgen deprivation therapy (ADT). The *HIF1A* +1772 C>T (rs11549465) polymorphism was genotyped, using DNA isolated from peripheral blood, in 1490 male subjects (754 with prostate cancer and 736 controls cancer-free) through Real-Time PCR. A nested group of cancer patients who were eligible for androgen deprivation therapy was followed up. Univariate and multivariate models were used to analyse the response to hormonal treatment and the risk for developing distant metastasis. Age-adjusted odds ratios were calculated to evaluate prostate cancer risk.

Results showed that patients under ADT carrying the *HIF1A* +1772 T-allele have increased risk for developing distant metastasis (OR, 2.0; 95%CI, 1.1–3.9) and an independent 6-fold increased risk for resistance to ADT after multivariate analysis (OR, 6.0; 95%CI, 2.2–16.8). This polymorphism was not associated with increased risk for being diagnosed with prostate cancer (OR, 0.9; 95%CI, 0.7–1.2).

The *HIF1A* +1772 genetic polymorphism predicts more aggressive prostate cancer behaviour, supporting the involvement of HIF1a in prostate cancer biological progression and ADT resistance. Molecular profiles using hypoxia markers may help predict clinically relevant prostate cancer and response to ADT.

3.1.2. Overview and methods

Currently, only incipient but scarce markers help to predict whether PCa will be an aggressive, fast growing disease or an indolent slow growing type of cancer [214]. The hypoxia inducible factor 1 alpha (HIF-1α) is a transcription factor coded by the *HIF1A* gene that regulates cellular response to hypoxia [215,216], inducing cancer progression through activation of many genes involved in regulatory cancer

biology (angiogenesis, cell metabolism, cell survival, and epithelial-to-mesenchymal transition) [217]. The *HIF1A* gene harbours several SNPs, including a C-to-T substitution at locus +1772 that result in aminoacid modification (proline by serine). Previous in vitro studies showed higher transcriptional activity of the variant allele under both normoxic and hypoxic conditions [217,215], whereas additional research associated this SNP with increased tumour microvessel density [215,217,120].

In prostate cancer, the few molecular epidemiology studies in this SNP were conducted in distinct ethnic populations and clinicopathological characteristics, leading to conflicting results [218-220]. Furthermore, the association of *HIF1A* +1772 C>T with prostate cancer progression, metastasis and refractoriness to androgen deprivation therapy (ADT) merits further evaluation in larger series of patients. In the present study we sought to analyse the association of the functional SNP +1772 C>T in *HIF1A* with PCa using prostatic biopsy-proven controls, and to predict the response to treatment in men receiving ADT.

Histologically confirmed prostate cancers (n = 754) or non-cancers (n = 736) were included in a case-control study. Patients were recruited from five Hospitals in Portugal between 1990 and 2009: Portuguese Institute of Oncology – Porto Centre, S. João Hospital, Porto Military Hospital, Porto Hospital Centre, and Central Lisbon Hospital Centre. The study was approved by hospital's research ethics committees and consent obtained from participants. The non-PCa control group comprises men referred for prostate biopsy, but with normal or benign prostatic histology. Patients with highgrade prostatic intraepithelial neoplasia or a biopsy suspicious of cancer were excluded. A nested sample of subjects from the group of PCa patients (those eligible for androgen deprivation therapy, ADT, (n = 429) was followed up for several years. These patients were submitted to orchiectomy or luteinising hormone releasing hormone agonist (LHRHa) (with or without anti-androgen) immediately after diagnosis or after relapsing from surgery/radiotherapy. Resistance to ADT was defined as the time from ADT initiation to two consecutive rises of PSA greater than the PSA nadir or progression of bone lesions [221,222].

The white cell fraction of blood samples was used to extract DNA (QIAmp DNA Blood Mini Kit, Qiagen). The *HIF1A* +1772 C>T (rs11549465) genetic polymorphism was genotyped by Real-Time PCR using a pre-designed validated Taqman assay (Applied Biosystems). Procedures implemented for quality control included double sampling in about 5% of samples and the use of negative controls in every run.

3.1.3. Results

One-thousand four hundred ninety individuals were included in this study, 736 cancer-free controls and 754 with a positive biopsy for prostate cancer (median age, 66.8 and 68.0 years old, respectively, p = 0.001). Biopsy findings in the control cancer-free group revealed normal histology (10.9%), benign prostatic hyperplasia (33.4%), chronic prostatitis (55.2%) and atrophy (0.5%). As expected, PCa patients presented significantly higher serum PSA levels at diagnosis (p < 0.0001). *HIF1A* +1772 (rs11549465) genotype distributions by group and risk analysis is shown in Table 3.

Table 3. *HIF1A* +1772 genotype distribution and risk for prostate cancer

		Prostate cancer			
	Control	All		High-grade (Gleason<7)	
HIF1A genotypes	N	N	aOR (95%CI)	N	aOR (95%CI)
Additive model					
CC	566	579	Referent	333	Referent
CT	156	164	1.0 (0.8-1.3)	83	0.9 (0.7-1.2)
TT	14	11	0.9 (0.4-2.1)	7	1.0 (0.4-2.5
Dominant model					
CC	566	579	Referent	333	Referent
T carriers	170	175	1.0 (0.8-1.3)	90	0.9 (0.7-1.2)

aOR (95%CI), age-adjusted odds ratios and the respective 95% confidence intervals

Both additive and dominant genetic models were not associated with prostate cancer risk or high grade disease. The distribution of *HIF1A* +1772 C>T genotypes among the non-cancer control subjects were in agreement with Wardy–Weinberg equilibrium (p = 0.988). Furthermore, we found that this SNP was not associated to earlier onset of disease, using Kaplan–Meier plots and functions (data not shown). In the group of prostate cancer patients, analyses of the association between *HIF1A* +1772 genetic variants and patient's clinicopathological characteristics showed over-representation of T-allele in the group of patients not treated with definitive therapy (p = 0.05) and who developed metastasis at any time during the course of malignant disease (Table 4).

Table 4. Genotype distribution in PCa subjects (n=754) according to clinicopathological characteristics

	HIF1A +1772 C>T genotypes			
	CC (n=579)	CT (n=164)	TT (n=11)	p
Definitive therapy				
No	228 (75.0)	69 (22.7)	7 (2.3)	
Yes	281 (78.5)	76 (21.2)	1 (0.3)	0.05*
Clinical stage				
Localized	262 (78.9)	67 (20.2)	3 (0.9)	
Advanced	222 (76.0)	66 (22.6)	4 (1.4)	0.639*
Gleason score				
< 7	177 (75.0)	56 (23.7)	3 (1.3)	
≥ 7	333 (78.7)	83 (19.6)	7 (1.7)	0.443*
Tumor percent[a]	17.0 (6.0-40.0)	20.0 (5.0-38.5)	65.0 (50.0-80.0)	0.185**

Data are presented as number of cases and respective percentage.
[a] Median (interquartile range). * Chi-square test; ** Kruskal-Wallis test.
Columns do not sum up because of missing data.

From the group of 754 patients with prostate cancer, 429 were eligible for androgen deprivation therapy, either due to advanced disease at diagnosis or due to disease progression. The clinicopathological characteristics of this nested group are shown in Table 5.

Table 5. Clinicopathological characteristics features of the group of patients under ADT (n=429)

	n (%)
Age at diagnosis, yrs	
Median (IQR)	70.0 (64.9-75.4)
PSA at diagnosis, ng/ml	
Median (IQR)	19.0 (8.9-51.6)
Gleason score	
<7	128 (32.2)
≥ 7	269 (67.8)
Clinical stage	
Localized	156 (38.7)
Advanced	247 (61.3)
Metastasis at ADT initiation	
No	286 (75.9)

Yes	91 (24.1)
Definitive therapy	
No	299 (69.7)
RP/RT	130 (30.3)
ADT pharmacological group	
aLHRH alone	91 (21.2)
aLHRH + antiandrogen	338 (78.8)

ADT, androgen deprivation therapy; aLHRH, luteinising hormone releasing hormone agonist; RP/RT, radical prostatectomy/radiotherapy; IQR, interquartile range

From the group of patients on ADT, 194 (45.2%) developed resistance to hormonal therapy. The median (95%CI) follow up time was 91.8 (79.8–103.7) months. Univariate age-adjusted empirical time-to-ADT resistance analysis on clinical covariates showed that Gleason grade > 7 (HR, 2.8; 95%CI, 2.0–4.1), advanced clinical stage (HR, 3.7; 95%CI, 2.5–5.3), definitive treatment (HR, 0.6; 95%CI, 0.4–0.8), PSA > 20 ng/ml (HR, 1.9; 95%CI, 1.5–2.6) and presence of metastasis at ADT initiation (HR, 2.9; 95%CI, 2.1–3.9) were all significantly associated with resistance to ADT. The associations between HIF1A +1772 C>T genotypes and the time-to-event age-adjusted univariate and multivariate analyses are shown in Table 6.

Table 6. Association of *HIF1A* +1722 C>T polymorphism with resistance to ADT

	Resistance to ADT				
		Univariate		Multivariate*	
HIF1A +1722 C>T	LR	HR (95%CI)	p	HR (95%CI)	p
Additive model	2.24				
CC		Referent		Referent	
CT		0.8 (0.6-1.2)	0.288	1.0 (0.7-1.5)	0.918
TT		1.8 (0.7-4.6)	0.183	6.1 (2.2-17.0)	0.001
Dominant model	2.70				
CC		Referent		Referent	
T carriers		0.9 (0.6-1.2)	0.460	1.1 (0.8-1.7)	0.536
Recessive model	3.86				
C carriers		Referent		Referent	
TT		1.9 (0.8-4.8)	0.149	6.0 (2.2-16.8)	0.001

LR, likelihood ratio; ADT, androgen deprivation therapy; HR, hazard ratio; 95%CI, 95% confidence interval. * Cox regression using as covariates: Gleason grade, clinical stage, PSA ≥ 20 ng/ml, definitive therapy and existence of metastasis at the time of hormonal castration initiation.

Although we have not found association of HIF1A +1772 C>T polymorphism with resistance to ADT on univariate analysis, in the recessive model the T homozygous genotype was associated with a 6-fold higher risk for developing resistance to ADT, after adjustment for relevant clinicopathological variables (Gleason grade, clinical stage, PSA > 20 ng/ml, definitive therapy and existence of metastases at the time of hormonal castration initiation) (Table 6). The risk of developing metastasis at any time during the course of disease in patients under ADT was significantly higher for T-allele carriers, still after adjustment for other clinical covariates (Gleason grade, clinical stage and PSA > 20 ng/ml) (Table 7).

Table 7. Risk for metastasis in patients receiving androgen deprivation therapy

	Univariate analysis*			Multivariate analysis**		
HIF1A +1722	n	OR (95%CI)	P	n	OR (95%CI)	p
Additive model	380			323		
CC		Referent			Referent	
CT		1.7 (1.0-2.7)			1.9 (1.0-3.6)	
TT		3.5 (0.6-19.4)	0.055		14.9 (1.0-223.1)	0.031[a]
Dominant model	380			323		
CC		Referent			Referent	
T carriers		1.7 (1.1-2.8)	0.023		2.0 (1.1-3.9)	0.027
Recessive model	380			323		
C carriers		Referent			Referent	
TT		3.1 (0.6-17.1)	0.199		12.9 (0.9-190.1)	0.063

[a] *p* for trend. OR (95%CI), odds ratio with 95% confidence interval.
* Age-adjusted ORs.
** Multivariate logistic regression analysis using Gleason grade, clinical stage and PSA ≥ 20 ng/ml as covariates.

3.1.4. Discussion

Hypoxia is a frequent event during prostate cancer progression, while the hypoxia-responsive gene *HIF1A* codes for a key transcription factor that has been proposed as a modulator of PCa initiation and progression [85,151,223]. We analysed a functional SNP (+1772 C>T) in the *HIF1A* gene in prostate cancer patients and controls and found lack of association, although a relatively large population with approximately 1500 men was analysed. Concordantly, two large case-control studies from the United States of America and China also observed no risk for having PCa in carriers of this polymorphism [224,220], even though

opposite results have been also reported [218,225]. The C-by-T substitution in the +1772 locus at the oxygen-dependent domain of the *HIF1A* gene results in a proline-to-serine substitution and was shown to stabilise *HIF1A* and enhance its activity as a transcription factor in both normoxia and hypoxia [215,226]. In agreement, albeit we hypothesised those carriers of T allele were more susceptible to have cancer, our data, together with other, suggest no influence in earlier stages of prostate cancer development. As PCa natural history usually reveals slow growing indolent tumours, the initial steps of carcinogenesis are not likely to be relevant sources of hypoxia, thereby inducing the activation of other than the HIF-1α pathway. Actually, a previous report found that *HIF1A* +1772 C>T genotypes were not correlated with HIF-1α and VEGF expression in localised prostatic tumours [218]. However, HIF-1α overexpression has been reported in cancer precursor lesions, high grade prostate intraepithelial neoplasia, and early stage PCa, compared with normal prostate epithelium [151].

Previous studies have shown overexpression of HIF-1α in many tumours with advanced grade, implying HIF-1α as an independent prognostic factor in cancer [120]. In addition, increasing evidence suggests that genetic markers may be independent predictors of outcome in PCa with various SNPs predicting decreased progression-free and overall survival [227-229]. Data presented here show that the homozygous T genotype and T-allele of *HIF1A* +1772 C>T is associated with increased relapsing after ADT, whereas the T allele is prone to higher risk for having distant metastasis, still after adjustment for empirical covariates (adjusted by Gleason grade, clinical stage and PSA > 20 ng/ml for the risk of metastasis; and by Gleason grade, clinical stage, PSA > 20 ng/ml, definitive therapy and existence of metastases at the time of hormonal castration initiation for the risk of disease recurrence after ADT). While the recessive model (TT versus CT/CC) was significantly associated with resistance to ADT, the dominant (TT/CT versus CC) and additive models were significant for metastasis development under ADT. A recently published meta-analysis suggests that both the T allele and TT genotype were significantly associated with increased cancer risk [230]. Experimental data also support a functional role for the C-by-T substitution at the allele and homozygous genotype level [215,226,231]. We found that additivity was better fitted for metastasis but not to ADT resistance, even though the low number of patients carrying the TT genotype in metastasis analyses yielded a very wide CI, hence deserving careful interpretation.

Our findings in a large cohort of patients that received ADT, support a role for HIF-1α in the pathophysiology of castration resistance and the *HIF1A* +1772 C>T polymorphism as a potential pharmacogenomics predictor of the response to ADT. Concordantly, a recent study demonstrated that HIF1a expression contributed both to metastasis and chemo-resistance of castration resistant prostate cancer [232]. A study comparing *HIF1A* +1772 C>T genotypes between castration-resistant PCa and non-cancer men showed that the T-allele was overrepresented in the cancer group, although it was not associated with survival [219]. Noteworthy, this report presents data from 196 castration-resistant patients using univariate analysis. Another study observed a somatic rare mutation at the same locus in 1/15 androgen-independent prostate tumours, whereas functional studies demonstrated in androgen-independent prostate cancer cells that the T-allele is associated with increased transcriptional activity and protein expression [226]. Therefore, we hypothesise that carrying the T-allele, which stabilises HIF-1α protein and upregulates the *HIF1A* gene expression, may offer a selective advantage to androgen-independent tumour cells through the upregulation of several genes involved in metastasis, angiogenesis, epithelial-to-mesenchymal transition or in other cancer-associated mechanisms [138,85,233-235]. The SNP in *HIF1A* at locus +1772 represents a germline variant, suggesting a cumulative impact of higher HIF-1α expression since birth. However, we hypothesise that *HIF1A* +1772 functional SNP repercussion when combined with hypoxic environmental events or with other genetic risk factors is triggered to higher extent in response to hypoxia-inductive treatments such as ADT. When confirmed in larger and independent samples, additional therapeutic schemes (such as CYP17A1 inhibitors or chemotherapy) could be offered to carriers of the poor responder TT genotype as alternative to ADT. These patients could also be enrolled in clinical trials with drugs that target HIF-1α function (e.g. tasquinimod and other agents that target HIF-1α or its downstream products) [236-239].
Present findings should be further extended and replicated by future studies focusing on genetic polymorphisms as predictors of treatment response to allow tailored therapy in PCa patients. Using this focused candidate gene approach to evaluate the *HIF1A* +1772 C>T SNP gives us an incomplete analysis of hypoxia mechanism. Other hypoxia-related SNPs were not included in this study. However, our study has several strengths such as the selection of the candidate gene based on biological evidence of functional importance; statistical analyses accounted for relevant clinical and pathological factors. In this study all men (including the

controls) were screened for prostate cancer based on both PSA level and digital rectal exam during the recruitment period and diagnosis was determined by standard biopsy or surgical sample, thus making outcome misclassification unlikely.

Our findings suggest that the *HIF1A* +1772 C>T might be a useful marker of aggressive PCa, particularly a predictor of the response to ADT, thus a plausible candidate to include in a panel of risk prediction SNPs in combination with clinical and pathologic features.

3.2. Clinical study 2

[Ribeiro R, Monteiro CP, Azevedo A, Cunha V, Ramanakumar AV, Fraga A, Pina F, Lopes C, Medeiros R, Franco EL. Performance of an Adipokine Pathway-Based Multilocus Genetic Risk Score for Prostate Cancer Risk Prediction. PLoS ONE 2012; 7 (6): e39236]

3.2.1. Summary

Few biomarkers are available to predict prostate cancer risk. Single nucleotide polymorphisms (SNPs) tend to have weak individual effects but, in combination, they have stronger predictive value. We used a candidate pathway approach to investigate 29 functional SNPs in key genes from relevant adipokine pathways in a sample of 1006 men eligible for prostate biopsy, which included data from putative functional SNPs from the *VEGF/KDR* pathway, since VEGF is produced in adipose tissue and VEGFR2 expressed in tumors and surrounding vessels. We used stepwise multivariate logistic regression and bootstrapping to develop a multilocus genetic risk score by weighting each risk SNP empirically based on its association with disease. Seven common functional polymorphisms were associated with overall and high-grade prostate cancer (Gleason≥7), whereas three variants were associated with high metastatic-risk prostate cancer (PSA≥20 ng/mL and/ or Gleason≥8). All the examined SNPs in *VEGF* (3 SNPs) and *KDR* (1 SNP) genes did not reach significance in association analysis, therefore they were not further included in multilocus genetic risk analyses. Nevertheless, the addition of genetic variants to age and PSA improved the predictive accuracy for overall and high-grade prostate cancer, using either the area under the receiver-operating characteristics curves (P<0.02), the net reclassification improvement (P<0.001) and integrated discrimination improvement (P<0.001) measures. These results suggest that functional polymorphisms in adipokine pathways may act individually and cumulatively to affect risk and severity of prostate cancer, supporting the influence of adipokine pathways in the pathogenesis of prostate cancer.

3.2.2. Overview and methods

Prostate cancer is a complex and unpredictable disease, with risk being affected by advancing age, ethnic background and family history. Although the causes of prostate cancer are not yet fully understood, genetic variation influences disease risk [240].

Many prostatic biopsies are unnecessary [241], which underscores the need for better prediction models with increased specificity to aid clinicians decide whether

or not to recommend biopsy. After diagnosis, some cancers are indolent and cause no clinical problems, whereas others progress and may be fatal [38]. Therefore, it is important to search for biomarkers of aggressive clinical outcome. Genetic markers provide good candidates for such a role. Single-nucleotide polymorphisms (SNPs) identified as loci associated with prostate cancer in genome-wide association studies (GWAS) are common but confer only small increases in risk and the mechanisms underlying their association with prostate cancer risk remain unknown [242,243].

Common polymorphisms in adipokine pathways including SNPs in genes coding for VEGF/VEGFR2 pathway are plausible candidates that may help predict prostate cancer susceptibility. In this report, we tested the hypothesis that SNPs in candidate genes involved in adipokine pathways may contribute to prostate cancer susceptibility and aggressiveness in a population of men referred for diagnostic surveillance.

Participants were enrolled after being referred to the urology departments of the participating hospitals for prostatic transrectal ultrasound guided biopsy (8–13 cores), on the basis of abnormal digital rectal examinations and/or single baseline PSA levels over 2.5 ng/mL. We selected a control group of patients with non-prostate cancer (benign prostate hyperplasia [BPH] or chronic prostatitis) from the prospectively enrolled men undergoing prostate biopsy. Prostate pathology and Gleason scores were determined via biopsy. None of the participants had undergone prostate cancer treatment (hormonal castration, surgery, chemotherapy, or radiotherapy). All remaining 1006 eligible Caucasian patients were included for molecular analysis.

Candidate SNPs were selected from the best evidence from published studies and through public databases that provide information on the phenotypic risks. From a total of 29 literature-defined putative functional SNPs in 19 different genes and corresponding to 9 adipokine pathways, 4 SNPs were related with VEGF/VEFR2 pathway (Table 8).

Table 8. Characteristics of SNPs from the VEGF/KDR pathway included in this study

Gene	SNP ID	Substitution	Locus	Region
KDR	rs2071559	T>C	- 604	promoter
VEGF	rs2010963	G>C	+ 405	5'-UTR
VEGF	rs833061	C>T	- 460	promoter
VEGF	rs3025039	C>T	+ 936	3'-UTR

SNP, single nucleotide polymorphism; VEGF, vascular endothelial growth factor gene; KDR, VEGFR2 gene.

SNPs were genotyped using TaqMan allelic discrimination (Applied Biosystems) or polymerase chain reaction - restriction fragment length polymorphism analysis. SNPs in *VEGF* and *KDR* were studied by Taqman.

3.2.3. Results

A total of 449 histologically confirmed prostate cancer and 557 non-prostate cancer patients were included in the analyses. We evaluated the associations between each individual SNP on prostate cancer susceptibility. No association was found for *VEGF* and *KDR* SNPs with overall, high-grade and high-risk for metastasis PCa (Table 9).

Table 9. Age-adjusted Odds Ratios and 95% CI of prostate cancer according to VEGF/KDR pathway polymorphisms

		Age-adjusted ORs					
Genetic	NPC	All PCa		HGPCa[a]		HRPCaM[b]	
Polymorphism	n	n	OR (95%CI)	n	OR (95%CI)	n	OR (95%CI)
KDR -604 T>C							
Additive model							
TT	154	127	Referent	105	Referent	48	Referent
CT	281	215	0.9(0.7-1.2)	177	0.9(0.7-1.3)	72	0.8(0.5-1.3)
CC	122	107	1.1(0.7-1.5)	92	1.1(0.8-1.6)	35	1.0(0.6-1.6)
Dominant model							
TT	154	127	Referent	105	Referent	48	Referent
C carriers	403	322	1.0(0.7-1.3)	269	1.0(0.7-1.3)	107	0.9(0.6-1.3)
Recessive model							
T carriers	435	342	Referent	282	Referent	120	Referent
CC	122	107	1.1(0.8-1.5)	92	1.3(0.9-1.6)	35	1.1(0.7-1.7)
VEGF -460 C>T							
Additive model							
CC	131	114	Referent	99	Referent	46	Referent
CT	274	201	0.9(0.6-1.2)	166	0.8(0.6-1.1)	74	0.8(0.5-1.2)
TT	151	13	1.1(0.8-1.5)	108	1.0(0.7-1.5)	34	0.7(0.4-1.1)
Dominant model							
TT	151	133	Referent	108	Referent	34	Referent
C carriers	405	315	0.9(0.6-1.1)	265	0.9(0.6-1.2)	120	1.2(0.8-1.9)

Recessive model							
T carriers	425	334	Referent	274	Referent	108	Referent
CC	131	114	1.1(0.8-1.4)	99	1.1(0.8-1.5)	46	1.3(0.9-2.0)
VEGF +405 G>C							
Additive model							
GG	251	200	Referent	169	Referent	77	Referent
GC	252	197	1.0(0.8-1.3)	162	1.0(0.7-1.3)	66	0.8(0.6-1.2)
CC	54	50	1.2(0.8-1.9)	41	1.2(0.8-1.9)	10	0.7(0.3-1.4)
Dominant model							
GG	251	200	Referent	169	Referent	77	Referent
C carriers	306	247	1.0(0.8-1.3)	203	1.0(0.8-1.3)	76	0.8(0.6-1.2)
Recessive model							
G carriers	503	397	Referent	331	Referent	143	Referent
CC	54	50	1.2(0.8-1.9)	41	1.2(0.8-1.9)	10	0.7(0.4-1.5)
VEGF +936 G>C							
Additive model							
CC	421	341	Referent	282	Referent	114	Referent
CT	123	100	1.0(0.7-1.3)	87	1.0(0.7-1.4)	39	1.1(0.7-1.6)
TT	11	8	0.9(0.3-2.2)	5	0.7(0.2-2.0)	2	0.7(0.1-3.2)
Dominant model							
CC	421	341	Referent	282	Referent	114	Referent
T carriers	134	108	1.0(0.7-1.3)	92	1.0(0.7-1.3)	41	1.0(0.7-1.6)
Recessive model							
C carriers	544	441	Referent	369	Referent	153	Referent
TT	11	8	0.9(0.4-2.2)	5	0.7(0.2-2.0)	2	0.7(0.1-3.1)

N, number of evaluable patients; SNP, single nucleotide polymorphism; OR (95%CI), age-adjusted odds-ratio and respective 95% confidence interval.

[a] HGPCa,High-grade Prostate Cancer (Gleason grade ≥7)

[b] HRPCaM, High-risk Prostate Cancer for metastasis (Gleason grade≥8 and/or PSA≥20 $ng.mL^{-1}$)

When we estimated the overall mutually-adjusted effects by stepwise multivariate logistic regression, only the SNPs in *LEPR* Gln223Arg, *SPP1*-66 T>G, *IGF1R*+3174 G>A, *IGFBP3*-202A>C, *FGF2*+223C>T and *IL6*-597G>A, plus age and PSA remained independently associated with risk for overall, and for high-grade prostate cancer. The SNPs in VEGF/KDR analysed didn't reach significance for inclusion in the risk score.

The inclusive (age and PSA added to the multi-locus genetic set) linear risk scores computed on the basis of the above logistic regression models were tested using goodness of fit, were significantly greater than for the models based on the restricted age plus PSA score, for all prostate cancers (P=0.0002) and high-grade prostate cancers (P=0.0001), after likelihood ratio test and confirmed via the net reclassification improvement (NRI) and integrated discrimination improvement (IDI) comparisons.

3.2.4. Discussion

Functional SNPs in genes coding for molecules involved in adipokine pathways may modulate the expression, transport, or signaling of adipokines, thereby influencing prostate cancer risk and biology. Our findings show that SNPs in genes from adipokine pathways (leptin, interleukin-6, fibroblast growth factor 2, osteopontin, and insulin growth factor) may influence the development of prostate cancer and aggressive disease. Nevertheless, several of the candidate SNPs in adipokine pathways known to affect oncogenesis, investigated here, were not associated with prostate cancer risk. Most of our null results for candidate SNPs, namely in VEGF-460, VEGF+405, VEGF+936, were in agreement with other studies [244-247]. To our knowledge, there have been no prior reports of null associations of KDR-604 and other functional SNPs in other genes with prostate cancer. Although a wealth of evidence demonstrates the effects of individual VEGF on prostate carcinogenesis, it is unlikely that the overall pathophysiological impact is due to the influence of a simple genotypic variation *in vivo*. Here, we showed that consideration of the cumulative susceptibility contributed by SNPs from adipokine pathways helps in risk stratification. Our analyses indicated that the inclusive (age and PSA added to the multi-locus genetic set) risk score provides improvements in discrimination and prediction of all prostate cancer, and high-grade prostate cancer. The effect of the studied SNPs in *VEGF* and *KDR* were not strong enough to be included as risk genotypes in the inclusive model, therefore other more robust genetic markers may cooperate to influence the endocrine and paracrine activity of adipokine pathways that leads to tumor development and progression. However, we cannot exclude that other SNPs in VEGF/KDR pathway may prove to exert a more solid effect in PCa.

3.3. Clinical study 3

[Ribeiro R, Monteiro C, Ramanakumar AV, Guedes A, Francisco N, Ferreira AL, Fraga A, Sousa M, Cunha V, Azevedo A, Maurício J, Lobo F, Pina F, Calais-da-Silva FM, Calais-da-Silva FE, Lopes C, Franco EL, Medeiros R. Inherited variation in adipokine pathway genes may determine prognosis for prostate cancer patients receiving androgen-deprivation therapy. Submitted]

3.3.1. Summary

Androgen deprivation therapy (ADT) is commonly used to treat advanced and recurrent prostate cancer, although prognosis varies widely among individuals. We evaluated whether polymorphisms in adipokine pathway genes may predict clinical outcomes among prostate cancer patients. We enrolled 483 patients who underwent ADT and genotyped them for 27 functional single nucleotide polymorphisms (SNPs) in 17 genes from 9 adipokine pathways, including SNPs from the VEGF/KDR pathway. SNPs were also combined by pathway according to functional characteristics.

The *ADIPOQ* +45 T>G G homozygous carriers were more likely to present biochemical progression and to die than T-allele carriers. Having the *ADIPOQ* +276 G>T G homozygous genotype and the tumor necrosis factor high activation genetic profile were associated with reduced likelihood of resistance to ADT. Presence of the *IL6* -572 G>C C-allele was independently associated with all-cause mortality. The *LEPR* Gln223Arg G-allele variant was associated with a more than twofold increased risk of developing metastasis. The SNPs in VEGF and KDR genes were not associated with any of the clinical outcomes studied after adjustment for other relevant variables. Genetic polymorphisms in specific adipokine pathways might have a clinical role in evaluating prognosis among men treated with ADT, as opposite to the effect of SNPs in VEGF/KDR pathway, either alone or in combination.

3.3.2. Overview and methods

In the last decades, depletion or blockage of androgen action has been the standard of care for men with advanced prostate cancer [248]. Response to treatment is not durable since patients become resistant to ADT, leading to castration-resistance status, an invariably fatal condition [249]. Although mechanisms responsible for prostate cancer cell survival after ADT are not entirely understood, there is evidence that AR-dependent and AR-independent pathways may be implicated [250,251].

While germline DNA polymorphisms in androgen pathways were shown to influence the response to ADT, no study has examined the predictive role of polymorphisms in genes of adipokine pathways on clinical outcomes after ADT initiation. Some functional SNPs in genes encoding molecules of these pathways (e.g. VEGF/KDR among others) have been shown to be associated with prostate cancer risk [244,252-254] and a recent study found that obese men were at increased risk of developing castration-resistant prostate cancer and metastasis [255]. We studied a cohort of prostate cancer patients treated with ADT to examine the prognostic significance of 27 functional adipokine pathway SNPs with risk of metastasis, response to chemical/surgical castration, and all-cause mortality (ACM).

Patients with histopathologically confirmed prostate cancer and treated with ADT between 1990 and 2009 were included in this study (n=483). Patients were recruited from 4 Hospitals in Portugal. ADT consisted of orchiectomy or treatment with luteinizing hormone releasing hormone- agonist (LHRHa) with or without anti-androgen after diagnosis of advanced or metastatic prostate cancer or after relapsing from primary local therapy with curative intent. Hormonal treatment was continued at least until disease progression, based on serum PSA levels, imaging, and clinical findings. The primary endpoint was resistance to ADT, defined as the time from ADT initiation to two consecutive rises of PSA (1 week apart) greater than the PSA nadir (defined as biochemical progression) or progression of bone lesions (new or size increase, soft tissue metastasis, or at least 2 new metastatic spots in bone scintigraphy), despite at least two consecutive hormonal manipulations [221,222]. The secondary endpoints included overall survival, defined as the time from ADT initiation to death from any cause, and appearance of distant metastasis at any time during the course of the disease (identified by x-rays, computed tomography scans or bone scintigraphy), after diagnosis.

Candidate genes involved in adipokine pathways known to affect oncogenesis were selected, including 3 SNPs in *VEGF* and 1 SNP in *KDR* (mentioned in Table 8 of Experimental study 2). A total of 27 literature-defined putative functional SNPs in 17 different genes were chosen, corresponding to 9 adipokine pathways. We also examined combinations of SNPs by adipokine pathway according to their functional implications (Table 10).

Table 10. VEGF/KDR pathway SNPs included in experimental study 3 and the rationale for combined analysis

Pathway	SNPs	Genotypes	Functional outcomes	SNP functional combinations
VEGF/KDR	*KDR* -604	TT	↑signaling	Expression *
		[256]	↑activation	(-460/+405)
	VEGF-460	C carrier	↑expression	Expression **
		[257,258]	↑activation	(-460/+405/+936)
	VEGF+405	GG	↑expression	Activation ***
		[257,258]	↑activation	(-460/+405/KDR)
	VEGF+936	CC	↑expression	Activation ****
		[259]	↑activation	(-460/+405/+936/KDR)

* Expression 2 *VEGF* SNPs (-460/+405, according to ref [257]): *low* vs. *high.*
** Expression 3 *VEGF* SNPs: *high*, -460/+405 high/936 CC; *intermediate*, -460/+405 high/936 T carrier and -460/+405 low/936 CC; *low*, -460/+405 low/936 T carrier.
*** Activation 2 *VEGF* SNPs: *high*, -460/+405 high/*KDR* TT; *intermediate*, -460/+405 high/*KDR* Ccarrier and -460/+405 low/*KDR* TT; *low*, -460/+405 low/*KDR* Ccarrier.
**** Activation 3 *VEGF* SNPs: *high*, high or intermediate expression/*KDR* TT; *intermediate*, high expression/ *KDR* Ccarrier and low expression/ *KDR* TT; *low*, low or intermediate expression/ *KDR* Ccarrier.

Allelic discrimination through Taqman genotyping (Applied Biosystems) or polymerase chain reaction, followed by restriction fragment length polymorphism analysis was used for genotyping.

3.3.3. Results

The median duration between ADT initiation and disease progression was 91.8 months, while the median follow-up from ADT initiation to death or last visit was 126.9 months. Empirical analysis using Cox regression was then performed to evaluate the association of SNPs and their functional combinations with the outcomes of interest.

The genotypes *ADIPOQ* +276 TT/TG, *IL6R* Asp358Ala CC and *ADIPOQ* +45 GG, and the high expression *ADIPOQ* haplotype, low TNFa expression and low/intermediate TNFa activation genetic profiles were significantly associated with biochemical progression under hormonal castration. However, the VEGF and KDR SNPs, either individually or combined, were not associated with resistance to ADT (Table 11).

Table 11. Association of SNPs in genes of adipokine pathways with resistance to ADT

SNPs and combined SNPs	MGF (%)	Resistance to ADT			
		Model	No.	LR	aHR (95%CI)
KDR-604	48	Dominant	463	2.07	1.13 (0.84-1.52)
VEGF+405	38	Dominant	463	3.24	1.20 (0.92-1.58)
VEGF-460	44	Recessive	457	3.90	1.30 (0.95-1.78)
VEGF+936	13	Recessive	440	2.68	1.80 (0.58-5.65)
VEGF expression 2 SNP [1]	---	---	457	2.35	1.16 (0.86-1.55)
VEGF expression, L/I vs H [1]	---	---	436	2.51	1.18 (0.89-1.55)
VEGF activation, L vs I/H [1]	---	---	457	3.77	1.33 (0.93-1.90)
VEGF activation, L/I vs H [1]	---	---	436	2.69	1.19 (0.89-1.59)

ADT, androgen deprivation therapy; No., number of subjects; MGF, minor genotype frequency in the cohort; LR, likelihood ratio; aHR (95%CI), age-adjusted hazard ratio and respective 95% confidence interval; SNP, single nucleotide polymorphism. *KDR*, vascular endothelial receptor 2; *VEGF*, vascular endothelial growth factor. L, low; I, intermediate; H, high.

Moreover, the *IL6R* Asp358Ala CC and *ADIPOQ* +45 GG, *IL6*-572 C carriers and high VEGF activation 2SNPs were associated with shorter time to ACM following ADT (Table 12). A 62% higher risk for all-cause mortality was associated with carrying high/intermediate activation of VEGF/KDR pathway (combined *VEGF*-460/*VEGF*+405/*KDR*-604).

Table 12. Association of SNPs in genes of adipokine pathways with all-cause mortality

SNPs and combined SNPs	MGF (%)	All-cause mortality			
		Model	No.	LR	aHR (95%CI)
KDR-604	48	Recessive	468	16.29	1.16 (0.80-1.68)
VEGF+405	38	Recessive	468	16.87	1.28 (0.83-1.96)
VEGF-460	44	Recessive	462	13.85	1.14 (0.77-1.68)
VEGF+936	13	Dominant	445	18.24	1.23 (0.83-1.83)
VEGF expression 2 SNP	---	---	462	13.43	1.02 (0.72-1.45)
VEGF expression, L/I vs H	---	---	441	15.93	1.07 (0.77-1.49)
VEGF activation, L vs I/H	---	---	462	18.51	1.62 (1.09-2.41)
VEGF activation, L/I vs H	---	---	441	17.24	1.28 (0.87-1.88)

ADT, androgen deprivation therapy; No., number of subjects; MGF, minor genotype frequency in the cohort; LR, likelihood ratio; aHR (95%CI), age-adjusted hazard ratio and respective 95% confidence interval; SNP, single nucleotide polymorphism. *KDR*, vascular endothelial receptor 2; *VEGF*, vascular endothelial growth factor. L, low; I, intermediate; H, high.

A significant relation with increased risk for developing distant metastasis was observed in the *LEPR* Gln223Arg G carriers, *LEPR* Lys109Arg homozygous G carriers, *TNFRSF1A* -329 G carriers, and for the high/intermediate LEPR signaling genetic profiles, but not with *VEGF* or *KDR* genetic polymorphisms.
The predictive effects of SNPs on time to biochemical progression under hormonal castration and ACM were then evaluated in presence of significant clinicopathological predictors (from Table 1) using Cox regression. Only the effect of *ADIPOQ* +45 and +276 SNPs and of the TNFa activation genetic profile on the response to ADT remained strong after adjustment for clinical factors. Analysis of the secondary endpoint ACM after adjusting for other predictors showed that *ADIPOQ* +45 T>G and *IL6* -572 G>C remained significant predictors. On multivariate logistic regression, patients with the combined high/intermediate LEPR signaling genetic profile remained associated with greater risk of developing distant metastatic disease (OR=3.41, 95%CI: 1.71-6.79).

3.3.4. Discussion

We examined whether germline polymorphisms in adipokine pathways are determinants of the response to ADT. The time to biochemical progression under hormonal castration was influenced by two SNPs in *ADIPOQ* and by combined SNPs in TNFa pathway activation. The predictive ability of *ADIPOQ* +45 extended towards the secondary endpoint ACM, together with *IL6*-572 genetic polymorphism. Additionally, our results also suggest an association of the combined LEPR genetic profile with development of distant metastasis. The combined VEGF/KDR activation genetic profile yielded prognostic relevance only on univariate analysis, thereby revealing lower robustness within the whole adipokine pathway analysis.
Androgen deprivation therapy remains the mainstay treatment for advanced and recurrent prostate cancer [260,221]. The mechanisms responsible for castration-resistant prostate cancer development are not clearly established. Despite obvious interest in AR-dependent pathways, other independent pathways have been described [250,261], in which androgen-refractory cells use alternative survival pathways to overcome the growth inhibition imposed by ADT [250,262]. Adipokine pathways, have been implicated in intracellular signals such as those activated in hormonal castration resistance [263]. Furthermore, mitogenic and anti-apoptoptic

effects of some adipokines (e.g. leptin, IL-6, IGF-1) seem to be limited to androgen-refractory prostate cancer cells [264-266].

Inherited genetic markers have been fairly explored as predictors of prostate cancer outcomes. Although we took a focused candidate gene approach to evaluate the association of key SNPs in adipokine pathways with relevant prostate cancer outcomes in a cohort of patients in ADT, our study has some limitations. Although we included only functional SNPs from genes in adipokine pathways, our SNP panel and SNP combinations could be incomplete. Strengths of our study include the large size and homogeneous population. The long follow-up time allowed analysis of primary and secondary end points with large number of events (46.4% for disease progression under ADT; 32.2% for mortality; 44.9% for metastasis).

3.4. Clinical study 4

[Fraga A, Ribeiro R, Coelho A, Vizcaíno JR, Coutinho H, Lopes JM, Príncipe P, Lobato C, Lopes C, Medeiros R. Putative functional genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer. Submitted]

3.4.1. Summary

In this study we sought if, in their quest to handle hypoxia, prostate tumors express target hypoxia-associated molecules and their correlation with putative functional genetic polymorphisms.

Representative areas of prostate carcinoma (n=51) and of nodular prostate hyperplasia (BPH) (n=20) were analysed for HIF-1α, CAIX, LOX and VEGFR2 immunohistochemistry expression using a tissue microarray. DNA was isolated from peripheral blood and used to genotype functional polymorphisms at the corresponding genes (*HIF1A* +1772 C>T, rs11549465; *CA9* +201 A>G; rs2071676; *LOX* +473 G>A, rs1800449; *KDR* – 604 T>C, rs2071559).

Immunohistochemistry disclosed predominance of positive CAIX and VEGFR2 expression in epithelial cells of prostate carcinomas compared to BPH (P=0.043 and P=0.035, respectively). In addition, the VEGFR2 expression score in prostate epithelial cells was higher in organ-confined and extra prostatic carcinoma compare to BPH (P=0.031 and P=0.004, respectively). Notably, for LOX protein the immunoreactivity score was significantly higher in organ-confined carcinomas compare to BPH (P=0.015). The genotype-phenotype analyses showed higher LOX staining intensity for carriers of the homozygous *LOX +473* G-allele (P=0.011), and that *KDR* -604 T-allele carriers were more prone to have higher VEGFR2 expression in prostate epithelial cells (P<0.006).

The expression on prostate epithelial cells of target molecules in hypoxia pathways analysed here (VEGFR2, CAIX and LOX) allowed differentiating malignant from benign prostate disease. Two of the genetic polymorphisms (*LOX* +473 G>A and *KDR* – 604 T>C), account for a potential gene-environment effect in the activation of hypoxia-driven pathways in prostate carcinoma. Further research in larger series is warranted to validate present findings.

3.4.2. Overview and methods

During tumor growth, the oxygen supply and nutrients scarcity urges malignant cells to signal to the microenvironment their needs. The hypoxia inducible factor 1 alpha (HIF-1α) is a key factor by which tumors regulate the

response to hypoxia, triggering cascades with pro-tumoral effects [138,147]. HIF-1α mechanism implies targeting hypoxia response elements in promoters of downstream target genes, notably vascular endothelial growth factor (*VEGF)*, carbonic anhydrase IX (*CA9)*, and lysyl oxidase (*LOX)* promoters, resulting in more aggressive, treatment resistant phenotype [138,147,10]. In prostate carcinoma, a large study has demonstrated the relevance of intrinsic markers of tumor hypoxia for localized disease and outcome of radical treatment [2].

Recent findings indicate that genetic variants may modulate the predisposition for prostate carcinoma and associate with clinical outcome [214,267]. Single nucleotide polymorphisms (SNPs) in genes coding for molecules involved in the response to hypoxia, particularly a functional polymorphism in *HIF1A* gene at locus +1772 C>T [9,231,218,219,226,224,220], has been studied in association with prostate carcinoma with controversial results. However, we are not aware of studies implicating SNPs in other genes (e.g. *LOX*, *CA9*, *KDR)* of HIF-1α-mediated hypoxia downstream pathways.

Based on the role of hypoxia-associated molecules in cancer, we hypothesized an association, at the genetic and protein level, between *HIF1A*, *LOX*, *CA9* and *KDR* genetic variants, the protein expression and prostate carcinoma.

Seventy-one patients with prostate pathology (n=51 with carcinoma, and n=20 with nodular hyperplasia, BPH) were included, after informed consent and approval by hospitals' ethical committees. Patient's clinicopathological data (Table 13) was collected from clinical files and pathological staging determined as organ-confined (T1-T2) (OCPCa) or extra prostatic (T3-T4) (EPCa) disease.

Table 13. Descriptive clinicopathological data of participating patients

	BPH	OCPCa	EPCa
Age at diagnosis, yrs	67.8 ± 8.4	61.3 ± 6.4	63.3 ± 6.3
PSA at diagnosis, ng/mL	5.5 ± 5.1	6.6 ± 2.4	11.9 ± 5.6
Weight of the prostate, g	94.8 ± 32.1	45.9 ± 14.3	56.6 ± 22.7
Gleason Score			
< 7	-	14 (43.8)	0 (0.0)
≥ 7	-	18 (56.3)	19 (100)
Percentage of tumor *, %	-	15.0 (6.3 – 20.0)	57.0 (28.8 - 78.8)

Descriptive data of continuous variables is presented as mean ± standard deviation, except for percentage of tumor [data shown as median (interquartile range)]. Categorical variable is depicted as number of observations and respective frequencies. BPH, prostate nodular hyperplasia; EPCa, extra prostatic cancer; OCPCa, organ-confined prostate carcinoma; PSA, prostate specific antigen. * on prostatectomy specimens.

The white cell fraction from peripheral blood was used to extract DNA (QIAmp DNA Blood Mini Kit, Qiagen). Four putative functional SNPs (3 non-synonymous and 1 in the promoter region) in 4 candidate genes involved in key hypoxia pathways were selected (*HIF1A* +1772 C>T, rs11549465; *CA9* +201 A>G, rs2071676; *LOX* +473 G>A, rs1800449; *KDR* -604 T>C, rs2071559). Genotyping was done by Real-Time PCR using Taqman ssays (Applied Biosystems).

Representative areas of carcinoma and of nodular hyperplasia were selected and included into tissue microarray as previously described [268]. Slides were stained with anti-HIF-1α (Novus Biologicals), anti-LOX, (Abcam), anti-VEGFR2 (Abcam) and anti-CAIX, (Novus Biologicals) and immunohistochemical evaluation was independently reviewed by two pathologists. Qualitative and quantitative measurements were made for VEGFR2 expression in vasculature and prostate epithelial cells, and HIF-1α, LOX and CAIX in prostate epithelial cells, for both carcinoma and nodular hyperplasia. VEGFR2 intensity was multiplied by the percentage of tumor cells at that intensity level (VEGFR2 H-score); for LOX the score was calculated by multiplicating the percentage of positive cells with staining intensity (LOX immunoreactivity score, IRS). A representative image of the expression of each aforementioned protein is shown in Figure 8.

Figure 8. Representative microscopy images of staining for hypoxia markers in prostate tissues (MO, 400x)



A) HIF-1α - notice the granular cytoplasmic immunoreactivity of the malignant epithelial cells. In this case, more than 50% of the glands stained. B) LOX - strong and diffuse nuclear immunoreactivity of the epithelial cells. C) CAIX - note a focal apical cytoplasmic immunoreactivity in epithelial cells. D) VEGFR2 - moderate nuclear and weak cytoplasmic expression of the epithelial cells

3.4.3. Results

Epithelial cells staining positivity for CAIX and VEGFR was significantly higher in prostate carcinomas compared with BPH (P=0.043 and P=0.035, respectively) (Figure 9). Concurrently, despite non-significant, both HIF-1α and LOX immunoreactivities had a tendency to be elevated in carcinomas (P=0.111 and P=0.266, respectively) (Figure 9).

Figure 9. Frequency of patients with positive staining in benign and malignant epithelial cells



CAIX, carbonic anhydrase IX; HIF-1α, hypoxia inducible factor - 1 alpha; LOX, lysyl oxidase; VEGFR2, vascular endothelial growth factor receptor 2. BPH, nodular prostate hyperplasia; EP, extra prostatic disease; OC, organ-confined disease.

Notably, although not significantly more expressed in prostate carcinomas, the LOX IRS, was significantly more elevated in organ-confined carcinomas than BPH (P=0.015) (Figure 10), and higher in patients with positive HIF-1α expression (P=0.053) (Figure 11).

Figure 10. Comparison of LOX immunoreactivity score in prostate epithelial cells of benign and malignant patients.



BPH, nodular prostate hyperplasia; EP, extra prostatic disease; OC, organ-confined disease. LOX, lysyl oxidase; IRS, immunoreactivity score. Kruskall-Wallis followed by Mann-Whitney non-parametric tests were used to calculate differences between prostatic pathologies.

Figure 11. LOX immunoreactivity score by HIF-1α positivity in epithelial cells



Patients with positive HIF-1α expression are prone to higher LOX IRS. HIF-1α, hypoxia inducible factor – 1 alpha; LOX, lysyl oxidase. IRS, immunoreactivity score. Mann-Whitney non-parametric test was used to calculate differences between positive and negative HIF-1α expression.

VEGFR2 immunoreactivity was observed in vascular endothelial cells (only in 20% of all samples) and epithelial cells (70% of patients with extra prostatic carcinomas and approximately half of organ-confined carcinomas). Noteworthy, the VEGFR2 H-score in epithelial cells was statistically distinct between BPH and organ-confined or extra prostatic carcinomas (P=0.031 and P=0.004, respectively) (Figure 12).

Figure 12. Expression of VEGFR2 (H score) in prostate epithelial cells according to prostatic diseases



BPH, nodular prostate hyperplasia; EP, extra prostatic disease; OC, organ-confined disease. VEGFR2, vascular endothelial growth factor receptor 2. Kruskall-Wallis followed by Mann-Whitney non-parametric tests were used to calculate differences between prostatic pathologies.

The genotypic distribution in polymorphisms *HIF1A* +1772 C>T, *LOX* +473 G>A, *CA9* +201 A>G and *KDR* -604 T>C is shown in Table 14. There was no over-represented genotype in disease groups.

Table 14. Genotypic distribution of functional SNPs in genes of hypoxia pathways by disease status using additive and recessive models analyses

	Prostatic disease status			
HIF1A +1772 C>T genotypes	BPH	OCPCa	EPCa	P *
Additive model				
CC	10 (0.59)	23 (0.82)	14 (0.78)	
CT	5 (0.29)	5 (0.18)	4 (0.22)	
TT	2 (0.12)	0 (0.0)	0 (0.0)	0.144
Recessive model				
CC	10 (0.59)	23 (0.82)	14 (0.78)	
TT/CT	7 (0.41)	5 (0.18)	4 (0.22)	0.205
LOX +473 G>A genotypes				
Additive model				
GG	6 (0.71)	16 (0.55)	13 (0.72)	
GA	2 (0.29)	11 (0.38)	4 (0.22)	
AA	0 (0.0)	2 (0.07)	1 (0.06)	0.740
Recessive model				
GG	6 (0.71)	16 (0.55)	13 (0.72)	
AA/GA	2 (0.29)	13 (0.45)	5 (0.28)	0.442
CA9 +201 A>G genotypes				
Additive model				
GG	3 (0.38)	9 (0.31)	5 (0.29)	
GA	5 (0.62)	18 (0.62)	10 (0.59)	
AA	0 (0.0)	2 (0.07)	2 (0.12)	0.882
Recessive model				
GG	3 (0.38)	9 (0.31)	5 (0.29)	
GA/AA	5 (0.62)	20 (0.69)	12 (0.71)	0.918
KDR -604 T>C genotypes				
Additive model				
CC	6 (0.33)	8 (0.26)	3 (0.17)	
CT	8 (0.45)	15 (0.48)	13 (0.72)	
TT	4 (0.22)	8 (0.26)	2 (0.11)	0.436
Recessive model				
CC	6 (0.33)	8 (0.26)	3 (0.17)	
TT/CT	12 (0.67)	23 (0.74)	15 (0.83)	0.515

* Fisher exact test. BPH, nodular prostate hyperplasia; OCPCa, organ-confined prostate carcinoma; EPCa, extra prostatic carcinoma. *CA9*, carbonic anhydrase IX gene; *HIF1A*, hypoxia inducible factor 1 alpha gene; *KDR*, vascular endothelial growth factor receptor 2 gene; *LOX*, lysyl oxidase gene.

Regarding genotype-phenotype relation, there was lack of association between *HIF1A* +1772 C>T and *CA9* +201 A>G genotypes with HIF-1α and CAIX protein expression (Table 15).

Table 15. Association of the genetic polymorphisms in *HIF1A* +1772 C>T and *CA9* +201 A>G with HIF-1α and CAIX immunoreactivity in prostatic epithelial cells

	Recessive models (*HIF1A* and *CA9*)		
HIF-1α expression	CC	TT/CT	P *
Negative	28 (0.76)	9 (0.24)	
Positive	10 (0.77)	3 (0.23)	0.928
< 50%	32 (0.74)	11 (0.26)	
≥ 50%	6 (0.86)	1 (0.14)	0.516
CAIX expression	GG	GA/AA	
Negative	9 (0.75)	20 (0.69)	
Positive	3 (0.25)	9 (0.31)	0.699

* Fisher exact test

In contrast, LOX expression was significantly more intense in carriers of the *LOX +473* homozygous G allele compared to AA/AG (P=0.011), despite no significance was achieved for IRS (but with similar trend) (Figure 13). Alongside, *KDR* -604 T-allele carriers were more prone to have VEGFR2 expression in prostate epithelial cells but not in vessels (Table 16). The VEGFR2 H-score was significantly higher in T-allele carriers compared to homozygous C (Figure 14).

Figure 13. LOX protein expression (both for immunoreactivity score and staining intensity) according to *LOX* +473 G>A polymorphism



IRS, immunoreactivity score; *LOX*, lysy oxidase; a.u., arbitrary units.

Figure 14. VEGFR2 protein expression (H score) according to *KDR* -604 T>C polymorphism. *KDR*, gene coding for VEGFR2 protein



VEGFR2, vascular endothelial growth factor receptor 2.

Table 16. Association of the *KDR-604 T>C* genetic polymorphism with VEGFR2 immunoreactivity in vessels and in prostatic epithelial cells

	Additive model				Recessive model		
VEGFR⁺ cells	CC	CT	TT	P *	CC	TT/CT	P *
Vessels							
Negative	11 (0.3)	22 (0.5)	9 (0.2)		11 (0.3)	31 (0.7)	
Positive	3 (0.3)	5 (0.4)	4 (0.3)	0.681	3 (0.3)	9 (0.7)	0.626
Epithelial							
Negative	11 (0.4)	13 (0.5)	4 (0.1)		11 (0.4)	17 (0.6)	
Positive	3 (0.1)	14 (0.5)	9 (0.4)	0.039	3 (0.1)	23 (0.9)	0.030

* Fisher exact test

Only data from prostate carcinomas was used to evaluate if hypoxia proteins associated with Gleason score or PSA>10 ng/mL (Table 17). Statistical trends were observed for higher VEGFR2 H-score expression in more undifferentiated carcinomas (Gleason ≥7) (P=0.099) and in patients with prostate specific antigen (PSA) ≥ 10 (P=0.085), and for positive CAIX expression in prostate carcinomas from patients with PSA above 10 (P=0.078).

Table 17. Expression of proteins from hypoxia pathways in prostate cancer patients, by Gleason grade and PSA value

	Gleason grade (n=38)			PSA at diagnosis (n=36)		
	<7	≥7	P	<10	≥10	P
VEGFR2 H-score [a]	30.9±24.7	60.1±17.9	0.099	30.2±1.2	80.0±33.5	0.085
LOX IRS score [a]	10.2±1.6	7.6±1.1	0.184	9.2±1.1	6.6±1.8	0.242
HIF-1α expression [b]						
Negative	6 (0.50)	19 (0.73)		17 (0.65)	8 (0.80)	
Positive	6 (0.50)	7 (0.27)	0.163	9 (0.35)	2 (0.20)	0.335*
CAIX expression [b]						
Negative	10 (0.83)	15 (0.58)		19 (0.73)	5 (0.50)	
Positive	2 (0.17)	11 (0.42)	0.117*	7 (0.27)	5 (0.50)	0.078

PSA, prostate specific antigen; VEGFR2, vascular endothelial growth factor receptor 2; LOX, lysyl oxidase; HIF1a, hypoxia inducible factor 1 alpha; CAIX, carbonic anhydrase IX. [a] Kruskal Wallis and Mann-Whitney U tests for VEGFR2 H-score in epithelial cells; [b] Chi-square test.* Fisher exact test.

3.4.4. Discussion

The hypoxia-driven HIF-1α upregulation activates downstream pathways involved in metabolism (e.g. CAIX), angiogenesis (e.g. VEGF/VEGFR2 pathway) and extracellular matrix activity (e.g. LOX), which can modulate cancer behavior [269]. Experimental and clinical studies in prostate carcinoma demonstrated that HIF-1α overexpression was associated with malignancy, progression and metastatic potential [126] [2]. Here, we found a non-significant statistical trend for higher HIF-1α protein expression in prostate carcinomas compared to BPH, which may be due to the limited number of samples. Besides vascular endothelial cells also prostate epithelial cells express VEGFR2, which were shown to signal through the AKT/mTOR/P70S6K pathway [270]. We found that VEGFR2 was expressed in the epithelium and endothelial cells, though more frequently expressed in epithelial tumor cells of organ confined or extra prostatic carcinomas than in BPH. Hence, in the prostate VEGFR2 expression is mainly expressed in malignant epithelium where its ligand VEGF may exert a direct effect in tumor cell growth. Previous immunohistochemistry studies reported VEGFR2 expression in high-grade prostate intra-epithelial neoplasia and carcinomas of the prostate [271], whereas gene expression findings in prostate cancer cell lines evidenced suppressive growth and promotion of apoptosis with *KDR* antisense oligonucleotide [272]. Taken together

with present data, these findings indicate that VEGFR2 expression in epithelial prostate carcinoma cells supports a function for VEGF that is not limited to angiogenesis. Thus, abrogation of VEGFR2 signalling in malignant epithelial cells may prove an effective therapeutic modality for the treatment of prostate cancer. At present, two anti-angiogenic drugs are being tested in the phase III setting for men with prostate cancer, carbozantinib (a dual VEGFR2/MET inhibitor) and tasquinimod (down-regulator of HIF-1α), that showed beneficial and encouraging results on phase II trials [273].

Tumor cells have to adapt to the hypoxia-driven switch in metabolism, with consequent acidosis, in order to survive. CAIX is a membrane-bound protein crucial for pH regulation in the highly metabolically active malignant cells. In agreement, carbonic anhydrase IX gene (*CA9*) is a target of HIF-1α and is up-regulated in response to hypoxia [274]. *CA9* mRNA expression increases reliably following hypoxia incubation of PC-3 cells [275], although no significant differences on mRNA expression were found when comparing BPH with prostate carcinomas [10]. Other studies described lack of CAIX expression in primary prostate carcinoma and hypothesized alternate pathways for maintaining pH balance [276,277]. Conversely, our results disclosed increased frequency of cases with epithelial cell positivity for CAIX expression in organ confined and extra prostatic carcinomas compared to BPH. Our findings taken together with reports of CAIX expression in epithelial prostate carcinoma cells [275,10] sustain the need for reconsidering CAIX role in prostate carcinoma.

The lysyl oxidase gene (*LOX*), was shown to be directly regulated by HIF-1α transcription factor and essential for hypoxia-induced metastasis and cancer cell proliferation [192]. In the prostate we found that LOX immunoreactivity score was associated with HIF-1α positivity, thus supporting the regulatory nature of HIF-1α in LOX expression. Furthermore, although the number of cases with positive LOX expression in carcinomas was similar to BPH, the LOX IRS was significantly higher in organ confined prostate carcinomas compared with BPH. Interestingly, increased expression of *LOX* mRNA in prostate carcinomas compared with BPH was previously observed [10]. LOX biological functions that include effects in cell growth, migration and polarity agrees with the increased LOX expression found in our carcinoma samples.

In this study, evaluation of protein expression according to SNPs in their coding genes disclosed a genotype-phenotype effect for the *LOX* and *KDR* SNPs, but no functional validation at the protein level was observed for the studied *HIF1A* and

CA9 SNPs. The C-to-T substitution at locus +1772 (rs11549465) in *HIF1A* gene localizes in the oxygen-dependent domain of the gene where the variant allele was shown to stabilize *HIF1A* mRNA and enhance *HIF1A* transcriptional activity [215]. Notwithstanding the functional rationale, association of this SNP with prostate carcinoma risk and with microvessel density, yielded conflicting results [9,218,220,224]. In our study, the lack of statistical differences in *HIF1A* +1772 C>T genotypes for HIF-1α protein expression, agrees with a previous report in prostatic carcinoma [218]. However, the low frequency of TT carriers in our sample (only 2 cases) may have influenced statistical power, since the HIF-1α protein and mRNA overexpression have been associated with the TT genotype [231,278].
A functional genetic variant on *KDR* gene that codifies for VEGFR2 is located in the promoter region (-604 T>C, rs2071559), where the C-allele has been associated with lower transcription activity, and decreased serum VEGFR2 level [256]. Interestingly, we found that T carriers had a significantly higher VEGFR2 expression in prostate epithelial cells, thereby suggesting that this SNP might prove useful for predictive and/or prognostic evaluations in prostate carcinoma, warranting future studies.
A SNP in exon 1 of *CA9* gene is located at locus +201 (rs2071676), where an A-to-G substitution leads to a change of valine-by-methionine in codon 33. Even though we observed an over representation of CAIX positive immunoreactivity in prostate carcinoma compared to BPH, the nonsynonymous SNP in *CA9* +201 was unable to explain variations in the levels of CAIX protein expression in the prostatic tissue, suggesting lack of influence in protein expression, even though the impact of this nonsynonymous substitution (valine to methionine) in CAIX protein activity remains to be confirmed.
The *LOX* gene is translated and secreted as a proenzyme (Pro-LOX), and then processed to a functional enzyme (LOX) and a propeptide (LOX-PP) . We studied a SNP in *LOX* gene that has been identified at locus +473 G>A (rs1800449), that cause an aminoacid substitution (Arg158Glu). This SNP locates at a highly conserved region within LOX-PP, where the A-allele was found to decrease the protective capacity of LOX-PP, while increasing the Pro-LOX-associated invasive ability of tumor cells [279]. When evaluating LOX immunoreactivity and expression intensity by immunohistochemistry in prostate tissues, we found it significantly lower in carriers of the *LOX* +473 A-allele. In the present study, we found that LOX was primarily present at the nucleus of epithelial cells, which fits with other reports asserting that this enzyme may have important functions in secretory cells, as

catalyser of histones in the nucleus [280]. Thus, our findings seem to suggest a wider variety of functions for LOX in prostate epithelial cells, beyond those related to cross-link formation in collagen and elastin, which merit further research. We hypothesize that the trafficking of LOX towards inside the cell or a specific cell compartment may be subordinated to the structural molecular characteristics and folding of the protein, which could be determined by *LOX* +473 G>A polymorphism. Our endeavour to study the genotype-phenotype correlation in key hypoxia markers and its association with prostate cancer yielded encouraging findings, even though results should be interpreted in the context of potential limitations. The lack of statistical significance for genotypic frequencies between disease groups on the putative functional target SNPs in *HIF1A*, *LOX*, *CA9* and *KDR* likely reflects underpowered sample size. This was a major issue as conclusions were impracticable for genetic association analysis and limited for genotype-phenotype inferences. Further limitations arisen from stratification of carcinomas by stage, Gleason score or PSA level, showing at most only statistical trends for increased expression of VEGFR2 and CAIX in more aggressive phenotypes. Nevertheless, considering the hypothesis-generating nature of this study, we report findings that provide important clues to further work in larger samples. Another issue may be related with raised concern over similar hypoxic dysregulation for both prostate carcinoma and benign hyperproliferative diseases. However, inclusion of BPH patients as controls arranged for age-matching with elderly prostate cancer patients, similar clinical and diagnostic procedures (including prostate biopsy) making the possibility of crossover remote; and this group represents the normality in men at that age, since most men of that age carry benign prostate hyperplasia.

CONCLUSIONS AND FUTURE PERSPECTIVES

4.1. General conclusion

Hypoxia is usually found in large solid tumors and is a known inducer of metastasis, being strongly correlated to poorer outcomes. In prostate cancer, as in angiogenesis dependent tumors, there is now evidence of intratumoral hypoxia's profound effect in cancer progression through HIF-mediated regulation of molecules that mediate functional interactions with key aspects of angiogenesis and metastasis.

We have thoroughly revised the state of the art of HIF-mediated molecular mechanisms in cancer in a HIF-1α centric perspective where HIF-1α is crucial for the initiation of angiogenesis, tumor growth, progression, and metastasis. In prostate cancer, the combination of insightful studies on cancer hypoxia suggests the existence of a regulatory circuit between molecules or pathways (such as VEGF, LOX, or CAIX) downstream of HIF-1a, which synergistically modulate tumor microenvironment and promote prostate cancer aggressiveness.

The orchestrator role attributed to HIF as a master regulator of the transcription of genes encoding factors involved in these processes provides the rationale for including HIF inhibitors in prostate cancer therapy regimens, particularly in patients with localized or locally advanced disease, with elevated expression of hypoxia driven molecules in primary tumors.

Additional studies are needed to clarify the cross-talk between cellular players in the hypoxic prostate tumor microenvironment, whereas further insight from translational and clinical data connecting prostate tumor hypoxia with metastasis and mortality will definitively contribute toward novel, personalized therapies.

We have shown here that a *HIF1A* SNP was able to predict disease progression and aggressiveness in a large series of prostate cancer patients. The *VEGF* and *KDR* SNPs had a low predictive and prognostic value for prostate cancer. However, the study concerning the relationship between *HIF1A* and other genetic markers such as *CA9*, *LOX* and *VEGF/KDR* with prostate cancer aggressiveness remains incomplete yet running in the laboratory. We hypothesize that synergistic influence of these SNPs (and eventually others) combined according to their phenotypic effect, will add predictive and prognostic value to clinicopathological variables in the context of prostate cancer.

Prostate carcinoma growth triggers hypoxia, which regulates *HIF1A* expression that in turn impacts the expression of downstream pathways including LOX, CAIX and VEGFR2 in tumor cells. From the putatively functional SNPs included here we observed that only the genetic variants in *LOX* and *KDR* were functionally associated with differential protein expression in malignant epithelial cells. Thereby, no functional confirmation was observed for the SNP in *HIF1A*, even though this SNP was associated with resistance to ADT and bone metastasis development in the genetic epidemiology study. Conversely, for the *KDR* SNP we analysed, albeit there was overexpression of VEGFR2 in prostate tumor cells for the variant genotype, no association was found with PCa risk, or with endpoint analysis in patients undergoing ADT. These seemingly controversial findings might rely on the heterogeneity of patients and diseases for the molecular epidemiology and histochemical studies. Therefore, future immunohistochemical studies should use prostate tumor samples from ADT patients in order to inform more appropriately about a rapidly growing cancer that upwardly impacts hypoxia. In these tumors, higher concordance between germline DNA-to-gene/protein expressions would be expected. Results presented here warrant further research in larger samples in order to evaluate the predictive and prognostic value of *KDR* and *LOX* SNPs in prostate carcinoma.

4.2. Future perspectives

With advances in genotyping and sequencing technologies, continued discovery of novel genetic markers associated with disease initiation, progression and response or resistance to treatment is expected. Furthermore, multicentric large scale studies are required in order to generate novel markers with increased precision. Therefore, we expect to foster investigation by increasing the number of SNPs, performing "GWAS local" in hypoxia markers, and always correlating with phenotypic expression. From combining markers from key pathways involved in prostate cancer hypoxia to the participation/implementation of collaborative studies, we anticipate a shorter route towards the translation of these discoveries into the development of novel tests to assist clinical decision making reasoning and to assist patient stratification in clinical trials. Large clinical trials involving multi institutional collaborations will be required to prospectively validate the utility of these markers for clinical decision making.

In the framework of the line of research presented here, we are aware that information from gene expression analysis (from both *in vitro* and FFPE tissues) will be required for validation of results. In addition, analysing expression profiles of microRNAs might also reveal a hypoxia-associated microRNA predictive or prognostic role that can independently forecast outcome.

REFERENCES

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144 (5):646-674. doi:10.1016/j.cell.2011.02.013

2. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, Eeles R, Cooper C, Sydes M, Dearnaley D, Parker C (2008) Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. The lancet oncology 9 (4):342-351. doi:10.1016/S1470-2045(08)70076-7

3. Park SY, Kim YJ, Gao AC, Mohler JL, Onate SA, Hidalgo AA, Ip C, Park EM, Yoon SY, Park YM (2006) Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer research 66 (10):5121-5129. doi:10.1158/0008-5472.CAN-05-1341

4. Horii K, Suzuki Y, Kondo Y, Akimoto M, Nishimura T, Yamabe Y, Sakaue M, Sano T, Kitagawa T, Himeno S, Imura N, Hara S (2007) Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Molecular cancer research : MCR 5 (4):383-391. doi:10.1158/1541-7786.MCR-06-0226

5. Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, Malone PR, Harris AL (2005) The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 11 (21):7658-7663. doi:10.1158/1078-0432.CCR-05-0460

6. Butterworth KT, McCarthy HO, Devlin A, Ming L, Robson T, McKeown SR, Worthington J (2008) Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype. International journal of cancer Journal international du cancer 123 (4):760-768. doi:10.1002/ijc.23418

7. Milosevic M, Chung P, Parker C, Bristow R, Toi A, Panzarella T, Warde P, Catton C, Menard C, Bayley A, Gospodarowicz M, Hill R (2007) Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer research 67 (13):6022-6025. doi:10.1158/0008-5472.CAN-07-0561

8. Wiklund FE, Adami HO, Zheng SL, Stattin P, Isaacs WB, Gronberg H, Xu J (2009) Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 18 (5):1659-1662. doi:10.1158/1055-9965.EPI-08-1148

9. Fraga A, Ribeiro R, Principe P, Lobato C, Pina F, Mauricio J, Monteiro C, Sousa H, Calais da Silva F, Lopes C, Medeiros R (2014) The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration. European journal of cancer 50 (2):359-365. doi:10.1016/j.ejca.2013.09.001

10. Stewart GD, Gray K, Pennington CJ, Edwards DR, Riddick AC, Ross JA, Habib FK (2008) Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. Oncology reports 20 (6):1561-1567

11. Padhani AR, Krohn KA, Lewis JS, Alber M (2007) Imaging oxygenation of human tumours. European radiology 17 (4):861-872. doi:10.1007/s00330-006-0431-y

12. Choi MR, Stanton-Maxey KJ, Stanley JK, Levin CS, Bardhan R, Akin D, Badve S, Sturgis J, Robinson JP, Bashir R, Halas NJ, Clare SE (2007) A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. Nano letters 7 (12):3759-3765. doi:10.1021/nl072209h

13. Potosky AL, Miller BA, Albertsen PC, Kramer BS (1995) The role of increasing detection in the rising incidence of prostate cancer. JAMA : the journal of the American Medical Association 273 (7):548-552

14. Hsing AW, Chokkalingam AP (2006) Prostate cancer epidemiology. Frontiers in bioscience : a journal and virtual library 11:1388-1413

15. Nordstrom T, Aly M, Eklund M, Egevad L, Gronberg H (2014) A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml. European urology 65 (6):1184-1190. doi:10.1016/j.eururo.2013.07.005

16. Balistreri CR, Candore G, Lio D, Carruba G (2014) Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments. Cancer gene therapy 21 (1):2-11. doi:10.1038/cgt.2013.77

17. Sissung TM, Price DK, Del Re M, Ley AM, Giovannetti E, Figg WD, Danesi R (2014) Genetic variation: effect on prostate cancer. Biochimica et biophysica acta 1846 (2):446-456. doi:10.1016/j.bbcan.2014.08.007

18. Chun FK, Briganti A, Jeldres C, Erbersdobler A, Schlomm T, Steuber T, Gallina A, Walz J, Perrotte P, Huland H, Graefen M, Karakiewicz PI (2007) Zonal origin of localized prostate cancer does not affect the rate of biochemical recurrence after radical prostatectomy. European urology 51 (4):949-955; discussion 955. doi:10.1016/j.eururo.2006.07.008

19. Signoretti S, Loda M (2006) Defining cell lineages in the prostate epithelium. Cell cycle 5 (2):138-141

20. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG (2007) Inflammation in prostate carcinogenesis. Nature reviews Cancer 7 (4):256-269. doi:10.1038/nrc2090

21. Nelson WG, De Marzo AM, Isaacs WB (2003) Prostate cancer. The New England journal of medicine 349 (4):366-381. doi:10.1056/NEJMra021562

22. Bostwick DG, Shan A, Qian J, Darson M, Maihle NJ, Jenkins RB, Cheng L (1998) Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer 83 (9):1995-2002

23. Chung LW, Hsieh CL, Law A, Sung SY, Gardner TA, Egawa M, Matsubara S, Zhau HE (2003) New targets for therapy in prostate cancer: modulation of stromal-epithelial interactions. Urology 62 (5 Suppl 1):44-54

24. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA: a cancer journal for clinicians 59 (4):225-249. doi:10.3322/caac.20006

25. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA: a cancer journal for clinicians 62 (1):10-29. doi:10.3322/caac.20138

26. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of U (2014) EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. European urology 65 (1):124-137. doi:10.1016/j.eururo.2013.09.046

27. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F, European Association of U (2008) EAU guidelines on prostate cancer. European urology 53 (1):68-80. doi:10.1016/j.eururo.2007.09.002

28. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F (2012) International variation in prostate cancer incidence and mortality rates. European urology 61 (6):1079-1092. doi:10.1016/j.eururo.2012.02.054

29. Pinheiro PS, Tyczynski JE, Bray F, Amado J, Matos E, Parkin DM (2003) Cancer incidence and mortality in Portugal. European journal of cancer 39 (17):2507-2520

30. Majeed A, Babb P, Jones J, Quinn M (2000) Trends in prostate cancer incidence, mortality and survival in England and Wales 1971-1998. BJU international 85 (9):1058-1062

31. Montgomery JS, Price DK, Figg WD (2001) The androgen receptor gene and its influence on the development and progression of prostate cancer. The Journal of pathology 195 (2):138-146. doi:10.1002/1096-9896(200109)195:2<138::AID-PATH961>3.0.CO;2-Y

32. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Maattanen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A, Investigators E (2014) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384 (9959):2027-2035. doi:10.1016/S0140-6736(14)60525-0

33. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A, Investigators E (2009) Screening and prostate-cancer mortality in a randomized European study. The New England journal of medicine 360 (13):1320-1328. doi:10.1056/NEJMoa0810084

34. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD, Team PP (2009) Mortality results from a randomized prostate-cancer screening trial. The New England journal of medicine 360 (13):1310-1319. doi:10.1056/NEJMoa0810696

35. Neal DE, Leung HY, Powell PH, Hamdy FC, Donovan JL (2000) Unanswered questions in screening for prostate cancer. European journal of cancer 36 (10):1316-1321

36. Hemminki K, Czene K (2002) Age specific and attributable risks of familial prostate carcinoma from the family-cancer database. Cancer 95 (6):1346-1353. doi:10.1002/cncr.10819

37. Nupponen N, Visakorpi T (1999) Molecular biology of progression of prostate cancer. European urology 35 (5-6):351-354. doi:19907

38. Damber JE, Aus G (2008) Prostate cancer. Lancet 371 (9625):1710-1721. doi:10.1016/S0140-6736(08)60729-1

39. Semenza GL (2000) HIF-1 and human disease: one highly involved factor. Genes & development 14 (16):1983-1991

40. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nature reviews Cancer 3 (10):721-732. doi:10.1038/nrc1187

41. Kaelin WG, Jr. (2002) Molecular basis of the VHL hereditary cancer syndrome. Nature reviews Cancer 2 (9):673-682. doi:10.1038/nrc885

42. Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, Garcia JG, Semenza GL (2005) Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105 (2):659-669. doi:10.1182/blood-2004-07-2958

43. Semenza GL, Rue EA, Iyer NV, Pang MG, Kearns WG (1996) Assignment of the hypoxia-inducible factor 1alpha gene to a region of conserved synteny on mouse chromosome 12 and human chromosome 14q. Genomics 34 (3):437-439. doi:10.1006/geno.1996.0311

44. Iyer NV, Leung SW, Semenza GL (1998) The human hypoxia-inducible factor 1alpha gene: HIF1A structure and evolutionary conservation. Genomics 52 (2):159-165. doi:10.1006/geno.1998.5416

45. Wang GL, Semenza GL (1995) Purification and characterization of hypoxia-inducible factor 1. The Journal of biological chemistry 270 (3):1230-1237

46. Tian H, McKnight SL, Russell DW (1997) Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes & development 11 (1):72-82

47. Wenger RH (2002) Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 16 (10):1151-1162. doi:10.1096/fj.01-0944rev

48. Vandromme M, Gauthier-Rouviere C, Lamb N, Fernandez A (1996) Regulation of transcription factor localization: fine-tuning of gene expression. Trends in biochemical sciences 21 (2):59-64

49. Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL (1997) Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. The Journal of biological chemistry 272 (31):19253-19260

50. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL (1996) Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. The Journal of biological chemistry 271 (30):17771-17778

51. Michel G, Minet E, Ernest I, Roland I, Durant F, Remacle J, Michiels C (2000) A model for the complex between the hypoxia-inducible factor-1 (HIF-1) and its consensus DNA sequence. Journal of biomolecular structure & dynamics 18 (2):169-179. doi:10.1080/07391102.2000.10506656

52. Huang LE, Gu J, Schau M, Bunn HF (1998) Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proceedings of the National Academy of Sciences of the United States of America 95 (14):7987-7992

53. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG, Jr. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292 (5516):464-468. doi:10.1126/science.1059817

54. Bruick RK, McKnight SL (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294 (5545):1337-1340. doi:10.1126/science.1066373

55. Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, Klausner RD (1997) The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proceedings of the National Academy of Sciences of the United States of America 94 (6):2156-2161

56. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, Kaelin WG, Jr. (1998) Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Molecular and cellular biology 18 (2):732-741

57. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (6733):271-275. doi:10.1038/20459

58. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nature cell biology 2 (7):423-427. doi:10.1038/35017054

59. Tanimoto K, Makino Y, Pereira T, Poellinger L (2000) Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. The EMBO journal 19 (16):4298-4309. doi:10.1093/emboj/19.16.4298

60. Brahimi-Horn MC, Pouyssegur J (2005) The hypoxia-inducible factor and tumor progression along the angiogenic pathway. International review of cytology 242:157-213. doi:10.1016/S0074-7696(04)42004-X

61. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG, Jr., Pavletich NP (2002) Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science 296 (5574):1886-1889. doi:10.1126/science.1073440

62. Yu F, White SB, Zhao Q, Lee FS (2001) HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proceedings of the National Academy of Sciences of the United States of America 98 (17):9630-9635. doi:10.1073/pnas.181341498

63. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292 (5516):468-472. doi:10.1126/science.1059796

64. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. The EMBO journal 20 (18):5197-5206. doi:10.1093/emboj/20.18.5197

65. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, Yoo MA, Song EJ, Lee KJ, Kim KW (2002) Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111 (5):709-720

66. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML (2002) Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295 (5556):858-861. doi:10.1126/science.1068592

67. Wykoff CC, Sotiriou C, Cockman ME, Ratcliffe PJ, Maxwell P, Liu E, Harris AL (2004) Gene array of VHL mutation and hypoxia shows novel hypoxia-induced

genes and that cyclin D1 is a VHL target gene. British journal of cancer 90 (6):1235-1243. doi:10.1038/sj.bjc.6601657

68. Melillo G (2006) Inhibiting hypoxia-inducible factor 1 for cancer therapy. Molecular cancer research : MCR 4 (9):601-605. doi:10.1158/1541-7786.MCR-06-0235

69. Chan DA, Sutphin PD, Denko NC, Giaccia AJ (2002) Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. The Journal of biological chemistry 277 (42):40112-40117. doi:10.1074/jbc.M206922200

70. Dameron KM, Volpert OV, Tainsky MA, Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265 (5178):1582-1584

71. Blancher C, Moore JW, Robertson N, Harris AL (2001) Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Cancer research 61 (19):7349-7355

72. Bouvet M, Ellis LM, Nishizaki M, Fujiwara T, Liu W, Bucana CD, Fang B, Lee JJ, Roth JA (1998) Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer research 58 (11):2288-2292

73. Gao N, Ding M, Zheng JZ, Zhang Z, Leonard SS, Liu KJ, Shi X, Jiang BH (2002) Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. The Journal of biological chemistry 277 (35):31963-31971. doi:10.1074/jbc.M200082200

74. Gao N, Jiang BH, Leonard SS, Corum L, Zhang Z, Roberts JR, Antonini J, Zheng JZ, Flynn DC, Castranova V, Shi X (2002) p38 Signaling-mediated hypoxia-inducible factor 1alpha and vascular endothelial growth factor induction by Cr(VI) in DU145 human prostate carcinoma cells. The Journal of biological chemistry 277 (47):45041-45048. doi:10.1074/jbc.M202775200

75. Haddad JJ, Land SC (2001) A non-hypoxic, ROS-sensitive pathway mediates TNF-alpha-dependent regulation of HIF-1alpha. FEBS letters 505 (2):269-274

76. Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, Schumacker PT (2000) Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. The Journal of biological chemistry 275 (33):25130-25138. doi:10.1074/jbc.M001914200

77. Zander R, Vaupel P (1985) Proposal for using a standardized terminology on oxygen transport to tissue. Advances in experimental medicine and biology 191:965-970

78. Semenza GL (2002) HIF-1 and tumor progression: pathophysiology and therapeutics. Trends in molecular medicine 8 (4 Suppl):S62-67

79. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C, Gassmann M, Candinas D (2001) HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 15 (13):2445-2453. doi:10.1096/fj.01-0125com

80. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proceedings of the National Academy of Sciences of the United States of America 94 (15):8104-8109

81. Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer research 49 (23):6449-6465

82. Kimura H, Braun RD, Ong ET, Hsu R, Secomb TW, Papahadjopoulos D, Hong K, Dewhirst MW (1996) Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer research 56 (23):5522-5528

83. Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer research 58 (7):1408-1416

84. Dewhirst MW (1998) Concepts of oxygen transport at the microcirculatory level. Seminars in radiation oncology 8 (3):143-150

85. Kimbro KS, Simons JW (2006) Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocrine-related cancer 13 (3):739-749. doi:10.1677/erc.1.00728

86. Kaelin WG, Jr. (2005) ROS: really involved in oxygen sensing. Cell metabolism 1 (6):357-358. doi:10.1016/j.cmet.2005.05.006

87. Muzandu K, Shaban Z, Ishizuka M, Kazusaka A, Fujita S (2005) Nitric oxide enhances catechol estrogen-induced oxidative stress in LNCaP cells. Free radical research 39 (4):389-398

88. Gleadle JM, Ratcliffe PJ (1997) Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase. Blood 89 (2):503-509

89. Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, Hunter R, Stratford I, West C (2001) Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clinical cancer research : an official journal of the American Association for Cancer Research 7 (4):928-934

90. Bristow RG, Hill RP (2008) Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nature reviews Cancer 8 (3):180-192. doi:10.1038/nrc2344

91. Price BD, Calderwood SK (1992) Gadd45 and Gadd153 messenger RNA levels are increased during hypoxia and after exposure of cells to agents which elevate the levels of the glucose-regulated proteins. Cancer research 52 (13):3814-3817

92. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A (1996) Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. The Journal of biological chemistry 271 (51):32529-32537

93. Semenza GL (2003) Angiogenesis in ischemic and neoplastic disorders. Annual review of medicine 54:17-28. doi:10.1146/annurev.med.54.101601.152418

94. Dachs GU, Tozer GM (2000) Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. European journal of cancer 36 (13 Spec No):1649-1660

95. Acker T, Plate KH (2003) Role of hypoxia in tumor angiogenesis-molecular and cellular angiogenic crosstalk. Cell and tissue research 314 (1):145-155. doi:10.1007/s00441-003-0763-8

96. Vaupel P (2004) The role of hypoxia-induced factors in tumor progression. The oncologist 9 Suppl 5:10-17. doi:10.1634/theoncologist.9-90005-10

97. Vaupel P, Kelleher DK, Hockel M (2001) Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Seminars in oncology 28 (2 Suppl 8):29-35

98. Acs G, Xu X, Chu C, Acs P, Verma A (2004) Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 100 (11):2376-2386. doi:10.1002/cncr.20244

99. Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y, van Tinteren H, Harris AL, van Diest PJ, van der Wall E (2005) Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. Journal of clinical pathology 58 (2):172-177. doi:10.1136/jcp.2004.019885

100. Chan N, Milosevic M, Bristow RG (2007) Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future oncology 3 (3):329-341. doi:10.2217/14796694.3.3.329

101. Chaudary N, Hill RP (2007) Hypoxia and metastasis. Clinical cancer research : an official journal of the American Association for Cancer Research 13 (7):1947-1949. doi:10.1158/1078-0432.CCR-06-2971

102. Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer metastasis reviews 26 (2):225-239. doi:10.1007/s10555-007-9055-1

103. Brand KA, Hermfisse U (1997) Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 11 (5):388-395

104. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nature reviews Cancer 4 (11):891-899. doi:10.1038/nrc1478

105. Vordermark D, Kraft P, Katzer A, Bolling T, Willner J, Flentje M (2005) Glucose requirement for hypoxic accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha). Cancer letters 230 (1):122-133. doi:10.1016/j.canlet.2004.12.040

106. Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, Turley H, Harris AL, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA (2005) Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer. British journal of cancer 93 (10):1128-1136. doi:10.1038/sj.bjc.6602828

107. Semenza GL (2000) HIF-1: mediator of physiological and pathophysiological responses to hypoxia. Journal of applied physiology 88 (4):1474-1480

108. Ryan HE, Lo J, Johnson RS (1998) HIF-1 alpha is required for solid tumor formation and embryonic vascularization. The EMBO journal 17 (11):3005-3015. doi:10.1093/emboj/17.11.3005

109. Acker T, Plate KH (2002) A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology. Journal of molecular medicine 80 (9):562-575. doi:10.1007/s00109-002-0355-1

110. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM (2001) Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer research 61 (6):2736-2743

111. Kerbel RS (1998) New targets, drugs, and approaches for the treatment of cancer: an overview. Cancer metastasis reviews 17 (2):145-147

112. Pugh CW, Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nature medicine 9 (6):677-684. doi:10.1038/nm0603-677

113. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nature medicine 9 (6):669-676. doi:10.1038/nm0603-669

114. Shi YH, Fang WG (2004) Hypoxia-inducible factor-1 in tumour angiogenesis. World journal of gastroenterology 10 (8):1082-1087

115. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. The American journal of pathology 157 (2):411-421

116. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. Journal of the National Cancer Institute 93 (4):309-314

117. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M (1996) Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77 (5):858-863

118. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, Nichols PW (1995) Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. Journal of the National Cancer Institute 87 (21):1603-1612

119. Jaeger TM, Weidner N, Chew K, Moore DH, Kerschmann RL, Waldman FM, Carroll PR (1995) Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. The Journal of urology 154 (1):69-71

120. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer research 59 (22):5830-5835

121. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E (2003) Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97 (6):1573-1581. doi:10.1002/cncr.11246

122. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G (2001) Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 7 (6):1661-1668

123. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, Semenza GL (2001) Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer research 61 (7):2911-2916

124. Hockel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. Journal of the National Cancer Institute 93 (4):266-276

125. Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G (2003) The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity. The EMBO journal 22 (8):1857-1867. doi:10.1093/emboj/cdg173

126. Zhong H, Agani F, Baccala AA, Laughner E, Rioseco-Camacho N, Isaacs WB, Simons JW, Semenza GL (1998) Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer research 58 (23):5280-5284

127. Saramaki OR, Savinainen KJ, Nupponen NN, Bratt O, Visakorpi T (2001) Amplification of hypoxia-inducible factor 1alpha gene in prostate cancer. Cancer genetics and cytogenetics 128 (1):31-34

128. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG, Jr. (2002) Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer cell 1 (3):237-246

129. George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, Dewolf WC, Kantoff PW, Bubley GJ (2004) Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology 63 (2):327-332. doi:10.1016/j.urology.2003.09.059

130. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer research 60 (6):1541-1545

131. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P, Semenza GL (2003) Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer research 63 (5):1138-1143

132. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E (2002) Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. The Journal of biological chemistry 277 (31):27975-27981. doi:10.1074/jbc.M204152200

133. Stiehl DP, Jelkmann W, Wenger RH, Hellwig-Burgel T (2002) Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS letters 512 (1-3):157-162

134. Wartenberg M, Ling FC, Muschen M, Klein F, Acker H, Gassmann M, Petrat K, Putz V, Hescheler J, Sauer H (2003) Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 17 (3):503-505. doi:10.1096/fj.02-0358fje

135. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer research 62 (12):3387-3394

136. Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Pinover WH, Greenberg RE, Stobbe C, Hanks GE (2001) Hypoxia in human prostate carcinoma: an Eppendorf PO2 study. American journal of clinical oncology 24 (5):458-461

137. Janssen HL, Haustermans KM, Balm AJ, Begg AC (2005) Hypoxia in head and neck cancer: how much, how important? Head & neck 27 (7):622-638. doi:10.1002/hed.20223

138. Fraga A, Ribeiro R, Medeiros R (2009) [Tumor hypoxia: the role of HIF]. Actas urologicas espanolas 33 (9):941-951

139. Young SD, Marshall RS, Hill RP (1988) Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proceedings of the National Academy of Sciences of the United States of America 85 (24):9533-9537

140. Postovit LM, Adams MA, Lash GE, Heaton JP, Graham CH (2002) Oxygen-mediated regulation of tumor cell invasiveness. Involvement of a nitric oxide signaling pathway. The Journal of biological chemistry 277 (38):35730-35737. doi:10.1074/jbc.M204529200

141. Overgaard J (2007) Hypoxic radiosensitization: adored and ignored. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25 (26):4066-4074. doi:10.1200/JCO.2007.12.7878

142. Denko NC, Fontana LA, Hudson KM, Sutphin PD, Raychaudhuri S, Altman R, Giaccia AJ (2003) Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22 (37):5907-5914. doi:10.1038/sj.onc.1206703

143. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H (2000) Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. The Prostate 42 (1):73-78

144. Baltaci S, Orhan D, Gogus C, Turkolmez K, Tulunay O, Gogus O (2001) Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low- and high-grade prostatic intraepithelial neoplasia and prostatic carcinoma. BJU international 88 (1):100-103

145. Brune B, Zhou J (2007) Hypoxia-inducible factor-1alpha under the control of nitric oxide. Methods in enzymology 435:463-478. doi:10.1016/S0076-6879(07)35024-6

146. Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441 (7092):437-443. doi:10.1038/nature04871

147. Harris AL (2002) Hypoxia--a key regulatory factor in tumour growth. Nature reviews Cancer 2 (1):38-47. doi:10.1038/nrc704

148. Kaidi A, Qualtrough D, Williams AC, Paraskeva C (2006) Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer research 66 (13):6683-6691. doi:10.1158/0008-5472.CAN-06-0425

149. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P (2005) Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer research 65 (16):7259-7266. doi:10.1158/0008-5472.CAN-04-4480

150. Sorensen BS, Alsner J, Overgaard J, Horsman MR (2007) Hypoxia induced expression of endogenous markers in vitro is highly influenced by pH. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 83 (3):362-366. doi:10.1016/j.radonc.2007.04.028

151. Zhong H, Semenza GL, Simons JW, De Marzo AM (2004) Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer detection and prevention 28 (2):88-93. doi:10.1016/j.cdp.2003.12.009

152. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP, Ferrara N, Johnson RS (2004) Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer cell 6 (5):485-495. doi:10.1016/j.ccr.2004.09.026

153. Chung AS, Lee J, Ferrara N (2010) Targeting the tumour vasculature: insights from physiological angiogenesis. Nature reviews Cancer 10 (7):505-514. doi:10.1038/nrc2868

154. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC (2003) Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Molecular and cellular biology 23 (24):9361-9374

155. Lofstedt T, Fredlund E, Holmquist-Mengelbier L, Pietras A, Ovenberger M, Poellinger L, Pahlman S (2007) Hypoxia inducible factor-2alpha in cancer. Cell cycle 6 (8):919-926

156. Pietras A, Johnsson AS, Pahlman S (2010) The HIF-2alpha-driven pseudo-hypoxic phenotype in tumor aggressiveness, differentiation, and vascularization. Current topics in microbiology and immunology 345:1-20. doi:10.1007/82_2010_72

157. Monsef N, Helczynski L, Lundwall A, Pahlman S, Anders B (2007) Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands. The Prostate 67 (11):1219-1229. doi:10.1002/pros.20594

158. Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L (1997) Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proceedings of the National Academy of Sciences of the United States of America 94 (11):5667-5672

159. Mori R, Dorff TB, Xiong S, Tarabolous CJ, Ye W, Groshen S, Danenberg KD, Danenberg PV, Pinski JK (2010) The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. The Prostate 70 (15):1692-1700. doi:10.1002/pros.21204

160. Stewart RJ, Panigrahy D, Flynn E, Folkman J (2001) Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. The Journal of urology 165 (2):688-693. doi:10.1097/00005392-200102000-00095

161. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438 (7070):967-974. doi:10.1038/nature04483

162. Gille H, Kowalski J, Yu L, Chen H, Pisabarro MT, Davis-Smyth T, Ferrara N (2000) A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3'-kinase activation and endothelial cell migration. The EMBO journal 19 (15):4064-4073. doi:10.1093/emboj/19.15.4064

163. Safran M, Kaelin WG, Jr. (2003) HIF hydroxylation and the mammalian oxygen-sensing pathway. The Journal of clinical investigation 111 (6):779-783. doi:10.1172/JCI18181

164. Weber DC, Tille JC, Combescure C, Egger JF, Laouiti M, Hammad K, Granger P, Rubbia-Brandt L, Miralbell R (2012) The prognostic value of expression of HIF1alpha, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy. Radiation oncology 7:66. doi:10.1186/1748-717X-7-66

165. Li R, Younes M, Wheeler TM, Scardino P, Ohori M, Frolov A, Ayala G (2004) Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. The Prostate 58 (2):193-199. doi:10.1002/pros.10321

166. Kim JW, Tchernyshyov I, Semenza GL, Dang CV (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell metabolism 3 (3):177-185. doi:10.1016/j.cmet.2006.02.002

167. Ward PS, Thompson CB (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer cell 21 (3):297-308. doi:10.1016/j.ccr.2012.02.014

168. Potter C, Harris AL (2004) Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell cycle 3 (2):164-167

169. Chiche J, Ilc K, Laferriere J, Trottier E, Dayan F, Mazure NM, Brahimi-Horn MC, Pouyssegur J (2009) Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer research 69 (1):358-368. doi:10.1158/0008-5472.CAN-08-2470

170. Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI, Stanbridge EJ (2001) Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. The American journal of pathology 158 (3):905-919. doi:10.1016/S0002-9440(10)64038-2

171. Saarnio J, Parkkila S, Parkkila AK, Waheed A, Casey MC, Zhou XY, Pastorekova S, Pastorek J, Karttunen T, Haukipuro K, Kairaluoma MI, Sly WS (1998) Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 46 (4):497-504

172. Wykoff CC, Beasley N, Watson PH, Campo L, Chia SK, English R, Pastorek J, Sly WS, Ratcliffe P, Harris AL (2001) Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. The American journal of pathology 158 (3):1011-1019. doi:10.1016/S0002-9440(10)64048-5

173. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL (2003) Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer research 63 (19):6130-6134

174. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL (2001) Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 19 (16):3660-3668

175. Hussain SA, Ganesan R, Reynolds G, Gross L, Stevens A, Pastorek J, Murray PG, Perunovic B, Anwar MS, Billingham L, James ND, Spooner D, Poole CJ, Rea DW, Palmer DH (2007) Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. British journal of cancer 96 (1):104-109. doi:10.1038/sj.bjc.6603530

176. Ord JJ, Agrawal S, Thamboo TP, Roberts I, Campo L, Turley H, Han C, Fawcett DW, Kulkarni RP, Cranston D, Harris AL (2007) An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. The Journal of urology 178 (2):677-682. doi:10.1016/j.juro.2007.03.112

177. Grabmaier K, Vissers JL, De Weijert MC, Oosterwijk-Wakka JC, Van Bokhoven A, Brakenhoff RH, Noessner E, Mulders PA, Merkx G, Figdor CG, Adema GJ, Oosterwijk E (2000) Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. International journal of cancer Journal international du cancer 85 (6):865-870

178. Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL, O'Byrne KJ (2003) Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 21 (3):473-482

179. Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, Pouyssegur J, Berra E (2007) HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. International journal of cancer Journal international du cancer 120 (7):1451-1458. doi:10.1002/ijc.22436

180. Li Y, Wang H, Oosterwijk E, Selman Y, Mira JC, Medrano T, Shiverick KT, Frost SC (2009) Antibody-specific detection of CAIX in breast and prostate cancers. Biochemical and biophysical research communications 386 (3):488-492. doi:10.1016/j.bbrc.2009.06.064

181. Thiry A, Dogne JM, Masereel B, Supuran CT (2006) Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends in pharmacological sciences 27 (11):566-573. doi:10.1016/j.tips.2006.09.002

182. Lochter A, Bissell MJ (1995) Involvement of extracellular matrix constituents in breast cancer. Seminars in cancer biology 6 (3):165-173. doi:10.1006/scbi.1995.0017

183. Chung LW, Baseman A, Assikis V, Zhau HE (2005) Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. The Journal of urology 173 (1):10-20. doi:10.1097/01.ju.0000141582.15218.10

184. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR (2002) Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clinical cancer research : an official journal of the American Association for Cancer Research 8 (9):2912-2923

185. Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhatia J, Taichman RS, McCauley LK, Keller ET, Pienta KJ (2003) Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 97 (3 Suppl):739-747. doi:10.1002/cncr.11181

186. Erler JT, Giaccia AJ (2006) Lysyl oxidase mediates hypoxic control of metastasis. Cancer research 66 (21):10238-10241. doi:10.1158/0008-5472.CAN-06-3197

187. Kakkad SM, Solaiyappan M, O'Rourke B, Stasinopoulos I, Ackerstaff E, Raman V, Bhujwalla ZM, Glunde K (2010) Hypoxic tumor microenvironments reduce collagen I fiber density. Neoplasia 12 (8):608-617

188. Taboga SR, Vidal Bde C (2003) Collagen fibers in human prostatic lesions: histochemistry and anisotropies. Journal of submicroscopic cytology and pathology 35 (1):11-16

189. Zhang Y, Nojima S, Nakayama H, Jin Y, Enza H (2003) Characteristics of normal stromal components and their correlation with cancer occurrence in human prostate. Oncology reports 10 (1):207-211

190. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang

GP, van de Vijver MJ, Brown PO (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS medicine 3 (3):e47. doi:10.1371/journal.pmed.0030047

191. Gao Y, Xiao Q, Ma H, Li L, Liu J, Feng Y, Fang Z, Wu J, Han X, Zhang J, Sun Y, Wu G, Padera R, Chen H, Wong KK, Ge G, Ji H (2010) LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proceedings of the National Academy of Sciences of the United States of America 107 (44):18892-18897. doi:10.1073/pnas.1004952107

192. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT, Jeffrey SS, Giaccia AJ (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440 (7088):1222-1226. doi:10.1038/nature04695

193. Kirschmann DA, Seftor EA, Fong SF, Nieva DR, Sullivan CM, Edwards EM, Sommer P, Csiszar K, Hendrix MJ (2002) A molecular role for lysyl oxidase in breast cancer invasion. Cancer research 62 (15):4478-4483

194. Palamakumbura AH, Vora SR, Nugent MA, Kirsch KH, Sonenshein GE, Trackman PC (2009) Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling. Oncogene 28 (38):3390-3400. doi:10.1038/onc.2009.203

195. Hofbauer KH, Gess B, Lohaus C, Meyer HE, Katschinski D, Kurtz A (2003) Oxygen tension regulates the expression of a group of procollagen hydroxylases. European journal of biochemistry / FEBS 270 (22):4515-4522

196. Xiao Q, Ge G (2012) Lysyl oxidase, extracellular matrix remodeling and cancer metastasis. Cancer microenvironment : official journal of the International Cancer Microenvironment Society 5 (3):261-273. doi:10.1007/s12307-012-0105-z

197. Li T, Sun L, Miller N, Nicklee T, Woo J, Hulse-Smith L, Tsao MS, Khokha R, Martin L, Boyd N (2005) The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 14 (2):343-349. doi:10.1158/1055-9965.EPI-04-0490

198. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U (2008) Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proceedings of the National Academy of Sciences of the United States of America 105 (17):6392-6397. doi:10.1073/pnas.0802047105

199. Schietke R, Warnecke C, Wacker I, Schodel J, Mole DR, Campean V, Amann K, Goppelt-Struebe M, Behrens J, Eckardt KU, Wiesener MS (2010) The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1. The Journal of biological chemistry 285 (9):6658-6669. doi:10.1074/jbc.M109.042424

200. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, Saito Y, Johnson RS, Kretzler M, Cohen CD, Eckardt KU, Iwano M, Haase VH (2007) Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. The Journal of clinical investigation 117 (12):3810-3820. doi:10.1172/JCI30487

201. Kagan HM, Li W (2003) Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. Journal of cellular biochemistry 88 (4):660-672. doi:10.1002/jcb.10413

202. Uzel MI, Scott IC, Babakhanlou-Chase H, Palamakumbura AH, Pappano WN, Hong HH, Greenspan DS, Trackman PC (2001) Multiple bone morphogenetic protein 1-related mammalian metalloproteinases process pro-lysyl oxidase at the correct physiological site and control lysyl oxidase activation in mouse embryo fibroblast cultures. The Journal of biological chemistry 276 (25):22537-22543. doi:10.1074/jbc.M102352200

203. Ren C, Yang G, Timme TL, Wheeler TM, Thompson TC (1998) Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. Cancer research 58 (6):1285-1290

204. Contente S, Yeh TJ, Friedman RM (2009) Tumor suppressive effect of lysyl oxidase proenzyme. Biochimica et biophysica acta 1793 (7):1272-1278. doi:10.1016/j.bbamcr.2009.04.013

205. Min C, Kirsch KH, Zhao Y, Jeay S, Palamakumbura AH, Trackman PC, Sonenshein GE (2007) The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer. Cancer research 67 (3):1105-1112. doi:10.1158/0008-5472.CAN-06-3867

206. Wu M, Min C, Wang X, Yu Z, Kirsch KH, Trackman PC, Sonenshein GE (2007) Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells. Cancer research 67 (13):6278-6285. doi:10.1158/0008-5472.CAN-07-0776

207. Le QT, Harris J, Magliocco AM, Kong CS, Diaz R, Shin B, Cao H, Trotti A, Erler JT, Chung CH, Dicker A, Pajak TF, Giaccia AJ, Ang KK (2009) Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27 (26):4281-4286. doi:10.1200/JCO.2008.20.6003

208. Woznick AR, Braddock AL, Dulai M, Seymour ML, Callahan RE, Welsh RJ, Chmielewski GW, Zelenock GB, Shanley CJ (2005) Lysyl oxidase expression in bronchogenic carcinoma. American journal of surgery 189 (3):297-301. doi:10.1016/j.amjsurg.2004.11.031

209. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, White JG, Keely PJ (2008) Collagen density promotes mammary tumor initiation and progression. BMC medicine 6:11. doi:10.1186/1741-7015-6-11

210. Bignon M, Pichol-Thievend C, Hardouin J, Malbouyres M, Brechot N, Nasciutti L, Barret A, Teillon J, Guillon E, Etienne E, Caron M, Joubert-Caron R, Monnot C, Ruggiero F, Muller L, Germain S (2011) Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type IV collagen assembly in the endothelial basement membrane. Blood 118 (14):3979-3989. doi:10.1182/blood-2010-10-313296

211. Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, Mikels A, Vaysberg M, Ghermazien H, Wai C, Garcia CA, Velayo AC, Jorgensen B, Biermann D, Tsai D, Green J, Zaffryar-Eilot S, Holzer A, Ogg S, Thai D, Neufeld G, Van Vlasselaer P, Smith V (2010) Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nature medicine 16 (9):1009-1017. doi:10.1038/nm.2208

212. Johnson RC, Nelson GW, Troyer JL, Lautenberger JA, Kessing BD, Winkler CA, O'Brien SJ (2010) Accounting for multiple comparisons in a genome-wide association study (GWAS). BMC genomics 11:724. doi:10.1186/1471-2164-11-724

213. Sion AM, Figg WD (2006) Lysyl oxidase (LOX) and hypoxia-induced metastases. Cancer biology & therapy 5 (8):909-911

214. Wiklund F (2010) Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers? Genome Med 2 (7):45. doi:gm166 [pii]

10.1186/gm166

215. Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, Oue N, Yasui W, Imai K, Nakachi K, Poellinger L, Nishiyama M (2003) Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 24 (11):1779-1783. doi:10.1093/carcin/bgg132

216. Semenza GL (1999) Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annual review of cell and developmental biology 15:551-578. doi:10.1146/annurev.cellbio.15.1.551

217. Smaldone MC, Maranchie JK (2009) Clinical implications of hypoxia inducible factor in renal cell carcinoma. Urologic oncology 27 (3):238-245. doi:10.1016/j.urolonc.2007.12.001

218. Foley R, Marignol L, Thomas AZ, Cullen IM, Perry AS, Tewari P, O'Grady A, Kay E, Dunne B, Loftus B, Watson WR, Fitzpatrick JM, Woodson K, Lehman T, Hollywood D, Lynch TH, Lawler M (2009) The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers. Cancer biology & therapy 8 (2):118-124

219. Chau CH, Permenter MG, Steinberg SM, Retter AS, Dahut WL, Price DK, Figg WD (2005) Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. Cancer biology & therapy 4 (11):1222-1225

220. Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ, Ma J (2007) Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. The Prostate 67 (12):1354-1361. doi:10.1002/pros.20589

221. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A (2011) EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59 (4):572-583. doi:S0302-2838(11)00046-7 [pii]

10.1016/j.eururo.2011.01.025

222. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 (7):1148-1159. doi:26/7/1148 [pii]

10.1200/JCO.2007.12.4487

223. Anastasiadis AG, Stisser BC, Ghafar MA, Burchardt M, Buttyan R (2002) Tumor hypoxia and the progression of prostate cancer. Current urology reports 3 (3):222-228

224. Li P, Cao Q, Shao PF, Cai HZ, Zhou H, Chen JW, Qin C, Zhang ZD, Ju XB, Yin CJ (2012) Genetic polymorphisms in HIF1A are associated with prostate cancer risk in a Chinese population. Asian journal of andrology 14 (6):864-869. doi:10.1038/aja.2012.101

225. Orr-Urtreger A, Bar-Shira A, Matzkin H, Mabjeesh NJ (2007) The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1 alpha is associated with increased risk for prostate cancer. The Prostate 67 (1):8-13. doi:10.1002/pros.20433

226. Fu XS, Choi E, Bubley GJ, Balk SP (2005) Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. The Prostate 63 (3):215-221. doi:10.1002/pros.20190

227. Teixeira AL, Ribeiro R, Morais A, Lobo F, Fraga A, Pina F, Calais-da-Silva FM, Calais-da-Silva FE, Medeiros R (2009) Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. The pharmacogenomics journal 9 (5):341-346. doi:10.1038/tpj.2009.20

228. Teixeira AL, Ribeiro R, Cardoso D, Pinto D, Lobo F, Fraga A, Pina F, Calais-da-Silva F, Medeiros R (2008) Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clinical cancer research : an official journal of the American Association for Cancer Research 14 (11):3367-3371. doi:10.1158/1078-0432.CCR-07-5119

229. Xu J, Zheng SL, Isaacs SD, Wiley KE, Wiklund F, Sun J, Kader AK, Li G, Purcell LD, Kim ST, Hsu FC, Stattin P, Hugosson J, Adolfsson J, Walsh PC, Trent JM, Duggan D, Carpten J, Gronberg H, Isaacs WB (2010) Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 107 (5):2136-2140. doi:10.1073/pnas.0914061107

230. Zhao T, Lv J, Zhao J, Nzekebaloudou M (2009) Hypoxia-inducible factor-1alpha gene polymorphisms and cancer risk: a meta-analysis. Journal of experimental & clinical cancer research : CR 28:159. doi:10.1186/1756-9966-28-159

231. Vainrib M, Golan M, Amir S, Dang DT, Dang LH, Bar-Shira A, Orr-Urtreger A, Matzkin H, Mabjeesh NJ (2012) HIF1A C1772T polymorphism leads to HIF-1alpha mRNA overexpression in prostate cancer patients. Cancer biology & therapy 13 (9):720-726. doi:10.4161/cbt.20554

232. Ranasinghe WK, Xiao L, Kovac S, Chang M, Michiels C, Bolton D, Shulkes A, Baldwin GS, Patel O (2013) The role of hypoxia-inducible factor 1alpha in determining the properties of castrate-resistant prostate cancers. PloS one 8 (1):e54251. doi:10.1371/journal.pone.0054251

233. Jeong CW, Yoon CY, Jeong SJ, Hong SK, Byun SS, Kwak C, Lee SE (2013) The role of hypoxia-inducible factor-1alpha and -2alpha in androgen insensitive prostate cancer cells. Urologic oncology 31 (8):1448-1456. doi:10.1016/j.urolonc.2012.03.022

234. Mathieu J, Zhang Z, Zhou W, Wang AJ, Heddleston JM, Pinna CM, Hubaud A, Stadler B, Choi M, Bar M, Tewari M, Liu A, Vessella R, Rostomily R, Born D, Horwitz M, Ware C, Blau CA, Cleary MA, Rich JN, Ruohola-Baker H (2011) HIF induces human embryonic stem cell markers in cancer cells. Cancer research 71 (13):4640-4652. doi:10.1158/0008-5472.CAN-10-3320

235. Dai Y, Bae K, Siemann DW (2011) Impact of hypoxia on the metastatic potential of human prostate cancer cells. International journal of radiation oncology, biology, physics 81 (2):521-528. doi:10.1016/j.ijrobp.2011.04.027

236. Bratt O, Haggman M, Ahlgren G, Nordle O, Bjork A, Damber JE (2009) Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. British journal of cancer 101 (8):1233-1240. doi:10.1038/sj.bjc.6605322

237. Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Bjork A, Nordle O, Forsberg G, Carducci MA, Armstrong AJ (2011) Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29 (30):4022-4028. doi:10.1200/JCO.2011.35.6295

238. Jennbacken K, Welen K, Olsson A, Axelsson B, Torngren M, Damber JE, Leanderson T (2012) Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050). The Prostate 72 (8):913-924. doi:10.1002/pros.21495

239. Liu XQ, Xiong MH, Shu XT, Tang RZ, Wang J (2012) Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth. Molecular pharmaceutics 9 (10):2863-2874. doi:10.1021/mp300193f

240. Gronberg H (2003) Prostate cancer epidemiology. Lancet 361 (9360):859-864. doi:10.1016/S0140-6736(03)12713-4

241. Vickers AJ, Roobol MJ, Lilja H (2012) Screening for prostate cancer: early detection or overdetection? Annual review of medicine 63:161-170. doi:10.1146/annurev-med-050710-134421

242. Lindstrom S, Schumacher F, Siddiq A, Travis RC, Campa D, Berndt SI, Diver WR, Severi G, Allen N, Andriole G, Bueno-de-Mesquita B, Chanock SJ, Crawford D, Gaziano JM, Giles GG, Giovannucci E, Guo C, Haiman CA, Hayes RB, Halkjaer J, Hunter DJ, Johansson M, Kaaks R, Kolonel LN, Navarro C, Riboli E, Sacerdote C, Stampfer M, Stram DO, Thun MJ, Trichopoulos D, Virtamo J, Weinstein SJ, Yeager M, Henderson B, Ma J, Le Marchand L, Albanes D, Kraft P (2011) Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers--results from BPC3. PloS one 6 (2):e17142. doi:10.1371/journal.pone.0017142

243. Febbo PG (2009) Genomic approaches to outcome prediction in prostate cancer. Cancer 115 (13 Suppl):3046-3057. doi:10.1002/cncr.24350

244. Moore SC, Leitzmann MF, Albanes D, Weinstein SJ, Snyder K, Virtamo J, Ahn J, Mayne ST, Yu H, Peters U, Gunter MJ (2009) Adipokine genes and prostate cancer risk. International journal of cancer Journal international du cancer 124 (4):869-876. doi:10.1002/ijc.24043

245. Wang H, St Julien KR, Stevenson DK, Hoffmann TJ, Witte JS, Lazzeroni LC, Krasnow MA, Quaintance CC, Oehlert JW, Jelliffe-Pawlowski LL, Gould JB, Shaw GM, O'Brodovich HM (2013) A genome-wide association study (GWAS) for bronchopulmonary dysplasia. Pediatrics 132 (2):290-297. doi:10.1542/peds.2013-0533

246. Danforth KN, Rodriguez C, Hayes RB, Sakoda LC, Huang WY, Yu K, Calle EE, Jacobs EJ, Chen BE, Andriole GL, Figueroa JD, Yeager M, Platz EA, Michaud DS,

Chanock SJ, Thun MJ, Hsing AW (2008) TNF polymorphisms and prostate cancer risk. The Prostate 68 (4):400-407. doi:10.1002/pros.20694

247. Jacobs EJ, Hsing AW, Bain EB, Stevens VL, Wang Y, Chen J, Chanock SJ, Zheng SL, Xu J, Thun MJ, Calle EE, Rodriguez C (2008) Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 17 (4):972-977. doi:10.1158/1055-9965.EPI-07-2787

248. Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schroder FH, Sternberg CN, Studer UE (2012) Contemporary role of androgen deprivation therapy for prostate cancer. European urology 61 (1):11-25. doi:10.1016/j.eururo.2011.08.026

249. Scher HI, Kelly WM, Zhang ZF, Ouyang P, Sun M, Schwartz M, Ding C, Wang W, Horak ID, Kremer AB (1999) Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 91 (3):244-251

250. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nature reviews Cancer 1 (1):34-45. doi:10.1038/35094009

251. Attar RM, Takimoto CH, Gottardis MM (2009) Castration-resistant prostate cancer: locking up the molecular escape routes. Clinical cancer research : an official journal of the American Association for Cancer Research 15 (10):3251-3255. doi:10.1158/1078-0432.CCR-08-1171

252. Ribeiro R, Vasconcelos A, Costa S, Pinto D, Morais A, Oliveira J, Lobo F, Lopes C, Medeiros R (2004) Overexpressing leptin genetic polymorphism (-2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease. Prostate 59 (3):268-274. doi:10.1002/pros.20004

253. Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, De Marzo AM, Isaacs WB, Drake CG, Shugart YY, Platz EA (2009) Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. The Prostate 69 (8):874-885. doi:10.1002/pros.20933

254. Kwon EM, Salinas CA, Kolb S, Fu R, Feng Z, Stanford JL, Ostrander EA (2011) Genetic polymorphisms in inflammation pathway genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 20 (5):923-933. doi:1055-9965.EPI-10-0994 [pii]

10.1158/1055-9965.EPI-10-0994

255. Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ (2011) Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. BJU Int. doi:10.1111/j.1464-410X.2011.10754.x

256. Wang Y, Zheng Y, Zhang W, Yu H, Lou K, Zhang Y, Qin Q, Zhao B, Yang Y, Hui R (2007) Polymorphisms of KDR gene are associated with coronary heart disease. Journal of the American College of Cardiology 50 (8):760-767. doi:10.1016/j.jacc.2007.04.074

257. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63 (4):812-816

258. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene:

correlation with variation in VEGF protein production. Cytokine 12 (8):1232-1235. doi:10.1006/cyto.2000.0692

S1043-4666(00)90692-6 [pii]

259. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37 (6):443-448. doi:54076 [pii]

260. Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. JAMA 294 (2):238-244. doi:294/2/238 [pii]

10.1001/jama.294.2.238

261. Devlin HL, Mudryj M (2009) Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 274 (2):177-186. doi:S0304-3835(08)00458-8 [pii]

10.1016/j.canlet.2008.06.007

262. Schroder FH (2008) Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol 53 (6):1129-1137. doi:S0302-2838(08)00060-2 [pii]

10.1016/j.eururo.2008.01.049

263. Chen J (2011) Multiple signal pathways in obesity-associated cancer. Obes Rev 12 (12):1063-1070. doi:10.1111/j.1467-789X.2011.00917.x

264. Onuma M, Bub JD, Rummel TL, Iwamoto Y (2003) Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem 278 (43):42660-42667. doi:10.1074/jbc.M304984200

M304984200 [pii]

265. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW (1999) Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 38 (3):199-207. doi:10.1002/(SICI)1097-0045(19990215)38:3<199::AID-PROS4>3.0.CO;2-H [pii]

266. Iwamura M, Sluss PM, Casamento JB, Cockett AT (1993) Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 22 (3):243-252

267. Ribeiro RJ, Monteiro CP, Azevedo AS, Cunha VF, Ramanakumar AV, Fraga AM, Pina FM, Lopes CM, Medeiros RM, Franco EL (2012) Performance of an adipokine pathway-based multilocus genetic risk score for prostate cancer risk prediction. PloS one 7 (6):e39236. doi:10.1371/journal.pone.0039236

268. Pertega-Gomes N, Vizcaino JR, Miranda-Goncalves V, Pinheiro C, Silva J, Pereira H, Monteiro P, Henrique RM, Reis RM, Lopes C, Baltazar F (2011) Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC cancer 11:312. doi:10.1186/1471-2407-11-312

269. Semenza GL (2012) Hypoxia-inducible factors in physiology and medicine. Cell 148 (3):399-408. doi:10.1016/j.cell.2012.01.021

270. Saraswati S, Kumar S, Alhaider AA (2013) alpha-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway. Molecular cancer 12:147. doi:10.1186/1476-4598-12-147

271. Hahn D, Simak R, Steiner GE, Handisurya A, Susani M, Marberger M (2000) Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. The Journal of urology 164 (2):506-510

272. Song J, Song Y, Guo W, Jia J, Jin Y, Bai A (2014) Regulatory roles of KDR antisense oligonucleotide on the proliferation of human prostate cancer cell line PC-3. Journal of BUON : official journal of the Balkan Union of Oncology 19 (3):770-774

273. Schweizer MT, Carducci MA (2013) From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer. Cancer journal 19 (1):99-106. doi:10.1097/PPO.0b013e31827e0b86

274. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer research 60 (24):7075-7083

275. Stewart GD, Nanda J, Brown DJ, Riddick AC, Ross JA, Habib FK (2009) NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. International journal of cancer Journal international du cancer 124 (1):223-232. doi:10.1002/ijc.23934

276. Smyth LG, O'Hurley G, O'Grady A, Fitzpatrick JM, Kay E, Watson RW (2010) Carbonic anhydrase IX expression in prostate cancer. Prostate cancer and prostatic diseases 13 (2):178-181. doi:10.1038/pcan.2009.58

277. Pertega-Gomes N, Vizcaino JR, Attig J, Jurmeister S, Lopes C, Baltazar F (2014) A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC cancer 14:352. doi:10.1186/1471-2407-14-352

278. Kim HO, Jo YH, Lee J, Lee SS, Yoon KS (2008) The C1772T genetic polymorphism in human HIF-1alpha gene associates with expression of HIF-1alpha protein in breast cancer. Oncology reports 20 (5):1181-1187

279. Min C, Yu Z, Kirsch KH, Zhao Y, Vora SR, Trackman PC, Spicer DB, Rosenberg L, Palmer JR, Sonenshein GE (2009) A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer. Cancer research 69 (16):6685-6693. doi:10.1158/0008-5472.CAN-08-4818

280. Wakasaki H, Ooshima A (1990) Immunohistochemical localization of lysyl oxidase with monoclonal antibodies. Laboratory investigation; a journal of technical methods and pathology 63 (3):377-384

Documento descargado de http://www.elsevier.es el 15/02/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.

ACTAS UROLÓGICAS ESPAÑOLAS

www.elsevier.es/actasuro



Review – Oncology

Tumor hypoxia. The role of HIF

Avelino Fraga, Ricardo Ribeiro, and Rui Medeiros*

Instituto Português Oncologia, Oncologia Molecular, Porto, Portugal

ARTICLE INFORMATION

Article history:
Received on 16 April 2009
Accepted on 25 June 2009

Keywords:
HIF
Hypoxia
Cancer

A B S T R A C T

Solid tumors usually occur and progress in a hypoxic environment, suggesting that tumor cells are resistant to apoptosis and are associated to an increased angiogenesis, which makes them more aggressive, with invasive capacity and resistant to treatment.

The genetic and biological mechanisms underlying this phenomenon are still unclear, but many studies suggest a role of HIF in this process. Under hypoxic conditions, the alpha subunit is not destroyed, and will activate transcription of a set of genes contributing to tumor aggressiveness. Its expression is associated to an increased metastatic potential that has been shown in both animal studies and human tumors.

Tumor hypoxia has emerged as a key factor in tumor progression and is associated to a poor prognosis, particularly in kidney and prostate tumors. The purpose of this study was to review the significance of hypoxia in carcinogeneses and tumor progression by reviewing the current knowledge on the subject and the mechanisms of action and activation of HIF-1α.

© 2009 AEU. Published by Elsevier España, S.L. All rights reserved.

Hipoxia tumoral. Papel del factor inducible por hipoxia

Keywords:
HIF
Hypoxia
Cancer

A B S T R A C T

Los tumores sólidos, por lo general, existen y progresan en un ambiente de hipoxia; así se observa que las células tumorales son resistentes a la apoptosis y se acompañan de un aumento de la angiogénesis, volviéndose más agresivas, con capacidad invasora y resistentes al tratamiento.

La genética y los mecanismos biológicos subyacentes a este fenómeno son todavía poco claros, pero muchos estudios sugieren un papel del factor inducible por hipoxia *(hipoxia inducible factor* [HIF]) en este proceso. En condiciones de hipoxia, la subunidad alfa no es destruida y activará la transcripción de un conjunto de genes que contribuyen a la agresividad del tumor. Su expresión está asociada a un aumento del potencial metastásico que se verifica tanto en estudios animales, como en tumores humanos.

**Author for correspondence.*
Email: avfraga@gmail.com (A. Fraga).

0210-4806/$ - see front matter © 2009 AEU. Published by Elsevier España, S.L. All rights reserved

Documento descargado de http://www.elsevier.es el 15/02/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.

La hipoxia tumoral se ha convertido en un factor clave en la progresión tumoral y se asocia a un mal pronóstico, sobre todo en tumores de riñón y próstata. Este trabajo tiene por objetivo revisar la importancia de la hipoxia en la carcinogénesis y en la progresión tumoral, presentando una revisión de los conocimientos actuales sobre el tema, mecanismos de acción y la activación del HIF-1α.

© 2009 AEU. Publicado por Elsevier España, S.L. Todos los derechos reservados.

Introduction

Hypoxia-inducible factor (HIF) is a transcription factor that regulates cells' response to hypoxia and acts as a regulator of oxygen homeostasis[1-3]. Wang and Semenza's[4] identification of the HIF transcription system is crucial for understanding the physiology of O_2; we now know that HIF and hypoxia are the main determinants of angiogenesis and that, for instance, they regulate the processes of invasion and metastasis that determine the tumor's aggressiveness.

The transcription factor activates genes that codify proteins that increase the availability of oxygen and permit metabolic adaptation in the absence of oxygen; it controls the expression of dozens of genes and protein products involved in angiogenesis, erythropoiesis, glycolysis, invasion, apoptosis, vascular tone, pH regulation, epithelial homeostasis, and drug resistance.

More than 60 target genes induced by HIF have been identified[2]; others are suppressed[7]; many functions are HIF-dependent[7].

Molecular structure of HIF-1α

The *HIF1A* gene, which codifies HIF-1α, is located in the 14q21-q24 *locus*[9], which contains 15 exons[10]. It is a heterodimer composed of alpha chains (regulated by O_2) and beta chains, arranged in a helix-loop-helix (bHLH); it belongs to a family of transcription factors consisting of three alpha subunits (HIF-1α, HIF-2α, HIF-3α) and one beta subunit (HIF 1α), also known as aryl hydrocarbon nuclear translocator (ARNT)[4,11,15].

There are two nuclear localization signals (NLS), located on the C-terminal (aminoacids 718-721) and on the N-terminal (aminoacids 17-33), but only the C-terminal is responsible for the nuclear accumulation of HIF-1α[16]. It is also known that HIF contains two transactivation domains (TAD) in the C-terminal (aminoacids 531-575 and 786-826), separated by a sequence of aminoacids (575-786) that inhibit transactivation[17] (Fig. 1).

The N-terminal of the molecule (aminoacid 1-390) contains the bHLH-PAS domain, necessary for dimerization and binding to DNA[18]. The interaction between the bHLH domains of the two subunits regulates their dimerization[19].

The C-terminal domain's function is to signal the translocation of HIF-1α for the nucleus, protein stabilization, and interaction with coactivator p300[17]. In the domain of oxygen-dependent degradation (ODD) domain of HIF-1α, proline residues in positions 402 and 564 have an important effect on the stability of the protein in normoxic conditions, as they permit, when hydroxylated, recognition by the von Hippel-Lindau protein (pVHL) and subsequent activation of the ubiquitin degradation pathway[20-25]. The hydroxylation of proline residues in the ODD domain of HIF-1α is the critical point that regulates the protein's stability[26,27] (Fig. 2). The transcription activity of HIF1A genes is thus regulated by the cellular oxygen tension.

Molecular mechanisms of HIF and of HIF1A activation

In the presence of O_2, the proline hydroxylation domains (PHD1, 2, 3) provoke specific hydroxylation in two proline residues (P402 y P564) in the HIF-1α ODD, which allows pVHL to recognize HIF-1α; the E3-ubiquitin complex is formed, which will transform HIF-1α into a degradation target[30-33]. Jaakkola et al[32] showed that the interaction between pVHL and the specific HIF-1α domain is regulated by the hydroxylation of the proline residue (HIF-1α P564) by an enzyme called HIF-1α prolyl hydroxylase (HIF-PH), which requires iron and oxygen.

Another O_2 sensor is the factor inhibiting HIF-1 (FIH-1), which hydroxylates HIF-1α in the presence of O_2, at the asparagine residue 803 in the transcription activation domain of the C-terminal (C-TAD), and is inactive in hypoxia, which permits interaction with co-activators CBP/p300[34,35] (fig. 2).

In hypoxic conditions, molecular O_2 is not available, and thus the enzymes are inactive, which implies elevated levels of HIF-1α[36]. HIF-1α is not hydroxylated, and therefore not degraded; this causes it to accumulate in heterodimerized form with the beta subunit (HIF-β). This heterodimer migrates toward the nucleus, where it binds to the specific DNA sequences, and activates genes involved in the adaptation to hypoxia, cell survival, angiogenesis, and metastasis, such as, for instance, vascular endothelial growth factor (VEGF), transforming growth factor alpha (TGF-α), glucose transporter 1 (GLUT-1), and carbonic anhydrase IX (CA9), among many others known to be involved in tumor development and aggressiveness[37,38].

Therefore, the main regulator of HIF is oxygen[22,39]. The second in order of importance are oncogenes, which may contribute to stabilize or degrade protein. For example, protein p53, the product of the tumor suppressor gene TP53, inhibits the activity of HIF-1α and becomes a target for proteasomal degradation[40]. However, TP53 deletions or mutations may facilitate the accumulation of HIF-1α in conditions of hypoxia, increasing the expression of VEGF in tumor cells.

The product of the tumor suppressor gene VHL also regulates the stability of HIF-1α[42], since in the presence of oxygen pVHL can bind to the HIF-1α subunit and become

Documento descargado de http://www.elsevier.es el 15/02/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.



Figure 1 – Molecular structure of HIF-1α. Adapted from Shi YH[55].

Figure 2 - Stability and activity of the hypoxia-inducible factor. Adapted from Brahimi-Horn and Pouyssegur[94].

Documento descargado de http://www.elsevier.es el 15/02/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.



Figure 3 – HIF-1α signaling and regulation pathways: oncogenes, growth factors, and hypoxia. Adapted from Shi YH et al[4].

a target for prolyl-hydroxylation[25-27]. Additionally, other oncogenes (v-Src or RasV12) inhibit prolyl-hydroxylation, which implies stabilization of HIF-1α[39-42].

We also know that the expression of the *HIF1A* gene can be regulated through other pathways, mainly the those of intracellular signaling, such as protein-kinase B (Akt) and phosphatidylinositol 3'-kinase (PI3K), although its role in these regulation pathways is not yet clear.

Other HIF1A-regulating molecules have been described, such as the oxygen-reactive species (ROS) involved in carcinogenesis, or cytokines like the tumor necrosis factor (TNF-α) and angiotensin[49-53], which signal pathways such as RAS/RAF1/MEK1/ERK1/2 and/or p53/JNK, activated as a response to oncogenes, growth factors, or hypoxia (Fig. 3).

General functions of the HIF1A gene

Hypoxia is a diminished oxygen tension, defined in clinical terms as a reduction of the availability of oxygen to critical levels (tension under 7%)[53].

HIF-1α is involved in the response to hypoxia, in oxygen homeostasis, and in myocardial, brain and retinal ischemia, pulmonary hypertension, preeclampsia, intrauterine growth retardation, and cancer. It plays a crucial role in physiological homeostatic and etiopathological mechanisms. It acts on target genes because its function is regulated by growth factors and genetic abnormalities involved in tumor progression[54,55].

Aberrant blood vessels can disappear at any time, but they can sometimes be reutilized, causing local reoxygenation, stimulating sudden changes of hypoxia and reoxygenation as a result of local angiogenesis[56-59].

The tumor's environment is well characterized; it is understood as a fluctuation between hypoxia and nutrient deprivation that leads to genetic and epigenetic adaptation of cell clones, which increases its invasion and metastatic capacity.

Additionally, these adaptations to hypoxia make tumors more difficult to treat and more resistant to therapies. An important part of this process is the adaptation of gene products as a response to hypoxia, and the fact that many of these hypoxia-regulated genes are mediated by HIF1A[60]; approximately 1% of the genome is estimated to be regulated by hypoxia.

Tumor hypoxia by itself is an important epigenetic factor in the regulation of the HIF-1α protein. In addition to inhibiting PSDs and HIF-1α, hypoxia generates oxygen free radicals capable of stabilizing the HIF-1α protein and of inducing the *HIF* and *VEGF* genes[61,62].

Documento descargado de http://www.elsevier.es el 15/02/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.



Figure 4 – Responses determined by the hypoxia-inducible factor: it acts as the main physiologic regulator of hypoxia. Adapted from Acker and Plate[93].

When hypoxia is established, there is a cell response to prevent apoptosis[63], and the HIF-1α transcription factor is activated, which generates a heterodimer with HIF-1 (ARNT) in the hypoxia response element (HRE), which leads to a multiple cell response and the activation of oncogenes[64], increased vascularization with the production of VEGF, increased glucose transport (GLUT1), increased activity of carbonic anhydrase (CA9), and even the induction of several apoptotic genes[65-67]. HIF is known to act on genes that codify erythropoietin, transferrin, endothelin-1, inducible nitric oxide synthase (iNOS), hemoxygenase 1, insulin growth factor-2 (IGF-2), insulin-like growth factor-binding proteins 1, 2 and 3 (IGFBP 1, 2, 3), glucose transporters (GLUT), and glycolytic enzymes[18,28,68] (Fig. 4). This promotes metabolic adaptation to hypoxia, and is also regulated by O_2 tension, depending on the expression of the HIF-1α subuinit[69]. Malignant cells' ability to adapt to hypoxia is fundamental for tumor growth (Table 1).

Table 1 – Molecules regulated by HIF-1# and their pathophysiologic action

Molecule	Function	References
VEGF	Angiogenesis	5-7, 16, 37, 38, 66, 68, 71-78
Erythropoietin	Erythropoiesis	5-7, 16, 66, 68, 77, 78
GLUT-1	Glycolysis	5-7, 16, 37, 38, 66, 68, 77, 78
TGF-α	Invasion and metastasis	5-7, 37, 38, 78
Transferrin	Apoptosis	5-7, 16, 68, 77, 78
Endothelin	Vascular tone	5-7, 16, 68, 77, 78
CA 9	pH regulator	5-7, 37, 38, 66, 77, 78
iNOS	Drug resistance	5-7, 16, 68, 77, 78 8
IGFBP-1, 2, 3	Homeostasis	5-7, 16, 68, 77, 78

Hypoxia, hypoxia inducible factor, and cancer

Hypoxia is significantly less in tumors in which the average O_2 tension exceeds 1.5%[53,79,80].

In order to survive, tumor cells must adapt to a low pO_2; many genomic products are involved in tumor neoangiogenesis. These adaptations contribute to phenotypic survival and clinical aggressiveness[81]. Tumor hypoxia has been associated with poor prognosis in many kinds of cancer[82].

Tumor cell clones can adapt to hypoxic microenvironments in both primary and metastatic sites. The genetic and epigenetic mechanisms of adaptation to hypoxia (genetic instability, aerobic glycolysis, loss of control of the cell cycle, loss of apoptosis signaling) are characteristic of malignancy[60] (Fig. 5).

There is evidence that hypoxia may control and maintain genetic instability. This genetic instability may reduce DNA repair and increase the rate of mutation[66].

Intratumor hypoxia is a factor of poor prognosis observed in prostate, breast, musculoskeletal, head and neck, and cervical cancer[83-85]; it is associated with a higher rate of failure of radiotherapy, chemotherapy, and with increased metastases[66].

We know that the activation of aerobic glycolysis represents an initial event in the process of neoplastic transformation, probably as a response to increased cell proliferation[86], since rapidly proliferating cells consume more oxygen. Tumors have increased glycolysis, and we know that the concentration of glucose and of components of the glycolytic pathway have an effect on HIF[87,88]. The tumor pH is more acidic due to an increased production of lactate and CO_2. In order to survive,

Documento descargado de http://www.elsevier.es el 15/02/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.



Figure 5 – HIF-1α regulation.

cells must maintain a balance between the intracellular and the extracellular pH; this is achieved thanks to several transporters. Carbonic anhydrase IX (CA9) plays a fundamental role in this balance; several studies have shown a correlation between hypoxia, angiogenesis, HIF-1α, and CA9[89].

Therefore, HIF levels are adapted for cells to maintain a high rate of proliferation; on the other hand, the increased cell proliferation may induce an increased expression of HIF[28]. In conditions of hypoxia, where the action of growth factors leads to an increased cell proliferation and thus to an increased oxygen requirement, HIF-1α is more expressed and activated, inducing the expression of genes that codify the pro-angiogenic molecules that permit metabolic adaptation to hypoxia; this is the most powerful activator of genes that codify glycolytic enzymes and pro-angiogenic growth factors[28,90-93], since tumors cannot thrive without angiogenesis that allows the diffusion of oxygen, glucose, and other nutrients[77,78].

Angiogenesis is the development of new blood vessels from the preexisting vessel network, and plays a preponderant role in various pathophysiologic mechanisms, both benign (cicatrization, wounds, ischemia, diabetic retinopathy) and malignant (tumor growth and metastasis); VEGF plays a fundamental role in angiogenesis, and is regulated by HIF[94-96].

Currently, there is evidence that tumor blood vessels are disorganized and lack an adequate structure for circulation, which often leads to collapse. Since tumor development requires oxygen, nutrients, and an adequate metabolic function, it is necessary to promote angiogenesis factors in order to inhibit the apoptosis of tumor cells triggered by hypoxia. Therefore, angiogenesis as a response to tumor hypoxia is mediated by HIF-1α[55].

HIF-1α has been considered a key factor in the regulation of VEGF and its receptor (VEGRF), as well as of other angiogenic factors. Several immunohistochemical studies conducted on various tumor models[71] show that the expression of HIF-1α is associated with an increase in VEGF and of vascularization and metastasis, which imply a worse prognosis[72,76]. There seems to be a direct relationship between angiogenesis and metastasis in several kinds of tumors, such as melanoma, glyoma, lung, breast, ovary, bladder, and prostate cancers[97,98]. It has been proven that HIF-1α target proteins are implicated in the proliferation, survival, adhesion, and mobility of cancer cells.

On the other hand, an increased expression of HIF-1α, in combination with inactivated mutations in suppressor genes such as VHL, p53, PTEN or the amplification of the oncogenes Akt, RAS, ERK1/2, has often been observed in cancer patients; these abnormalities are associated with tumor growth, invasion, and metastasis.

Zhong et al[99] have demonstrated an increased expression of HIF-1α in approximately 53% of tumors, including cancer

Documento descargado de http://www.elsevier.es el 15/02/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.

of colon, stomach, pancreas, lung, ovary, prostate, kidney, melanoma, and glyoblastoma. The increased expression of HIF-1α is associated with a shorter survival in breast and uterine cancer, and with poor response to treatment in nasopharyngeal cancer, highlighting the role of tumor hypoxia in prognosis[72,100-104] (Table 2).

In prostate cancer, it is expressed in the initial stages of carcinogenesis, and this expression is associated with diagnostic and prognostic indicators of early relapse and metastasis; HIF-1 may be a potential poor-prognosis biomarker. Its importance in tumor progression becomes a potential target in chemoprevention strategies and in the ability to inhibit angiogenesis[60]. Experimental studies with mice prostate cancer cells show that an overexpression of HIF-1α is associated with more growth and metastatic potential[108]. Similarly, a greater expression of HIF-1α has been found in human prostate tumors[48,99]. The *VEGF* gene, induced mainly by HIF-1α, has been frequently found to be overexpressed in prostate cancer, especially in patients with metastatic or hormone-resistant cancer; this suggests a central action of this molecule in this process[105,106].

The activation of oncogenes and growth factors can induce the HIF system in non-hypoxidating cells, or amplify the response to hypoxia. In fact, several growth factors and cytokines of the stroma and parenchyma also act as regulators and are capable of inducing the expression of HIF-1α, its binding and transactivation capacity, such as the epidermal growth factor (EGF)[46], TGFα[92,107], factors IGF-1 and IGF-2[109], and interleukin 1b[110]. Additionally, recent studies show that HIF may play an important role in resistance to treatment[111-113].

The HIF system acts as the main regulator of the response to hypoxia, triggering the cascade of mechanisms that permit the tumor to adapt to a hostile environment, and emerges as an important transcription factor in the biology of cancer.

Conclusion

The activation of HIF is regulated by several mechanisms that arise from the stabilization of the HIF-1α subunits, which involves multiple signals and pathways.



Figure 6 - Role of HIF in cell survival and death. Adapted from Acker and Plate[93].

Hypoxia, some tumor suppressor genes, growth factors, and cytokines increase the stability and/or transactivation of HIF1A, which results in an increased production of HIF-1α and consequently, tumor angiogenesis, metabolic adaptation to hypoxia, and a prolonged cell survival, due to the action on several target genes. HIF-1α is crucial for the initiation of angiogenesis, tumor growth, progression, and metastasis.

Thus, it seems critical to develop techniques to block or inhibit angiogenesis and the HIF1α factor to reduce the chances of it becoming a more aggressive cancer. This would reduce cancer morbidity and mortality.

HIF-1α may be an early marker for carcinogenesis, valuable for predicting tumor progression and prognosis.

REFERENCES

1. Semenza GL. HIF-1 and human disease: One highly involved factor. Genes Dev. 2000;14:1983-91.
2. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721-32.
3. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002;2:673-82.
4. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995;270:1230-7.
5. Semenza GL. HIF 1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002;8:S62-7.
6. Semenza GL. Involvement of HIF 1 in human cancer. Intern Med. 2002;41:79-83.

Table 2 – Tumors that show overexpression of HIF assessed with immunohistochemistry

References	99	83-85	97, 98	72, 100-104	48, 60, 105-108
Colon	X				
Stomach	X				
Pancreas	X				
Lung	X		X		
Ovary	X		X		
Uterus		X		X	
Prostate	X	X	X		X
Kidney	X				
Glioma	X		X		
Breast		X	X	X	
Head and neck		X			
Melanoma	X		X		

Documento descargado de http://www.elsevier.es el 15/02/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.

7. Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood. 2005;105:659-69.
8. ain RK. Normalizing tumor vasculature with anti angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7:987-9.
9. Semenza GL, Rue EA, Iyer NV, Pang MG, Kearns WG. Assignment of the hypoxia inducible factor 1a gene to a region of conserved synteny on mouse chromosome 12 and human chromosome 14q. Genomics. 1996;34:437-9.
10. Iyer NV, Leung SW, Semenza GL. The human hypoxia inducible factor 1 alpha gene: HIF1A structure and evolutionary conservation. Genomics. 1998;52:159-65.
11. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 1997;11:72-82.
12. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA. 1997; 94:4273-8.
13. Flamme I, Frohlich T, Von Reutern M, Kappel A, Damert A, Risau W. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels. Mech Dev. 1997;63:51-60.
14. Gu YZ, Moran SM, Hogenesch JB, Wartman L, Bradfield CA. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr. 1998;7:205-13.
15. Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factores, and O2-regulated gene expression. FASEB J 2002;16:1151-62.
16. Vandromme M, GauthierRouviere C, Lamb N, Fernandez A. Regulation of transcription factor localization: Fine-tuning of gene expression. Trends Biochem Sci. 1996;21:59-64.
17. Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL. Transactivation and inhibitory domains of hypoxia-inducible factor 1 alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem. 1997;272:19253-60.
18. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem. 1996;271: 17771-8.
19. Michel G, Minet E, Ernest I, Roland I, Durant F, Remacle J, et al. A model for the complex between the hypoxia-inducible factor-1 (HIF-1) and its consensus DNA sequence. J Biomol Struc Dyn. 2000;18:169-79.
20. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1 alpha is mediated by an O-2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 1998;95:7987-92.
21. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHLmediated destruction by proline hydroxylation: Implications for O2 sensing. Science. 2001;292:464-8.
22. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294:1337-40.
23. Pause A, Lee S, Worrell RA, Chen DYT, Burguess WH, Marston Linehan W, et al. The von Hipple-Lindau tumor suppressor gene product forms a stable complex with human cul-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA. 1997;94:2156-61.
24. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, et al. Regulation of hypoxia –inducible mRNAs by the von Hipple-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol. 1998;18:732-41.
25. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumor suppressor protein VHL targets hypoxia inducible factores for oxygen –dependent proteolysis. Nature. 1999;399:271-5.
26. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, et al. Ubiquitination of hypoxia inducible factor requires direct binding to the beta domain of the von Hipple-Lindau protein. Nat Cell Biol 2000;2:423-7.
27. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia inducible factor 1 alpha by the von Hipple Lindau tumor suppressor protein. EMBO J. 2000;19:4298-309.
28. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia- inducible factor 1. J Biol Chem. 1996;271:32529-37.
29. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell.2001;107:43-54.
30. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr, Pavletich NP. Structure of an HIF-1alpha-pVHL complex: Hydroxyproline recognition in signaling. Science. 2002;296:1886-9.
31. Yu F, White SB, Zhao Q, Lee FS. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA. 2001;98:9630-5.
32. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Piel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468-72.
33. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxiainducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 2001;20:5197-6.
34. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell. 2002;111:709-20.
35. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 2002;295:858-61.
36. Boddy JL. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via HIF1a, HIF2a and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res. 2005;11.7658-63.
37. Wykoff CC, Sotiriou C, Cockman ME, Ratcliffe PJ; Maxwell P, Liu E, et al. Gene array of VHL mutation and hipoxia shows novel hipoxia induced genes and that cyclin D1 is a VHL target gene. Br J Cancer. 2004;90:1235-43.
38. Melillo G. Inhibiting hypoxia inducible factor 1 for cancer therapy. Mol Cancer Res. 2006;4:601-5.
39. Chan DA, Sutphin PD, Denko NC, Giaccia AJ. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. J Biol Chem. 2002;277:40112-7.
40. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by P53 regulation of thrombospondin-1. Science. 1994;265:1582-4.

Documento descargado de http://www.elsevier.es el 15/02/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.

41. Bouvet M, Ellis LM, Nishizaki M, Fujiwara T, Liu WB, Bucana CD, et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res. 1998;58:2288-92.
42. Blancher C, Moore JW, Robertson N, Harris AL. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1 alpha, HIF-2 alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3 '-kinase/Akt signaling pathway. Cancer Res. 2001;61:7349-55.
43. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001;21:3995-4004.
44. Arsham AM, Plas DR, Thompson CB, Simon MC. Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription. J Biol Chem. 2002;277:15162-70.
45. Mottet D, Dumont V, Deccache Y, Demazy C, Ninane N, Raes M, et al. Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. J Biol Chem. 2003;278:31277-85.
46. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, et al. Modulation of hypoxiainducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3- inase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res. 2000;60: 1541-5.
47. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/ phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res. 2003;9:2416-25.
48. Outi RS, Kimmo JS, Nina NN, Ola B, Tapio V. Amplification of HIF 1a gene in prostate cancer. Cancer Genet Cytogenet. 2001;128:31-4.
49. Gao N, Ding M, Zheng JZ, Shi X, Jiang BH. Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J Biol Chem. 2002;277:31963-71.
50. Gao N, Jiang BH, Corum L, Roberts JR, Antonini J, Zheng JZ, et al. p38 aignaling-mediated hypoxia- inducible factor 1alpha and vascular endothelial growth factor induction by Cr(VI) in DU145 human prostate carcinoma cells. J Biol Chem. 2002;277:45041-8.
51. Haddad JJ, Land SC. A non-hypoxic, ROS-sensitive pathway mediates TNF-alpha-dependent regulation of HIF-1alpha. FEBS Lett. 2001;505:269-74.
52. Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1 alpha during hypoxia - A mechanism of O-2 sensing. J Biol Chem. 2000;275:25130-8.
53. Zander R, Vaupel P. Proposal for using a standardized terminology on oxygen transport to tissue. Adv Exp Med Biol. 1985;191:965-70.
54. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C, et al. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J. 2001;15:2445-53.
55. Yong-HS, Wei GF. Hypoxia-inducible factor-1 in tumor angiogenesis. World J Gastroenterol. 2004;10:1082-7.
56. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49: 6449-65.
57. Kimura H, Braun RD, Ong ET, Hsu R, Secomb TW, Papahadjopoulos D, et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 1996; 56: 5522-8.
58. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998;58:1408-16.
59. Dewhirst MW. Concepts of oxygen transport at the microcirculatory level. Semin Radiat Oncol. 1998;8:143-50.
60. Kimbro KS, Simons JW. Hypoxia-inducible factor in human breast and prostate cancer. Endocrine Related Cancer. 2006;13:739-49.
61. Kaelin WG. ROS: really involved in oxygen sensing. Cell Metabolism. 2005;1:357-8.
62. Muzandu K, Shaban Z, Ishizuka M, Kasusaka A, Fujita S. Nitric Oxide enhances catechol estrogen induced oxidative stress in LNCaP cells. Free Radical Research. 2005;39: 389-98.
63. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia inducible factor 1. Annu Ver Cell Dev Biol. 1999;15:551-78.
64. Gleadle JM, Ratcliffe PJ. Induction of hypoxia inducible factor 1, erythropoietin, vascular endothelial growth factor and glucose transporter 1 by hypoxia: evidence against a regulatory role for Src kinase. Blood. 1997;89:503-9.
65. Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, et al. Glucose transporter glut 1 expression correlates with tumor hypoxia and predicts metastasis free survival in advanced carcinoma of the cervix. Clin Cancer Res. 2001;7:928-34.
66. Bristow RG, Richard P. Hypoxia, DNA repair and genetic instability. Hill in Nature Reviews. 2008;8:180-92.
67. Prince BD, Calderwood SK. GADD45 and GADD153 messenger RNA levels are increased during hypoxia and after exposure of cells to agents which elevate the levels of the glucose regulated proteins. Cancer Res. 1992;52: 3814-7.
68. Semenza GL. Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med. 2003;54:17-28.
69. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer. 2000;36:1649-60.
70. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koods RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia inducible factor 1. Mol Cell Biol. 1996;16:4604-13.
71. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, et al. The expression and distribution of the hypoxiainducible factors HIF-1 alpha and HIF-2 alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 2000;157:411-21.
72. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst. 2001;93: 309-14.
73. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung

Documento descargado de http://www.elsevier.es el 15/02/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.

cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer. 2001;85:881-90.
74. Shi BM, Wang XY, Mu QL, Wu TH, Liu HJ, Yang Z. Angiogenesis effect on rat liver after administration of expression vector encoding vascular endothelial growth factor D. World J Gastroenterol. 2003;9:312-5.
75. Toi M, Hoshina S, Takayangi T, Tominaga T. Association of vascular endothelial growth-factor expression with tumor angiogenesis and with early relapse in primary breast-cancer. Jpn Cancer Res. 1994;85:1045-9.
76. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996;77:858-63.
77. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: Identification of a molecular progression switch. Cancer Res. 2001;61: 2736-43.
78. Kerbel RS. New targets, drugs and approaches for the treatment of cancer: an overview. Cancer Metastasis Rev. 1998;17:145-7.
79. Vaupel P. The role of hypoxia induced factores in tumor progression. Oncologist. 2004;9 Suppl 5:10-7.
80. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Seminars in Oncology. 2001;28:29-35.
81. Acs G, Xu X, Chu C, Acs P, Verma A. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer. 2004;100:2376-86.
82. Vleugel MM, Greijer AE, Shvarts A, Van Der Groep P, Van Berkel M, Aarbodem Y, Van Tinteren H, et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol. 2005;58:172-7.
83. Chan N, Milosevic M, Bristow RG. Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol. 2007;3:329-41.
84. Chaudary N, Hill RP. Hypoxia and metastasis. Clin Cancer Res. 2007;13:1947-9.
85. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact in clinical outcome. Cancer Metastasis Ver. 2007;26:225-39.
86. Brand KA, Hermfisse U. Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J. 1997;11:388-95.
87. Gatenby RA, Gilles RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891-9.
88. Vordermark D, Kraft P, Katzer A, Bolling T, Willner J, Flentje M. Glucose requirement for hypoxic accumulation of hypoxia inducible factor 1alpha. Cancer Lett. 2005;230: 122-33.
89. Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, Turley H, Harris AL, et al. Angiogenesis and hypoxia in lymph node metastasis is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer. BR J Cancer. 2005;93: 1128-36.
90. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 2000;88:1474-80.
91. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. Embol J. 1998;17:3005-15.
92. Acker T, Plate KH. A role of hypoxia and hypoxia inducible transcription factores in tumor physiology. J Mol Med. 2002;80:562-75.
93. Acker T, Plate KH. A role of hypoxia in tumor angiogenesis –molecular and cellular angiogenic crosstalk. Cell Tissue Res. 2003;80:562-75.
94. Brahimi-Horn MC, Pouyssegur J. The hypoxia inducible factor and tumor progression along the angiogenic pathway. Int Rev Cytol. 2005;242:157-213.
95. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003;9:677-84.
96. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptores. Nat Med. 2003;9:669-76.
97. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, et al. Angiogenesis in bladder cancer relationship between microvessel density and tumor prognosis. J Natl Cancer Inst. 1995;87:1603-12.
98. Jaeger TM, Weidner N, Chew K, Moore DH, Kerschmann RL, Waldman FM, et al. Tumor angiogenesis correlateswith lymph-node metastases in invasive bladder-cancer. J Urol. 1995;154:69-71.
99. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999;59:5830-5.
100. Bos R, Van der Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, et al. Levels of hypoxiainducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer. 2003;97:1573-81.
101. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res. 2001;7:1661-8.
102. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001;61:2911-6.
103. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266-76.
104. Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity. EMBO J. 2003;22: 1857-67.
105. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 2002;1:237–46.
106. George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, et al. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology. 2004;63:327-32.
107. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 2003;63:1138-43.
108. Zhong H, Agani F, Baccala AA, Laughner E, Rioseco-Camacho N, Isaacs WB, et al. Increased expression of hypoxia inducible factor 1 alpha in rat and human prostate cancer. Cancer Res. 1998; 58:5280-4.
109. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycindependent signaling pathway. J Biol Chem. 2002;277:27975-81.
110. Stiehl DP, Jelkmann W, Wenger RH, Hellwig-Burgel T. Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett. 2002;512:157-62.

Documento descargado de http://www.elsevier.es el 15/02/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.

111. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities and problems for cancer therapy. Cancer Res. 1998;58:1408-16.
112. Wartenberg M, Ling FC, Muschen M, Klein F, Acker H, Gassmann M, et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J. 2003;17:503-5.
113. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP, et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002;62:3387-94.

Hypoxia and Prostate Cancer Aggressiveness: A Tale With Many Endings

Avelino Fraga,[1,2,3] Ricardo Ribeiro,[3,4,5,6] Paulo Príncipe,[1,3] Carlos Lopes,[2] Rui Medeiros[3,4,6]

Abstract

Angiogenesis, increased glycolysis, and cellular adaptation to hypoxic microenvironment are characteristic of solid tumors, including prostate cancer. These representative features are the cornerstone of cancer biology, which are well correlated with invasion, metastasis, and lethality, as well as likely with the success of prostate cancer treatment (eg, tumor hypoxia has been associated with resistance to chemotherapy and radiotherapy). It is well established that prostate cancer cells also metabolically depend on enhanced glucose transport and glycolysis for expansion, whereas growth is contingent with neovascularization to permit diffusion of oxygen and glucose. While hypoxia inducible factor 1 alpha (HIF-1α) remains the central player, the succeeding activated molecules and pathways track distinct branches, all positively correlated with the degree of intratumoral hypoxia. Among these, the vascular endothelial growth factor axis as well as the lysyl oxidase and carbonic anhydrase IX activities are notable in prostate cancer and merit further study. Here, we demonstrate their linkage with HIF-1α as a tentative explanatory mechanism of prostate cancer aggressiveness. Hypoxia drives a tale where HIF-1α-dependent effects lead to many influences in distinct key cancer biology features, rendering targeted therapies toward targets at the endings less efficient. The most appropriate approach will be to inhibit the upstream common driver (HIF-1α) activity. Additional translational and clinical research initiatives in prostate cancer are required to prove its usefulness.

Clinical Genitourinary Cancer, Vol. 13, No. 4, 295-301 © 2015 Elsevier Inc. All rights reserved.
Keywords: Carbonic anhydrase, Hypoxia, Hypoxia-inducible factor 1, Lysyl oxidase, Prostate cancer, Vascular endothelial growth factor

Introduction

Neoangiogenesis is a characteristic of progressing solid tumors. During tumor growth, malignant cells become progressively distant from the vasculature, oxygen supply, and nutrients, urging tumor cells to signal to the microenvironment the requirement to form new blood vessels. Tumors have been reported to possess extensive regions of hypoxia relative to the corresponding normal tissue.[1,2] At least partially, this is due to the rapid proliferation of tumor mass that distances cells from the oxygen carrying vasculature, but is also the consequence of distorted and irregular characteristics of newly formed vessels, ultimately leading to inefficient oxygen transport. It is well established that solid tumors, like prostate cancer, exist under fluctuating oxygen tensions and are exposed to both acute and chronic hypoxia.[3-5]

The hypoxic tumor microenvironment correlates with increased tumor invasiveness, metastasis, and resistance to radiotherapy and chemotherapy.[2,6-8] Hypoxia has a detrimental effect on the efficacy of treatment and consequently in the clinical outcomes of patients with prostate cancer, being an independent poor prognostic indicator for patients with prostate and other cancers.[2,3]

Over 1% of the genome is transcriptionally responsive to hypoxia, although this varies according to cell type.[9] A large number of endogenous markers of hypoxia which are up-regulated under hypoxic conditions include the vascular endothelial growth factor A (VEGF-A), prolyl hydroxylase 2 (PHD2), inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX-2), carbonic anhydrase IX (CAIX), lysyl oxidase (LOX), hypoxia inducible factor 1α (HIF-1α), hypoxia inducible factor 2α (HIF-2α),

[1]Urology Department, Porto Hospital Centre, St António Hospital, Porto, Portugal
[2]ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal
[3]Center for Urological Research, Porto Hospital Centre, Porto, Portugal
[4]Molecular Oncology Group, CI, Portuguese Institute of Oncology, Porto, Portugal
[5]Genetics Laboratory, Faculty of Medicine, University of Lisbon, Lisbon, Portugal
[6]Research Department, Portuguese League Against Cancer, North Centre, Porto, Portugal

Submitted: Aug 28, 2014; Revised: Mar 13, 2015; Accepted: Mar 23, 2015; Epub: Mar 28, 2015

Address for correspondence: Avelino Fraga, MD, Centro Hospitalar do Porto, Hospital Santo António, Serviço de Urologia, 8° Piso, Largo Prof. Abel Salazar, 4099-001 Porto, Portugal
Fax: +351 222 030 411; e-mail contact: avfraga@gmail.com

1558-7673/$ - see frontmatter © 2015 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.clgc.2015.03.006

glucose transporter 1 (GLUT-1), erythropoietin (EPO), E-cadherin, and angiopoietin 2 (Ang2), among others (Figure 1).[10-12] Most of these genes have previously been shown to be up-regulated by hypoxia in in vitro and in vivo tumor models, resulting in a more aggressive, treatment-resistant phenotype.[13-16] Nonetheless, of all these hypoxia biomarkers, none could adequately predict tumor hypoxia,[1] even though a biomarker that could reliably and easily identify a man's prostate cancer oxygen status would be useful for personalized medicine. Current knowledge suggests that rather than considering individual genes, a panel of genes may provide a more accurate reflection of tumor hypoxia.[17,18] Moreover, tumor hypoxia is cyclical, with a mix of acute and chronic hypoxia in a constantly changing environment due to a changeable microvascular supply.[1]

A recent large study identified HIF-1α and VEGF as intrinsic markers of tumor hypoxia and angiogenesis, which were associated with risk of biochemical failure in patients with localized prostate cancer.[19] In another study, it was shown that LOX and GLUT-1 were significantly overexpressed in malignant compared to benign prostate tissue and were correlated with Gleason score.[20] LOX and GLUT-1 have been previously reported as hypoxia-associated genes, respectively involved in matrix remodeling and glucose transport,[21,22] which are key features of cancer aggressiveness. Hypoxic cancer cells overexpress GLUT-1 to accelerate glucose intake mainly

Figure 1 Hypoxia-Induced HIF-1α-Driven Modulation of Key Genes and Resulting Biological Effect



During tumor growth, the unavoidable low availability of oxygen in some areas triggers oxygen-sensing mechanisms, notably prolyl hydrolases (PHDs), which regulate HIF-1α activity (if down-regulated, or alternatively proteasomal degradation). In addition, mitochondria-mediated use of oxygen produces reactive oxygen species that suppress PHD2 activity, further stabilizing HIF-1α. Alternative hypoxia-independent or -dependent pathways for HIF-1α up-regulation include binding of growth factors (IGF, EGF, TGF) to tyrosine kinase receptors that signal *HIF1A* transcription through MAPK and PI3K/Akt/mTOR pathways (by up-regulating the transcription factor eIF-4E). Stabilized and active HIF-1α protein enters the nucleus and binds to HIF-1β to form a complex that regulates the expression of key genes that code for proteins with relevant functions in prostate cancer development and progression. Regulation of genes encoding proteins responsible for metabolic reprograming (eg, *GLUT1, ALDOA, PGK1, LDH, PDK1, HK1*, and *HK2* that switch tumor cell toward glycogenolysis as the main source of energy); genes responsible for pH regulation (eg, *MCT1, MCT4*, and *CA9* that alkalinize the intracellular environment); genes involved in tumor cell apoptosis and survival (eg, *IGF2, TGFA, BNIP3, CCND1, TP53*, and *VEGFA*, which down-regulate apoptosis while inducing survival); genes accounting for neoangiogenesis (eg, *VEGF, PDGF, ANGPT2*, and *SERPINE1* that up-regulate sprouting of new tumor vessel; and genes coding for modulators of invasion and metastasis (eg, the proteolytic *CTSD, MMP2*, and *PLAUR*, migration inducers *TGFA, MET*, and *LOX*, and adhesion molecules E-cadherin and vimentin).

Abbreviations: *ALDOA* = aldolase A gene; *ANGPT2* = angiopoietin 2 gene; *BNIP3* = bcl2/adenovirus e1b 19 kDa protein-interacting protein 3 gene; *CA9* = carbonic anhydrase 9 gene; CAIX = carbonic anhydrase IX; CathpsD = cathepsin D gene; *CCND1* = cyclin D1 gene; *CTSD* = cathepsin D gene; ECM = extracellular matrix; EGF = epidermal growth factor; eIF-4E = eukaryotic translation initiation factor 4E; *GLUT1* = solute carrier family 2 (facilitated glucose transporter) member 1 or *SLC2A1* gene; HIF-1α = hypoxia-inducible factor 1 alpha; HIF-1β = hypoxia-inducible factor 1 beta; *HK1* = hexokinase 1 gene; *HK2* = hexokinase 2 gene; IGF = insulin growth factor; *IGF2* = insulin growth factor 2 gene; *LDH* = lactate dehydrogenase A gene; LOX = lysyl oxidase; *LOX* = lysyl oxidase gene; MAPK = mitogen activated protein kinase pathway; *MCT1* = solute carrier family 16 (monocarboxylic acid transporter) member 1 or SLC16A1 gene; *MCT4* = solute carrier family 16 (monocarboxylic acid transporter) member 1 or SLC16A3 gene; *MET* = met protooncogene gene; *MMP2* = matrix metalloproteinase 2 gene; O_2 = molecular oxygen; *PDGF* = platelet-derived growth factor gene; PDHA = pyruvate dehydrogenase A; *PDK1* = pyruvate dehydrogenase kinase isoenzyme 1 gene; *PGK1* = phosphoglycerate kinase 1 gene; PHD2 = prolyl hydrolase 2; PI3K/mTOR = phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway; *PLAUR* = plasminogen activator receptor urokinase-type gene; ROS = reactive oxygen species; *SERPINE1* = serpin peptidase inhibitor member 1 or plasminogen activator inhibitor type 1 gene; TCA = tricarboxylic acid cycle; TGF = transforming growth factor; *TGFA* = transforming growth factor alpha gene; *TP53* = tumor protein p53 gene; *VEGFA* = vascular endothelial growth factor A gene.

for anaerobic respiration, preventing death due to oxygen deficiency.[21] LOX is an extracellular matrix protein that is consistently overexpressed in hypoxic human tumor cells[9,22] and is also a useful marker of the hypoxia response in vitro.[20,22] Nevertheless, further studies at the protein level are needed to confirm LOX and GLUT-1 as useful hypoxia markers in prostate cancer.

A Common Tumor Hypoxia-Driven Mechanism (Through HIF-1α) With Many Paths and Therapeutic Implications

The hypoxia-inducible factor induces the transcription of numerous genes involved in multiple functions on hypoxia conditions.[5,23,24] HIF-1α is a heterodimeric transcription factor that is the prototypical hypoxia-associated molecule.[25] Is the key of master regulator in the hypoxic response of cells by the activity of PHD (prolyl hydroxylase domain) and orchestrates the hypoxic response (Figure 2). Usually HIF-1α has cytoplasmic localization, but under hypoxic conditions it is detected and localized in the nucleus, where it binds to HIF-1β and induces transcription causing up-regulation of effector genes by binding to the hypoxia response element within their promoter regions (Figure 2).[26,27] Under hypoxic conditions, HIF-1α induces expression of pro-angiogenic factors and endothelial cell mitogens, eg, vascular endothelial growth factor A (VEGF-A), thus inducing proliferation, sprouting and tube formation of endothelial cells and sustained angiogenesis.[28] Unlike HIF-1α, HIF-2α protein is expressed only in some cell types, can escape degradation, and is transcriptionally active at near-normoxic conditions.[29,30] Still, HIF-2α contributes as HIF-1α to the development of tumor aggressiveness.[30,31] In the prostate, focal HIF-2α expression has been detected in benign neuroendocrine-like and malignant cells,[32] being more pronounced in larger prostate tumors.[33] Thus, the role of HIF-2α in hypoxia-associated tumors, particularly prostate cancer, warrants further investigation.

HIF-1α protein has been shown to be increased in prostate cancer tissue sections compared to benign prostatic hypertrophy (BPH) and to be associated with higher risk for biochemical failure.[19,26] One study reported a trend for higher HIF-1α mRNA expression in prostate cancer versus BPH samples.[20] However, this finding agrees with previous studies showing that HIF-1α is decisively regulated at the posttranslational level.[33,34] Additionally, a direct link between androgen receptors and pro-angiogenic factors may exist, as HIF-1α expression is increased with androgens[33] and decreased in prostatectomy specimen treated with preoperative androgen deprivation therapy.[19,35]

Neovascularization is essential for physiologic processes, including in the cancer pathophysiology. In fact, it is well established that tumor growth is associated with increased vascularity.[14,36,37] Mounting evidence from in vitro and in vivo models indicates vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis through an effect in endothelial cell growth and proliferation.[37] VEGF binds 2 highly related receptor tyrosine kinases, VEGFR-1 and VEGFR-2. VEGFR-1 expression is up-regulated by hypoxia via an HIF-1α dependent mechanism, thereby favoring the activation of VEGF/VEGFR-1 and -2 signaling pathways due to increased availability of both ligand and receptors.[38]

It is known that oxygen tension plays a key role in regulating the expression of VEGF,[39] whereas VEGF inhibition suppresses pathologic angiogenesis in a wide variety of preclinical models. More specifically, hypoxia may trigger vascular endothelial growth factor (VEGF) expression via the transcription complex of hypoxia-inducible factor HIF-1α (Figure 1). Hypoxia and the consequential angiogenesis may play a major role in prostate cancer progression,[40] as VEGF and HIF-1α is increased in prostate cancer compared to BPH.[26,41]

Tumor cells usually have a high rate of glucose uptake accompanied by elevated glucose consumption through the preferential activation of the glycolytic pathway.[42] Several genes involved in glucose uptake and glycolysis (eg, *GLUT1* and most genes coding for enzymes in the glycolytic pathway) have been shown to be targets of HIF-1α.[43] Additionally, HIF-1α activation inhibits mitochondrial metabolism by promoting the expression of pyruvate dehydrogenase kinase 1 to inhibit pyruvate dehydrogenase activity,[44] thereby diverting pyruvate to lactate. Noteworthy, despite the decreased flux of glucose-derived pyruvate into the mitochondria, in place of oxidative metabolism, cancers rely on reductive reactions from glutamine carbon.[45] Enhanced lactate production and the production of CO_2 induced by anaerobic conditions contributes to the major acid load in tumor environment. The production of CO_2 induced by anaerobic conditions further contributes to the major acid load in the tumor environment. One of the striking features of cancer cells is their ability to acidify their environment, and the orientation of CAIX suggests that it may serve as one of the mechanisms by which cancer cells regulate extracellular pH and induce cytoplasmic alkalization, playing a role in the adaptation of tumors to hypoxic conditions by regulating the pH of the intracellular and extracellular compartment (Figure 1).[46,47]

The membrane-bound enzyme CAIX catalyzes the reversible conversion of CO_2 to carbonic acid and contributes to the modulation of pH in tumor cells.[48] The CAIX is HIF dependent and has been shown to be up-regulated in multiple human cancers.[48] A correlation between hypoxia, angiogenesis, HIF-1α, and CAIX in tumors and metastasis has been reported,[49] although the involvement of cancer-associated antigen in prostate tumor progression and metastasis through the modulation of pH remains elusive.

Despite being normally expressed in normal tissues, CAIX becomes highly expressed when tumor cell hypoxia occurs in malignancies.[50] CAIX is up-regulated by hypoxia,[51] and its gene is a target of HIF-1α (Figure 1).[52] Interestingly, the degree of CAIX expression was found to be a prognostic factor of poor survival in many cancer types.[53-58] Prostate cancer cell lines can express CAIX during severe hypoxic,[59] which is a good marker of hypoxia particularly for androgen-independent cell lines, with reliable increases in *CA9* mRNA expression after hypoxia exposure.[20] Even though initial findings showed an absence of CAIX expression in primary prostate cancers,[59,60] others have observed moderate expression in both BPH and malignant prostatic tissue.[20] Thus, the clinical usefulness of CAIX as a diagnostic tool with implications for therapy and patient outcome remains to be elucidated.

Figure 2 Integration of Hypoxia With HIF-1α-Associated Mechanisms in Prostate Cancer, Specifically Downstream-Activated LOX, VEGF, and CAIX Pathways, and Emergence of Metastatic Traits



The hypoxic environment at the growing prostate tumor primary site conducts HIF-1α toward phosphorylation and translocation to the nucleus instead of the usual proteosomal degradation in normoxia. Here, both the stimulus to increase HIF-1α availability and the suppression of PHD activity concur to hamper HIF-1α degradation. Within the nucleus of the malignant cell, this transcription factor initiates the expression of genes (eg, *VEGF, LOX, CA9*) notable for their role in driving prostate cancer progression and metastasis. Taken together, these molecules are responsible for modulating the tumor microenvironment through recruitment of TAMs, promoting angiogenesis (neoangiogenesis with loss of pericytes, contributing to tortuous and permeable vessels), inducing E-M-T and metastasis, thus promoting prostate cancer aggressiveness.

Abbreviations: CA9 = carbonic anhydrase IX; E-M-T = epithelial-to-mesenchymal transition; HIF-1α = hypoxia inducible factor subunit 1 alpha; HIF-1β = hypoxia inducible factor subunit 1 beta; LOX = lysyl oxidase; MAPK = mitogen activated protein kinase; PHD = prolyl hydrolases; PI3K = phosphoinositol-3-kinase; TAM = tumor-associated macrophages; VEGF = vascular endothelial growth factor; VHL = von Hippel-Lindau.

The clinical and pathologic heterogeneity found in cancers highly depends on reciprocal interactions between malignant cells and their dynamic microenvironment.[61] The cross-talk between cells and with extracellular matrix (ECM) in tumor microenvironment seems to be critical in many aspects of cancer development, including maintenance of cancer cell dormancy, cancer progression and metastasis, and drug resistance.[61] The ECM of solid tumors is composed of a complex meshwork of fibrillar collagens, glycoproteins, and proteoglycans,[62,63] which affect metastasis, proliferation, angiogenesis, adhesion, migration, invasion, and drug delivery.[64,65]

Hypoxia is an important microenvironment factor in the development of cancer, and while HIF-1α has been shown to be the key regulator of the cellular response to hypoxia,[61,66] the relationship between tumor hypoxia and components of ECM is far less known. The role of ECM components and remodeling in cancer has only been a focus of research during the last years. Recent findings suggest that hypoxia mediates collagen 1 fiber remodeling in the ECM of tumors, which may impact delivery of macromolecular agents and the dissemination of cells.[67] Collagen type I is the major structural ECM component in prostate tumors,[64,68,69] with cancer cell invasion occurring radially along its fibers.[67] Moreover, cells of myofibroblast phenotype in the reactive stroma of Gleason 3–scored prostate cancers exhibited elevated collagen type 1 synthesis, which was first observed in activated periacinar fibroblasts adjacent to prostatic intraepithelial neoplasia.[64]

In a previously described hypoxia gene signature,[70] LOX was shown to be directly regulated by HIF-1α and essential for hypoxia-induced metastasis in several cancer models.[66,71] In agreement with this finding, hypoxia-induced cancer cell invasion was severely impaired through inhibition of LOX expression.[72,73] Cancer cell proliferation was stimulated by LOX in a HIF-1α-dependent manner both in vitro and in vivo.[73] Thus, the regulatory circuit between LOX and HIF-1α act in synergy to foster tumor formation in the adaptation of tumor cells to hypoxia (Figure 1).

The LOX family of oxidases oxidizes lysine residues in collagens and elastin, resulting in the covalent cross-linking and stabilization of these ECM structural components, thus providing collagen and elastic fibers with most of their tensile strength and structural integrity.[74] The accurately regulated expression and activity of the LOX family of oxidases are a prerequisite for them to exert critical functions in connective tissue homeostasis. LOX mRNA level is highly up-regulated under hypoxic conditions mediated by HIF-1α at the transcriptional level.[63] In addition to the well-documented roles in connective tissue homeostasis, the LOX family of oxidases participates in other critical biological functions, including cell migration, cell polarity, epithelial-to-mesenchymal transition (EMT), and angiogenesis.[75-79]

LOX is synthesized as a pro-enzyme (Pro-LOX) from stromal cells, from normal epithelial cells, or from tumor cells under hypoxic conditions, and is secreted where it undergoes extracellular proteolytic processing by pro-collagen C-proteinases to a functional enzyme and a pro-peptide (LOX-PP).[80,81] Levels of Pro-LOX production in prostate cancer epithelium are decreased as a function of prostate cancer progression.[82] A recent study proposed that Pro-LOX, but not LOX-PP, is a tumor suppressor.[83] Further studies showed that LOX-PP is an active inhibitor of prostate cancer and other tumor cells growth and of RAS-dependent signaling.[73,84,85]

Although LOX was initially implicated as a tumor suppressor, now it is accepted as a poor prognosis marker, particularly in promoting metastasis in breast, lung, prostatic, head and neck, and bronchogenic carcinomas.[23,66,71,82,86,87] Cancer invasion is facilitated by stromal collagen reorganization, and this behavior is significantly increased in collagen-dense tissues (Figure 1).[88] Many ECM modifying enzymes, including matrix metalloproteinases and LOX family oxidases, are aberrantly expressed during malignant transformation, progression, and metastasis of cancers.[66]

Lysyl oxidase-like 2 (LOXL2), a LOX oxidase family member, accumulates in the endothelial ECM and regulates sprouting angiogenesis through assembling type IV collagen in the endothelial basement membrane.[89] Therefore, oxidases of the LOX family play roles in cancer progression and metastasis, promoting not only cancer cell migration and invasion but also angiogenesis in concert with pro-angiogenic factors under hypoxia. Furthermore, inhibition of LOXL2 resulted in a marked reduction in activated fibroblasts and endothelial cells, as well as decreased production of growth factors and cytokines.[90] In agreement, a recent report in advanced renal cell carcinoma patients receiving therapy with angiogenesis inhibitors (pazopanib and sunitinib) disclosed an association of a *LOXL2* intronic single nucleotide polymorphism (rs4872122) with overall survival, suggesting its potential role as a predictive biomarker for antiangiogenic drugs and as a therapeutic target in cancer.[91]

LOX is a potent chemokine inducing directional migration of varied cell types; when it is present, it strongly induces directional migration of cells,[66] and it regulates cell polarity and the EMT process (Figure 1).[66,73] Hypoxia represses E-cadherin expression and promotes EMT.[77,79] HIF-1α enhanced EMT in vitro and induced epithelial cell migration through up-regulation of LOX.[77-79,92] The up-regulated expression of LOX and LOXL2 under hypoxia is required and sufficient for hypoxic repression of E-cadherin, possibly through stabilization of the SNAIL transcription factor.[77,78] Further studies are warranted to investigate the contribution of individual LOX family members to the induction of EMT in the context of dynamic microenvironment during cancer cell invasion and metastasis.

Conclusion

Hypoxia is usually found in large solid tumors and is a known inducer of metastasis, being strongly correlated to poorer outcomes. In prostate cancer, as in angiogenesis-dependent tumors, there is now evidence of intratumoral hypoxia's profound effect in cancer progression through HIF-mediated regulation of molecules that mediate functional interactions with key aspects of angiogenesis and metastasis. So far, the combination of insightful studies on cancer hypoxia suggests the existence of a regulatory circuit between molecules or pathways (such as VEGF, LOX, or CAIX) downstream of HIF-1α, which synergistically modulate tumor microenvironment and promote prostate cancer aggressiveness.

The orchestrator role attributed to HIF as a master regulator of the transcription of genes encoding factors involved in these

processes provides the rationale for including HIF inhibitors in prostate cancer therapy regimens, particularly in patients with localized or locally advanced disease, with elevated expression of hypoxia-driven molecules in primary tumors. Additional studies are needed to clarify the cross-talk between cellular players in the hypoxic prostate tumor microenvironment, whereas insight from further translational and clinical data connecting prostate tumor hypoxia with metastasis and mortality will definitively contribute toward novel, personalized therapies.

Clinical Practice Points

- Hypoxia is an important factor in the development of cancer, and HIF1alpha has been shown to be a central molecule in the progression of prostate cancer. However, the relation between HIF1alpha and other factors such as CAIX, LOX and VEGF in prostate cancer is yet to be investigated. It is understood that there is some relation, but no interrelation, between the factors in the context of prostate cancer.
- In this review, we demonstrate the straight relation between these factors, and we believe that these factors are the same processes determinated by hypoxia.
- Further studies on the relation between HIF1alpha, CAIX, LOX, and VEGFR2 and the different mechanisms and proteins that determinate the progression of prostate cancer are required in an effort to find biomarkers.

Disclosure

The authors have stated that they have no conflicts of interest.

References

1. Vaupel P. The role of hypoxia-induced factors in tumor progression. *Oncologist* 2004; 9(suppl 5):10-7.
2. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. *Semin Oncol* 2001; 28: 29-35.
3. Movsas B, Chapman JD, Hanlon AL, et al. Hypoxia in human prostate carcinoma: an Eppendorf PO2 study. *Am J Clin Oncol* 2001; 24:458-61.
4. Janssen HL, Haustermans KM, Balm AJ, et al. Hypoxia in head and neck cancer: how much, how important? *Head Neck* 2005; 27:622-38.
5. Fraga A, Ribeiro R, Medeiros R. [Tumor hypoxia: the role of HIF]. *Actas Urol Esp* 2009; 33:941-51.
6. Young SD, Marshall RS, Hill RP. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. *Proc Natl Acad Sci U S A* 1988; 85:9533-7.
7. Postovit LM, Adams MA, Lash GE, et al. Oxygen-mediated regulation of tumor cell invasiveness. Involvement of a nitric oxide signaling pathway. *J Biol Chem* 2002; 277:35730-7.
8. Overgaard J. Hypoxic radiosensitization: adored and ignored. *J Clin Oncol* 2007; 25:4066-74.
9. Denko NC, Fontana LA, Hudson KM, et al. Investigating hypoxic tumor physiology through gene expression patterns. *Oncogene* 2003; 22:5907-14.
10. Brahimi-Horn MC, Pouyssegur J. The hypoxia-inducible factor and tumor progression along the angiogenic pathway. *Int Rev Cytol* 2005; 242:157-213.
11. Gupta S, Srivastava M, Ahmad N, et al. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. *Prostate* 2000; 42:73-8.
12. Baltaci S, Orhan D, Gogus C, et al. Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low- and high-grade prostatic intraepithelial neoplasia and prostatic carcinoma. *BJU Int* 2001; 88:100-3.
13. Brune B, Zhou J. Hypoxia-inducible factor-1alpha under the control of nitric oxide. *Methods Enzymol* 2007; 435:463-78.
14. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. *Nature* 2006; 441:437-43.
15. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer* 2002; 2:38-47.
16. Kaidi A, Qualtrough D, Williams AC, et al. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. *Cancer Res* 2006; 66:6683-91.
17. Wiklund FE, Adami HO, Zheng SL, et al. Established prostate cancer susceptibility variants are not associated with disease outcome. *Cancer Epidemiol Biomarkers Prev* 2009; 18:1659-62.
18. Fraga A, Ribeiro R, Principe P, et al. The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration. *Eur J Cancer* 2014; 50:359-65.
19. Vergis R, Corbishley CM, Norman AR, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. *Lancet Oncol* 2008; 9:342-51.
20. Stewart GD, Gray K, Pennington CJ, et al. Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. *Oncol Rep* 2008; 20:1561-7.
21. Wincewicz A, Sulkowska M, Koda M, et al. Significant coexpression of GLUT-1, Bcl-xL, and Bax in colorectal cancer. *Ann N Y Acad Sci* 2007; 1095:53-61.
22. Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. *Nature* 2006; 440:1222-6.
23. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, et al. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. *Cancer Res* 2005; 65:7259-66.
24. Sorensen BS, Alsner J, Overgaard J, et al. Hypoxia induced expression of endogenous markers in vitro is highly influenced by pH. *Radiother Oncol* 2007; 83:362-6.
25. Semenza GL. Targeting HIF-1 for cancer therapy. *Nat Rev Cancer* 2003; 3:721-32.
26. Zhong H, Semenza GL, Simons JW, et al. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. *Cancer Detect Prev* 2004; 28:88-93.
27. Tang N, Wang L, Esko J, et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. *Cancer Cell* 2004; 6:485-95.
28. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. *Nat Rev Cancer* 2010; 10:505-14.
29. Hu CJ, Wang LY, Chodosh LA, et al. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. *Mol Cell Biol* 2003; 23:9361-74.
30. Lofstedt T, Fredlund E, Holmquist-Mengelbier L, et al. Hypoxia inducible factor-2alpha in cancer. *Cell Cycle* 2007; 6:919-26.
31. Pietras A, Johnsson AS, Pahlman S. The HIF-2alpha-driven pseudo-hypoxic phenotype in tumor aggressiveness, differentiation, and vascularization. *Curr Top Microbiol Immunol* 2010; 345:1-20.
32. Monsef N, Helczynski L, Lundwall A, et al. Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands. *Prostate* 2007; 67:1219-29.
33. Boddy JL, Fox SB, Han C, et al. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. *Clin Cancer Res* 2005; 11:7658-63.
34. Kallio PJ, Pongratz I, Gradin K, et al. Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. *Proc Natl Acad Sci U S A* 1997; 94:5667-72.
35. Mori R, Dorff TB, Xiong S, et al. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. *Prostate* 2010; 70:1692-700.
36. Stewart RJ, Panigrahy D, Flynn E, et al. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. *J Urol* 2001; 165:688-93.
37. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. *Nature* 2005; 438:967-74.
38. Gille H, Kowalski J, Yu L, et al. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3′-kinase activation and endothelial cell migration. *EMBO J* 2000; 19:4064-73.
39. Safran M, Kaelin WG Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. *J Clin Invest* 2003; 111:779-83.
40. Weber DC, Tille JC, Combescure C, et al. The prognostic value of expression of HIF1alpha, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy. *Radiat Oncol* 2012; 7:66.
41. Li R, Younes M, Wheeler TM, et al. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. *Prostate* 2004; 58:193-9.
42. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? *Nat Rev Cancer* 2004; 4:891-9.
43. Wenger RH. Cellular adaptation to hypoxia: O_2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O_2-regulated gene expression. *FASEB J* 2002; 16:1151-62.
44. Kim JW, Tchernyshyov I, Semenza GL, et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. *Cell Metab* 2006; 3:177-85.
45. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. *Cancer Cell* 2012; 21:297-308.
46. Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. *Cell Cycle* 2004; 3:164-7.
47. Chiche J, Ilc K, Laferriere J, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. *Cancer Res* 2009; 69:358-68.

48. Ivanov S, Liao SY, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. *Am J Pathol* 2001; 158:905-19.
49. Van den Eynden GG, Van der Auwera I, Van Laere SJ, et al. Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer. *Br J Cancer* 2005; 93:1128-36.
50. Saarnio J, Parkkila S, Parkkila AK, et al. Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity. *J Histochem Cytochem* 1998; 46:497-504.
51. Wykoff CC, Beasley N, Watson PH, et al. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. *Am J Pathol* 2001; 158:1011-9.
52. Sowter HM, Raval RR, Moore JW, et al. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. *Cancer Res* 2003; 63:6130-4.
53. Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. *J Clin Oncol* 2001; 19:3660-8.
54. Hussain SA, Ganesan R, Reynolds G, et al. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. *Br J Cancer* 2007; 96:104-9.
55. Ord JJ, Agrawal S, Thamboo TP, et al. An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. *J Urol* 2007; 178:677-82.
56. Grabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal cell carcinoma—associated antigen G250. *Int J Cancer* 2000; 85:865-70.
57. Swinson DE, Jones JL, Richardson D, et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non—small-cell lung cancer. *J Clin Oncol* 2003; 21:473-82.
58. Trastour C, Benizri E, Ettore F, et al. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. *Int J Cancer* 2007; 120:1451-8.
59. Li Y, Wang H, Oosterwijk E, et al. Antibody-specific detection of CAIX in breast and prostate cancers. *Biochem Biophys Res Commun* 2009; 386:488-92.
60. Thiry A, Dogne JM, Masereel B, et al. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. *Trends Pharmacol Sci* 2006; 27:566-73.
61. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; 144:646-74.
62. Lochter A, Bissell MJ. Involvement of extracellular matrix constituents in breast cancer. *Semin Cancer Biol* 1995; 6:165-73.
63. Chung LW, Baseman A, Assikis V, et al. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. *J Urol* 2005; 173:10-20.
64. Tuxhorn JA, Ayala GE, Smith MJ, et al. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. *Clin Cancer Res* 2002; 8:2912-23.
65. Cooper CR, Chay CH, Gendernalik JD, et al. Stromal factors involved in prostate carcinoma metastasis to bone. *Cancer* 2003; 97:739-47.
66. Erler JT, Giaccia AJ. Lysyl oxidase mediates hypoxic control of metastasis. *Cancer Res* 2006; 66:10238-41.
67. Kakkad SM, Solaiyappan M, O'Rourke B, et al. Hypoxic tumor microenvironments reduce collagen I fiber density. *Neoplasia* 2010; 12:608-17.
68. Taboga SR, Vidal Bde C. Collagen fibers in human prostatic lesions: histochemistry and anisotropies. *J Submicrosc Cytol Pathol* 2003; 35:11-6.
69. Zhang Y, Nojima S, Nakayama H, et al. Characteristics of normal stromal components and their correlation with cancer occurrence in human prostate. *Oncol Rep* 2003; 10:207-11.
70. Chi JT, Wang Z, Nuyten DS, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. *PLoS Med* 2006; 3:e47.
71. Gao Y, Xiao Q, Ma H, et al. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. *Proc Natl Acad Sci U S A* 2010; 107:18892-7.
72. Kirschmann DA, Seftor EA, Fong SF, et al. A molecular role for lysyl oxidase in breast cancer invasion. *Cancer Res* 2002; 62:4478-83.
73. Palamakumbura AH, Vora SR, Nugent MA, et al. Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling. *Oncogene* 2009; 28:3390-400.
74. Hofbauer KH, Gess B, Lohaus C, et al. Oxygen tension regulates the expression of a group of procollagen hydroxylases. *Eur J Biochem* 2003; 270:4515-22.
75. Xiao Q, Ge G. Lysyl oxidase, extracellular matrix remodeling and cancer metastasis. *Cancer Microenviron* 2012; 5:261-73.
76. Li T, Sun L, Miller N, et al. The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. *Cancer Epidemiol Biomarkers Prev* 2005; 14:343-9.
77. Sahlgren C, Gustafsson MV, Jin S, et al. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. *Proc Natl Acad Sci U S A* 2008; 105:6392-7.
78. Schietke R, Warnecke C, Wacker I, et al. The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1. *J Biol Chem* 2010; 285:6658-69.
79. Higgins DF, Kimura K, Bernhardt WM, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. *J Clin Invest* 2007; 117:3810-20.
80. Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. *J Cell Biochem* 2003; 88:660-72.
81. Uzel MI, Scott IC, Babakhanlou-Chase H, et al. Multiple bone morphogenetic protein 1—related mammalian metalloproteinases process pro-lysyl oxidase at the correct physiological site and control lysyl oxidase activation in mouse embryo fibroblast cultures. *J Biol Chem* 2001; 276:22537-43.
82. Ren C, Yang G, Timme TL, et al. Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. *Cancer Res* 1998; 58:1285-90.
83. Contente S, Yeh TJ, Friedman RM. Tumor suppressive effect of lysyl oxidase proenzyme. *Biochim Biophys Acta* 2009; 1793:1272-8.
84. Min C, Kirsch KH, Zhao Y, et al. The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer. *Cancer Res* 2007; 67:1105-12.
85. Wu M, Min C, Wang X, et al. Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells. *Cancer Res* 2007; 67:6278-85.
86. Le QT, Harris J, Magliocco AM, et al. Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. *J Clin Oncol* 2009; 27:4281-6.
87. Woznick AR, Braddock AL, Dulai M, et al. Lysyl oxidase expression in bronchogenic carcinoma. *Am J Surg* 2005; 189:297-301.
88. Provenzano PP, Inman DR, Eliceiri KW, et al. Collagen density promotes mammary tumor initiation and progression. *BMC Med* 2008; 6:11.
89. Bignon M, Pichol-Thievend C, Hardouin J, et al. Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type IV collagen assembly in the endothelial basement membrane. *Blood* 2011; 118:3979-89.
90. Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase—like-2 impedes the development of a pathologic microenvironment. *Nat Med* 2010; 16:1009-17.
91. Johnson T, Xu C, Choueiri TK, et al. Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC). *J Clin Oncol* 2014; 32(5 suppl), abstr 4503.
92. Sion AM, Figg WD. Lysyl oxidase (LOX) and hypoxia-induced metastases. *Cancer Biol Ther* 2006; 5:909-11.

Provided for non-commercial research and education use.
Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

http://www.elsevier.com/authorsrights

Author's personal copy

European Journal of Cancer (2014) 50, 359–365

Available at www.sciencedirect.com

ScienceDirect

journal homepage: www.ejcancer.com

The *HIF1A* functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration

Avelino Fraga [a,b,*], Ricardo Ribeiro [c,d,e,f], Paulo Príncipe [a], Carlos Lobato [g], Francisco Pina [h], Joaquina Maurício [i], Cátia Monteiro [c,e], Hugo Sousa [c], F. Calais da Silva [j], Carlos Lopes [b], Rui Medeiros [b,c,e]

[a] *Urology Department, Sto António Hospital, Porto Hospital Centre, Porto, Portugal*
[b] *ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal*
[c] *Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal*
[d] *Genetics Laboratory, Faculty of Medicine, University of Lisbon, Lisboa, Portugal*
[e] *LPCC – Portuguese League Against Cancer (NRNorte), Porto, Portugal*
[f] *Instituto Rocha Cabral, Lisboa, Portugal*
[g] *Urology Department, D. Pedro V Military Hospital, Porto, Portugal*
[h] *Urology Department, S. João Hospital, Porto, Portugal*
[i] *Medical Oncology Department, Portuguese Institute of Oncology, Porto, Portugal*
[j] *Urology Department, Central Lisbon Hospital Centre, Lisboa, Portugal*

Available online 30 September 2013

KEYWORDS
Androgen deprivation therapy
Hypoxia inducible factor 1 alpha
Metastasis
Prostate cancer
Single nucleotide polymorphism

Abstract The hypoxia inducible factor 1 alpha (HIF1a) is a key regulator of tumour cell response to hypoxia, orchestrating mechanisms known to be involved in cancer aggressiveness and metastatic behaviour. In this study we sought to evaluate the association of a functional genetic polymorphism in *HIF1A* with overall and metastatic prostate cancer (PCa) risk and with response to androgen deprivation therapy (ADT).

The *HIF1A* +1772 C>T (rs11549465) polymorphism was genotyped, using DNA isolated from peripheral blood, in 1490 male subjects (754 with prostate cancer and 736 controls cancer-free) through Real-Time PCR. A nested group of cancer patients who were eligible for androgen deprivation therapy was followed up. Univariate and multivariate models were used to analyse the response to hormonal treatment and the risk for developing distant metastasis. Age-adjusted odds ratios were calculated to evaluate prostate cancer risk.

Our results showed that patients under ADT carrying the *HIF1A* +1772 T-allele have increased risk for developing distant metastasis (OR, 2.0; 95%CI, 1.1–3.9) and an independent 6-fold increased risk for resistance to ADT after multivariate analysis (OR, 6.0; 95%CI, 2.2–16.8). This polymorphism was not associated with increased risk for being diagnosed with prostate cancer (OR, 0.9; 95%CI, 0.7–1.2).

* *Corresponding author*. Address: Porto Hospital Centre, St. António Hospital, Urology Department, Largo Prof. Abel Salazar, 4000-001 Porto, Portugal. Tel.: +351 222077507; fax: +351 220900642.
E-mail address: avfraga@gmail.com (A. Fraga).

0959-8049/$ - see front matter © 2013 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.ejca.2013.09.001

Author's personal copy

The *HIF1A* +1772 genetic polymorphism predicts a more aggressive prostate cancer behaviour, supporting the involvement of HIF1a in prostate cancer biological progression and ADT resistance. Molecular profiles using hypoxia markers may help predict clinically relevant prostate cancer and response to ADT.

© 2013 Elsevier Ltd. All rights reserved.

1. Introduction

Prostate cancer (PCa) remains a major public health concern because it is the most common malignant neoplasia and the second leading cause of cancer death in men [1].

Clinically, it is a heterogeneous disease, with aggressiveness risk differing greatly among individuals despite similar clinical and pathological characteristics. Currently, only incipient but scarce markers help to predict whether PCa will be an aggressive, fast growing disease or an indolent slow growing type of cancer [2]. Therefore, new strategies to help clinicians distinguish between lethal and indolent prostate cancer are needed. Recent findings indicate that genetic variants may predispose to more aggressive prostate cancer [3–5], which is supported by epidemiological studies that propose genetic background influences cancer prognosis [6–8]. Recent genome-wide association studies (GWAS) revealed numerous genetic variants associated with prostate cancer risk, although only little discriminatory ability was shown for fatal forms of the disease [9].

Intratumoural hypoxia is a hallmark of solid neoplasias. It is well established that hypoxic tumoural microenvironment initiates multiple cellular responses, ultimately resulting in cancer progression [10,11]. The hypoxia inducible factor 1 alpha (HIF1a) is a transcription factor coded by the *HIF1A* gene that regulates cellular response to hypoxia [12,13], inducing cancer progression through activation of many genes involved in regulatory cancer biology (angiogenesis, cell metabolism, cell survival, and epithelial-to-mesenchymal transition) [14]. The *HIF1A* gene harbours several SNPs, including a C-to-T substitution at locus +1772 that result in aminoacid modification (proline by serine). Previous *in vitro* studies showed higher transcriptional activity of the variant allele under both normoxic and hypoxic conditions [12,14], whereas additional research associated this SNP with increased tumour microvessel density [12,14,15].

Recent studies yielded conflicting results regarding the involvement of *HIF1A* +1772 C>T genetic polymorphism in cancer, albeit a significant positive association remained after meta-analysis in Caucasian women specific cancers [16,17]. In prostate cancer, the few studies were conducted in distinct ethnic populations and clinicopathological characteristics leading to conflicting results [16,18,19]. Furthermore, the association of *HIF1A* +1772 C>T SNP with prostate cancer progression, metastasis and refractoriness to androgen deprivation therapy (ADT) merits further evaluation in larger series of patients. In the present study we sought to analyse the association of the functional SNP +1772 C>T in *HIF1A* with PCa using prostatic biopsy-proven controls, and to predict the response to treatment in men receiving ADT.

2. Patients and methods

2.1. Patients

Subjects with histological confirmation, whether on biopsy or surgical specimen, of prostate cancer ($n = 754$) or absence of malignancy ($n = 736$) were included in a case-control study. Patients were recruited from five Hospitals in Portugal between 1990 and 2009: Portuguese Institute of Oncology – Porto Centre, S. João Hospital, Porto Military Hospital, Porto Hospital Centre, and Central Lisbon Hospital Centre. The study was approved by hospital's research ethics committees and consent obtained from participants.

The non-PCa control group comprises men referred for prostate biopsy (8–13 cores) on the basis of abnormal digital rectal examination and/or single baseline PSA levels over 2.5 ng/ml, but with normal or benign prostatic histology. Subjects without malignancy at biopsy (BPH or chronic prostatitis) were considered controls since (1) diagnosis was contemporary, (2) were age matched with elderly cancer patients, (3) all were submitted to digital rectal examination, PSA estimate and prostatic biopsy, making remote the possibility of crossover, (4) most men have benign diseases of the prostate by the 7th–8th decades of life, making it normal in men of that age, (5) bias would be expectable if only men without prostatic disease were eligible, because of the much younger range of ages. Patients with high-grade prostatic intraepithelial neoplasia or a biopsy suspicious of cancer were excluded.

A nested sample of subjects from the group of PCa patients (those eligible for androgen deprivation therapy, ADT, ($n = 429$) was followed up for several years. These patients were submitted to orchiectomy or luteinising hormone releasing hormone agonist (LHRHa) (with or without anti-androgen) immediately after diagnosis or after relapsing from surgery/radiotherapy. Resistance to ADT was defined as the time from ADT initiation to two consecutive rises of PSA greater than the PSA nadir or progression of bone lesions [20,21].

Author's personal copy

The time intervals between visits to the clinic were those routinely in use and determined by international, namely European, guidelines [20,22]. Information was collected through chart review.

2.2. Genotyping

A venous blood sample (6 ml) was obtained by forearm venipuncture and the white cell fraction used to extract DNA (QIAmp DNA Blood Mini Kit, Qiagen). Blood samples for genetic analysis were collected independent of treatment initiation. The *HIF1A* +1772 C>T (rs11549465) genetic polymorphism was genotyped by Real-Time PCR using a pre-designed validated Taqman assay (Applied Biosystems). Procedures implemented for quality control included double sampling in about 5% of samples and the use of negative controls in every run.

2.3. Statistical analysis

The Kolmogorov–Smirnov test was used to assess departure from normality of continuous variables, while medians and interquartile ranges were used as descriptive statistics. The Mean differences between groups for data not normally distributed was compared by Mann–Whitney or Kruskal–Wallis tests. The departure from Hardy-Weinberg equilibrium for *HIF1A* +1772 C>T polymorphism in the non-prostate cancer group was tested by Pearson's chi-square.

Unconditional logistic regression was used to estimate age-adjusted odds ratios (aORs) and 95% confidence intervals (95%CIs) for the associations between the polymorphism and development of prostate cancer based on additive, recessive and dominant genetic models (additive, CC versus Ct versus tt, and based on the minor allele: dominant, CC versus Ct + tt; recessive, CC + Ct versus tt). We examined the association of *HIF1A* +1772 C>T genetic polymorphism with overall prostate cancer and restricted to high-grade prostate cancer (combined Gleason score $\geqslant 7$) in comparison with controls non-cancers.

Serum PSA at diagnosis was stratified according to a 20 ng/ml cutoff, the combined Gleason score was stratified into two groups (<7 versus $\geqslant 7$), whereas clinical stage was further stratified as localised (T1–T2) or advanced (defined as a tumour invading and extending beyond the prostate capsule and/or extending into adjacent tissue, involving regional lymph nodes and/or distant metastatic sites). The time-to-resistance to ADT was calculated as the interval (in months) since the beginning of ADT until the date of resistance to ADT or last visit.

Empirical analyses were conducted to determine covariates for multivariate models. For time-to-event analyses, age-adjusted Cox regression models were used to assess risk of ADT resistance, whereas age-adjusted logistic regression models were used to evaluate the risk for metastasis. Then, multivariate analysis included relevant clinical variables from empirical evaluation and genetic models. A multivariate Cox proportional hazards model was derived to identify the independent predictive risks for biochemical progression under hormonal castration, while a multivariate logistic regression model was performed to evaluate clinical and genetic predictive factors for prostate cancer metastasis. Statistical analyses were done using STATA version 10.0 (StataCorp, College Station, Texas).

3. Results

One-thousand four hundred ninety individuals were included in this study, 736 cancer-free controls and 754 with a positive biopsy for prostate cancer (median age, 66.8 and 68.0 years old, respectively, $p = 0.001$). Biopsy findings in the control cancer-free group revealed normal histology (10.9%), benign prostatic hyperplasia (33.4%), chronic prostatitis (55.2%) and atrophy (0.5%). As expected, PCa patients presented significantly higher serum PSA levels at diagnosis ($p < 0.0001$).

HIF1A +1772 (rs11549465) genotype distribution by group and risk analysis is shown in Table 1. Both additive and dominant genetic models were not associated with prostate cancer risk or high grade disease. The distribution of *HIF1A* +1772 C>T genotypes among the non-cancer control subjects were in agreement with Wardy–Weinberg equilibrium ($p = 0.988$). Furthermore, we found that this SNP was not associated to earlier onset of disease, using Kaplan–Meier plots and functions (data not shown).

In the group of prostate cancer patients, analyses of the association between *HIF1A* +1772 genetic variants and patient's clinicopathological characteristics showed over-representation of T-allele in the group of patients not treated with definitive therapy ($p = 0.05$) and who developed metastasis at any time during the course of malignant disease (Table 2).

From the group of 754 patients with prostate cancer, 429 were eligible for androgen deprivation therapy, either due to advanced disease at diagnosis or due to disease progression. The clinicopathological characteristics of this nested group are shown in Table 3. From the group of patients on ADT, 194 (45.2%) developed resistance to hormonal therapy. The median (95%CI) follow-up time was 91.8 (79.8–103.7) months.

Univariate age-adjusted empirical time-to-ADT resistance analysis on clinical covariates showed that Gleason grade $\geqslant 7$ (HR, 2.8; 95%CI, 2.0–4.1), advanced clinical stage (HR, 3.7; 95%CI, 2.5–5.3), definitive treatment (HR, 0.6; 95%CI, 0.4–0.8), PSA $\geqslant$ 20 ng/ml (HR, 1.9; 95%CI, 1.5–2.6) and presence of metastasis at ADT initiation (HR, 2.9; 95%CI, 2.1–3.9) were all

Author's personal copy

Table 1
HIF1A +1772 genotype distribution and risk for prostate cancer.

	Control	Prostate cancer			
		All		High-grade (Gleason ⩾7)	
HIF1A genotypes	*N*	*N*	aOR (95%CI)	*N*	aOR (95%CI)
Additive model					
CC	566	579	Referent	333	Referent
CT	156	164	1.0 (0.8–1.3)	83	0.9 (0.7–1.2)
TT	14	11	0.9 (0.4–2.1)	7	1.0 (0.4–2.5)
Dominant model					
CC	566	579	Referent	333	Referent
T carriers	170	175	1.0 (0.8–1.3)	90	0.9 (0.7–1.2)

aOR(95%CI), age-adjusted odds ratios and the respective 95% confidence intervals.

Table 2
Genotype distribution in PCa subjects ($n = 754$) according to clinicopathological characteristics.

	HIF1A +1772 C>T genotypes			
	CC ($n = 579$)	CT ($n = 164$)	TT ($n = 11$)	*p*
Definitive therapy				
No	228 (75.0)	69 (22.7)	7 (2.3)	
Yes	281 (78.5)	76 (21.2)	1 (0.3)	0.05*
Clinical stage				
Localised	262 (78.9)	67 (20.2)	3 (0.9)	
Advanced	222 (76.0)	66 (22.6)	4 (1.4)	0.639*
Gleason score				
<7	177 (75.0)	56 (23.7)	3 (1.3)	
⩾7	333 (78.7)	83 (19.6)	7 (1.7)	0.443*
Tumour percent[a]	17.0 (6.0–40.0)	20.0 (5.0–38.5)	65.0 (50.0–80.0)	0.185**

Data are presented as number of cases and respective percentage.
[a] Median (interquartile range).
* Chi-square test.
** Kruskal–Wallis test. Columns do not sum up because of missing data.

significantly associated with resistance to ADT. The associations between *HIF1A* +1772 C>T genotypes and the time-to-event age-adjusted univariate and multivariate analyses are shown in Table 4. Although we have not found association of *HIF1A* +1772 C>T polymorphism with resistance to ADT on univariate analysis, in the recessive model the T homozygous genotype was associated with a 6-fold higher risk for developing resistance to ADT, after adjustment for relevant clinicopathological variables (Gleason grade, clinical stage, PSA ⩾ 20 ng/ml, definitive therapy and existence of metastases at the time of hormonal castration initiation) (Table 4). The risk of developing metastasis at any time during the course of disease in patients under ADT was significantly higher for T-allele carriers, still after adjustment for other clinical covariates (Gleason grade, clinical stage and PSA ⩾ 20 ng/ml) (Table 5).

4. Discussion

Hypoxia is a frequent event during prostate cancer progression, while the hypoxia-responsive gene *HIF1A* codes for a key transcription factor that has been proposed as a modulator of PCa initiation and progression [23–25]. We analysed a functional SNP (+1772 C>T) in the *HIF1A* gene in prostate cancer patients and controls and found lack of association, although a relatively large population with approximately 1500 men was analysed. Concordantly, two large case-control studies from the United States of America and China also observed no risk for having PCa in carriers of this polymorphism [19,26], even though opposite results have been also reported [16,27]. The C-by-T substitution in the +1772 locus at the oxygen-dependent domain of the *HIF1A* gene results in a proline-to-serine substitution and was shown to stabilise *HIF1A* and enhance its activity as a transcription factor in both normoxia and hypoxia [12,28]. In agreement, albeit we hypothesised those carriers of T allele were more susceptible to have cancer, our data, together with other, suggest no influence in earlier stages of prostate cancer development. As PCa natural history usually reveals slow growing indolent tumours, the initial steps of carcinogenesis are not likely to be relevant sources of hypoxia, thereby inducing the

Author's personal copy

Table 3
Clinicopathological characteristics features of the group of patients under that received ADT ($n = 429$).

	n (%)
Age at diagnosis, yrs	
Median (IQR)	70.0 (64.9–75.4)
PSA at diagnosis, ng/ml	
Median (IQR)	19.0 (8.9–51.6)
Gleason score	
<7	128 (32.2)
⩾7	269 (67.8)
Clinical stage	
Localised	156 (38.7)
Advanced	247 (61.3)
Metastasis at ADT initiation	
No	286 (75.9)
Yes	91 (24.1)
Definitive therapy	
No	299 (69.7)
RP/RT	130 (30.3)
ADT pharmacological group	
aLHRH alone	91 (21.2)
aLHRH + antiandrogen	338 (78.8)

ADT, androgen deprivation therapy; aLHRH, luteinising hormone releasing hormone agonist; RP/RT, radical prostatectomy/radiotherapy; IQR, interquartile range.

activation of other than the HIF1a pathway. Actually, a previous report found that *HIF1A* +1772 C>T genotypes were not correlated with HIF1a and VEGF expression in localised prostatic tumours [16]. However, HIF1a overexpression has been reported in cancer precursor lesions, high grade prostate intraepithelial neoplasia, and early stage PCa, compared with normal prostate epithelium [24].

Previous studies have shown overexpression of HIF1a in many tumours with advanced grade, implying HIF1a as an independent prognostic factor in cancer [15]. In addition, increasing evidence suggests that genetic markers may be independent predictors of outcome in PCa with various SNPs predicting decreased progression-free and overall survival [3–6]. Data presented here show that the homozygous T genotype T-allele of *HIF1A* +1772 C>T is associated with increased relapsing after ADT, whereas the T allele is prone to higher risk for having distant metastasis, still after adjustment for empirical covariates (adjusted by Gleason grade, clinical stage and PSA ⩾ 20 ng/ml for the risk of metastasis; and by Gleason grade, clinical stage, PSA ⩾ 20 ng/ml, definitive therapy and existence of metastases at the time of hormonal castration initiation for the risk of disease recurrence after ADT). While the recessive model (TT versus CT/CC) was significantly associated with resistance to ADT, the dominant (TT/CT versus CC) and additive models were significant for metastasis development under ADT. A recently published meta-analysis suggests that both the T allele and TT genotype were significantly associated with increased cancer risk [17]. Experimental data also support a functional role for the C-by-T substitution at the allele and homozygous genotype level [12,28,29]. We found that additivity was better fitted for metastasis but not to ADT resistance, even though the low number of patients carrying the TT genotype in metastasis analyses yielded a very wide CI, hence deserving careful interpretation.

Our findings in a large cohort of patients that received ADT, support a role for HIF1a in the pathophysiology of castration resistance and the *HIF1A* +1772 C>T polymorphism as a potential pharmacogenomic predictor of the response to ADT. Concordantly, a recent study demonstrated that HIF1a expression contributed both to metastasis and chemo-resistance of castration resistant prostate cancer [30]. A study comparing *HIF1A* +1772 C>T genotypes between castration-resistant PCa and non-cancer men showed that the T-allele was overrepresented in the cancer group, although it was not associated with survival [18]. Noteworthy, this report presents data from 196 castration-resistant

Table 4
Association of *HIF1A* +1772 C>T polymorphism with resistance to ADT.

		Resistance to ADT			
		Univariate		Multivariate*	
HIF1A +1772 C>T	LR	HR (95%CI)	*p*	HR (95%CI)	*p*
Additive model	2.24				
CC		Referent		Referent	
CT		0.8 (0.6–1.2)	0.288	1.0 (0.7–1.5)	0.918
TT		1.8 (0.7–4.6)	0.183	6.1 (2.2–17.0)	0.001
Dominant model	2.70				
CC		Referent			
T carriers		0.9 (0.6–1.2)	0.460	1.1 (0.8–1.7)	0.536
Recessive model	3.86				
C carriers		Referent		Referent	
TT		1.9 (0.8–4.8)	0.149	6.0 (2.2–16.8)	0.001

LR, likelihood ratio. ADT, androgen deprivation therapy. HR, hazard ratio; 95%CI, 95% confidence interval.
* Cox regression using as covariates: Gleason grade, clinical stage, PSA ⩾ 20 ng/ml, definitive therapy and existence of metastases at the time of hormonal castration initiation.

Author's personal copy

Table 5
Risk for metastasis in patients receiving androgen deprivation therapy

	Univariate analysis*			Multivariate analysis**		
HIF1A +1772 C>T	*N*	OR (95%CI)	*p*	*N*	OR (95%CI)	*p*
Additive model	380			323		
CC		Referent			Referent	
CT		1.7 (1.0–2.7)			1.9 (1.0–3.6)	
TT		3.5 (0.6–19.4)	0.055[a]		14.9 (1.0–223.1)	0.031[a]
Dominant model						
CC		Referent			Referent	
T carriers	380	1.7 (1.1–2.8)	0.023	323	2.0 (1.1–3.9)	0.027
Recessive model	380			323		
C carriers		Referent			Referent	
TT		3.1 (0.6–17.1)	0.199		12.9 (0.9–190.1)	0.063

[a] *p* for trend. OR (95%CI), odds ratio with 95% confidence interval.
* Age-adjusted ORs.
** Multivariate logistic regression analysis using Gleason grade, clinical stage and PSA with cut-off 20 ng/ml as covariates.

patients using univariate analysis. Another study observed a somatic rare mutation at the same locus in 1/15 androgen-independent prostate tumours, whereas functional studies demonstrated in androgen-independent prostate cancer cells that the T-allele is associated with increased transcriptional activity and protein expression [28]. Therefore, we hypothesise that carrying the T-allele, which stabilises HIF1a protein and upregulates the *HIF1A1* gene expression, may offer a selective advantage to androgen-independent tumour cells through the upregulation of several genes involved in metastasis, angiogenesis, epithelial-to-mesenchymal transition or in other cancer-associated mechanisms [10,23,31–33]. The SNP in *HIF1A* at locus +1772 represents a germline variant, suggesting a cumulative impact of higher HIF1a expression since birth. However, we hypothesise that *HIF1A*+1772 functional SNP repercussion when combined with hypoxic environmental events or with other genetic risk factors is triggered to higher extent in response to hypoxia-inductive treatments such as ADT. When confirmed in larger and independent samples, additional therapeutic schemes (such as CYP17A1 inhibitors or chemotherapy) could be offered to carriers of the poor responder TT genotype as alternative to ADT. These patients could also be enrolled in clinical trials with drugs that target HIF1a function (e.g. tasquinimod and other agents that target HIF1a or its downstream products) [34–37].

Present findings should be further extended and replicated by future studies focusing on genetic polymorphisms as predictors of treatment response to allow tailored therapy in PCa patients. Using this focused candidate gene approach to evaluate the *HIF1A* +1772 C>T SNP gives us an incomplete analysis of hypoxia mechanism. Other hypoxia-related SNPs were not included in this study. However, our study has several strengths such as the selection of the candidate gene based on biological evidence of functional importance; statistical analyses accounted for relevant clinical and pathological factors. In this study all men (including the controls) were screened for prostate cancer based on both PSA level and digital rectal exam during the recruitment period and diagnosis was determined by standard biopsy or surgical sample, thus making outcome misclassification unlikely.

Our findings suggest that the *HIF1A* +1772 C>T might be a useful marker of aggressive PCa, particularly a predictor of the response to ADT, thus a plausible candidate to include in a panel of risk prediction SNPs in combination with clinical and pathologic features.

5. Conflict of interest statement

None declared.

Acknowledgement

Grant support: Authors acknowledge support from the Portuguese Science and Technology Foundation and Operational Programme “Factores de Competitividade (COMPETE) (PTDC/SAU-FC/71552/2006 and FCOMP-01-0124-FEDER-011113)”, the Portuguese League Against Cancer – North Centre, the Calouste Gulbenkian Foundation (Oncology/2008/Project No. 96736) and from an unrestricted educational Grant for basic research in Molecular Oncology from Novartis Oncology Portugal. R.R. was the recipient of a PhD Grant from POPH/FSE (SFRH/BD/30021/2006) and of an International Cancer Technology Transfer Fellowship from the Union for International Cancer Control (UICC-ICRETT, ICR/10/079/2010).

References

[1] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61(2):69–90.
[2] Wiklund F. Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers? Genome Med 2010;2(7):45.
[3] Xu J, Zheng SL, Isaacs SD, Wiley KE, Wiklund F, Sun J, et al. Inherited genetic variant predisposes to aggressive but not

Author's personal copy

indolent prostate cancer. Proc Natl Acad Sci U S A 2010;107(5):2136–40.
[4] Teixeira AL, Ribeiro R, Cardoso D, Pinto D, Lobo F, Fraga A, et al. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Cancer Res 2008;14(11):3367–71.
[5] Teixeira AL, Ribeiro R, Morais A, Lobo F, Fraga A, Pina F, et al. Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. Pharmacogenomics J 2009;9(5):341–6.
[6] Wiklund FE, Adami HO, Zheng SL, Stattin P, Isaacs WB, Gronberg H, et al. Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol Biomarkers Prev 2009;18(5):1659–62.
[7] Wright ME, Peters U, Gunter MJ, Moore SC, Lawson KA, Yeager M, et al. Association of variants in two vitamin e transport genes with circulating vitamin e concentrations and prostate cancer risk. Cancer Res 2009;69(4):1429–38.
[8] Swanson GP, Yu C, Kattan MW, Hermans MR. Validation of postoperative nomograms in prostate cancer patients with long-term follow-up. Urology 2011;78(1):105–9.
[9] Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008;358(9):910–9.
[10] Fraga A, Ribeiro R, Medeiros R. Tumor hypoxia: the role of HIF. Actas Urol Esp 2009;33(9):941–51.
[11] Hill RP, Marie-Egyptienne DT, Hedley DW. Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 2009;19(2):106–11.
[12] Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, et al. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 2003;24(11):1779–83.
[13] Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999;15:551–78.
[14] Smaldone MC, Maranchie JK. Clinical implications of hypoxia inducible factor in renal cell carcinoma. Urol Oncol 2009;27(3):238–45.
[15] Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59(22):5830–5.
[16] Foley R, Marignol L, Thomas AZ, Cullen IM, Perry AS, Tewari P, et al. The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers. Cancer Biol Ther 2009;8(2):118–24.
[17] Zhao T, Lv J, Zhao J, Nzekebaloudou M. Hypoxia-inducible factor-1alpha gene polymorphisms and cancer risk: a meta-analysis. J Exp Clin Cancer Res 2009;28:159.
[18] Chau CH, Permenter MG, Steinberg SM, Retter AS, Dahut WL, Price DK, et al. Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. Cancer Biol Ther 2005;4(11):1222–5.
[19] Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ, et al. Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. Prostate 2007;67(12):1354–61.
[20] Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59(4):572–83.
[21] Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 2008;26(7):1148–59.
[22] Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. European association of urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59(1):61–71.
[23] Kimbro KS, Simons JW. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 2006;13(3):739–49.
[24] Zhong H, Semenza GL, Simons JW, De Marzo AM. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 2004;28(2):88–93.
[25] Anastasiadis AG, Stisser BC, Ghafar MA, Burchardt M, Buttyan R. Tumor hypoxia and the progression of prostate cancer. Curr Urol Rep 2002;3(3):222–8.
[26] Li P, Cao Q, Shao PF, Cai HZ, Zhou H, Chen JW, et al. Genetic polymorphisms in HIF1A are associated with prostate cancer risk in a Chinese population. Asian J Androl 2012;14(6):864–9.
[27] Orr-Urtreger A, Bar-Shira A, Matzkin H, Mabjeesh NJ. The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1 alpha is associated with increased risk for prostate cancer. Prostate 2007;67(1):8–13.
[28] Fu XS, Choi E, Bubley GJ, Balk SP. Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate 2005;63(3):215–21.
[29] Vainrib M, Golan M, Amir S, Dang DT, Dang LH, Bar-Shira A, et al. HIF1A C1772T polymorphism leads to HIF-1α mRNA overexpression in prostate cancer patients. Cancer Biol Ther 2012;13(9):720–6.
[30] Ranasinghe WKB, Xiao L, Kovac S, Chang M, Michiels C, Bolton D, et al. The role of hypoxia-inducible factor 1a in determining the properties of castrate-resistant prostate cancers. PLoS ONE 2013;8(1).
[31] Jeong CW, Yoon CY, Jeong SJ, Hong SK, Byun SS, Kwak C, et al. The role of hypoxia-inducible factor-1alpha and -2alpha in androgen insensitive prostate cancer cells. Urol Oncol 2013.
[32] Mathieu J, Zhang Z, Zhou W, Wang AJ, Heddleston JM, Pinna CM, et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 2011;71(13):4640–52.
[33] Dai Y, Bae K, Siemann DW. Impact of hypoxia on the metastatic potential of human prostate cancer cells. Int J Radiat Oncol Biol Phys 2011;81(2):521–8.
[34] Bratt O, Häggman M, Ahlgren G, Nordle O, Björk A, Damber JE, et al. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br J Cancer 2009;2009(101):1233–40.
[35] Pili R, Häggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, et al. Phase II randomized, doubleblind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 2011;29:4022–8.
[36] Jennbacken K, Welén K, Olsson A, Axelsson B, Törngren M, Damber JE. Leanderson T Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050). Prostate 2012;72(8):913–24.
[37] Liu XQ, Xiong MH, Shu XT, Tang RZ, Wang J. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth. Mol Pharm 2012;9(10):2863–74.

OPEN ACCESS Freely available online

PLoS one

Performance of an Adipokine Pathway-Based Multilocus Genetic Risk Score for Prostate Cancer Risk Prediction

Ricardo J. T. Ribeiro[1,2,3,4]*, Cátia P. D. Monteiro[1,4], Andreia S. M. Azevedo[1,4], Virgínia F. M. Cunha[1,4], Agnihotram V. Ramanakumar[3], Avelino M. Fraga[1,2,5], Francisco M. Pina[6], Carlos M. S. Lopes[2], Rui M. Medeiros[1,2,4], Eduardo L. Franco[3]

1 Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal, **2** ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal, **3** Division of Cancer Epidemiology, Department of Oncology, McGill University, Montreal, Canada, **4** LPCC–Portuguese League Against Cancer (NRNorte), Porto, Portugal, **5** Urology Department, D. Pedro V Military Hospital, Porto, Portugal, **6** Urology Department, S. João Hospital, Porto, Portugal

Abstract

Few biomarkers are available to predict prostate cancer risk. Single nucleotide polymorphisms (SNPs) tend to have weak individual effects but, in combination, they have stronger predictive value. Adipokine pathways have been implicated in the pathogenesis. We used a candidate pathway approach to investigate 29 functional SNPs in key genes from relevant adipokine pathways in a sample of 1006 men eligible for prostate biopsy. We used stepwise multivariate logistic regression and bootstrapping to develop a multilocus genetic risk score by weighting each risk SNP empirically based on its association with disease. Seven common functional polymorphisms were associated with overall and high-grade prostate cancer (Gleason≥7), whereas three variants were associated with high metastatic-risk prostate cancer (PSA≥20 ng/mL and/or Gleason≥8). The addition of genetic variants to age and PSA improved the predictive accuracy for overall and high-grade prostate cancer, using either the area under the receiver-operating characteristics curves ($P<0.02$), the net reclassification improvement ($P<0.001$) and integrated discrimination improvement ($P<0.001$) measures. These results suggest that functional polymorphisms in adipokine pathways may act individually and cumulatively to affect risk and severity of prostate cancer, supporting the influence of adipokine pathways in the pathogenesis of prostate cancer. Use of such adipokine multilocus genetic risk score can enhance the predictive value of PSA and age in estimating absolute risk, which supports further evaluation of its clinical significance.

Citation: Ribeiro RJT, Monteiro CPD, Azevedo ASM, Cunha VFM, Ramanakumar AV, et al. (2012) Performance of an Adipokine Pathway-Based Multilocus Genetic Risk Score for Prostate Cancer Risk Prediction. PLoS ONE 7(6): e39236. doi:10.1371/journal.pone.0039236

Editor: Michael Scheurer, Baylor College of Medicine, United States of America

Received February 15, 2012; **Accepted** May 17, 2012; **Published** June 29, 2012

Copyright: © 2012 Ribeiro et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Portuguese Foundation for Science and Technology (PTDC/SAL-FCF/71552/2006); the Research Centre on Environment, Genetics and Oncobiology of the University of Coimbra (CIMAGO 07/09); the Portuguese League Against Cancer – North Centre; and by an unrestricted educational grant for basic research in Molecular Oncology from Novartis Oncology Portugal. RR is the recipient of a PhD grant from Programa Operacional Potencial Humano/Fundo social Europeu (POPH/FSE, SFRH/BD/30021/2006) and of an International Cancer Technology Transfer Fellowship from the Union for International Cancer Control (UICC-ICRETT, ICR/10/079/2010). AVR was supported by funding from the Cancer Research Society to the Division of Cancer Epidemiology at McGill University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have read the journal's policy and have the following conflicts: Co-author Rui Medeiros is a PLoS ONE Editorial Board member. The authors received funding from Novartis Oncology Portugal. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

* E-mail: oriebir.r@gmail.com

Introduction

Prostate cancer is a complex and unpredictable disease, with risk being affected by advancing age, ethnic background and family history. Although the causes of prostate cancer are not yet fully understood, genetic variation influences disease risk [1]. Prostate cancer is usually accompanied by a rise in the concentration of serum PSA, which has been used for decades as a sensitive but poorly specific biomarker, and a controversial predictor of prostate cancer mortality [2,3]. Many prostatic biopsies are unnecessary [4], which underscores the need for better prediction models with increased specificity to aid clinicians decide whether or not to recommend biopsy. Furthermore, this is especially relevant in men with mildly elevated PSA values (3–10 ng/mL), but where the risk for being diagnosed with prostate cancer is only about 20–25% [5]. After diagnosis, some cancers are indolent and cause no clinical problems, whereas others progress and may be fatal [6]. Therefore, it is important to search for biomarkers of aggressive clinical outcome. Genetic markers provide good candidates for such a role.

Single-nucleotide polymorphisms (SNPs) identified as loci associated with prostate cancer in genome-wide association studies (GWAS) are common but confer only small increases in risk and the mechanisms underlying their association with prostate cancer risk remain unknown [7,8]. Recently, selected SNPs from GWAS were analyzed and converted into a genetic risk score, which was shown to reduce the number of biopsies although it did not discriminate aggressive cases [9].

The association between body mass and risk of prostate cancer is supported by meta-analyses that suggest increased risk of aggressive prostate cancer in the obese [10], and by studies using methods to estimate abdominal adiposity [11]. Recent work has focused on the role of adipokines and obesity-related molecules in

the etiology of prostate cancer [12,13]. Variants in genes encoding components of these pathways have been evaluated for prostate cancer risk and promising candidates have been identified [14,15,16,17]. These candidate genes code for molecules found to be over- or under-expressed in obesity [18,19,20] and are involved in several biological mechanisms that modulate tumor proliferation, apoptosis, angiogenesis, motility, migration, and immunity [12,21], i.e., traits that ultimately influence tumor behavior. Thus, common polymorphisms in adipokine pathways are plausible candidates that may help predict prostate cancer susceptibility. However, few studies have examined prostate cancer risk in the context of multi-loci SNPs in different adipokine pathways. In this report, we tested the hypothesis that SNPs in candidate genes involved in adipokine pathways may contribute to prostate cancer susceptibility and aggressiveness in a population of men referred for diagnostic surveillance. We also assessed the clinical utility of an adipokine genetic risk score to enhance the predictive value of age and PSA to predict high-risk individuals for screening and therapeutic management.

Results

A total of 449 histologically confirmed prostate cancer and 557 non-prostate cancer patients were included in the analyses. Prostate cancer patients were older (P<0.0001) and presented with significantly higher circulating levels of PSA and a lower free/total PSA ratio (P<0.0001 and P<0.0001, respectively) (Table 1).

We evaluated the associations between each individual SNP on prostate cancer susceptibility (Table S2). In the dominant effect models (referent: wild-type homozygote) there were significant decreases in risk for *LEPR* Gln223Arg (aOR = 0.6, 95%CI: 0.5–0.8, aOR = 0.6, 95%CI: 0.5–0.8 and aOR = 0.5, 95%CI: 0.4–0.8, for all, high-grade and high-risk prostate cancer for metastasis, respectively) and for *FGF2*+223 C>T (aOR = 0.7, 95%CI: 0.5–1.0 in high-grade prostate cancer). An increase in risk of high-grade prostate cancer was found in carriers of the *IL6R* Asp358Ala variant (aOR = 1.3, 95%CI: 1.0–1.7). In the recessive effect models (referent: wild-type homozygotes and heterozygotes) a significantly increased risk was observed for *IGF1R*+3174 G>A (aOR = 1.3, 95%CI: 1.0–1.9 for overall prostate cancer), *IGFBP3*-202 A>C (aOR = 1.3, 95%CI: 1.0–1.8 and aOR = 1.3, 95%CI: 1.0–1.8, for overall and high-grade prostate cancer, respectively) and with *SPP1*-66 T>C (aOR = 1.8, 95%CI: 1.1–3.0, aOR = 1.9, 95%CI: 1.1–3.2 and aOR = 2.4, 95%CI: 1.2–4.8, in overall, high-grade and high-risk prostate cancer for metastasis, respectively). Likewise, a significant protective effect for high-grade prostate cancer was observed for carriers of the *IL6*-597 G>A variant (aOR = 0.7, 95%CI: 0.4–1.0). Age-stratification on the aforementioned seven SNPs indicated that effects were mostly restricted to subjects below the median age (of non-cancer group, Table S3).

Figure 1 shows that among prostate cancer cases there was a shorter waiting time-to-onset in *IL6R* Asp358Ala C-allele carriers (P = 0.026) and in *IGF1R*+3174 AA homozygous (P = 0.002). None of the other five SNPs influenced the time to onset of disease (data not shown).

To test our hypothesis that genetic variability in SNPs from adipokine pathways may contribute a combined effect for prostate cancer risk and/or aggressiveness, we estimated the overall mutually-adjusted effects by stepwise multivariate logistic regression. The SNPs in *LEPR* Gln223Arg, *SPP1*-66 T>G, *IGF1R*+3174 G>A, *IGFBP3*-202 A>C, *FGF2*+223 C>T and *IL6*-597 G>A, plus age and PSA remained independently associated with risk for overall, and for high-grade prostate cancer (Table 2). In the prostate cancer group with high risk for metastasis, only the *LEPR* Gln223Arg, *SPP1*-66 T>G and *FGF2*+223 C>T genetic variants, age and PSA persisted (Table 2). Within all groups, bootstrap analysis confirmed results (Table 2).

The inclusive (age and PSA added to the multi-locus genetic set) linear risk scores computed on the basis of the above logistic regression models were tested as overall risk predictors categorized in tertiles based on the distribution in the non-prostate cancer group. As shown in Table 3, the risk for prostate cancer and high-grade prostate cancer increased according to the tertile of risk score (P_{trend} <0.0001 for both outcome categories). The age-adjusted ORs for unit changes in the inclusive risk score were 2.52 (95%CI: 2.0–3.2) and 2.77 (95%CI: 2.2–3.5) for all prostate cancers and high-grade prostate cancers, respectively. The goodness of fit for the logistic regression models based on the inclusive score were significantly greater than for the models based on the restricted age plus PSA score, for all prostate cancers (P = 0.0002) and high-grade prostate cancers (P = 0.0001), after likelihood ratio test.

Figure 2 shows the ROC curves for the all-inclusive genetic risk score and for the age and PSA-based risk score. The AUC estimates for both outcomes (all prostate cancers and high-grade prostate cancers) were significantly higher for the all-inclusive score than with the age plus PSA predictor, P = 0.0099 and P = 0.0196, respectively (Figure 2). The statistically superior predictive value of the all-inclusive score was confirmed via the NRI (all prostate cancers: 9.5%, P<0.0001, high-grade prostate cancer: 13.3%, P<0.0001) and IDI (all prostate cancers: 0.021, P<0.0001, high-grade prostate cancer: 0.024, P<0.0001) comparisons.

Table 1. Age and hormonal variables by disease status.

	Disease Status						
	Non-Prostate cancer			Prostate cancer			
	N[a]	Mean	Median	N[a]	Mean	Median	P[b]
Age, years	553	66.2	66.2	447	68.1	69.0	<0.0001
PSA, ng/mL	540	7.5	5.9	437	26.9	8.2	<0.0001
Free PSA, ng/mL	485	1.6	1.2	373	2.4	1.1	0.373
Free/Total PSA ratio	482	0.22	0.20	372	0.16	0.14	<0.0001
Serum Testosterone, ng/mL	494	478.0	444.5	381	471.5	443.0	0.690

[a]Number of evaluable patients for each variable;
[b]Differences between groups, Mann-Whitney test. PSA, prostate specific antigen.
doi:10.1371/journal.pone.0039236.t001



Figure 1. Kaplan Meier analyses plots of significant genetic polymorphisms. (A) *IL6R* D358A A>C and (B) *IGF1R*+3174 G>A. In figure 1A the dashed line corresponds to AA and the dotted line to CC/CA genotype. In figure 1B the dashed line represents AA, whereas the solid corresponds to GG/GA genotype. The Log Rank test was used to compare genotypes in *IL6R* D358A A>C (P = 0.026) and *IGF1R*+3174 G>A (P = 0.002).
doi:10.1371/journal.pone.0039236.g001

Genotype distributions in four SNPs deviated from Hardy-Weinberg equilibrium (Table S1). In sensitivity analysis of three relevant SNPs, equilibrium was achieved after restricting the control group to constrained conditions, whereas the trend towards increased risk remained stable, regardless of control group used (restricted or unrestricted) (Table S4). Three of these four deviated SNPs ended up in the all-inclusive risk score. Therefore, as an additional step to clarify the relative importance of these SNPs we tested a four SNP risk score (excluding the 3 SNPs that were not in equilibrium). Findings showed that the predictive and discriminative ability of the inclusive risk score based on 4 SNPs remained significant (data not shown). Therefore, we used the all inclusive score.

Discussion

Adipose tissue deregulation has been proposed as a relevant mechanism underlying obesity-related cancer, due to inappropriate release of biologically active adipokines. Thus, functional SNPs in genes coding for molecules involved in adipokine pathways may modulate the expression, transport, or signaling of adipokines, thereby influencing prostate cancer risk and biology. Our findings show that SNPs in genes from adipokine pathways (leptin, interleukin-6, fibroblast growth factor 2, osteopontin, and insulin growth factor) may influence the development of prostate cancer and aggressive disease. Interestingly, we found that both the *LEPR* Gln223Arg homozygous A and *SPP1*-66 homozygous G were significantly associated with all outcomes (risks of overall, high-grade, and high metastatic-risk prostate cancers).

The pleiotrophic effects of leptin, namely in tumor development and progression are mediated by its receptor [12,13]. Studies of SNPs affecting this pathway provided inconsistent results in prostate cancer. The leptin SNP at position -2548 was proposed as a susceptibility locus for prostate cancer [14,15], albeit our data do not support this contention. Conversely, we found an increased risk in *LEPR* Gln223Arg homozygous A for prostate cancer, whereas others observed no such association [14,16]. *LEPR* Gln223Arg AA carriers have lower leptin binding affinity to soluble leptin receptor and have increased circulating free leptin and soluble leptin receptor levels [22,23]. Therefore, there is increased availability of leptin for binding to the long leptin receptor signaling isoform in the prostate tumor cell membrane. Cumulatively, the aminoacid change in this SNP may influence the signal for receptor intracellular recycling or degradation [24], modulating the availability of membrane-bound leptin receptor in tumor cells.

Osteopontin is a cytokine-like extracellular matrix molecule, that influences cell migration and anti-apoptosis in cancer [25]. This molecule has been implicated in aggressive and metastatic disease, and is one of a four-gene signature in prostate cancer that predicts metastasis and death [26,27]. The T-to-G substitution at position -66 in the human *SPP1* gene modulates promoter activity [28]. The modified bioavailability of osteopontin may induce TH1-to-Th2 shift, modulating the microenvironment [28], and tumor development.

The IGF1-mediated activation of IGF1R has been demonstrated to contribute to tumor progression [29]. The IGF binding proteins modulate the effects of IGF1 and its biological function in different tissues. Recent evidence indicates increased risk of prostate cancer in individuals with high serum IGF1 levels, whereas risk was decreased in those with high levels of IGFBP-3 [30]. Furthermore, it was also found that the *IGFBP3*-202 A>C SNP was associated with prostate cancer and with low circulating levels of IGFBP3 [30]. The present study corroborates previous findings on the *IGFBP3*-202 A>C CC genotype risk for prostate cancer and high-grade disease [30,31]. Cumulatively, functional studies confirmed the underexpression of *IGFBP3* in C-allele carriers [32], resulting in increased IGF1 bioavailability. Signaling through the IGF1R is required for growth and survival [29]. The synonymous *IGF1R* SNP at locus +3174 was described as a possible splicing regulator [33], thereby generating protein diversity [34] and serving as a mechanism for modulating gene expression [35]. Our findings showing that AA carriers remained independently associated with risk for all and for high-grade prostate cancer, suggest that this SNP may modulate IGF1R cell surface protein quantity, as well as IGF1R/IGF1R internalization and degradation, consequently influencing prostate tumor growth. Insulin receptor substrate –1 (IRS1) is the primary docking protein of IGF1R, which mediates PI3K pathway activation within the IGF1/IGF1R system. Although the *IRS1* Gly972Arg SNP results in structural protein differences [36] in our study this SNP was not associated with prostate cancer risk, confirming previous findings [37].

FGF2 may have a role in tumorigenesis and cancer progression through induction of angiogenesis [38]. The *FGF*+223 variant in

Table 2. Stepwise multivariate logistic regression and Bootstrap analyses.

		All PCa		Restricted to high-grade PCa		Restricted to high-risk PCa for Metastasis	
		Multivariate model	Bootstrap	Multivariate model	Bootstrap	Multivariate model	Bootstrap
	Genotype	OR (95%CI)[a]	OR (95%CI)[b]	OR (95%CI)[a]	OR (95%CI)[b]	OR (95%CI)[a]	OR (95%CI)[b]
Age at diagnosis		1.03 (1.01–1.05)	1.02 (1.00–1.04)	1.03 (1.01–1.05)	1.03 (1.01–1.06)	1.07 (1.03–1.11)	1.07 (1.03–1.11)
PSA at diagnosis		1.07 (1.04–1.09)	1.06 (1.04–1.09)	1.07 (1.05–1.10)	1.07 (1.04–1.11)	1.07 (1.04–1.09)	1.14 (1.09–1.19)
LEPR Gln223Arg	G carriers	Referent	Referent	Referent	Referent	Referent	Referent
(A>G)	AA	1.52 (1.14–2.02)	1.53 (1.13–2.07)	1.56 (1.15–2.12)	1.57 (1.14–2.14)	1.50 (0.91–2.45)	1.55 (0.93–2.58)
SPP1-66 T>G	T carriers	Referent	Referent	Referent	Referent	Referent	Referent
	GG	1.86 (1.07–3.23)	1.77 (1.00–3.13)	1.97 (1.10–3.52)	1.89 (1.03–3.49)	2.64 (1.16–6.01)	2.52 (1.12–5.64)
IGF1R+3174 G>A	G carriers	Referent	Referent	Referent	Referent		
	AA	1.33 (0.93–1.89)	1.34 (0.94–1.93)	1.40 (0.96–2.05)	1.39 (0.93–2.09)	–	–
IGFBP3-202 A>C	A carriers	Referent	Referent	Referent	Referent		
	CC	1.40 (1.02–1.92)	1.38 (1.01–1.88)	1.40 (1.00–1.95)	1.39 (1.00–1.93)	–	–
FGF2+223 C>T	T carriers	Referent	Referent	Referent	Referent	Referent	Referent
	CC	1.45 (0.98–2.14)	1.45 (0.98–2.16)	1.55 (1.00–2.38)	1.54 (1.00–2.38)	2.20 (1.01–4.78)	2.22 (1.02–4.85)
IL6-597 G>A	AA	Referent	Referent	Referent	Referent		
	G carriers	1.42 (0.92–2.19)	1.37 (0.88–2.13)	1.61 (0.99–2.62)	1.58 (0.97–2.56)	–	–

Age and PSA analyzed as continuous variables. PCa, prostate cancer. [a]Stepwise multivariate logistic regression; [b]MonteCarlo simulation (1000 replications). Empirical confounding variables were independently analyzed in each model (overall prostate cancer and both restricted groups).
doi:10.1371/journal.pone.0039236.t002

exon 1 is associated with FGF2 expression at the transcriptional and translational level [39]. Our findings show increased risk for all, high-grade, and high-metastasis risk prostate cancer among CC carriers, which are coherent with a functional upregulation of FGF2. This molecule interacts with a family of four distinct, high-affinity tyrosine kinase receptors, FGFR 1–4. Although increased availability of FGF2 and changes in FGFR2 receptor availability could play a role in the initiation and progression of prostate cancer, we did not find an association between the *FGFR2* rs2981582 in exon 2 and prostate cancer.

Initiation and progression of prostate cancer are stimulated by IL-6 [40]. Previous findings reported no association of the *IL6*-174 G>C SNP with prostate cancer [17,41], except for a small study of aggressive disease risk [42]. We did not find an association for the *IL6*-174 G>C SNP and prostate cancer. On the other hand, we found that carriers of the *IL6*-597 G-allele were at increased risk for high-grade prostate cancer. In fact, functional SNPs in the promoter region of *IL6* (-174, -572 and -597) do not act independently in the regulation of IL6 transcription [43]. The GG genotype in *IL6*-597 is linked to the GG genotype in *IL6*-174, which is associated with increased IL6 mRNA and protein levels. Therefore, the higher risk of high-grade prostate cancer associated with the *IL6*-597 G-allele may be due to increased IL6. IL6 signals are transmitted via a heterodimeric receptor complex consisting of a soluble interleukin-6 alpha subunit and a membrane-bound signal-transducing subunit, IL6ST. The common *IL6R* Asp385Ala variant is responsible for serum levels of soluble IL6R and IL6 and associates with IL6R membrane binding due to altered cleavage site [44], therefore, explaining our findings. The predominant activation of trans-signaling IL6/soluble IL6R pathway in aggressive prostate cancer [45], together with the functional IL6R Asp358Ala influence in this mechanism, supports the increased risk for high-grade prostate cancer we observed for C carriers (Ala carriers).

Several of the candidate SNPs in adipokine pathways known to affect oncogenesis, investigated here, were not associated with prostate cancer risk. Most of our null results for candidate SNPs in *ADIPOQ*+276, *VEGF*-460, *VEGF*+405, *VEGF*+936, *PPARG* Pro12Ala and *TNF*-308, are in agreement with other studies [14,17,46,47]. To our knowledge, there have been no prior reports

Table 3. Tertiles of inclusive genetic risk score (GRS) and age-adjusted OR (CI 95%) for prostate cancer.

Inclusive Risk Score	Non-prostate cancer	All prostate cancer		High-grade prostate cancer	
Tertiles	N	N	aOR (95%CI)	N	aOR (95%CI)
T1	185	78	Referent	46	Referent
T2	186	101	1.2 (0.9–1.8)	85	1.7 (1.1–2.6)
T3	186	270	3.2 (2.3–4.6)	243	4.8 (3.2–7.2)

Tertiles for all prostate cancer: T1 (<2.74897), T2 (2.74897–3.15913), T3 (≥3.15913). Tertiles for high-grade prostate cancer: T1 (<2.85839), T2 (2.85839–3.30669), T3 (≥3.30669). The genetic risk scores were computed separately derived for overall and high-grade prostate cancer. aOR, age-adjusted ORs (95%CI).
doi:10.1371/journal.pone.0039236.t003



Figure 2. ROC curves and AUC for the inclusive risk score and PSA plus age alone. (A) All prostate cancer and (B) restricted to high-grade prostate cancer. Solid line corresponds to the all inclusive score, whereas dashed line represents the PSA and age risk score. The dotted line indicates the behavior of a hypothetical random score. The Likelihood ratio test was used to estimate the superiority of the inclusive risk score relative to that of the age+PSA score for all prostate cancer (inclusive: AUC = 0.6806, PSA and age: AUC = 0.6476, P = 0.0002) and high-grade prostate cancer (inclusive: AUC = 0.7119, PSA and age: AUC = 0.6808, P = 0.0001). PSA, prostate specific antigen.
doi:10.1371/journal.pone.0039236.g002

of null associations of *KDR*-604, *PPARD*-87, *PPARGC1A* Gly482-Ser, *TNFRSF1A*-329, *ADIPOQ*+45, *ADIPOQ*-11426, *IL6ST* Gly148Arg, *IL6*-6331, and *TNF*-863 functional SNPs with prostate cancer.

We observed that some SNPs have a significant risk effect mainly in younger ages. The all-life exposure to increased levels of adipokines and pathway activation may influence early development of prostate cancer. Furthermore, *IL6R* Asp358Ala and *IGF1R* +3174 SNPs were significantly associated with early-onset prostate cancer, possibly due to accelerated tumor formation.

We tested each SNP for association with two clinically-relevant definitions of unfavorable outcomes: high-grade (combined Gleason score ≥7) and high-metastasis risk (combined Gleason score ≥8 and/or PSA≥20 ng/mL) prostate cancers. Combined Gleason score is a powerful predictor of disease progression and mortality [48], whereas Gleason score ≥8 is associated with aggressive biological behavior and increased risk of occult

disseminated disease [49]. We found functional variants in genes from leptin, osteopontin, insulin growth factor, fibroblast growth factor 2 and interleukin 6 pathways to be related with high-grade prostate cancer, while SNPs in the leptin, osteopontin and fibroblast growth factor 2 axis associate with high-metastasis risk prostate cancer. These pathways are known to be involved in aggressive prostate cancer, lending support for these SNPs as clinical markers of aggressive disease. The SNPs in the risk score predict high grade/aggressive disease, but they also predict overall prostate cancer risk. The ability to predict overall as well as high grade cancers might be due to the significant proportion of high grade prostate cancer (Gleason≥7) (83%) in our cancer population.

Although a wealth of evidence demonstrates the effects of individual adipokines on prostate carcinogenesis, it is unlikely that the overall pathophysiological impact is due to the influence of a single adipokine in vivo. We showed that consideration of the cumulative susceptibility contributed by SNPs from adipokine pathways helps in risk stratification. Our analyses indicate that the inclusive (age and PSA added to the multi-locus genetic set) risk score provides improvements in discrimination and prediction of all prostate cancer, and high-grade prostate cancer. We suggest that risk genotypes in the inclusive model may cooperate to influence the endocrine and paracrine activity of adipokine pathways that leads to tumor development and progression. However, the mechanisms underlying these high-order interactions among genetic polymorphisms in adipokine pathways genes in modulating prostate cancer risk remain to be fully elucidated.

In this cohort of men subjected to prostate biopsy due to abnormal clinical and/or PSA findings where an extensive biopsy scheme was used, we showed that by adding a genetic score based on 7 SNPs significantly improved the discriminative ability of an established parsimonious model with only PSA and age. The AUC increased significantly from 0.65 to 0.68 for all prostate cancer and from 0.68 to 0.71 in high grade prostate cancer, when the genetic variants were added to the model. Furthermore, the improved predictive value of the score for prostate cancer risk persisted with a four SNPs risk score (excluding SNPs deviated from Hardy-Weinberg equilibrium). Although we present the largest effort to date to study the association between adipokine genetic risk score and risk of prostate cancer, our results should be interpreted in the context of several potential limitations. We took a focused candidate gene approach to evaluate key SNPs in adipokine pathways but our SNP panel could be incomplete. Likewise, several newly reported prostate cancer risk-associated SNPs from genome-wide association studies were not included in the risk prediction model. Had we been able to include them, the overall risk prediction might have improved. We also estimated risk associations in this study population with an exploratory intent, without having the opportunity to validate our findings in a separate sample of patients undergoing prostate cancer screening. Therefore, further studies in independent populations are required. Finally, despite our relatively large sample size, we had limited statistical power to examine genetic variants in relation to high-metastasis risk prostate cancer, because of the small number of cases in this group. However, our study has several strengths: i) it was prospective and large enough for key outcomes of interest, ii) most of the genes and SNPs selected were based on biological evidence of functional importance; iii) study design and statistical analyses accounted for relevant risk factors such as ethnicity and age [50], and although we did not have data on heredity information in a large set of subjects, only 2.2% were actually younger than 55 years of age, suggesting that hereditary prostate cancers were rare in our sample; iv) we used statistical strategies to assess the robustness of associations, such as bootstrap resampling and discrimination improvement measures; and v) all men were screened for prostate cancer based on both PSA level and digital rectal exam during the recruitment period and diagnosis was determined by standard biopsy, thus making outcome misclassification unlikely.

In summary, we identified SNPs in adipokine pathways that are associated with prostate cancer development and with a more aggressive phenotype. The inclusion of SNPs in the risk score model significantly improved, albeit modestly, the performance of PSA and age to predict overall prostate cancer and high-grade prostate cancer risk in men subjected to biopsy. The inclusion of further functional SNPs in a susceptibility model for prostate cancer is warranted, in order to determine a multi-locus model to accurately predict prostate cancer and disease aggressiveness. The use of improved risk models, such as the one described here, may impact public health strategies if shown to have clinical utility when combined with individualized screening and risk reduction strategies.

Materials and Methods

Ethics Statement

This study was approved by the ethics committees of Porto Military Hospital and São João Hospital (Porto, Portugal). Patients were included after signing a written informed consent.

Subjects

Participants were enrolled between September 2007 and October 2010, after being referred to the urology departments of the participating hospitals for prostatic transrectal ultrasound guided biopsy (8–13 cores), on the basis of abnormal digital rectal examinations and/or single baseline PSA levels over 2.5 ng/mL. Our study population consisted of 1099 consecutively-admitted Caucasian men who had histological evaluation and consented for genotyping.

We selected a control group of patients with non-prostate cancer (benign prostate hyperplasia [BPH] or chronic prostatitis) from the prospectively enrolled men undergoing prostate biopsy. Our choice of this control group was based on the following reasons: (i) diagnosis was contemporary with that of cancers; (ii) their advanced age at diagnosis allowed matching with elderly cancer patients; (iii) all patients underwent digital rectal examination, PSA testing and prostate needle biopsy, making the possibility of crossover remote. Most men develop BPH or chronic prostatitis by the 7th–8th decades of life, making it normal in men of that age to carry benign prostatic disease. This permitted our control group subjects to have comparable ages to those of our prostate cancer patients, thus minimizing the likelihood of outcome misclassification. Had we restricted controls to men without prostatic disease there would have been a severe imbalance in age distributions, which would introduce bias.

Prostate pathology and Gleason scores were determined via biopsy. In re-biopsed individuals only the last, most relevant pathological diagnosis was considered. Ninety-three men were excluded from the study due to a pathology report of high-grade prostatic intraepithelial neoplasia or a biopsy suspicious of cancer only. None of the participants had undergone prostate cancer treatment (hormonal castration, surgery, chemotherapy, or radiotherapy). All remaining 1006 eligible patients were included for molecular analysis.

Genetic Variants and Genotyping

Candidate SNPs were selected from the best evidence from published studies and through public databases that provide information on the phenotypic risks. Candidate genes involved in adipokine pathways known to affect oncogenesis were selected. SNPs with minor allele frequencies <0.05 were excluded. A total of 29 literature-defined putative functional SNPs in 19 different genes were selected, corresponding to 9 adipokine pathways (Table S1).

Genotyping for 22 SNPs (two in *ADIPOQ*, *IL6*, *IL6R*, *KDR*, three in *VEGF*, *LEP*, two in *LEPR*, *PPARG*, *PPARGC1A*, *PPARD*, *SPP1*, *IGF1R*, *IGFBP3*, *IRS1*, *FGF2*, *FGFR2*, *TNF*, *TNFRSF1A*) was performed using TaqMan allelic discrimination (Applied Biosystems), whereas 7 SNPs were genotyped through polymerase chain reaction - restriction fragment length polymorphism analysis (*IL6*-597/−572/−174, *ADIPOQ*+45, *IL6ST* Gly148Arg, *LEPR* Gln223Arg and *TNF*-863), using previously described protocols. For quality control we used non-template controls in all runs and blind replicate genotype assessment in 5% of the samples. For the majority of SNPs, we observed almost complete concordance among duplicates.

Statistical Analysis

The Mann-Whitney test was used to compare means between prostate cancer and non-cancer groups. The chi-square test was used to test for departures from Hardy-Weinberg equilibrium for each SNP based on the distribution among the non-prostate cancer group.

Unconditional logistic regression was used to estimate age-adjusted odds ratios (aORs) and 95% confidence intervals (95%CIs) for the associations between the polymorphisms and development of prostate cancer based on both recessive and dominant models. We examined the association of genetic markers with overall prostate cancer, restricted to high-grade prostate cancer (combined Gleason score ≥7), and restricted to high-risk prostate cancer for metastasis (PSA at diagnosis ≥20 ng/mL and/or combined Gleason score ≥8). Sensitivity analyses were conducted on the risk-associated SNPs that exhibited deviation from Hardy-Weinberg equilibrium. This was done by restricting the non-prostate cancer group to normal/BPH histology, and with serum PSA <4 ng/mL and then retesting the risk associations and departure from Hardy-Weinberg equilibrium.

To assess whether risk-associated SNPs affected time to clinical onset of disease we constructed Kaplan-Meier plots of the cumulative probabilities for having prostate cancer diagnosed at different ages according to each SNP. This analysis was conducted among prostate cancer cases only.

Stepwise multivariate logistic regression with backward elimination (P-value for retention = 0.15) was conducted in SNPs with aOR ≤0.7 or aOR ≥1.3 (30% decrease or increase in odds of the outcome) plus age and PSA as continuous variables. Bootstrapping analyses were performed through MonteCarlo simulation (1000 replications).

We constructed an inclusive multi-locus genetic risk score for each participant by summing the coefficients for each of the resulting variables after stepwise regression analyses. For each SNP, the risk genotypes were coded as 1 and the non-risk alleles as 0. The model was determined by multiplying the β coefficient by the SNPs, plus the γ coefficient by the PSA value and the α coefficient by the patient's age (Inclusive Risk Score $= \Sigma\ \beta i \times Xi + \gamma \times PSA + \alpha \times Age$; where Xi = SNPs scaled for risk, βi = coefficient for SNPs, γ = coefficient for PSA, α = coefficient for Age). A parsimonious risk score was calculated based on a model that included only PSA and age at diagnosis. These models were fitted independently using all prostate cancers and then restricted to high-grade prostate cancers as outcomes. A likelihood-ratio test was used to assess the goodness of fit between the two logistic regression models.

We assessed the clinical value of the above two scores in correctly predicting disease status by receiver operating characteristic (ROC) curve analysis. We compared the areas under the ROC curves (AUC) constructed with both scores (with and without genetic information), both for all prostate cancers and high-grade cancers, using a non-parametric algorithm [51].

We evaluated the improvement in model performance (PSA and age risk score) introduced by the inclusion of the SNPs risk information, using the net reclassification improvement (NRI) and the integrated discrimination improvement (IDI) tests [52,53]. The NRI measures the reclassification of men from one risk category to another by addition of the genetic information to the PSA and age prediction model, and the extent of clinical utility can be evaluated by the magnitude of the NRI. The IDI does not consider risk thresholds; rather it is the mean of increments and decrements in estimated probabilities of prostate cancer for cases and non cases, comparing models. Since the NRI measurement is heavily dependent on the threshold levels used, we used a threshold probability between 15% and 45%, similar to those previously reported in such clinical context [54].

All statistical analyses were conducted in STATA version 10.0 (StataCorp, College Station, Texas). For NRI and IDI calculations, we used the nriidi-package for Stata 11 [53].

Supporting Information

Table S1 Characteristics of candidate Single Nucleotide Polymorphisms (SNPs) involved in adipokine pathways potentially associated with cancer. HW-E, Hardy-Weinberg Equilibrium; *ADIPOQ*, adiponectin gene; *IL6*, interleukin-6 gene; *IL6R*, interleukin-6 receptor gene; *IL6ST*, interleukin-6 signal transducer gene; *KDR*, vascular endothelial growth factor receptor 2 gene; *VEGF*, vascular endothelial growth factor gene; *LEP*, leptin gene; *LEPR*, leptin receptor gene; *PPARGC1A*, Peroxisome proliferator-activated receptor gamma co-activator 1 alpha gene; *PPARD*, Peroxisome proliferator-activated receptor delta gene; *PPARG*, Peroxisome proliferator-activated receptor gamma gene; *SPP1*, osteopontin gene; *IRS1*, insulin receptor substrate 1 gene; *IGFBP3*, insulin growth factor binding protein 3 gene; *IGF1R*, insulin growth factor 1 receptor gene; *FGF2*, fibroblast growth factor 2 gene; *FGFR2*, fibroblast growth factor receptor 2 gene; *TNF*, tumoral necrosis factor alpha gene; *TNFRSF1A*, tumoral necrosis factor receptor 1 gene. [a] The percentage of successfully genotyped DNA samples from the 1006 participants.
(DOC)

Table S2 Age-adjusted Odds Ratios and 95%CI of prostate cancer (PCa) according to adipokine pathways polymorphisms. N, number of evaluable patients; SNP, single nucleotide polymorphism; OR (95%CI), age-adjusted odds-ratio and respective 95% confidence interval. [a] HGPCa,High-grade Prostate Cancer (Gleason grade ≥7). [b] HRPCaM, High-risk Prostate Cancer for metastasis (Gleason grade ≥8 and/or PSA ≥20 ng/mL).
(DOC)

Table S3 Age-adjusted Odds Ratios and 95%CI for prostate cancer (PCa) associated with selected *SNPs*, after age stratification. [a] High-grade Prostate Cancer, Gleason grade ≥7; [b] High-risk Prostate Cancer for metastasis, Gleason grade ≥8 and/or PSA ≥20 ng/mL; aOR (95%CI), age-

adjusted odds ratio and respective 95% Confidence Interval; PCa, Prostate Cancer; Median age at diagnosis = 67.5 years; *Evaluable individuals for analysis.
(DOC)

Table S4 Sensitivity analysis in SNPs with deviation from Hardy-Weinberg equilibrium. Risk for prostate cancer after restriction on the non-prostate cancer group to just benign prostate hyperplasia and normal or to PSA below 4 ng/mL. *Hardy-Weinberg equilibrium, Pearson chi-square analysis for differences between observed and expected genotype frequencies; **Age-adjusted odds ratios; BPH, Benign Prostate Hyperplasia; PSA, Prostate-specific Antigen; PSA, prostate-specific antigen; SNP, signle nucleotide polymorphism; aOR (95%CI), age-adjusted odds ratio and respective 95% confidence interval. [a] Biopsy findings: normal, 14.9%; BPH, 5.4%, chronic prostatitis, 74.7%; atrophy, 5%; [b] Biopsy findings: normal, 73.5%; BPH, 26.5%; [c] Biopsy findings: normal, 22.2%; BPH, 6.0%, chronic prostatitis, 65.8%; atrophy, 6.0%.
(DOC)

Author Contributions

Conceived and designed the experiments: RJTR FMP CMSL RMM ELF. Performed the experiments: RJTR CPDM ASMA VFMC AMF FMP. Analyzed the data: RJTR AVR ELF. Contributed reagents/materials/analysis tools: RJTR CMSL RMM. Wrote the paper: RJTR ELF.

References

1. Gronberg H (2003) Prostate cancer epidemiology. Lancet 361: 859–864.
2. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, et al. (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360: 1310–1319.
3. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1320–1328.
4. Vickers AJ, Roobol MJ, Lilja H (2011) Screening for Prostate Cancer: Early Detection or Overdetection? Annu Rev Med.
5. Morote J, Trilla E, Esquena S, Serrallach F, Abascal JM, et al. (2002) The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 10.1 and 20 ng/ml. Eur Urol 42: 333–337.
6. Damber JE, Aus G (2008) Prostate cancer. Lancet 371: 1710–1721.
7. Lindstrom S, Schumacher F, Siddiq A, Travis RC, Campa D, et al. (2011) Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers–results from BPC3. PLoS One 6: e17142.
8. Febbo PG (2009) Genomic approaches to outcome prediction in prostate cancer. Cancer 115: 3046–3057.
9. Aly M, Wiklund F, Xu J, Isaacs WB, Eklund M, et al. (2011) Polygenic risk score improves prostate cancer risk prediction: results from the stockholm-1 cohort study. Eur Urol 60: 21–28.
10. Hsing AW, Sakoda LC, Chua S Jr (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86: s843–857.
11. von Hafe P, Pina F, Perez A, Tavares M, Barros H (2004) Visceral fat accumulation as a risk factor for prostate cancer. Obes Res 12: 1930–1935.
12. Mistry T, Digby JE, Desai KM, Randeva HS (2007) Obesity and prostate cancer: a role for adipokines. Eur Urol 52: 46–53.
13. Ribeiro R, Lopes C, Medeiros R (2006) The link between obesity and prostate cancer: the leptin pathway and therapeutic perspectives. Prostate Cancer Prostatic Dis 9: 19–24.
14. Moore SC, Leitzmann MF, Albanes D, Weinstein SJ, Snyder K, et al. (2009) Adipokine genes and prostate cancer risk. Int J Cancer 124: 869–876.
15. Ribeiro R, Vasconcelos A, Costa S, Pinto D, Morais A, et al. (2004) Overexpressing leptin genetic polymorphism (−2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease. Prostate 59: 268–274.
16. Kote-Jarai Z, Singh R, Durocher F, Easton D, Edwards SM, et al. (2003) Association between leptin receptor gene polymorphisms and early-onset prostate cancer. BJU Int 92: 109–112.
17. Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, et al. (2009) Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate 69: 874–885.
18. Silha JV, Krsek M, Sucharda P, Murphy LJ (2005) Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond) 29: 1308–1314.
19. Gomez-Ambrosi J, Catalan V, Ramirez B, Rodriguez A, Colina I, et al. (2007) Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 92: 3719–3727.
20. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280: E745–751.
21. Park J, Euhus DM, Scherer PE (2011) Paracrine and Endocrine Effects of Adipose Tissue on Cancer Development and Progression. Endocr Rev.
22. Quinton ND, Lee AJ, Ross RJ, Eastell R, Blakemore AI (2001) A single nucleotide polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women. Hum Genet 108: 233–236.
23. Sun Q, Cornelis MC, Kraft P, Qi L, van Dam RM, et al. (2010) Genome-wide association study identifies polymorphisms in LEPR as determinants of plasma soluble leptin receptor levels. Hum Mol Genet 19: 1846–1855.
24. da Silva BA, Bjorbaek C, Uotani S, Flier JS (1998) Functional properties of leptin receptor isoforms containing the gln–>pro extracellular domain mutation of the fatty rat. Endocrinology 139: 3681–3690.
25. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, et al. (2006) The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 6: 819–830.
26. Weber GF, Lett GS, Haubein NC (2010) Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 103: 861–869.
27. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, et al. (2011) SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470: 269–273.
28. Hummelshoj T, Ryder LP, Madsen HO, Odum N, Svejgaard A (2006) A functional polymorphism in the Eta-1 promoter is associated with allele specific binding to the transcription factor Sp1 and elevated gene expression. Mol Immunol 43: 980–986.
29. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4: 505–518.
30. Chen W, Wang S, Tian T, Bai J, Hu Z, et al. (2009) Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur J Hum Genet 17: 1668–1675.
31. Li L, Huang X, Huo K (2010) IGFBP3 polymorphisms and risk of cancer: a meta-analysis. Mol Biol Rep 37: 127–140.
32. Deal C, Ma J, Wilkin F, Paquette J, Rozen F, et al. (2001) Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86: 1274–1280.
33. de Alencar SA, Lopes JC (2010) A comprehensive in silico analysis of the functional and structural impact of SNPs in the IGF1R gene. J Biomed Biotechnol 2010: 715139.
34. Modrek B, Lee C (2002) A genomic view of alternative splicing. Nat Genet 30: 13–19.
35. Chen M, Manley JL (2009) Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 10: 741–754.
36. Almind K, Inoue G, Pedersen O, Kahn CR (1996) A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest 97: 2569–2575.
37. Fall K, Stark JR, Mucci LA, Chan J, Stampfer MJ, et al. (2008) No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk. Prostate 68: 1416–1420.
38. Cronauer MV, Schulz WA, Seifert HH, Ackermann R, Burchardt M (2003) Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur Urol 43: 309–319.
39. Schulz S, Kohler K, Schagdarsurengin U, Greiser P, Birkenmeier G, et al. (2005) The human FGF2 level is influenced by genetic predisposition. Int J Cardiol 101: 265–271.
40. Culig Z, Steiner H, Bartsch G, Hobisch A (2005) Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95: 497–505.
41. Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, et al. (2010) PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis 31: 455–461.
42. Tan D, Wu X, Hou M, Lee SO, Lou W, et al. (2005) Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol 174: 753–756.
43. Terry CF, Loukaci V, Green FR (2000) Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 275: 18138–18144.
44. Mullberg J, Oberthur W, Lottspeich F, Mehl E, Dittrich E, et al. (1994) The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol 152: 4958–4968.
45. Santer FR, Malinowska K, Culig Z, Cavarretta IT (2010) Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer 17: 241–253.
46. Danforth KN, Rodriguez C, Hayes RB, Sakoda LC, Huang WY, et al. (2008) TNF polymorphisms and prostate cancer risk. Prostate 68: 400–407.

47. Jacobs EJ, Hsing AW, Bain EB, Stevens VL, Wang Y, et al. (2008) Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomarkers Prev 17: 972–977.
48. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293: 2095–2101.
49. Harnden P, Shelley MD, Coles B, Staffurth J, Mason MD (2007) Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncol 8: 411–419.
50. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, et al. (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59: 61–71.
51. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837–845.
52. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27: 157–172; discussion 207–112.
53. Sundstrom J, Byberg L, Gedeborg R, Michaelsson K, Berglund L (2011) Useful tests of usefulness of new risk factors: Tools for assessing reclassification and discrimination. Scand J Public Health 39: 439–441.
54. Cavadas V, Osorio L, Sabell F, Teves F, Branco F, et al. (2010) Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. Eur Urol 58: 551–558.

Functionality of genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer

Avelino Fraga [1,2,3], Ricardo Ribeiro [2,4,5,6]; André Coelho [7]; José Ramon Vizcaíno [7]; Helena Coutinho [8]; José Manuel Lopes [8,9]; Paulo Príncipe [1,2]; Carlos Lobato [10]; Carlos Lopes [3]; Rui Medeiros [3,4,6]

[1] Department of Urology, Porto Hospital Centre – St. António Hospital, Porto, Portugal

[2] Center for Urological Research, Department of Urology, Porto Hospital Centre – St. António Hospital, Porto, Portugal

[3] ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal

[4] Molecular Oncology Group - CI, Portuguese Institute of Oncology, Porto, Portugal

[5] Genetics Laboratory, Faculty of Medicine, University of Lisbon, Lisbon, Portugal

[6] Research Department, Portuguese League Against Cancer – North Centre, Porto, Portugal

[7] Department of Pathology, Porto Hospital Centre – St. António Hospital, Porto, Portugal

[8] Department of Pathology and Oncology, Faculty of Medicine, University of Porto

[9] Institute of Pathology and Molecular Immunology of University of Porto (IPATIMUP)

[10] Department of Urology, Porto Millitary Hospital, Porto, Portugal

Corresponding author:

Dr. Avelino Fraga, M.D.
Centro Hospitalar do Porto – Hospital Santo António
Department of Urology – 8º Piso
Largo Prof. Abel Salazar
4000-001 Porto
Portugal
Phone: 00 351 222 077 507
Fax: 00 351 220 900 642
Email: avfraga@gmail.com

Acknowledgements: Authors acknowledge the support from the Portuguese League Against Cancer – North Centre.

ABSTRACT

Purpose: In this study we sought if, in their quest to handle hypoxia, prostate tumors express target hypoxia-associated molecules and their correlation with putative functional genetic polymorphisms.

Methods: Representative areas of prostate carcinoma (n=51) and of nodular prostate hyperplasia (BPH) (n=20) were analysed for HIF-1α, CAIX, LOX and VEGFR2 immunohistochemistry expression using a tissue microarray. DNA was isolated from peripheral blood and used to genotype functional polymorphisms at the corresponding genes (*HIF1A* +1772 C>T, rs11549465; *CA9* +201 A>G; rs2071676; *LOX* +473 G>A, rs1800449; *KDR* – 604 T>C, rs2071559).

Results: Immunohistochemistry disclosed predominance of positive CAIX and VEGFR2 expression in epithelial cells of prostate carcinomas compared to BPH (P=0.043 and P=0.035, respectively). In addition, the VEGFR2 expression score in prostate epithelial cells was higher in organ-confined and extra prostatic carcinoma compare to BPH (P=0.031 and P=0.004, respectively). Notably, for LOX protein the immunoreactivity score was significantly higher in organ-confined carcinomas compare to BPH (P=0.015). The genotype-phenotype analyses showed higher LOX staining intensity for carriers of the homozygous *LOX +473* G-allele (P=0.011), and that *KDR* -604 T-allele carriers were more prone to have higher VEGFR2 expression in prostate epithelial cells (P<0.006).

Conclusions: The expression on prostate epithelial cells of VEGFR2, CAIX and LOX allowed differentiating malignant from benign prostate disease. Two of the genetic polymorphisms (*LOX* +473 G>A and *KDR* – 604 T>C), account for a potential gene-environment effect in the activation of hypoxia-driven pathways in prostate carcinoma. Further research in larger series is warranted to validate present findings.

Keywords: genetic polymorphism; hypoxia; immunohistochemistry; prostate cancer;

INTRODUCTION

Prostate carcinoma is a common and heterogeneous malignant neoplasia, with aggressiveness differing among individuals despite similar clinicopathological characteristics.

During tumor growth, the oxygen supply and nutrients scarcity urges malignant cells to signal to the microenvironment their needs. The hypoxia inducible factor 1 alpha (HIF-1α) is a key factor by which tumors regulate the response to hypoxia, triggering cascades with pro-tumoral effects [1,2]. HIF-1α mechanism implies targeting hypoxia response elements in promoters of downstream target genes, notably vascular endothelial growth factor (*VEGF)*, carbonic anhydrase IX (*CAIX)*, and lysyl oxidase (*LOX)* promoters, resulting in more aggressive, treatment resistant phenotype [1-3]. In prostate carcinoma, a large study has demonstrated the relevance of intrinsic markers of tumor hypoxia for localized disease and outcome of radical treatment [4].

Recent findings indicate that genetic variants may modulate the predisposition for prostate carcinoma and associate with clinical outcome [5,6]. Single nucleotide polymorphisms (SNPs) in genes coding for molecules involved in the response to hypoxia, particularly a functional polymorphism in *HIF1A* gene at locus +1772 C>T [7-13], has been studied in association with prostate carcinoma with controversial results. However, we are not aware of studies implicating SNPs in other genes (e.g. *LOX*, *CA9*, *KDR)* of HIF-1α-mediated hypoxia downstream pathways.

Based on the role of hypoxia-associated molecules in cancer, we hypothesized an association, at the genetic and protein level, between *HIF1A*, *LOX*, *CA9* and *KDR* genetic variants, the protein expression and prostate carcinoma. Hence, if these polymorphisms modulate the protein expression, then the knowledge of the genotype could help to identify patients at higher risk for prostate carcinoma and eventually more aggressive disease.

MATERIAL AND METHODS

Seventy-one patients with prostate pathology (n=51 with carcinoma, and n=20 with nodular hyperplasia, BPH) and elective for prostatic surgery at the Porto Hospital Centre - Sto. António Hospital and Porto Military Hospital were included, after informed consent ans approval by hospitals' ethical committees. Inclusion criteria were 45-75 years of age and for prostate carcinomas absence of

previous treatments. Patient’s clinicopathological data (Table 1) was collected from clinical files and pathological staging determined as organ-confined (T1-T2) (OCPCa) or extra prostatic (T3-T4) (EPCa) disease.

The white cell fraction from peripheral blood was used to extract DNA (QIAmp DNA Blood Mini Kit, Qiagen). Four putative functional SNPs (3 non-synonymous and 1 in the promoter region) in 4 candidate genes involved in key hypoxia pathways were selected (*HIF1A* +1772 C>T, rs11549465; *CA9* +201 A>G, rs2071676; *LOX* +473 G>A, rs1800449; *KDR* -604 T>C, rs2071559). Genotyping was done by Real-Time PCR using Taqman ssays (Applied Biosystems).

Representative areas of carcinoma and of nodular hyperplasia were selected and included into tissue microarray as previously described [14]. Slides were stained with mouse monoclonal antibody to HIF-1α (dilution 1:100, NB100-105, Novus Biologicals), and rabbit polyclonal antibodies to LOX, (dilution 1:100, ab 31238, Abcam), VEGFR2 (dilution 1:200, ab 2349, Abcam) and CAIX, (dilution 1:1000, NB100-417, Novus Biologicals) using the VENTANA BenchMark XT series slide-staining instrument (with the VENTANA ultraView DAB IHC detection kit, VENTANA, Tucson, AZ, United States). Immunohistochemical evaluation was independently reviewed by two pathologists (JRV and AC) to assess VEGFR2 expression in vasculature and prostate epithelial cells, and HIF-1α, LOX and CAIX in prostate epithelial cells (carcinoma and nodular hyperplasia). Discordant cases were discussed in order to attain a final consensus. Staining positivity was sought for VEGFR2 in vessels and epithelial cells, whereas CAIX, HIF-1α and LOX expression was only performed in prostatic epithelial cells (both in carcinoma and nodular hyperplasia). Briefly, scores were calculated as following: VEGFR2 intensity was multiplied by the percentage of tumor cells at that intensity level (VEGFR2 H-score); for LOX the score was calculated by multiplicating the percentage of positive cells with staining intensity (LOX immunoreactivity score, IRS). A representative image of the expression of each aforementioned protein is shown in Figure 1.

Descriptive statistics included means with respective standard errors, whereas departure from normality was assessed with Shapiro-Wilk test. Groups were compared through Kruskal-Wallis and Mann-Whitney test or Student t-test. Pearson chi-square tests were used to compare frequencies among categorical variables. Analyses were performed in SPSS 17.0.

RESULTS

Epithelial cells staining positivity for CAIX and VEGFR was significantly higher in prostate carcinomas compared with BPH (P=0.043 and P=0.035, respectively) (Figure 2). Concurrently, despite non-significant, both HIF-1α and LOX immunoreactivities had a tendency to be elevated in carcinomas (P=0.111 and P=0.266, respectively) (Figure 2). Notably, although not significantly more expressed in prostate carcinomas, the LOX IRS, was significantly more elevated in organ-confined carcinomas than BPH (P=0.015) (Figure 3), and higher in patients with positive HIF-1α expression (P=0.053) (Figure 4). VEGFR2 immunoreactivity was observed in vascular endothelial cells (only in 20% of all samples) and epithelial cells (70% of patients with extra prostatic carcinomas and approximately half of organ-confined carcinomas). Noteworthy, the VEGFR2 H-score in epithelial cells was statistically distinct between BPH and organ-confined or extra prostatic carcinomas (P=0.031 and P=0.004, respectively) (Figure 5).

The genotypic distribution in polymorphisms *HIF1A* +1772 C>T, *LOX* +473 G>A, *CA9* +201 A>G and *KDR* -604 T>C is shown in supplementary table 1. There was no over-represented genotype in disease groups. Regarding genotype-phenotype relation, there was lack of association between *HIF1A* +1772 C>T and *CA9* +201 A>G genotypes with HIF-1α and CAIX protein expression (Table 2). In contrast, LOX expression was significantly more intense in carriers of the *LOX +473* homozygous G allele compared to AA/AG (P=0.011), despite no significance was achieved for IRS (but with similar trend) (Figure 6). Alongside, *KDR* -604 T-allele carriers were more prone to have VEGFR2 expression in prostate epithelial cells but not in vessels (Table 3). The VEGFR2 H-score was significantly higher in T-allele carriers compared to homozygous C (Figure 7).

Only data from prostate carcinomas was used to evaluate if hypoxia proteins associated with Gleason score or PSA>10 ng/mL (Table 4). Statistical trends were observed for higher VEGFR2 H-score expression in more undifferentiated carcinomas (Gleason $\geq$7) (P=0.099) and in patients with prostate specific antigen (PSA) $\geq$ 10 (P=0.085), and for positive CAIX expression in prostate carcinomas from patients with PSA above 10 (P=0.078).

DISCUSSION

The hypoxia-driven HIF-1α upregulation activates downstream pathways involved in metabolism (e.g. CAIX), angiogenesis (e.g. VEGF/VEGFR2 pathway) and extracellular matrix activity (e.g. LOX), which can modulate cancer behavior [15]. Experimental and clinical studies in prostate carcinoma demonstrated that HIF-1α overexpression was associated with malignancy, progression and metastatic potential [16] [4]. Here, we found a non-significant statistical trend for higher HIF-1α protein expression in prostate carcinomas compared to BPH, which may be due to the limited number of samples.

Besides vascular endothelial cells also prostate epithelial cells express VEGFR2, which were shown to signal through the AKT/mTOR/P70S6K pathway [17]. We found that VEGFR2 was expressed in the epithelium and endothelial cells, though more frequently expressed in epithelial tumor cells of organ confined or extra prostatic carcinomas than in BPH. Hence, in the prostate VEGFR2 expression is mainly expressed in malignant epithelium where its ligand VEGF may exert a direct effect in tumor cell growth. Previous immunohistochemistry studies reported VEGFR2 expression in high-grade prostate intra-epithelial neoplasia and carcinomas of the prostate [18], whereas gene expression findings in prostate cancer cell lines evidenced suppressive growth and promotion of apoptosis with *KDR* antisense oligonucleotide [19]. Taken together with present data, these findings indicate that VEGFR2 expression in epithelial prostate carcinoma cells supports a function for VEGF that is not limited to angiogenesis. Thus, abrogation of VEGFR2 signalling in malignant epithelial cells may prove an effective therapeutic modality for the treatment of prostate cancer. At present, two anti-angiogenic drugs are being tested in the phase III setting for men with prostate cancer, carbozantinib (a dual VEGFR2/MET inhibitor) and tasquinimod (down-regulator of HIF-1α), that showed beneficial and encouraging results on phase II trials [20].

Tumor cells have to adapt to the hypoxia-driven switch in metabolism, with consequent acidosis, in order to survive. CAIX is a membrane-bound protein crucial for pH regulation in the highly metabolically active malignant cells. In agreement, carbonic anhydrase IX gene (*CA9*) is a target of HIF-1α and is up-regulated in response to hypoxia [21]. *CA9* mRNA expression increases reliably following hypoxia incubation of PC-3 cells [22], although no significant differences on mRNA expression were found when comparing BPH with prostate carcinomas [3]. Other studies described

lack of CAIX expression in primary prostate carcinoma and hypothesized alternate pathways for maintaining pH balance [23,24]. Conversely, our results disclosed increased frequency of cases with epithelial cell positivity for CAIX expression in organ confined and extra prostatic carcinomas compared to BPH. Our findings taken together with reports of CAIX expression in epithelial prostate carcinoma cells [22,3] sustain the need for reconsidering CAIX role in prostate carcinoma.

The lysyl oxidase gene (*LOX*), was shown to be directly regulated by HIF-1α transcription factor and essential for hypoxia-induced metastasis and cancer cell proliferation [25]. In the prostate we found that LOX immunoreactivity score was associated with HIF-1α positivity, thus supporting the regulatory nature of HIF-1α in LOX expression. Furthermore, although the number of cases with positive LOX expression in carcinomas was similar to BPH, the LOX IRS was significantly higher in organ confined prostate carcinomas compared with BPH. Interestingly, increased expression of *LOX* mRNA in prostate carcinomas compared with BPH was previously observed [3]. LOX biological functions that include effects in cell growth, migration and polarity agrees with the increased LOX expression found in our carcinoma samples.

In this study, evaluation of protein expression according to SNPs in their coding genes disclosed a genotype-phenotype effect for the *LOX* and *KDR* SNPs, but no functional validation at the protein level was observed for the studied *HIF1A* and *CA9* SNPs. The C-to-T substitution at locus +1772 (rs11549465) in *HIF1A* gene localizes in the oxygen-dependent domain of the gene where the variant allele was shown to stabilize *HIF1A* mRNA and enhance *HIF1A* transcriptional activity [26]. Notwithstanding the functional rationale, association of this SNP with prostate carcinoma risk and with microvessel density, yielded conflicting results [7,9,13,12]. In our study, the lack of statistical differences in *HIF1A* +1772 C>T genotypes for HIF-1α protein expression, agrees with a previous report in prostatic carcinoma [9]. However, the low frequency of TT carriers in our sample (only 2 cases) may have influenced statistical power, since the HIF-1α protein and mRNA overexpression have been associated with the TT genotype [8,27].

A functional genetic variant on *KDR* gene that codifies for VEGFR2 is located in the promoter region (-604 T>C, rs2071559), where the C-allele has been associated with lower transcription activity, and decreased serum VEGFR2 level [28]. Interestingly, we found that T carriers had a significantly higher VEGFR2 expression in prostate epithelial cells, thereby suggesting that this SNP

might prove useful for predictive and/or prognostic evaluations in prostate carcinoma, warranting future studies.

A SNP in exon 1 of *CA9* gene is located at locus +201 (rs2071676), where an A-to-G substitution leads to a change of valine-by-methionine in codon 33. Even though we observed an overrepresentation of CAIX positive immunoreactivity in prostate carcinoma compared to BPH, the nonsynonymous SNP in *CA9* +201 was unable to explain variations in the levels of CAIX protein expression in the prostatic tissue, suggesting lack of influence in protein expression, even though the impact of this nonsynonymous substitution (valine to methionine) in CAIX protein activity remains to be confirmed.

The *LOX* gene is translated and secreted as a proenzyme (Pro-LOX), and then processed to a functional enzyme (LOX) and a propeptide (LOX-PP) . We studied a SNP in *LOX* gene that has been identified at locus +473 G>A (rs1800449), that cause an aminoacid substitution (Arg158Glu). This SNP locates at a highly conserved region within LOX-PP, where the A-allele was found to decrease the protective capacity of LOX-PP, while increasing the Pro-LOX-associated invasive ability of tumor cells [29]. When evaluating LOX immunoreactivity and expression intensity by immunohistochemistry in prostate tissues, we found it significantly lower in carriers of the *LOX* +473 A-allele. In the present study, we found that LOX was primarily present at the nucleus of epithelial cells, which fits with other reports asserting that this enzyme may have important functions in secretory cells, as catalyser of histones in the nucleus [30]. Thus, our findings seem to suggest a wider variety of functions for LOX in prostate epithelial cells, beyond those related to cross-link formation in collagen and elastin, which merit further research. We hypothesize that the trafficking of LOX towards inside the cell or a specific cell compartment may be subordinated to the structural molecular characteristics and folding of the protein, which could be determined by *LOX* +473 G>A polymorphism.

Our endeavour to study the genotype-phenotype correlation in key hypoxia markers and its association with prostate cancer yielded encouraging findings, even though results should be interpreted in the context of potential limitations. The lack of statistical significance for genotypic frequencies between disease groups on the putative functional target SNPs in *HIF1A*, *LOX*, *CA9* and *KDR* likely reflects underpowered sample size. This was a major issue as conclusions were impracticable for genetic association analysis and limited for genotype-phenotype inferences. Further

limitations arisen from stratification of carcinomas by stage, Gleason score or PSA level, showing at most only statistical trends for increased expression of VEGFR2 and CAIX in more aggressive phenotypes. Nevertheless, considering the hypothesis-generating nature of this study, we report findings that provide important clues to further work in larger samples. Another issue may be related with raised concern over similar hypoxic dysregulation for both prostate carcinoma and benign hyperproliferative diseases. However, inclusion of BPH patients as controls arranged for age-matching with elderly prostate cancer patients, similar clinical and diagnostic procedures (including prostate biopsy) making the possibility of crossover remote; and this group represents the normality in men at that age, since most men of that age carry benign prostate hyperplasia.

Prostate carcinoma triggers an increase in hypoxia, which regulates *HIF1A* that in turn impacts downstream the expression of LOX, CAIX and VEGFR2 in tumor cells. In this study we observed that the inherited genetic variants in *LOX* and *KDR* seem to modulate the expression of LOX and VEGFR2 in carcinoma cells, supporting a gene-environment interaction in the activation of hypoxia-driven pathways in prostate carcinoma. Results presented here warrant further research in larger samples in order to evaluate the predictive and prognostic value of *KDR* and *LOX* SNPs in prostate carcinoma.

Conflict of interest: The authors declare that they have no conflict of interest

REFERENCES

1. Fraga A, Ribeiro R, Medeiros R (2009) [Tumor hypoxia: the role of HIF]. Actas urologicas espanolas 33 (9):941-951
2. Harris AL (2002) Hypoxia--a key regulatory factor in tumour growth. Nature reviews Cancer 2 (1):38-47. doi:10.1038/nrc704
3. Stewart GD, Gray K, Pennington CJ, Edwards DR, Riddick AC, Ross JA, Habib FK (2008) Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. Oncology reports 20 (6):1561-1567
4. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, Eeles R, Cooper C, Sydes M, Dearnaley D, Parker C (2008) Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. The lancet oncology 9 (4):342-351. doi:10.1016/S1470-2045(08)70076-7
5. Wiklund F (2010) Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers? Genome Med 2 (7):45. doi:gm166 [pii]10.1186/gm166

6. Ribeiro RJ, Monteiro CP, Azevedo AS, Cunha VF, Ramanakumar AV, Fraga AM, Pina FM, Lopes CM, Medeiros RM, Franco EL (2012) Performance of an adipokine pathway-based multilocus genetic risk score for prostate cancer risk prediction. PloS one 7 (6):e39236. doi:10.1371/journal.pone.0039236

7. Fraga A, Ribeiro R, Principe P, Lobato C, Pina F, Mauricio J, Monteiro C, Sousa H, Calais da Silva F, Lopes C, Medeiros R (2014) The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration. European journal of cancer 50 (2):359-365. doi:10.1016/j.ejca.2013.09.001
8. Vainrib M, Golan M, Amir S, Dang DT, Dang LH, Bar-Shira A, Orr-Urtreger A, Matzkin H, Mabjeesh NJ (2012) HIF1A C1772T polymorphism leads to HIF-1alpha mRNA overexpression in prostate cancer patients. Cancer biology & therapy 13 (9):720-726. doi:10.4161/cbt.20554
9. Foley R, Marignol L, Thomas AZ, Cullen IM, Perry AS, Tewari P, O'Grady A, Kay E, Dunne B, Loftus B, Watson WR, Fitzpatrick JM, Woodson K, Lehman T, Hollywood D, Lynch TH, Lawler M (2009) The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers. Cancer biology & therapy 8 (2):118-124
10. Chau CH, Permenter MG, Steinberg SM, Retter AS, Dahut WL, Price DK, Figg WD (2005) Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. Cancer biology & therapy 4 (11):1222-1225
11. Fu XS, Choi E, Bubley GJ, Balk SP (2005) Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. The Prostate 63 (3):215-221. doi:10.1002/pros.20190
12. Li P, Cao Q, Shao PF, Cai HZ, Zhou H, Chen JW, Qin C, Zhang ZD, Ju XB, Yin CJ (2012) Genetic polymorphisms in HIF1A are associated with prostate cancer risk in a Chinese population. Asian journal of andrology 14 (6):864-869. doi:10.1038/aja.2012.101
13. Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ, Ma J (2007) Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. The Prostate 67 (12):1354-1361. doi:10.1002/pros.20589
14. Pertega-Gomes N, Vizcaino JR, Miranda-Goncalves V, Pinheiro C, Silva J, Pereira H, Monteiro P, Henrique RM, Reis RM, Lopes C, Baltazar F (2011) Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC cancer 11:312. doi:10.1186/1471-2407-11-312
15. Semenza GL (2012) Hypoxia-inducible factors in physiology and medicine. Cell 148 (3):399-408. doi:10.1016/j.cell.2012.01.021

16. Zhong H, Agani F, Baccala AA, Laughner E, Rioseco-Camacho N, Isaacs WB, Simons JW, Semenza GL (1998) Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer research 58 (23):5280-5284
17. Saraswati S, Kumar S, Alhaider AA (2013) alpha-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway. Molecular cancer 12:147. doi:10.1186/1476-4598-12-147
18. Hahn D, Simak R, Steiner GE, Handisurya A, Susani M, Marberger M (2000) Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. The Journal of urology 164 (2):506-510
19. Song J, Song Y, Guo W, Jia J, Jin Y, Bai A (2014) Regulatory roles of KDR antisense oligonucleotide on the proliferation of human prostate cancer cell line PC-3. Journal of BUON : official journal of the Balkan Union of Oncology 19 (3):770-774
20. Schweizer MT, Carducci MA (2013) From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer. Cancer journal 19 (1):99-106. doi:10.1097/PPO.0b013e31827e0b86
21. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer research 60 (24):7075-7083
22. Stewart GD, Nanda J, Brown DJ, Riddick AC, Ross JA, Habib FK (2009) NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. International journal of cancer Journal international du cancer 124 (1):223-232. doi:10.1002/ijc.23934
23. Smyth LG, O'Hurley G, O'Grady A, Fitzpatrick JM, Kay E, Watson RW (2010) Carbonic anhydrase IX expression in prostate cancer. Prostate cancer and prostatic diseases 13 (2):178-181. doi:10.1038/pcan.2009.58
24. Pertega-Gomes N, Vizcaino JR, Attig J, Jurmeister S, Lopes C, Baltazar F (2014) A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC cancer 14:352. doi:10.1186/1471-2407-14-352
25. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT, Jeffrey SS, Giaccia AJ (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440 (7088):1222-1226. doi:10.1038/nature04695
26. Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, Oue N, Yasui W, Imai K, Nakachi K, Poellinger L, Nishiyama M (2003) Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 24 (11):1779-1783. doi:10.1093/carcin/bgg132
27. Kim HO, Jo YH, Lee J, Lee SS, Yoon KS (2008) The C1772T genetic polymorphism in human HIF-1alpha gene associates with expression of HIF-1alpha protein in breast cancer. Oncology reports 20 (5):1181-1187
28. Wang Y, Zheng Y, Zhang W, Yu H, Lou K, Zhang Y, Qin Q, Zhao B, Yang Y, Hui R (2007) Polymorphisms of KDR gene are associated with coronary heart disease. Journal of the American College of Cardiology 50 (8):760-767. doi:10.1016/j.jacc.2007.04.074
29. Min C, Yu Z, Kirsch KH, Zhao Y, Vora SR, Trackman PC, Spicer DB, Rosenberg L, Palmer JR, Sonenshein GE (2009) A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer. Cancer research 69 (16):6685-6693. doi:10.1158/0008-5472.CAN-08-4818
30. Wakasaki H, Ooshima A (1990) Immunohistochemical localization of lysyl oxidase with monoclonal antibodies. Laboratory investigation; a journal of technical methods and pathology 63 (3):377-384

LEGENDS

Figure 1. Representative microscopy images of staining for hypoxia markers in prostate tissues (MO, 400x). A) HIF-1α - notice the granular cytoplasmic immunoreactivity of the malignant epithelial cells. In this case, more than 50% of the glands stained. B) LOX - strong and diffuse nuclear immunoreactivity of the epithelial cells. C) CAIX - note a focal apical cytoplasmic immunoreactivity in epithelial cells. D) VEGFR2 - moderate nuclear and weak cytoplasmic expression of the epithelial cells

Figure 2. Frequency of patients with positive staining in benign (BPH) and malignant (organ-confined and extra prostatic disease) epithelial cells. CAIX, carbonic anhydrase IX; HIF-1α, hypoxia inducible factor - 1 alpha; LOX, lysyl oxidase; VEGFR2, vascular endothelial growth factor receptor 2. BPH, nodular prostate hyperplasia; EP, extra prostatic disease; OC, organ-confined disease.

Figure 3. Comparison of LOX immunoreactivity score in prostate epithelial cells of benign and malignant patients. BPH, nodular prostate hyperplasia; EP, extra prostatic disease; OC, organ-confined disease. LOX, lysyl oxidase; IRS, immunoreactivity score. Kruskall-Wallis followed by Mann-Whitney non-parametric tests were used to calculate differences between prostatic pathologies.

Figure 4. LOX immunoreactivity score by HIF-1α positivity in epithelial cells. Patients with positive HIF-1α expression are prone to higher LOX IRS. HIF-1α, hypoxia inducible factor – 1 alpha; LOX, lysyl oxidase. IRS, immunoreactivity score. Mann-Whitney non-parametric test was used to calculate differences between positive and negative HIF-1α expression.

Figure 5. Expression of VEGFR2 (H score) in prostate epithelial cells according to prostatic diseases. BPH, nodular prostate hyperplasia; EP, extra prostatic disease; OC, organ-confined disease. VEGFR2, vascular endothelial growth factor receptor 2. Kruskall-Wallis followed by Mann-Whitney non-parametric tests were used to calculate differences between prostatic pathologies.

Figure 6. LOX protein expression (both for immunoreactivity score and staining intensity) according to *LOX* +473 G>A polymorphism. IRS, immunoreactivity score; *LOX*, lysy oxidase; a.u., arbitrary units.

Figure 7. VEGFR2 protein expression (H score) according to *KDR* -604 T>C polymorphism. *KDR,* gene coding for VEGFR2 protein; VEGFR2, vascular endothelial growth factor receptor 2.

TABLES

Table 1. Descriptive clinicopathological data of participating patients

	BPH	**OCPCa**	**EPCa**
Age at diagnosis, yrs	67.8 ± 8.4	61.3 ± 6.4	63.3 ± 6.3
PSA at diagnosis, ng/mL	5.5 ± 5.1	6.6 ± 2.4	11.9 ± 5.6
Weight of the prostate, g	94.8 ± 32.1	45.9 ± 14.3	56.6 ± 22.7
Gleason Score			
< 7	-	14 (43.8)	0 (0.0)
≥ 7	-	18 (56.3)	19 (100)
Percentage of tumor *, %	-	15.0 (6.3 – 20.0)	57.0 (28.8 - 78.8)

Descriptive data of continuous variables is presented as mean ± standard deviation, except for percentage of tumor [data shown as median (interquartile range)]. Categorical variable is depicted as number of observations and respective frequencies. BPH, prostate nodular hyperplasia; EPCa, extra prostatic cancer; OCPCa, organ-confined prostate carcinoma; PSA, prostate specific antigen. * on prostatectomy specimens.

Table 2. Association of the genetic polymorphisms in *HIF1A* +1772 C>T and *CA9* +201 A>G with HIF-1α and CAIX immunoreactivity in prostatic epithelial cells

	Recessive models (*HIF1A* and *CA9*)		
HIF-1α expression	*CC*	*TT/CT*	P *
Negative	28 (0.76)	9 (0.24)	
Positive	10 (0.77)	3 (0.23)	0.928
< 50%	32 (0.74)	11 (0.26)	
≥ 50%	6 (0.86)	1 (0.14)	0.516
CAIX expression	GG	GA/AA	
Negative	9 (0.75)	20 (0.69)	
Positive	3 (0.25)	9 (0.31)	0.699

* Fisher exact test

Table 3. Association of the *KDR-604 T>C* genetic polymorphism with VEGFR2 immunoreactivity in vessels and in prostatic epithelial cells

	Additive model				Recessive model		
	CC	CT	TT	P *	CC	TT/CT	P *
Vessels VEGFR+							
Negative	11 (0.26)	22 (0.53)	9 (0.21)		11 (0.26)	31 (0.78)	
Positive	3 (0.25)	5 (0.42)	4 (0.33)	0.681	3 (0.25)	9 (0.22)	0.626
Epithelial cells VEGFR+							
Negative	11 (0.39)	13 (0.47)	4 (0.14)		11 (0.39)	17 (0.42)	
Positive	3 (0.11)	14 (0.54)	9 (0.35)	0.039	3 (0.11)	23 (0.58)	0.030

* Fisher exact test

Table 4. Expression of proteins from hypoxia pathways in prostate cancer patients, by Gleason grade and PSA value

	Gleason grade (n=38)			PSA at diagnosis (n=36)		
	<7	≥7	P	<10	≥10	P
VEGFR2 H-score [a]	30.9±24.7	60.1±17.9	0.099	30.2±1.2	80.0±33.5	0.085
LOX immunoreactivity score [a]	10.2±1.6	7.6±1.1	0.184	9.2±1.1	6.6±1.8	0.242
HIF-1α expression [b]						
Negative	6 (0.50)	19 (0.73)		17 (0.65)	8 (0.80)	
Positive	6 (0.50)	7 (0.27)	0.163	9 (0.35)	2 (0.20)	0.335 *
CAIX expression [b]						
Negative	10 (0.83)	15 (0.58)		19 (0.73)	5 (0.50)	
Positive	2 (0.17)	11 (0.42)	0.117 *	7 (0.27)	5 (0.50)	0.078

PSA, prostate specific antigen; VEGFR2, vascular endothelial growth factor receptor 2; LOX, lysyl oxidase; HIF1a, hypoxia inducible factor 1 alpha; CAIX, carbonic anhydrase IX. [a] Kruskal Wallis and Mann-Whitney U tests for VEGFR2 H-score in epithelial cells; [b] Chi-square test.* Fisher exact test.

Journal: International Urology & Nephrology

Title: Functionality of genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer

Authors names: Avelino Fraga, Ricardo Ribeiro; André Coelho; José Ramon Vizcaíno; Helena Coutinho; José Manuel Lopes; Paulo Príncipe; Carlos Lobato; Carlos Lopes; Rui Medeiros

Corresponding author: Dr. Avelino Fraga (M.D.), Department of Urology of the Centro Hospitalar do Porto – Hospital Santo António, *email:* avfraga@gmail.com

Supplementary table 1. Genotypic distribution of functional SNPs in genes of hypoxia pathways by disease status using additive and recessive models analyses

	Prostatic disease status			
HIF1A +1772 C>T genotypes	BPH	OCPCa	EPCa	P *
Additive model				
CC	10 (0.59)	23 (0.82)	14 (0.78)	
CT	5 (0.29)	5 (0.18)	4 (0.22)	
TT	2 (0.12)	0 (0.0)	0 (0.0)	0.144
Recessive model				
CC	10 (0.59)	23 (0.82)	14 (0.78)	
TT/CT	7 (0.41)	5 (0.18)	4 (0.22)	0.205
LOX +473 G>A genotypes				
Additive model				
GG	6 (0.71)	16 (0.55)	13 (0.72)	
GA	2 (0.29)	11 (0.38)	4 (0.22)	
AA	0 (0.0)	2 (0.07)	1 (0.06)	0.740
Recessive model				
GG	6 (0.71)	16 (0.55)	13 (0.72)	
AA/GA	2 (0.29)	13 (0.45)	5 (0.28)	0.442
CA9 +201 A>G genotypes				
Additive model				
GG	3 (0.38)	9 (0.31)	5 (0.29)	
GA	5 (0.62)	18 (0.62)	10 (0.59)	
AA	0 (0.0)	2 (0.07)	2 (0.12)	0.882
Recessive model				
GG	3 (0.38)	9 (0.31)	5 (0.29)	
GA/AA	5 (0.62)	20 (0.69)	12 (0.71)	0.918
KDR -604 T>C genotypes				
Additive model				
CC	6 (0.33)	8 (0.26)	3 (0.17)	
CT	8 (0.45)	15 (0.48)	13 (0.72)	
TT	4 (0.22)	8 (0.26)	2 (0.11)	0.436
Recessive model				
CC	6 (0.33)	8 (0.26)	3 (0.17)	
TT/CT	12 (0.67)	23 (0.74)	15 (0.83)	0.515

* Fisher exact test. BPH, nodular prostate hyperplasia; OCPCa, organ-confined prostate carcinoma; EPCa, extra prostatic carcinoma. *CA9*, carbonic anhydrase IX gene; *HIF1A*, hypoxia inducible factor 1 alpha gene; *KDR*, vascular endothelial growth factor receptor 2 gene; *LOX*, lysyl oxidase gene.

Inherited variation in adipokine pathway genes may determine prognosis for prostate cancer patients receiving androgen-deprivation therapy

Ricardo Ribeiro [1,2,3,4,5,6], Cátia Monteiro [1,5], Agnihotram V Ramanakumar [3], Ana Filipa Guedes [1], Natália Francisco [1], Ana Luísa Ferreira [1], Avelino Fraga [1,2,7], Marta Sousa [8], Virgínia Cunha [1,5], Andreia Azevedo [1,5], Joaquina Maurício [8], Francisco Lobo [9], Francisco Pina [10], Fernando M Calais-da-Silva [11], Fernando E Calais-da-Silva [11], Carlos Lopes [2], Eduardo L Franco [3], Rui Medeiros [1,2,5]

[1] Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal

[2] ICBAS, Abel Salazar Institute for the Biomedical Sciences, University of Porto, Porto, Portugal

[3] Division of Cancer Epidemiology, Department of Oncology, McGill University, Montreal, Canada

[4] Genetics Laboratory, Faculty of Medicine, University of Lisbon, Lisbon, Portugal

[5] LPCC, Research Department-Portuguese LeagueAgainst Cancer (NRNorte)

[6] Instituto Rocha Cabral, Lisbon, Portugal

[7] Urology Department, Porto Hospital Centre, Porto, Portugal

[8] Medical Oncology Department, Portuguese Institute of Oncology, Porto, Portugal

[9] Urology Department, Portuguese Institute of Oncology, Porto, Portugal

[10] Urology Department, S. João Hospital, Porto, Portugal

[11] Department of Urology, Central Lisbon Hospital Centre, Lisbon, Portugal

Key words: adipokines; androgen deprivation therapy; genetic polymorphism; castration-resistant prostate cancer

Corresponding author:

Dr. Ricardo Ribeiro

Molecular Oncology Group - CI

Portuguese Institute of Oncology

Edifício Laboratórios – Piso 4

Rua Dr. António Bernardino Almeida

4200-072 Porto

Portugal

Phone: + 351 912 157 736

Fax: + 351 225 084 001

Email: oriebir.r@gmail.com

ABSTRACT

Purpose

Androgen deprivation therapy (ADT) is commonly used to treat advanced and recurrent prostate cancer, although prognosis varies widely among individuals. We evaluated whether polymorphisms in adipokine pathway genes may predict clinical outcomes among prostate cancer patients.

Patients and Methods

We enrolled 483 patients who underwent ADT and genotyped them for 27 functional single nucleotide polymorphisms (SNPs) in 17 genes from 9 adipokine pathways. SNPs were also combined by pathway according to functional characteristics.

Results

The *ADIPOQ* +45 T>G G homozygous carriers were more likely to present biochemical progression (HR=4.1, 95%CI: 1.62-10.54) and to die (HR=5.0, 95%CI: 1.75-14.38) than T-allele carriers. Having the *ADIPOQ* +276 G>T G homozygous genotype and the tumor necrosis factor high activation genetic profile were associated with reduced likelihood of resistance to ADT (HR=0.71, 95%CI: 0.51-0.99 and HR=0.62, 95%CI: 0.41-0.93, respectively). Presence of the *IL6* -572 G>C C-allele was independently associated with all-cause mortality (HR=1.78, 95%CI: 1.01-3.13). The *LEPR* Gln223Arg G-allele variant was associated with a more than twofold increased risk of developing metastasis (OR=2.1, 95%CI: 1.2-3.6).

Conclusion

Genetic polymorphisms in adipokine pathways might have a clinical role in evaluating prognosis among men treated with ADT. In addition, combined targeting of identified adipokine pathways

may represent a therapeutic strategy for castration-resistant prostate cancer, metastasis development, thus improving survival.

INTRODUCTION

In the last decades, depletion or blockage of androgen action has been the standard of care for men with advanced prostate cancer [1]. Androgen deprivation therapy (ADT) results in decreased levels of serum prostate-specific antigen (PSA) as well as waning of androgen receptor (AR)-dependent growth. Response to treatment is not durable since patients become resistant to ADT, leading to castration-resistance status, an invariably fatal condition [2]. Clinical and tumor biology factors that may partially account for disease burden and thus serve as useful prognostic predictors, include Gleason score, serum PSA and distant metastasis [3]. Although mechanisms responsible for prostate cancer cell survival after ADT are not entirely understood, there is evidence that AR-dependent and AR-independent pathways may be implicated [4,5]. Single nucleotide polymorphisms (SNPs) in genes involved in biosynthesis and metabolism of steroids and androgens seem to influence response to ADT [6-9]. Recent findings showed also that susceptibility SNPs might also improve outcome prediction following ADT [10-13].

While germline DNA polymorphisms in androgen pathways were shown to influence the response to ADT, no study has examined the predictive role of polymorphisms in genes of adipokine pathways on clinical outcomes after ADT initiation. Adipokines are adipose tissue-produced and obesity-related molecules known to be mechanistically involved in prostate tumor aggressiveness [14,15]. Some functional SNPs in genes encoding molecules of these pathways have been shown to be associated with prostate cancer risk [16-19] and a recent study found that obese men were at increased risk of developing castration-resistant prostate cancer and metastasis [20]. We studied a cohort of prostate cancer patients treated with ADT to examine the prognostic significance of 27 functional adipokine pathway SNPs with risk of metastasis, response to chemical/surgical castration, and all-cause mortality (ACM).

MATERIALS AND METHODS

Patients

Patients with histopathologically confirmed prostate cancer and treated with ADT between 1990 and 2009 were included in this study (n=513). Patients were recruited from 4 Hospitals in Portugal: Portuguese Institute of Oncology – Porto Centre, Porto Military Hospital, Porto Hospital Centre, and Central Lisbon Hospital Centre. The research protocol and consent form were approved by the participating Institution's Ethics Committees. All patients signed an informed consent.

ADT consisted of orchiectomy or treatment with luteinizing hormone releasing hormone-agonist (LHRHa) with or without anti-androgen after diagnosis of advanced or metastatic prostate cancer or after relapsing from primary local therapy with curative intent. Patients with adjuvant hormonal therapy for localized disease were excluded (n=24). Hormonal treatment was continued at least until disease progression, based on serum PSA levels, imaging, and clinical findings. The primary endpoint was resistance to ADT, defined as the time from ADT initiation to two consecutive rises of PSA (1 week apart) greater than the PSA nadir (defined as biochemical progression) or progression of bone lesions (new or size increase, soft tissue metastasis, or at least 2 new metastatic spots in bone scintigraphy), despite at least two consecutive hormonal manipulations [21,22]. The secondary endpoints included overall survival, defined as the time from ADT initiation to death from any cause, and appearance of distant metastasis at any time during the course of the disease (identified by x-rays, computed tomography scans or bone scintigraphy), after diagnosis. Information concerning clinical endpoints was collected via standardized chart review (6 patients were excluded due to missing data).

Genetic variants and genotyping

Samples of peripheral blood were used for genotyping. Candidate genes involved in adipokine pathways known to affect oncogenesis were selected. SNPs were selected based on best evidence from published studies. A total of 27 literature-defined putative functional SNPs in 17 different genes were chosen, corresponding to 9 adipokine pathways (Supplementary table 1). We also examined combinations of SNPs by adipokine pathway according to their functional implications (Supplementary table 2).

Allelic discrimination through Taqman genotyping (Applied Biosystems) was used for 20 SNPs (two in *ADIPOQ*, rs1501299 and rs16861194; *IL6*, rs10499563; *IL6R*, rs2228145; *KDR*, rs2071559; three in *VEGF*, rs2010963, rs833061 and rs3025039; *LEP,* rs7799039; two in *LEPR*, rs1137100 and rs8179183; *PPARG*, rs1801282; *PGC1A*, rs8192678; *PPARD*, rs2016520; *OPN*, rs28357094; *IGF1R*, rs2229765; *IRS1*, rs1801278; *FGFR2*, rs2981582; *TNFA*, rs1800629; *TNFRSF1A*, rs4149570), whereas the remaining (three in *IL6*, rs1800797, rs1800796 and rs1800795; *ADIPOQ*, rs2241766; *IL6ST*, rs3729960; *LEPR*, rs1137101; *TNFA*, rs1800630) were genotyped by polymerase chain reaction, followed by restriction fragment length polymorphism analysis. We have previously referenced these genotyping protocols [23]. Quality control measures included negative controls in all runs and repeated genotyping in more than 5% of the samples.

Statistical analysis

We calculated descriptive statistics of clinicopathological characteristics for all patients. PSA at diagnosis was dichotomized at 20 ng/mL based on its association with micrometastasis[24].

Clinical stage was classified according to TNM as localized (T1-T2, with N0 and M0) or advanced (T3-T4 and/or N+ and/or M+).

For time-to-event analyses, age-adjusted Cox regression models were used to calculate hazard ratios (HR) and 95% confidence intervals (CIs) for the association between clinicopathological characteristics with each of the outcomes of interest, i.e., biochemical progression under hormonal castration and ACM. Age-adjusted logistic regression models were used to evaluate the risk for metastasis after diagnosis. Multivariate analysis was conducted after selecting confounding variables by empirical evaluation for each of clinical and genetic models. We used two different approaches based on the minor allele: a dominant ("aa" + "Aa" genotype versus "AA" genotype) and a recessive ("aa" genotype versus "Aa" + "AA" genotype) model to evaluate the individual association of 27 SNPs with the three outcomes. The model with the highest likelihood ratio was presented as the best-fitting genetic model for each SNP. Functionally combined SNPs in each pathway were dichotomized (low/intermediate vs. high; low vs. intermediate/high) and the one with highest likelihood ratio was retained. For the subset of clinical factors, SNPs and functional combinations of SNPs were selected on the basis of a regression P-value <0.15. A multivariate Cox proportional hazards model was derived by stepwise selection (P-value for retention < 0.05) to identify the independent prognostic factors for biochemical progression. A multivariate logistic regression model was similarly performed using only non metastatic patients at diagnosis, in order to evaluate clinical and genetic predictive factors for prostate cancer metastasis. Statistical analyses were conducted in STATA version 10.0 (StataCorp, College Station, Texas).

RESULTS

Clinical characteristics of the final 483 patients analyzed are presented in Table 1. At diagnosis, 27% of patients presented distant metastasis, 62% had clinically advanced disease (T3-T4 and/or N+ and/or M+), and 51% had a biopsy Gleason score ≥ 7 (4+3). The median duration between ADT initiation and disease progression was 91.8 months, while the median follow-up from ADT initiation to death or last visit was 126.9 months. Several clinical factors were identified to predict biochemical progression under hormonal castration and ACM (Table 1).

Logistic regression analysis showed that definitive therapy (OR=3.51; 95%CI: 1.86-6.61) and advanced clinical stage (T3-T4) (OR=4.08; 95%CI: 2.13-7.79) were associated with risk for distant metastasis on follow-up. Empirical analysis using Cox regression was then performed to evaluate the association of SNPs and their functional combinations with the outcomes of interest. As shown in Supplementary table 3, the genotypes *ADIPOQ* +276 TT/TG, *IL6R* Asp358Ala CC and *ADIPOQ* +45 GG, and the high expression *ADIPOQ* haplotype, low TNFa expression and low/intermediate TNFa activation genetic profiles were associated with biochemical progression under hormonal castration. Notably, the difference in median time to progression during ADT for the genotypes at *ADIPOQ* +45 was greater than 5 years, whereas for *ADIPOQ* +276 and the combined TNFa activation genetic profile the difference was respectively 15 and 24 months (Figure 1). Moreover, the *IL6R* Asp358Ala CC and *ADIPOQ* +45 GG, *IL6*-572 C carriers and high VEGF activation 2SNPs were associated with shorter time to ACM following ADT (Supplementary table 3). The median survival time was significantly lower for *ADIPOQ* +45 GG carriers (by more than 6 years difference) and for *IL6* -572 C-allele carriers (over 2 years of difference compared with -572 GG) (Figure 2). A significant relation with increased risk for

developing distant metastasis was observed in the *LEPR* Gln223Arg G carriers, *LEPR* Lys109Arg homozygous G carriers, *TNFRSF1A* -329 G carriers, and for the high/intermediate LEPR signaling genetic profiles (Supplementary table 4).

The predictive effects of SNPs with P<0.15 (univariate analysis) on time to biochemical progression under hormonal castration and ACM were evaluated in presence of significant clinicopathological predictors (from Table 1) using Cox regression. The effect of *ADIPOQ* +45 and +276 SNPs and of the TNFa activation genetic profile on the response to ADT remained strong after adjustment for clinical factors (Table 2). Analysis of the secondary endpoint ACM after adjusting for other predictors showed that *ADIPOQ* +45 T>G and *IL6* -572 G>C remained significant predictors, together with age at diagnosis, biopsy Gleason score, metastasis at ADT initiation and biochemical progression under hormonal castration (Table 2). On multivariate logistic regression, patients with the combined high/intermediate LEPR signaling genetic profile remained associated with greater risk of developing distant metastatic disease (OR=3.41, 95%CI: 1.71-6.79). In this model men that received definitive therapy and who presented with advanced clinical stage at diagnosis were at increased risk for developing metastasis on follow-up (OR=4.26, 95%CI: 2.24-8.13 and OR=3.29, 95%CI: 1.75-6.18, respectively).

DISCUSSION

We examined whether germline polymorphisms in adipokine pathways are determinants of the response to ADT. The time to biochemical progression under hormonal castration was influenced by two SNPs in *ADIPOQ* and by combined SNPs in TNFa pathway activation. The predictive ability of *ADIPOQ* +45 extended towards the secondary endpoint ACM, together with

IL6-572 genetic polymorphism. Additionally, our results also suggest an association of the combined LEPR genetic profile with development of distant metastasis.

Androgen deprivation therapy remains the mainstay treatment for advanced and recurrent prostate cancer [21,25]. Clinical variables such as stage, biopsy Gleason score, PSA serum levels and metastasis [3], are established factors that influence the response to ADT, albeit SNPs may also be useful for prognosticating the response to ADT. Out of 27 SNPs of 17 genes related with 9 adipokine pathways analyzed, we have identified two SNPs, *ADIPOQ* +45 and *ADIPOQ* +276 and a functional *TNFA*/*TNFRSF1A* combination that are associated with the response to ADT. The mechanisms responsible for castration-resistant prostate cancer development are not clearly established. Despite obvious interest in AR-dependent pathways, other independent pathways have been described [4,26], in which androgen-refractory cells use alternative survival pathways to overcome the growth inhibition imposed by ADT [4,27]. ADT is known to induce changes in adiposity and adipokine levels in circulation [28,29]. Adipokine pathways, have been implicated in intracellular signals such as those activated in hormonal castration resistance [30]. Furthermore, mitogenic and anti-apoptoptic effects of some adipokines (e.g. leptin, IL-6, IGF-1) seem to be limited to androgen-refractory prostate cancer cells [31-33].

In our study, *ADIPOQ* +45 G homozygous and *ADIPOQ* +276 T carriers had higher risks of biochemical progression under ADT. The G-allele in locus +45 and T-allele in locus +276 are associated with higher circulating adiponectin plasma levels [34,35]. Generally, low concentrations have been associated with prostate cancer risk and survival, rendering adiponectin a protective role against cancer [36-38]. Nevertheless, this effect could be dependent on the metabolic environment and tumor cell characteristics. ADT induces profound changes in metabolic environment, modulating specifically plasma adiponectin levels [29], and eventually modulating

the expression of adiponectin receptors, which have been shown to be receptive to cytokines and steroid hormones stimulus according to tumor cells androgen refractoriness status [39]. Additionally, adiponectin has the capacity to exert stimulatory growth and motile effects in some prostate tumor cells, depending on PTEN status [40,41]. Despite advances in understanding the role of adiponectin in prostate cancer risk, studies on castration-resistant prostate cancer are scarce. Although *ADIPOQ* polymorphisms have been inconsistently associated with prostate cancer risk [16,42,43], our study is the first to evaluate *ADIPOQ* SNPs in association with ADT resistance. When we combined SNPs in TNF pathway [*TNFA* -863 C>A (rs1800630), *TNFA* -308 G>A (rs1800629) and *TNFRSF1A* -329 G>T (rs4149570)] according to functional characteristics, the carriers of low/intermediate TNFa activity profile had increased risks of biochemical progression under hormonal castration. Interestingly, case-control studies have shown lack of association between *TNFA* variants at locus -863 or -308 and prostate cancer risk [44,45]. The TNF and TNFR superfamily plays crucial roles in mediating the inflammatory response and regulating immune function, in addition to triggering apoptosis of certain tumor cells [46]. TNFa-mediated activation of TNFR1 signaling is critical for activating tumor-reactive T cells and arresting multistage carcinogenesis [47,48]. More specifically, the proapoptotic actions of estrogen receptor beta in androgen-refractory prostate cancer cells required TNFa signaling [49]. The very low levels of testosterone as result of ADT, together with increased inflammatory markers [50], create an inflammatory environment for tumor under ADT. We hypothesize that this scenario may be altered by polymorphisms in *ADIPOQ* and by low/intermediate TNFa activation, which likely result in decreased inflammatory magnitude, further depressing immunosurveillance.

The few studies that examined the role of germline polymorphisms in association with prostate cancer mortality yielded inconsistent results [51-54]. In our cohort, where all patients

received ADT for prostate cancer while taking into consideration previous treatment modalities, *ADIPOQ* +45 T>G and *IL6* -572 G>C, remained independently associated with decreased survival. IL-6 has been implicated with poor prognosis in prostate cancer [55,56]. Activation of IL-6/IL6R pathway is linked with neuroendocrine differentiation of prostate cancer cells, promiscuous activation of the AR and regulation of prostate intracrine androgen production [57-59], mechanisms related with resistance to hormonal castration and ultimately mortality. In other studies unrelated to prostate cancer, the *IL6* -572 genetic polymorphism was a predictor of bone mineral density, metabolic syndrome and malignant conditions [60-62]. The -572 C allele has been associated with higher serum levels of IL-6 [60,63]. A glucocorticoid receptor element at position -557 to -552 likely influences steroid binding and regulates IL-6 secretion [61,64]. We observed after multivariate analysis that *IL6* -572 C carriers remained significantly associated with reduced overall survival following ADT, which might be the response to higher bioavailability of IL-6. In our study, the *ADIPOQ* +45 G homozygous carriers, besides being associated with biochemical progression under hormonal castration, showed worst survival compared with carriers of the T-allele. The G-allele is associated with higher circulating adiponectin plasma levels [35]. *In vitro* findings suggest adiponectin amplifies the activation of PI3kinase/Akt/mTOR pathway in prostate cancer cells with PTEN loss, which are features of aggressive tumors from patients with advanced or recurrent disease [65,66], as in this study. Moreover, recent findings suggest that AMPK, which is up-regulated by adiponectin signaling [40,41,67], if activated during energy stress conditions such as androgen deprivation therapy may represent an advantage that promotes tumor cell survival [68,69]. If further confirmed, these findings suggest the implementation of targeted dual inhibition of PI3K and mTOR in the treatment of advanced or recurrent prostate cancer patients, as previously proposed [30].

Leptin's actions in tumor development and progression are mediated by leptin receptor [14,15], which is strongly expressed in prostate tumors [70], where pathway activation induces aggressive cell phenotypes [71,72]. We found that carriers of the combined LEPR high/intermediate signaling genetic profile were at increased risk for developing metastatic disease. This means that carrying 2 or 3 risk alleles out of 3 SNPs in *LEPR* (Lys109Arg, Gln223Arg and Lys656Asn), which may represent higher LEPR signaling capacity, increases the risk for metastasis in patients receiving ADT. Since *LEPR* 109 and *LEPR* 223 were associated with metastasis in univariate analysis, the independent effect of the combined *LEPR* SNPs may rely on the influence of those two. Although the *LEPR* 223 polymorphism yielded mixed results in case-control studies [16,23,73], G carriers have a stronger leptin-binding affinity [74]. In addition, this polymorphism is associated with plasma soluble LEPR concentrations and may influence receptor recycling and degradation [75,76], thereby influencing free leptin levels and receptor availability at cell surface. The G-allele of *LEPR* 109 was also found to be associated with plasma soluble LEPR levels [75] and higher circulating leptin levels [77]. Moreover, recent work evidenced a central role for leptin signaling in tumor-initiating stem cells growth and survival [78].

Inherited genetic markers have been fairly explored as predictors of prostate cancer outcomes. Although we took a focused candidate gene approach to evaluate the association of key SNPs in adipokine pathways with relevant prostate cancer outcomes in a cohort of patients in ADT, our study has some limitations. Testosterone levels were not available in all men to confirm castration; therefore we relied on PSA measurements, clinical and imaging information to define progression under hormonal castration. Although we included only functional SNPs from genes in adipokine pathways, our SNP panel and SNP combinations could be incomplete. We did not explore potential gene-environment interactions due to missing data on body mass,

even though it might be important in ADT. Further studies exploring eventual synergies with adiposity measures are required. Strengths of our study include the large size and homogeneous population. The long follow-up time allowed analysis of primary and secondary end points with large number of events (46.4% for disease progression under ADT; 32.2% for mortality; 44.9% for metastasis).

At a time when alternative therapeutic opportunities arise in advanced prostate cancer [79,80], it is important to validate the use of germline polymorphisms to complement the value of clinical factors to prognosticate clinical course after ADT initiation, thereby providing a more personalized medicine approach to therapy and management. Our findings also underscore the need for examining the effectiveness of personalized therapies targeted towards adiponectin, tumoral necrosis factor and leptin pathways. If confirmed, our findings might help targeting patients with predictable precocious ADT failure and mortality for more aggressive intervention.

ACKNOWLEDGMENTS

This work was supported by the Portuguese Science and Technology Foundation (PTDC/SAL-FCF/71552/2006); the Research Centre on Environment, Genetics and Oncobiology of the University of Coimbra (CIMAGO 07/09); the Portuguese League Against Cancer – North Centre; Calouste Gulbenkian Foundation (Oncology/2008/Project nº96736); and by an unrestricted educational grant for basic research in Molecular Oncology from Novartis Oncology Portugal. RR is the recipient of a PhD grant from POPH/FSE (SFRH/BD/30021/2006) and of an International Cancer Technology Transfer Fellowship from the Union for International Cancer Control (UICC-ICRETT, ICR/10/079/2010).

REFERENCES

1. Pagliarulo V, Bracarda S, Eisenberger MA, et al: Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 61:11-25, 2012
2. Scher HI, Kelly WM, Zhang ZF, et al: Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 91:244-51, 1999
3. Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24:3984-90, 2006
4. Feldman BJ, Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45, 2001
5. Attar RM, Takimoto CH, Gottardis MM: Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 15:3251-5, 2009
6. Ross RW, Oh WK, Xie W, et al: Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 26:842-7, 2008
7. Hamada A, Sissung T, Price DK, et al: Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 14:3312-8, 2008
8. Yang M, Xie W, Mostaghel E, et al: SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 29:2565-73, 2011
9. Lindstrom S, Adami HO, Balter KA, et al: Inherited variation in hormone-regulating genes and prostate cancer survival. Clin Cancer Res 13:5156-61, 2007
10. Bao BY, Pao JB, Huang CN, et al: Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy. Int J Cancer 130:876-84, 2012
11. Tsuchiya N, Wang L, Suzuki H, et al: Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 24:1982-9, 2006
12. Teixeira AL, Ribeiro R, Cardoso D, et al: Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Cancer Res 14:3367-71, 2008
13. Teixeira AL, Ribeiro R, Morais A, et al: Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. Pharmacogenomics J 9:341-6, 2009
14. Mistry T, Digby JE, Desai KM, et al: Obesity and prostate cancer: a role for adipokines. Eur Urol 52:46-53, 2007
15. Ribeiro R, Lopes C, Medeiros R: The link between obesity and prostate cancer: the leptin pathway and therapeutic perspectives. Prostate Cancer Prostatic Dis 9:19-24, 2006
16. Moore SC, Leitzmann MF, Albanes D, et al: Adipokine genes and prostate cancer risk. Int J Cancer 124:869-76, 2009
17. Ribeiro R, Vasconcelos A, Costa S, et al: Overexpressing leptin genetic polymorphism (-2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease. Prostate 59:268-74, 2004
18. Wang MH, Helzlsouer KJ, Smith MW, et al: Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate 69:874-85, 2009

19. Kwon EM, Salinas CA, Kolb S, et al: Genetic polymorphisms in inflammation pathway genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 20:923-33, 2011

20. Keto CJ, Aronson WJ, Terris MK, et al: Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. BJU Int, 2011

21. Mottet N, Bellmunt J, Bolla M, et al: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59:572-83, 2011

22. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-59, 2008

23. Ribeiro RJ, Monteiro CP, Azevedo AS, et al: Performance of an adipokine pathway-based multilocus genetic risk score for prostate cancer risk prediction. PLoS One 7:e39236, 2012

24. Heidenreich A, Bellmunt J, Bolla M, et al: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61-71, 2011

25. Sharifi N, Gulley JL, Dahut WL: Androgen deprivation therapy for prostate cancer. JAMA 294:238-44, 2005

26. Devlin HL, Mudryj M: Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 274:177-86, 2009

27. Schroder FH: Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol 53:1129-37, 2008

28. Saylor PJ, Kozak KR, Smith MR, et al: Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist 17:212-9, 2012

29. Smith MR, Lee H, Fallon MA, et al: Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 71:318-22, 2008

30. Chen J: Multiple signal pathways in obesity-associated cancer. Obes Rev 12:1063-70, 2011

31. Onuma M, Bub JD, Rummel TL, et al: Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem 278:42660-7, 2003

32. Chung TD, Yu JJ, Spiotto MT, et al: Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 38:199-207, 1999

33. Iwamura M, Sluss PM, Casamento JB, et al: Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 22:243-52, 1993

34. Fredriksson J, Carlsson E, Orho-Melander M, et al: A polymorphism in the adiponectin gene influences adiponectin expression levels in visceral fat in obese subjects. Int J Obes (Lond) 30:226-32, 2006

35. Berthier MT, Houde A, Cote M, et al: Impact of adiponectin gene polymorphisms on plasma lipoprotein and adiponectin concentrations of viscerally obese men. J Lipid Res 46:237-44, 2005

36. Li H, Stampfer MJ, Mucci L, et al: A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 56:34-43, 2010

37. Michalakis K, Williams CJ, Mitsiades N, et al: Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev 16:308-13, 2007

38. Lu JP, Hou ZF, Duivenvoorden WC, et al: Adiponectin inhibits oxidative stress in human prostate carcinoma cells. Prostate Cancer Prostatic Dis 15:28-35, 2012

39. Mistry T, Digby JE, Chen J, et al: The regulation of adiponectin receptors in human prostate cancer cell lines. Biochem Biophys Res Commun 348:832-8, 2006

40. Tang CH, Lu ME: Adiponectin increases motility of human prostate cancer cells via adipoR, p38, AMPK, and NF-kappaB pathways. Prostate 69:1781-9, 2009

41. Barb D, Neuwirth A, Mantzoros CS, et al: Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocr Relat Cancer 14:995-1005, 2007

42. Kaklamani V, Yi N, Zhang K, et al: Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk. Metabolism 60:1234-43, 2011

43. Dhillon PK, Penney KL, Schumacher F, et al: Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 20:2618-27, 2011

44. Kesarwani P, Mandhani A, Mittal RD: Polymorphisms in tumor necrosis factor-A gene and prostate cancer risk in North Indian cohort. J Urol 182:2938-43, 2009

45. Danforth KN, Rodriguez C, Hayes RB, et al: TNF polymorphisms and prostate cancer risk. Prostate 68:400-7, 2008

46. Chen G, Goeddel DV: TNF-R1 signaling: a beautiful pathway. Science 296:1634-5, 2002

47. Muller-Hermelink N, Braumuller H, Pichler B, et al: TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13:507-18, 2008

48. Calzascia T, Pellegrini M, Hall H, et al: TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest 117:3833-45, 2007

49. McPherson SJ, Hussain S, Balanathan P, et al: Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci U S A 107:3123-8, 2010

50. Maggio M, Basaria S, Ceda GP, et al: The relationship between testosterone and molecular markers of inflammation in older men. J Endocrinol Invest 28:116-9, 2005

51. Gallagher DJ, Vijai J, Cronin AM, et al: Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res 16:2819-32, 2010

52. Penney KL, Pyne S, Schumacher FR, et al: Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 19:2869-76, 2010

53. Wiklund FE, Adami HO, Zheng SL, et al: Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol Biomarkers Prev 18:1659-62, 2009

54. Lin DW, FitzGerald LM, Fu R, et al: Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev 20:1928-36, 2011

55. Nakashima J, Tachibana M, Horiguchi Y, et al: Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6:2702-6, 2000

56. George DJ, Halabi S, Shepard TF, et al: The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 11:1815-20, 2005

57. Chun JY, Nadiminty N, Dutt S, et al: Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res 15:4815-22, 2009

58. Lee GT, Kwon SJ, Lee JH, et al: Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6-IL6 Loop. Prostate, 2011

59. Malinowska K, Neuwirt H, Cavarretta IT, et al: Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 16:155-69, 2009

60. Brull DJ, Montgomery HE, Sanders J, et al: Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 21:1458-63, 2001

61. Ferrari SL, Ahn-Luong L, Garnero P, et al: Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 88:255-9, 2003

62. Cozen W, Gebregziabher M, Conti DV, et al: Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev 15:2285-91, 2006

63. Kitamura A, Hasegawa G, Obayashi H, et al: Interleukin-6 polymorphism (-634C/G) in the promotor region and the progression of diabetic nephropathy in type 2 diabetes. Diabet Med 19:1000-5, 2002

64. Terry CF, Loukaci V, Green FR: Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 275:18138-44, 2000

65. Mulholland DJ, Tran LM, Li Y, et al: Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19:792-804, 2011

66. Sircar K, Yoshimoto M, Monzon FA, et al: PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 218:505-13, 2009

67. Zakikhani M, Dowling RJ, Sonenberg N, et al: The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) 1:369-75, 2008

68. Chhipa RR, Wu Y, Mohler JL, et al: Survival advantage of AMPK activation to androgen-independent prostate cancer cells during energy stress. Cell Signal 22:1554-61, 2010

69. Jeon SM, Chandel NS, Hay N: AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485:661-5, 2012

70. Hoon Kim J, Lee SY, Myung SC, et al: Clinical significance of the leptin and leptin receptor expressions in prostate tissues. Asian J Androl 10:923-8, 2008

71. Somasundar P, Yu AK, Vona-Davis L, et al: Differential effects of leptin on cancer in vitro. J Surg Res 113:50-5, 2003

72. Huang CY, Yu HS, Lai TY, et al: Leptin increases motility and integrin up-regulation in human prostate cancer cells. J Cell Physiol 226:1274-82, 2011

73. Kote-Jarai Z, Singh R, Durocher F, et al: Association between leptin receptor gene polymorphisms and early-onset prostate cancer. BJU Int 92:109-12, 2003

74. Quinton ND, Lee AJ, Ross RJ, et al: A single nucleotide polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women. Hum Genet 108:233-6, 2001

75. Sun Q, Cornelis MC, Kraft P, et al: Genome-wide association study identifies polymorphisms in LEPR as determinants of plasma soluble leptin receptor levels. Hum Mol Genet 19:1846-55, 2010

76. da Silva BA, Bjorbaek C, Uotani S, et al: Functional properties of leptin receptor isoforms containing the gln-->pro extracellular domain mutation of the fatty rat. Endocrinology 139:3681-90, 1998

77. Liu CL, Chang YC, Cheng SP, et al: The roles of serum leptin concentration and polymorphism in leptin receptor gene at codon 109 in breast cancer. Oncology 72:75-81, 2007

78. Park J, Scherer PE: Leptin and cancer: from cancer stem cells to metastasis. Endocr Relat Cancer 18:C25-9, 2011

79. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011

80. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-22, 2010

Figure 1. Kaplan-Meier estimates of cumulative incidence of disease progression under ADT by SNPs and functional combinations. The Log-rank test was used to analyze the equality of survival distributions for the different genotypes of *ADIPOQ* haplotype (P=0.010), *ADIPOQ* +45 T>G (P=0.008), *ADIPOQ* +276 G>T (P=0.039), *IL6R* Asp358Ala A>C (P=0.028), TNFa pathway expression (P=0.024), and TNFa pathway activation (P=0.048). ADT, androgen deprivation therapy. *TNFA* expression is defined as the functional combination of *TNFA* -308 and -863 SNPs, whereas TNFa activity includes besides the *TNFRSF1A*, two *TNFA* SNPs (detailed in supplementary table 2).

Figure 2. Kaplan-Meier estimates of survival following ADT, stratified by SNPs and functional combinations. The equality of survival distributions for the different genotypes of *IL6* -572 G>C (P=0.022), *ADIPOQ* +45 T>G (P=0.001), *IL6R* Asp358Ala A>C (P=0.016) and VEGF 2SNPs pathway activation (P=0.009) was tested with Log-rank. ADT, androgen deprivation therapy. VEGF pathway activation 2SNPs relates to the functional combination of two *VEGF* SNPs -460 and +405 plus the *KDR* -604 polymorphism (detailed in supplementary table 2).

Table 1. Clinicopathological characteristics of prostate cancer patients and univariate analysis of factors that predicted resistance to ADT and all-cause mortality

	N (%) *	Resistance to ADT		All-cause mortality	
		No. of Events	aHR (95%CI)	No. of Events	aHR (95%CI)
Age at diagnosis, years [a]	69.5(7.7)[b]		0.99 (0.97-1.01)		1.05 (1.02-1.07)
PSA at diagnosis					
< 20 ng/mL	235 (51)	75	Referent	57	Referent
≥ 20 ng/mL	224 (49)	134	1.94 (1.46-2.59)	89	1.58 (1.13-2.22)
Clinical stage					
Localized (T1-2)	171 (38)	35	Referent	30	Referent
Advanced (T3-4)	282 (62)	173	3.68 (2.53-5.33)	118	2.76 (1.83-4.17)
Biopsy Gleason score					
≤ 7 (3+4)	220 (49)	75	Referent	47	Referent
≥ 7 (4+3)	229 (51)	124	2.51 (1.86-3.39)	85	3.02 (2.08-4.39)
Definitive therapy					
None	327 (68)	168	Referent	120	Referent
Radical prostatectomy/Radiotherapy	156 (32)	56	0.57 (0.40-0.79)	34	0.77 (0.50-1.18)
Hormonal treatment modality					
LHRH-agonist/orchiectomy	102 (21)	42	Referent	16	Referent
Combined ADT	381 (79)	182	1.10 (0.77-1.58)	138	2.57 (1.48-4.48)
Metastases at ADT initiation					
No	297 (69)	111	Referent	79	Referent
Yes	131 (31)	94	3.52 (2.64-4.70)	67	2.96 (2.13-4.12)
Biochemical progression under hormonal castration					
No	259 (54)	--	---	26	Referent
Yes	224 (46)	--	---	126	5.55 (3.63-8.49)

* Column subtotals do not sum to 483 due to missing data. ADT, androgen deprivation therapy; PSA, prostate specific antigen; LHRH-agonist, luteinizing hormone releasing hormone agonist. aHR, age-adjusted hazard ratio; 95%CI, 95% confidence interval. [a] aHR calculated using age as a continuous variable; [b] Mean (standard deviation)

Table 2. Multivariate analysis of the association between adipokine pathway SNPs and resistance to ADT and all-cause mortality

	Resistance to ADT HR (95%CI)	All-cause mortality HR (95%CI)
Age at diagnosis, years	---	1.07 (1.04-1.11)
Metastasis at ADT initiation		
No	Referent	Referent
Yes	2.62 (1.81-3.80)	1.88 (1.23-2.90)
Gleason score		
≤ 7 (3+4)		Referent
≥ 7 (4+3)	---	1.70 (1.11-2.60)
Clinical stage		
Localized	Referent	
Advanced	2.43 (1.55-3.82)	---
Disease progression under ADT		
No		Referent
Yes	---	4.64 (2.75-7.83)
ADIPOQ + 45		
T carrier	Referent	Referent
GG	4.14 (1.62-10.54)	5.02 (1.75-14.38)
IL6 -572 G>C		
GG		Referent
C carrier	---	1.78 (1.01-3.13)
ADIPOQ +276		
T carrier	Referent	
GG	0.71 (0.51-0.99)	---
TNFa activation		
Low/intermediate	Referent	
High	0.62 (0.41-0.93)	---

ADT, androgen deprivation therapy; SNP, single nucleotide polymorphism; TNFa, tumor necrosis factor alpha; *ADIPOQ*, adiponectin gene; HR(95%CI), hazard ratio and 95% confidence interval.



No. at Risk											
Low/Interm	366	330	292	259	210	153	115	81	59	43	32
High	98	85	68	55	42	32	24	18	12	8	2



No. at Risk											
T carriers	455	407	356	313	251	184	139	99	71	52	35
GG	10	9	5	2	2	2	1	1	1	0	0



No. at Risk											
T carriers	223	195	166	144	112	78	61	45	28	20	7
GG	241	220	194	170	140	107	78	54	43	31	27



No. at Risk											
CC	66	52	45	38	31	20	16	9	5	4	2
A carriers	395	360	312	273	218	162	120	87	64	46	31



No. at Risk											
Low	191	168	143	123	105	78	49	33	24	19	11
High/Interm	266	240	211	186	143	104	87	63	45	31	22



No. at Risk											
Low/Interm	349	311	270	237	189	136	94	65	47	34	19
High	107	96	83	71	58	46	42	31	22	16	14


IL6 -572 G>C
Overall survival
1.00
0.75
0.50
0.25
0.00
GG
C carrier
0
24
48
72
96
120
144
Months since start of ADT
No. at Risk
GG 399 348 257 161 85 50 20
C carriers 57 48 29 18 11 4 1


IL6R Asp358Ala (A>C)
Overall survival
1.00
0.75
0.50
0.25
0.00
A carrier
CC
0
24
48
72
96
120
144
Months since start of ADT
No. at Risk
CC 68 53 35 22 11 5 0
A carriers 398 352 258 159 87 50 22


ADIPOQ +45 T>G
Overall survival
1.00
0.75
0.50
0.25
0.00
T carrier
GG
0
24
48
72
96
120
144
Months since start of ADT
No. at Risk
T carriers 460 403 294 184 100 57 22
GG 10 6 3 1 1 1 0


VEGF (2 SNPs) pathway activation
Overall survival
1.00
0.75
0.50
0.25
0.00
Low/Intermediate
High
0
24
48
72
96
120
144
Months since start of ADT
No. at Risk
Low/Interm 391 347 251 155 84 47 19
High 71 56 40 25 13 7 3

Supplementary table 1. Studied single nucleotide polymorphisms (SNPs) in genes coding for molecules involved on adipokine pathways

Pathway	Gene	Reference SNP ID	Nucleotide substitution	Genomic location	MGF (%)
Adiponectin	*ADIPOQ*	rs1501299	G>T	+ 276 intron 2	TT (11.7)
	ADIPOQ	rs2241766	T>G	+45 intron 2	GG (2.3)
	ADIPOQ	rs16861194	A>G	-11426 promoter	GG (1.1)
Interleukin - 6	*IL6*	rs1800795	G>C	-174 promoter	CC (13.1)
	IL6	rs1800796	G>C	-572 promoter	CC (0.4)
	IL6	rs1800797	G>A	-597 promoter	AA (13.9)
	IL6	rs10499563	T>C	-6331 promoter	CC (4.8)
	IL6R	rs2228145	A>C	Asp358Ala	CC (14.7)
	IL6ST	rs3729960	G>C	Gly148Arg	CC (1.5)
Vascular Endothelial Growth Factor	*KDR*	rs2071559	T>C	-604 promoter	TT (22.2)
	VEGF	rs2010963	G>C	+405 5'-UTR	CC (15.3)
	VEGF	rs833061	C>T	-460 promoter	CC (20.8)
	VEGF	rs3025039	C>T	+936 3'-UTR	TT (3.1)
Leptin	*LEP*	rs7799039	G>A	-2548 promoter	AA (16.8)
	LEPR	rs1137100	A>G	Lys109Arg	GG (5.7)
	LEPR	rs1137101	A>G	Gln223Arg	GG (16.4)
	LEPR	rs8179183	G>C	Lys656Asn	CC (2.9)
Peroxisome proliferator-activated receptor	*PPARGC1A*	rs8192678	A>G	Gly482Ser	GG (13.7)
	PPARD	rs2016520	T>C	-87 5'-UTR	CC (5.9)
	PPARG	rs1801282	C>G	Pro12Ala	GG (0.8)
Osteopontin	*SPP1*	rs28357094	T>G	-66 promoter	GG (5.9)

Insulin growth factor 1	*IRS1*	rs1801278	C>T	Gly972Arg	TT (1.9)
	IGF1R	rs2229765	G>A	+3174 exon 16	AA (21.1)
Fibroblast growth factor 2	*FGFR2*	rs2981582	C>T	Intron 2	TT (3.8)
Tumor necrosis factor alpha	*TNFA*	rs1800629	G>A	-308 promoter	AA (5.1)
	TNFA	rs1800630	C>A	-863 promoter	AA (3.8)
	TNFRSF1A	rs4149570	G>T	-329 promoter	TT (15.7)

MGF, minor genotype frequency in present study; *ADIPOQ*, adiponectin gene; *IL6*, interleukin-6 gene; *IL6R*, interleukin-6 receptor gene; *IL6ST*, interleukin-6 signal transducer gene; *KDR*, vascular endothelial growth factor receptor 2 gene; *VEGF*, vascular endothelial growth factor gene; *LEP*, leptin gene; *LEPR*, leptin receptor gene; *PPARGC1A*, Peroxisome proliferator-activated receptor gamma co-activator 1 alpha gene; *PPARD*, Peroxisome proliferator-activated receptor delta gene; *PPARG*, Peroxisome proliferator-activated receptor gamma gene; *SPP1*, osteopontin gene; *IRS1*, insulin receptor substrate 1 gene; *IGFBP3*, insulin growth factor binding protein 3 gene; *IGF1R*, insulin growth factor 1 receptor gene; *FGF2*, fibroblast growth factor 2 gene; *FGFR2*, fibroblast growth factor receptor 2 gene; *TNFA*, tumoral necrosis factor alpha gene; *TNFRSF1A*, tumoral necrosis factor receptor 1 gene.

Supplementary table 2. Rationale for functional combination of Single Nucleotide Polymorphisms (SNPs), according to adipokine pathways

Pathway	SNP	Genotypes	Functional outcomes	SNP functional combinations
Adiponectin	*ADIPOQ* +45 T>G	G carrier [1,2]	↑ expression	**haplotype** (combined according to reference [5]).
	ADIPOQ +276 G>T	T carrier [2,3]	↑ expression	
	ADIPOQ -11426	AA [4]	↑ expression	
Interleukin - 6	*IL6* -174	C carrier [6 7]	↑ expression, ↑ activation	**Signaling:** *high*, IL6R Ccarrier/IL6ST GG; *intermediate*, IL6R Ccarrier/IL6ST Ccarrier and IL6R AA/IL6ST GG; *low*, IL6R AA/IL6ST Ccarrier.
	IL6 -572	C carrier [7]	↑ expression, ↑ activation	**Expression:** *high*, ≥ 3/4 risk genotypes; *low*, 0-2/4 risk genotypes.
	IL6 -597	A carrier [7]	↑ expression, ↑ activation	**Activation:** *high*, high expression/high or intermediate signaling; *intermediate*, high expression/low signaling and low expression/high signaling; *low*, low expression/low or intermediate signaling.
	IL6 -6331	TT [8]	↑ expression, ↑ activation	
	IL6R 358	C carrier [9,10]	↑ signaling, ↑ activation	
	IL6ST 148	GG [11]	↑ signaling, ↑ activation	
Vascular Endothelial Growth Factor	*KDR* -604	TT [12]	↑ signaling, ↑ activation	**Expression 2 SNPs** (-460/+405, according to ref [13]): *low* vs. *high*.
	VEGF -460	C carrier [13,14]	↑ expression, ↑ activation	**Expression 3 SNPs:** *high*, -460/+405 high/936 CC; *intermediate*, -460/+405 high/936 T carrier and -460/+405 low/936 CC; *low*, -460/+405 low/936 T carrier.
	VEGF +405	GG [13,14]	↑ expression, ↑ activation	**Activation 2SNPs:** *high*, -460/+405 high/KDR TT; *intermediate*, -460/+405 high/KDR Ccarrier and -460/+405 low/KDR TT; *low*, -460/+405 low/KDR Ccarrier.
	VEGF +936	CC [15]	↑ expression, ↑ activation	**Activation 3SNPs:** *high*, high or intermediate expression/ KDR TT; *intermediate*, high expression/ KDR Ccarrier and low expression/ KDR TT; *low*, low or intermediate expression/ KDR Ccarrier.
Leptin	*LEP* -2548	AA [16]	↑ expression	**Signaling:** *high*, 3/3 risk alleles; *intermediate*, 2/3 risk alleles; *low*, 0-1/3 risk alleles
	LEPR 109	GG [17,18]	↑ signaling	**Activation:** *high*, high signaling/LEP AA or G carrier and intermediate signaling/LEP AA; *low*, low signaling/LEP AA or G carrier and intermediate signaling/LEP G carrier.
	LEPR 223	GG [17,19]	↑ signaling	
	LEPR 656	C carrier [20]	↑ signaling	
Peroxisome proliferator-activated receptor	*PPARGC1A* 482	AA [21]	↑ expression	**Number of risk alleles:** 0-3/3
	PPARD -87	TT [22]	↑ expression	

	PPARG 12	G carrier [23]	↓ activation	
Osteopontin	*SPP1* -66	TT [24]	↑ expression	---
Insulin growth factor	*IRS1* 972 *IGF1R* +3174	CC [25] GG [26]	↑ signaling ↑ signaling	**Signaling:** *high*, IRS1 CC/IGF1R GG; *intermediate*, IRS1 CC/IGF1R A carrier and IRS1 T carrier/IGF1R GG; *low*, IRS1 T carrier/IGF1R A carrier.
Fibroblast growth factor 2	*FGFR2*, rs2981582	T carrier [27]	↑ signaling	---
Tumor necrosis factor alpha	*TNFA* -308 *TNFA* -863 *TNFRSF1A* -329	A carrier [28] A carrier [29,30] T carrier [31]	↑ expression, ↑ activation ↑ expression, ↑ activation ↑ signaling, ↑ activation	**Expression:** *high*, -308 Acarrier/-863 Acarrier; *intermediate*, -308 Acarrier/-863 CC and -308 GG/-863 Acarrier; *low*, -308 GG/-863 CC. **Activation:** *high*, high or intermediate expression/TNFRSF1A GG; *intermediate*, high expression/TNFRSF1A Tcarrier and low expression/TNFRSF1A GG; *low*, low or intermediate expression/TNFRSF1A Tcarrier.

MGF, minor genotype frequency in present study; *ADIPOQ*, adiponectin gene; *IL6*, interleukin-6 gene; *IL6R*, interleukin-6 receptor gene; *IL6ST*, interleukin-6 signal transducer gene; *KDR*, vascular endothelial growth factor receptor 2 gene; *VEGF*, vascular endothelial growth factor gene; *LEP*, leptin gene; *LEPR*, leptin receptor gene; *PPARGC1A*, Peroxisome proliferator-activated receptor gamma co-activator 1 alpha gene; *PPARD*, Peroxisome proliferator-activated receptor delta gene; *PPARG*, Peroxisome proliferator-activated receptor gamma gene; *SPP1*, osteopontin gene; *IRS1*, insulin receptor substrate 1 gene; *IGFBP3*, insulin growth factor binding protein 3 gene; *IGF1R*, insulin growth factor 1 receptor gene; *FGF2*, fibroblast growth factor 2 gene; *FGFR2*, fibroblast growth factor receptor 2 gene; *TNFA*, tumoral necrosis factor alpha gene; *TNFRSF1A*, tumoral necrosis factor receptor 1 gene.

References

1. Berthier MT, Houde A, Cote M, et al: Impact of adiponectin gene polymorphisms on plasma lipoprotein and adiponectin concentrations of viscerally obese men. J Lipid Res 46:237-44, 2005
2. Pollin TI, Tanner K, O'Connell J R, et al: Linkage of plasma adiponectin levels to 3q27 explained by association with variation in the APM1 gene. Diabetes 54:268-74, 2005
3. Fredriksson J, Carlsson E, Orho-Melander M, et al: A polymorphism in the adiponectin gene influences adiponectin expression levels in visceral fat in obese subjects. Int J Obes (Lond) 30:226-32, 2006
4. Laumen H, Saningong AD, Heid IM, et al: Functional characterization of promoter variants of the adiponectin gene complemented by epidemiological data. Diabetes 58:984-91, 2009

5. Menzaghi C, Ercolino T, Di Paola R, et al: A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 51:2306-12, 2002
6. Fishman D, Faulds G, Jeffery R, et al: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369-76, 1998
7. Terry CF, Loukaci V, Green FR: Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 275:18138-44, 2000
8. Smith AJ, D'Aiuto F, Palmen J, et al: Association of serum interleukin-6 concentration with a functional IL6 -6331T>C polymorphism. Clin Chem 54:841-50, 2008
9. Galicia JC, Tai H, Komatsu Y, et al: Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes Immun 5:513-6, 2004
10. Rafiq S, Frayling TM, Murray A, et al: A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects. Genes Immun 8:552-9, 2007
11. Benrick A, Jirholt P, Wernstedt I, et al: A non-conservative polymorphism in the IL-6 signal transducer (IL6ST)/gp130 is associated with myocardial infarction in a hypertensive population. Regul Pept 146:189-96, 2008
12. Wang Y, Zheng Y, Zhang W, et al: Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol 50:760-7, 2007
13. Stevens A, Soden J, Brenchley PE, et al: Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63:812-6, 2003
14. Watson CJ, Webb NJ, Bottomley MJ, et al: Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12:1232-5, 2000
15. Renner W, Kotschan S, Hoffmann C, et al: A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37:443-8, 2000
16. Hoffstedt J, Eriksson P, Mottagui-Tabar S, et al: A polymorphism in the leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin. Horm Metab Res 34:355-9, 2002
17. Sun Q, Cornelis MC, Kraft P, et al: Genome-wide association study identifies polymorphisms in LEPR as determinants of plasma soluble leptin receptor levels. Hum Mol Genet 19:1846-55, 2010
18. Liu CL, Chang YC, Cheng SP, et al: The roles of serum leptin concentration and polymorphism in leptin receptor gene at codon 109 in breast cancer. Oncology 72:75-81, 2007
19. Quinton ND, Lee AJ, Ross RJ, et al: A single nucleotide polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women. Hum Genet 108:233-6, 2001
20. de Luis Roman D, de la Fuente RA, Sagrado MG, et al: Leptin receptor Lys656Asn polymorphism is associated with decreased leptin response and weight loss secondary to a lifestyle modification in obese patients. Arch Med Res 37:854-9, 2006
21. Ling C, Poulsen P, Carlsson E, et al: Multiple environmental and genetic factors influence skeletal muscle PGC-1alpha and PGC-1beta gene expression in twins. J Clin Invest 114:1518-26, 2004
22. Skogsberg J, Kannisto K, Cassel TN, et al: Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arterioscler Thromb Vasc Biol 23:637-43, 2003
23. Deeb SS, Fajas L, Nemoto M, et al: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-7, 1998
24. Giacopelli F, Marciano R, Pistorio A, et al: Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics 20:87-96, 2004

25. Almind K, Inoue G, Pedersen O, et al: A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest 97:2569-75, 1996

26. de Alencar SA, Lopes JC: A comprehensive in silico analysis of the functional and structural impact of SNPs in the IGF1R gene. J Biomed Biotechnol 2010:715139, 2010

27. Reeves GK, Travis RC, Green J, et al: Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci. JAMA 304:426-34, 2010

28. Karimi M, Goldie LC, Cruickshank MN, et al: A critical assessment of the factors affecting reporter gene assays for promoter SNP function: a reassessment of -308 TNF polymorphism function using a novel integrated reporter system. Eur J Hum Genet 17:1454-62, 2009

29. Skoog T, van't Hooft FM, Kallin B, et al: A common functional polymorphism (C-->A substitution at position -863) in the promoter region of the tumour necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha. Hum Mol Genet 8:1443-9, 1999

30. Hohjoh H, Tokunaga K: Allele-specific binding of the ubiquitous transcription factor OCT-1 to the functional single nucleotide polymorphism (SNP) sites in the tumor necrosis factor-alpha gene (TNFA) promoter. Genes Immun 2:105-9, 2001

31. Kim S, Moon SM, Kim YS, et al: TNFR1 promoter -329G/T polymorphism results in allele-specific repression of TNFR1 expression. Biochem Biophys Res Commun 368:395-401, 2008

Supplementary table 3. Association of SNPs in genes of adipokine pathways with resistance to ADT and all-cause mortality

	MGF	Resistance to ADT				All-cause mortality			
SNP IDs and combined SNPs [1]	(%)	Model	No.	LR	aHR (95%CI)	Model	No.	LR	aHR (95%CI)
KDR-604, *rs2071559*	48	Dominant	463	2.07	1.13(0.84-1.52)	Recessive	468	16.29	1.16(0.80-1.68)
VEGF+405, *rs2010963*	38	Dominant	463	3.24	1.20(0.92-1.58)	Recessive	468	16.87	1.28(0.83-1.96)
VEGF-460, *rs833061*	44	Recessive	**457**	**3.90**	**1.30(0.95-1.78)**	Recessive	462	13.85	1.14(0.77-1.68)
VEGF+936, *rs3025039*	13	Recessive	440	2.68	1.80(0.58-5.65)	Dominant	445	18.24	1.23(0.83-1.83)
VEGF expression 2 SNP [1]	---	---	457	2.35	1.16(0.86-1.55)	---	462	13.43	1.02(0.72-1.45)
VEGF expression 3 SNP LI_H [1]	---	---	436	2.51	1.18(0.89-1.55)	---	441	15.93	1.07(0.77-1.49)
VEGF activation 2 SNP LI_H [1]	---	---	**457**	**3.77**	**1.33(0.93-1.90)**	**---**	**462**	**18.51**	**1.62(1.09-2.41)**
VEGF activation 3 SNP LI_H [1]	---	---	436	2.69	1.19(0.89-1.59)	---	441	17.24	1.28(0.87-1.88)
IL6-174, *rs1800795*	38	Recessive	460	1.76	0.86(0.58-1.29)	Recessive	465	18.00	0.76(0.48-1.21)
IL6-572, *rs1800796*	6	Dominant	451	3.11	1.32(0.89-1.96)	Dominant	**456**	**22.58**	**1.71(1.10-2.66)**
IL6-597, *rs1800797*	37	Recessive	449	1.46	1.03(0.68-1.55)	Recessive	455	15.90	1.12(0.80-1.56)
IL6-6331, *rs10499563*	25	Dominant	462	1.61	1.16(0.59-2.28)	Recessive	467	15.94	0.89(0.64-1.24)
IL6R, *rs2228145*	39	Dominant	**461**	**5.96**	**0.66(0.46-0.96)**	Dominant	**466**	**19.20**	**0.62(0.40-0.94)**
IL6ST, *rs3729960*	16	Dominant	**461**	**4.26**	**1.27(0.94-1.72)**	Recessive	466	16.72	2.90(0.40-21.02)
IL6 activation LI_H [1]	---	---	**453**	**4.85**	**1.30(0.97-1.72)**	---	458	16.52	1.19(0.84-1.67)
IL6 expression risk [1]	---	---	456	2.60	1.18(0.89-1.56)	---	461	17.21	1.07(0.92-1.25)
IL6R signaling L_IH [1]	---	---	460	3.27	1.31(0.84-2.04)	---	465	14.67	1.13(0.68-1.88)
ADIPOQ+45, *rs2241766*	16	Recessive	**465**	**6.46**	**2.69(1.26-5.73)**	Recessive	**470**	**23.47**	**4.22(1.85-9.64)**
ADIPOQ +276, *rs1501299*	30	Recessive	**464**	**5.35**	**0.76(0.58-0.99)**	Recessive	**469**	**19.29**	**0.74(0.54-1.02)**

ADIPOQ -11426, *rs16861194*	9	Dominant	447	2.91	0.54(0.20-1.45)	Recessive	452	14.78	0.78(0.49-1.24)
ADIPOQ haplotype LI_H [1]	---	---	**461**	**1.51**	**1.51(1.10-2.06)**	---	466	17.53	1.29(0.87-1.90)
LEP-2548, *rs7799039*	39	Dominant	463	2.60	0.86(0.65-1.13)	Dominant	468	15.84	1.08(0.71-1.65)
*LEPR*109, *rs1137100*	21	Dominant	463	1.97	1.23(0.71-2.12)	Recessive	468	16.42	1.16(0.82-1.63)
*LEPR*223, *rs1137101*	42	Dominant	**462**	**4.13**	**1.27(0.95-1.71)**	Dominant	**467**	**19.31**	**1.42(0.98-2.05)**
*LEPR*656, *rs8179183*	19	Dominant	461	1.44	1.10(0.49-2.47)	Recessive	466	15.17	0.81(0.57-1.16)
LEP activation [1]	---	**---**	**460**	**4.42**	**0.50(0.20-1.21)**	---	465	13.93	0.84(0.37-1.90)
LEPR signaling LI_H [1]	---	---	460	2.45	1.18(0.86-1.60)	---	465	13.99	1.10(0.76-1.59)
PPARG, *rs1801282*	8	Recessive	461	1.70	0.68(0.25-1.85)	Recessive	466	16.23	0.58(0.18-1.86)
PGC1A, *rs8192678*	36	Recessive	460	1.68	1.02(0.77-1.34)	Recessive	465	15.21	1.22(0.75-2.00)
PPARD, *rs2016520*	23	Recessive	459	2.80	0.85(0.64-1.13)	Recessive	464	16.78	0.60(0.24-1.46)
PPARs risk alleles 0_123 [1]	---	---	457	1.25	1.02(0.79-1.31)	---	462	16.14	1.17(0.87-1.57)
OPN, *rs28357094*	26	Recessive	463	2.81	1.19(0.90-1.56)	Dominant	468	16.31	0.78(0.36-1.67)
IRS1, *rs1801278*	10	Recessive	452	2.56	0.68(0.28-1.65)	Recessive	456	10.84	0.62(0.23-1.69)
IGF1R, *rs2229765*	45	Recessive	459	1.94	0.90(0.64-1.25)	Recessive	464	15.62	0.93(0.63-1.39)
IGF signaling L_IH [1]	---	---	447	3.62	0.76(0.51-1.15)	---	451	11.48	0.71(0.44-1.14)
FGFR2, *rs2981582*	37	Recessive	459	2.93	1.20(0.84-1.71)	Recessive	464	15.70	0.77(0.48-1.23)
TNFA-308, *rs1800629*	19	Recessive	458	3.09	0.85(0.63-1.14)	Dominant	463	14.34	0.91(0.46-1.80)
TNFA-863, *rs1800630*	19	Dominant	**459**	**4.42**	**0.79(0.59-1.06)**	Dominant	464	15.92	0.78(0.55-1.10)
TNFRSF1A-329, *rs4149570*	39	Recessive	457	2.43	0.86(0.58-1.27)	Recessive	462	14.20	0.84(0.52-1.37)
TNFA activation LI_H [1]	---	**---**	**456**	**6.51**	**0.70(0.50-0.98)**	---	461	15.10	0.80(0.58-1.12)
TNFA expression L_IH [1]	---	**---**	**457**	**6.94**	**0.73(0.56-0.96)**	---	459	13.90	0.91(0.66-1.27)

Results are presented only for the best-fitting genetic model (based on the minor allele as dominant: aa + Aa genotype versus AA genotype, or recessive: aa genotype versus Aa + AA genotype) for each SNP or functional combination of SNPs by pathway (the model with the highest likelihood ratio was selected).[1] Functional combinations of SNPs in pathways are detailed in supplementary table 2. ADT, androgen deprivation therapy; No., number of subjects; MGF, minor genotype frequency in the cohort; LR, likelihood ratio; aHR (95%CI), age-adjusted hazard ratio and respective 95% confidence interval; SNP, single nucleotide polymorphism. *ADIPOQ*, adiponectin; *FGFR2*, fibroblast growth factor receptor 2; *IL6*, interleukin 6; *IL6R*, interleukin 6 receptor; *IL6ST*, interleukin 6 signal transducer; *IRS1*, insulin receptor substrate 1; *IGF1R*, insulin growth factor receptor 1; *KDR*, kinase insert domain receptor; *LEP*, leptin; *LEPR*, leptin receptor; *OPN*, osteopontin; *PPARD*, peroxisome proliferator-activated delta; *PPARG*, peroxisome proliferator-activated receptor gamma; *PGC1A*, peroxisome proliferator-activated receptor gamma coactivator 1; *TNFA*, tumoral necrosis factor alpha; *TNFRSF1A*, tumor necrosis factor receptor superfamily, member 1A; *VEGF*, vascular endothelial growth factor. Significant associations are in boldface.

The Pharmacogenomics Journal (2009) 9, 341–346
© 2009 Nature Publishing Group All rights reserved 1470-269X/09 $32.00
www.nature.com/tpj

ORIGINAL ARTICLE

Combined analysis of *EGF + 61G > A* and *TGFB1 + 869T > C* functional polymorphisms in the time to androgen independence and prostate cancer susceptibility

AL Teixeira[1,2,7], R Ribeiro[1,2,7], A Morais[3], F Lobo[3], A Fraga[4], F Pina[5], FM Calais-da-Silva[6], FE Calais-da-Silva[6] and R Medeiros[1,2]

[1]*Molecular Oncology Group–CI and Department of Virology, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal;* [2]*Abel Salazar Biomedical Sciences Institute, ICBAS, Porto University, Porto, Portugal;* [3]*Department of Urology, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal;* [4]*Department of Urology, Hospital Militar do Porto, Porto, Portugal;* [5]*Department of Urology, Hospital S. João, Porto, Portugal and* [6]*Department of Urology, Lisbon Medical Centre (Central Region), Lisbon, Portugal*

Correspondence:
Professor Dr R Medeiros, Instituto Português de Oncologia do Porto Francisco Gentil, EPE, Grupo de Oncologia Molecular – CI, Edifício Laboratórios, 4° piso, Rua Dr António Bernardino de Almeida, 4200-072 Porto, Portugal.
E-mail: ruimedei@ipoporto.min-saude.pt

[7]These authors contributed equally to this study.

Received 7 October 2008; revised 26 February 2009; accepted 14 April 2009; published online 2 June 2009

Proliferative mechanisms involving the epidermal growth factor (EGF) and transforming growth factor beta (TGF-β_1) ligands are potential alternative pathways for prostate cancer (PC) progression to androgen independence (AI). Thus, the combined effect of *EGF* and *TGFB1* functional polymorphisms might modulate tumor microenvironment and consequently its development. We studied *EGF + 61G > A* and *TGFB1 + 869T > C* functional polymorphisms in 234 patients with PC and 243 healthy individuals. Intermediate- and high-proliferation genetic profile carriers have increased risk for PC (odds ratio (OR) = 3.76, $P = 0.007$ and OR = 3.98, $P = 0.004$, respectively), when compared with low proliferation individuals. Multivariate analysis showed a significantly lower time to AI in the high proliferation group, compared with the low/intermediate proliferation genetic profile carriers (HR = 2.67, $P = 0.039$), after adjustment for age, metastasis and stage. Results suggest that combined analysis of target genetic polymorphisms may contribute to the definition of cancer susceptibility and pharmacogenomic profiles. Combined blockage of key molecules in proliferation signaling pathways could be one of the most promising strategies for androgen-independent prostate cancer.
The Pharmacogenomics Journal (2009) **9**, 341–346; doi:10.1038/tpj.2009.20; published online 2 June 2009

Keywords: *EGF/TGFB1* functional polymorphisms; prostate cancer; SNP variations; androgen independence

Introduction

Prostate cancer (PC) is one of the most common malignancies among men in the Western world and a major health problem in many industrialized countries.[1]

Despite recent advances in the detection of early PC there is little effective therapy for patients with locally advanced and/or metastatic disease. Patients diagnosed in advanced stages are frequently submitted to hormonal treatment with androgen deprivation therapy (ADT),[2] although most men will eventually fail this therapy and die from recurrent androgen-independent prostate cancer (AIPC). AIPC is an invariably lethal condition associated with significant deterioration of the quality of life.[3,4] Therefore, it is important to understand the mechanisms involved in AI progression.

It is known that the androgen pathway has a critical role in the survival of prostatic cells; however, progression into advanced PC and incurable forms has

been associated with the activation of other cascades mediated by growth factors responsible for the balance between cell growth rate and apoptosis. Cell proliferation is normally regulated by the concerted action of both mitogenic growth signals and antiproliferative signals that converge on regulators of the cell cycle. In fact, the prostate is known to be dependent not exclusively on androgens but also on growth factors.[5] Some authors suggest that aberrant growth and differentiation are because of inappropriate cellular environment.[6]

The epidermal growth factor (EGF) and the transforming growth factor-beta 1 (TGF-β_1) are the key players, with opposite roles, in cell proliferation. EGF activates several pro-oncogenic intracellular pathways leading to proliferation, differentiation and tumorigenesis of epithelial cells.[7,8] Cumulatively, its receptor (EGFR (epidermal growth factor receptor)) is proposed to participate in the pathogenesis and growth of several epithelial human cancers. In PC cells, EGFR ligands are frequently elevated and EGFR itself is commonly overexpressed.[9] Furthermore, EGFR expression increases during progression to AI.[10]

Epidermal growth factor is encoded by the *EGF* gene, located on chromosome 4q25-q27. Shabazi *et al.*[11] identified a functional G>A single nucleotide polymorphism at position +61 in the 5′-untranslated region of the *EGF* gene (rs4444903). *In vitro* studies showed that G-carriers have an increased EGF production in both normal and tumoral cells.[11–13] This functional polymorphism has been associated with several malignancies,[11–15] including an earlier report from our group in PC.[16]

Transforming growth factor-β_1 is a multifunctional regulatory polypeptide that controls many aspects of cellular function, such as cellular proliferation, differentiation, migration, apoptosis, adhesion, angiogenesis, immune surveillance and survival.[17] Nevertheless, TGF-β_1 has been suggested to play a dual role, acting as a suppressor in the early stages and as a tumor promoter in the later stages, by enhancing tumor cell motility and invasiveness.[18,19] Recently, a functional polymorphism was described in *TGFB1* gene (*TGFB1+869T>C*), responsible for a T-to-C substitution at nucleotide 29 of codon 10 (rs1982073). This variant is located in the hydrophobic core of the signal peptide, resulting in the replacement of a hydrophobic leucine with a small, neutral proline. This transition has been associated with higher circulating levels of TGF-β_1 (in homozygous C).[20,21]

Genetic variants, which influence *EGF* and *TGFB1* expressions and protein serum levels, may impact PC development and prognosis. Our purpose was to investigate the combination of *EGF+61G>A* and *TGFB1+869T>C* functional polymorphisms in PC and AIPC in response to ADT.

Results

Using the recessive model, frequencies for homozygous AA and AG/GG genotypes of *EGF+61G>A* polymorphism were, respectively, 0.32 and 0.68 for PC patients and 0.34 and 0.66 in the control group. The *TGFB1+869T>C* polymorphism frequencies for homozygous CC and CT/TT were 0.14 and 0.86 in PC group and 0.22 and 0.78 in the control group, respectively. Observed versus expected genotype frequencies were calculated, and no deviation from Hardy–Weinberg equilibrium was observed, except for the *TGFB1* polymorphism in control group (*EGF+61G>A*: PC group, $P=0.082$, control group, $P=0.073$; *TGFB1+869T>C*: PC group, $P=0.761$, control group, $P=0.020$).

High- and intermediate-proliferation genetic profiles' distributions were overrepresented in PC (0.56 and 0.42, respectively) and control (0.52 and 0.40, respectively) groups compared with the low-proliferation functional genetic profile (Table 1). The present results show a significantly higher risk for developing PC in the intermediate- and high-proliferation functional genetic profile carriers (odds ratio (OR)=3.76, 95% confidence interval (CI)=1.26–12.03 and OR=3.98, 95% CI=1.35–12.59, respectively). The population attributable risk (PAR) for intermediate and high proliferation groups was 30.8 and 42%, respectively.

The analysis of clinico-pathological characteristics according to the combined proliferation genetic profile showed no statistically significant associations of the combined polymorphisms with Gleason grade, distant metastasis and prostate specific antigen (PSA) at the time of diagnosis ($P=0.319$, $P=0.572$ and $P=0.254$, respectively).

Concerning AI-free interval after the beginning of ADT, we found a significantly reduced time-to-AI in high-proliferation functional genetic profile carriers (93.99 (6.87) months in low/intermediate proliferation group and 76.51 (6.15) months in high proliferation group), using a multivariate Cox regression model with age ($P=0.299$), tumor stage ($P<0.0001$), surgery ($P=0.982$) and hormonal

Table 1 Frequencies distribution and OR analysis in control and PC groups according to *EGF+61G>A* and *TGFB1+869T>C* combined proliferation functional genetic profile

	Control group	*PC group*	*OR*	*95% CI*	P-*value*
Combined genetic profile					
Low proliferation	19 (0.08)	5 (0.02)	—		
Intermediate proliferation	98 (0.40)	97 (0.42)	3.76	1.26–12.03	0.007
High proliferation	126 (0.52)	132 (0.56)	3.98	1.35–12.59	0.004

Abbreviations: OR, odds ratio; PC, prostate cancer.



Figure 1 Androgen independence-free survival (AIFS) according to *EGF-TGFB1* combined proliferation genetic profile in patients submitted to ADT.

treatment type ($P = 0.487$) as covariates (hazard ratio (HR) = 2.67, 95% CI = 1.05–6.79, $P = 0.039$) (Figure 1).

Discussion

The intricate balance between cell growth and proliferation factors versus apoptosis-inducing factors is mandatory for prostate growth regulation. Conversely, homeostatic disruptions in PC often trigger the loss of apoptosis and the overexpression of factors promoting cell survival and proliferation. A common deregulated mechanism in PC cells is distinguished by apoptotic evasion, uncontrolled proliferation and loss of differentiation.[17]

Growth factors play a significant role in the growth of normal, hyperplastic and malignant prostatic epithelium. There is a significant amount of evidence supporting that the EGF and the transforming growth factor-beta (TGF-β) families are among the most relevant mediators of proliferation in this type of cancer.[22,23] In line with these findings, our results suggest that TGF-β_1 and EGF combined effect may impact significantly in the individual PC risk, as well as in ADT outcome. However, a limitation to the study on PC susceptibility association with combined EGF and TGFB1 variants, resides in the significantly different mean age between PC and control groups, and the lack of information and subsequent adjustment for potentially relevant environmental factors. Therefore, conclusions on this issue should be interpreted cautiously owing to limitations inherent to the design.

Other line of evidence unfocused in target genes showed that in genome-wide association studies,[24–26] PC susceptibility loci do not reside within or near identifiable genes. It has been hypothesized that they exist in regulatory regions of DNA that control gene expression, or alternatively, in regions of DNA that code for microRNAs or other regulatory transcripts, as recently conceptualized by Glinsky.[27,28] Ultimately, our results and these new lines of research will encourage future studies to increase our understanding of the biological basis of PC, providing an opportunity to design new therapies.

Several lines of evidence support the involvement of EGF in PC development. The normal and tumoral prostatic epithelium produces large amounts of EGF,[29] its receptor was found to be overexpressed in prostatic tumors, and the EGF/EGFR pathway has been associated with AI development.[9,30] Cumulatively, it was shown that EGF and EGFR expression levels in PC cells are enhanced during disease progression to AI and metastatic PC.[10]

Transforming growth factor-β_1 exerts a wide variety of biological actions, through both autocrine and paracrine mechanisms. It's role has been associated with advanced disease and metastasis, through the induction of extracellular proteolysis, angiogenesis and immune suppression.[31] However, in the earlier stages of tumor development TGF-β_1 can act as an inhibitor of tumor progression.[32] According to Tang *et al.*,[33] the suppression of autocrine TGF-β_1 actions leads to the activation of tumorigenic properties. In fact, it was observed a dual role for TGF-β_1 in PC cells, with both an inhibitory or a stimulatory growth effect.[34] These apparently paradoxal findings can be attributed to TGF-β_1 concentration, which leads to proliferation in low TGF-β_1 environments, and induces growth arrest in the presence of high concentrations of TGF-β_1.[35] This ligand that potentially inhibit epithelial, endothelial and hematopoietic cell proliferation, is able to prevent progression through the cell cycle by inducing expression of cyclin kinase inhibitors p15, p21 and p27.[17] Furthermore, it regulates the expression of several key proteins in the control of cell-cycle progression from G1-to-S phase,[17] including *c-myc*. It was shown that TGF-β_1 can rapidly inhibit the transcription of *c-myc* in epithelial cells.[36] TGF-β_1 is also produced in prostatic stromal cells, inducing apoptosis through a paracrine mechanism in prostate epithelial cell. In fact, it was already shown that the TGF-β signaling pathway may have prognostic significance in PC patients and that *in vitro* restoration of TGF-β_1 signaling pathway in PC cells inhibits proliferation.[37,38]

Case–control molecular epidemiology studies from our group and others have shown promising results concerning the development of molecular markers for PC susceptibility and aggressiveness.[39–42] Specifically, it was hypothesized that functional polymorphisms with impact in growth factor and cytokine expression and circulating levels may influence individual susceptibility to PC, the response to treatment and prognosis significance.

The $EGF+61G>A$ polymorphism encodes a significant functional difference in EGF expression.[11–13] Conversely, it is expected that G-carriers will have a higher EGF availability in tumoral environment. $EGF+61G>A$ polymorphism has been the subject of investigation in case–control studies, involving other cancer types.[11–16] Recently, we have shown that this functional polymorphism was associated with

increased risk for PC, being diagnosed with aggressive disease and worst response to ADT.[16]

The *TGFB1+869T>C* functional polymorphism is responsible for significantly higher TGF-β_1 circulating levels in C-carriers and *in vitro* transfection experiments showed that the signal peptide in C-carriers caused a 2.8-fold increase in the secretion of TGF-β_1 compared with T-carriers.[43] The combined lower TGF-β_1 production in the presence of T-allele[21] and higher levels of EGF associated with the presence of G-allele, might contribute to a favorable long-term proliferative potential in prostate epithelial cells, which may increase PC risk.

Although interactions between cancer cells and the extracellular environment are important in processes such as invasion, angiogenesis and metastization, and TGF-β_1 and EGF are known to play a role in these mechanisms,[17,44] our results do not support this hypothesis. We suggest that, as we used a combined genetic profile of *EGF* and *TGFB1* based on the proliferation phenotype, we were unable to find an association with aggressive PC.

Patients with local or distant metastatic PC are usually treated primarily through pharmacological androgen suppression.[2] This hormonal therapy is initially efficient, although the majority of patients will subsequently become unresponsive to androgen inhibition[45] and consequently the development of AIPC is a clinical problem of major concern.[2,3] In fact, AIPC is a complex and heterogeneous form of PC with a high capacity of progression and metastization.[4] Conversely, the comprehension of molecular pathways underlying this disease is imperative.

The AIPC is a multistep/multievent process with different molecular patterns throughout development, involving changes in signaling pathways of growth suppressing or promoting factors.[46] It was hypothesized that EGF/EGFR and TGF-β_1/TGF-β_1RII pathways are involved in the acquisition of AIPC phenotype, either through an independent alternative proliferative stimulus, or through the interference with androgen receptor (AR) axis.[46,47]

The prostate is an androgen-dependent (AD) organ that undergoes involution after castration. Isaacs and Cooffey[48] suggested that the shift from AD-to-AIPC may be because of residual stem cells not responsive to androgens, which will emerge after ADT under the appropriate growth stimulus. It is well established that the microenvironment surrounding PC cells after ADT may play an important role in their behavior. Stem cells are usually quiescent and reside surrounded by a microenvironment that maintains the balance between quiescence and self-renewal stem cell population. TGF-β_1 and EGF have been implicated as modulators of stem cell proliferation, thereby regulating their homeostasis.[49]

In addition to the proposed mechanism for EGF and TGF-β_1 in AI development, we suggest that by selecting AI cell clones, ADT creates an opportunity for these undifferentiated stem cells to grow according to the involving microenvironment. Accordingly, carriers of a high-proliferation constitutive genetic profile will likely be exposed to an increased proliferative stimulus, thus contributing to AI disease. However, the small sample size in our study may limit the ability to discern meaningful differences. Further research is needed to evaluate the associations reported here in more details. In particular large, well-designed studies of ethnically diverse populations and functional studies on PC cells may help clarify which variants are truly causal for this disease.

Present results support that combined analysis of genetic polymorphisms might reinforce the clinical capacity to predict the response to treatment. Furthermore, these findings also support the need of other studies to ascertain the therapeutic value of targeted-combined therapies directed against both EGF/EGFR and TGF-β_1/TGF-β_1RII pathways.

In summary, we observed a statistically significant increased risk for developing PC in *EGF* and *TGFB1* combined high- and intermediate-proliferation functional genetic profile carriers. Cumulatively, the high-proliferation functional genetic profile carriers were more prone to develop AI.

Materials and methods

Study population

This case–control study was undertaken in 234 patients, with a mean age of 69.1 (7.48), with histopathologically diagnosed PC. The median follow-up time was 32 months (range 2.5–137 months). Patients distribution according to the stage at the time of diagnosis was 43.4% presenting localized disease (T_1–T_{2b}), 37.9% with locally advanced disease (T_3–T_4) and 18.7% with metastatic disease (N^+ and/or M^+). The types of hormonal treatment were as follows: anti-androgens plus luteinizing hormone-releasing hormone agonists (aLHRH) combination therapy (81.7%); aLHRH alone (8.7%) and anti-androgens alone (9.6%). Hormone resistance was evaluated through PSA recurrence, which was defined as two consecutive increasing PSA values more than $1.0\,ng\,ml^{-1}$ and differing by more than $0.2\,ng\,ml^{-1}$.

Men older than 40 years of age, without known history of cancer were recruited from the Portuguese Institute of Oncology—Porto Centre Blood Donor's Bank and included in the control group ($n=243$), with a mean age of 44.7 (11.55). Study was conducted according to the Helsinki Declaration principles. A venous blood sample (8 ml) was obtained from each subject by forearm venipuncture. White cell fraction was used to extract DNA according to salting-out procedure.[50]

EGF+61G>A and TGFB1 +869T>C genotyping

The *EGF+61G>A* polymorphism was analyzed through polymerase chain reaction (PCR) followed by RFLP (restriction fragment length polymorphism), as described in earlier reports.[15,16] Briefly, DNA was amplified in a 50-μl reaction mixture containing *EGF+61G>A* specific primers, PCR buffer 1×, Taq Polymerase 1 U, $MgCl_2$ 1.5 mM, dNTPs 0.2 mM, DNA 100 ng. PCR products (242 bp) were incubated overnight with *Alu*I restriction endonuclease at 37 °C. The restricted fragments were separated by electrophoresis on 3% agarose gels with ethidium bromide staining.

Table 2 Genotypes of the two polymorphisms combined into three functional categories according to functional proliferation outcome

Combination	*EGF+61G>A*	*TGFB1+869T>C*	*Genetic proliferation profile*
AA-CC	AA	CC	Low proliferation
AA-CT/TT	AA	CT/TT	Intermediate proliferation
AG/GG-CC	AG/GG	CC	Intermediate proliferation
AG/GG-CT/TT	AG/GG	CT/TT	High proliferation

The polymorphism was defined by presence (A) or absence (G) of an additional restriction site.

The *TGFB1+869T>C* polymorphism was analyzed by allelic discrimination using 7300 real-time PCR System (Applied Biosystems, Foster City, CA, USA). Real-time PCR were carried out using a 6-μl reaction mixture, containing 1× Master Mix (Applied Biosystems), with 1× probes (TaqMan assay C__22272997_10__, Applied Biosystems) and 90 ng of the DNA sample.

Quality control procedures implemented for genotyping included double sampling in about 10% of the samples to assess reliability and the use of negative controls to step-away false-positives. In PCR-RFLP method, two authors obtained the results independently, and the ambiguous were reanalysed.

Statistical analysis

Genotypes of the two polymorphisms were combined into three categories according to the functional consequences in cell proliferation: low-, intermediate- and high-proliferation genetic profile (Table 2). The rationale for defining high-proliferation functional genetic profile was to associate the overexpressing G-allele from *EGF +61G>A* polymorphism with the T-allele from *TGFB1 +869T>C* variant related to lower TGF-β_1 production. In the intermediate-functional genetic profile, we have combined *EGF+61G>A* and *TGFB1+869T>C* polymorphisms (AA plus CT/TT carriers, and AG/GG plus CC, respectively). The combination of *EGF+61G>A* homozygous A with *TGFB1+869T>C* homozygous C polymorphism corresponded to the low-proliferation genetic profile.

Genetic profiles proportions among groups were compared using the Pearson's χ^2-test. OR and 95% confidence interval (CI) were calculated as a measure of association between *EGF/TGFB1* combined genetic profiles in cases and controls. A Cox proportional hazard model was used to analyze the time to AI (determined by the interval of time since the beginning of ADT until AI or the last clinical visit), considering as covariates, age at diagnosis ($\geqslant$69 vs $<$69 years old), tumor stage (localized vs locally advanced vs distant metastases), surgery (radical prostatectomy vs none) and hormonal treatment type (anti-androgens plus aLHRH combination therapy vs aLHRH alone vs anti-androgens alone). Hardy–Weinberg equilibrium was tested using Pearson's χ^2-analysis to compare observed versus expected genotype frequencies.

We calculated the PAR, using the following formula: $PAR = PRF \times (1-1/OR)$. The PAR is the fraction of disease attributable to the risk factor, PRF is the percentage of the risk factor in case subjects, and OR is the odds ratio. All analyses were performed with SPSS 15.0 statistical software (SPSS Inc., Chicago, IL, USA) considering a level of significance $<$0.05.

Acknowledgments

We thank the Liga Portuguesa Contra o Cancro—Centro Regional do Norte (Portuguese League Against Cancer); Yamanouchi—Astellas European Foundation Award for Prostate Cancer; FCT—Fundação para a Ciência e Tecnologia (PTDC/SAU-FCF/71552/2006), Portuguese governmental foundation for science and technology; this project was partially sponsored by an unrestricted educational grant for basic research in Molecular Oncology from Novartis Oncology Portugal; RR is a recipient of a Doctoral degree grant from FCT (SFRH/BD/30021/2006); ALT is a recipient of a Master degree grant from Liga Portuguesa Contra o Cancro- Programa de Apoio à Investigação Oncológica no Norte de Portugal 2008.

Duality of interest

The authors disclose any commercial or other associations with acknowledged institutions that might pose a conflict of interest in connection with submitted material.

References

1 Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. *Front Biosc* 2006; **11**: 1388–1413.
2 Pronzato P, Rondini M. Hormonotherapy of advanced prostate cancer. *Ann Oncol* 2005; **4**: iv80–iv84.
3 Hellerstedt B, Pienta K. The current state of hormonal therapy for prostate cancer. *CA Cancer J Clin* 2002; **52**: 154–179.
4 Catalona WJ. Management of cancer of the prostate. *N Engl J Med* 1994; **331**: 996–1003.
5 Martín-Orozco R, Almaroz-Pro C, Rodríguez-Ubreva FJ, Cortés MA, Ropero S, Colomer R *et al.* EGF prevents the neuroendocrine differentiation of LNCaP Cells induced by serum deprivation: the modulator role of PI3K/Akt. *Neoplasia* 2007; **9**: 614–624.
6 Long R, Morrissey C, Fitzpatrick J. Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. *Clin Sci* 2005; **108**: 1–11.
7 Fisher DA, Lakshmanan J. Metabolism and effects of epidermal growth factor and related growth factors in mammals. *Endocr Rev* 1990; **11**: 418–442.
8 Groenen LC, Nice EC, Burgess AW. Structure-function relationships for the EGF/TGF- family of mitogens. *Growth Factors* 1994; **11**: 235–257.

9 Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A, Bologna M. Prostate cancer cell proliferation is strongly reduced by epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 *in vitro* on human cell lines primary cultures. *J Cancer Res Clin Oncol* 2003; **129**: 165–175.
10 Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R *et al.* Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. *Clin Cancer Res* 2002; **8**: 3438–3444.
11 Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC *et al.* Association between functional polymorphism in EGF gene and malignant melanoma. *Lancet* 2002; **359**: 397–401.
12 Bhowmick D, Zhuang Z, Wait SD, Weil RJ. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. *Cancer Res* 2004; **64**: 1220–1223.
13 Costa B, Ferreira P, Costa P, Canedo P, Oliveira P, Silva A *et al.* Association between functional EGF+61 polymorphism and glioma risk. *Clin Cancer Res* 2007; **13**: 2621–2625.
14 MacCarron S, Bateman A, Theaker J, Howell WM. EGF+61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma. *Int J Cancer* 2003; **107**: 673–675.
15 Ribeiro R, Soares A, Pinto D, Catarino R, Lopes C, Medeiros R. EGF genetic polymorphism is associated with clinical features but not malignant phenotype in neurofibromatosis type 1 patients. *J Neurooncol* 2007; **81**: 225–229.
16 Teixeira AL, Ribeiro R, Cardoso D, Pinto D, Lobo F, Fraga A *et al.* Genetic Polymorphism in EGF is associated with prostate cancer agressiveness and progression-free-interval in androgen blockade-treated patients. *Clin Cancer Res* 2008; **14**: 3367–3371.
17 Elliott R, Blobe G. Role of transforming growth factor beta in human cancer. *J Clin Oncol* 2005; **23**: 2078–2093.
18 Reiss M, Barcellos-Hoft MH. Transforming growth factor-b in breast cancer: a working hypothesis. *Breast Cancer Res Treat* 1997; **45**: 81–95.
19 Kretzschmar M. Transforming growth factor-b and breast cancer. Transforming growth factor-b/SMAD signaling effects and cancer. *Breast Cancer Res* 2000; **2**: 107–115.
20 Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC *et al.* Genetic control of the circulating concentration of transforming growth factor type beta1. *Hum Mol Genet* 1999; **8**: 93–97.
21 Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y. Association of a T29C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. *Circulation* 2000; **101**: 2783–2787.
22 Soulitzis N, Karyotis I, Delakas D, Spandidos DA. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. *Int J Oncol* 2006; **29**: 305–314.
23 Jakowlew S. Transforming growth factor-β in cancer and metastasis. *Cancer Metastatis Rev* 2006; **25**: 435–457.
24 Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A *et al.* Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. *Nat Genet* 2007; **39**: 977–983.
25 Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G *et al.* Cumulative association of five genetic variants with prostate cancer. *N Engl J Med* 2008; **358**: 910–919.
26 Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A *et al.* Multiple regions within 8q24 independently affect risk for prostate cancer. *Nat Genet* 2007; **39**: 638–644.
27 Glinsky GV. Phenotype-defining functions of multiple non-coding pathway. *Cell Cycle* 2008; **7**: 1630–1639.
28 Glinsky GV. An SNP-guided microRNA map of fifteen common human disorders identifies a consensus disease phenocode aiming at principal components of the nuclear import pathway. *Cell Cycle* 2008; **7**: 2570–2583.
29 Gregory H, Willshire IR, Kavanagh JP, Blacklock NJ, Chowdury S, Richards RC. Urogastrone-epidermal growth factor concentrations in prostatic fluid of normal individuals and patients with benign prostatic hypertrophy. *Clin Sci (Lond)* 1986; **70**: 359–363.
30 Harper ME, Glynne-Jones E, Goddard L, Mathews P, Nicholson RI. Expression of androgen receptor and growth factors in premalignant lesions of the prostate. *J Pathol* 1998; **186**: 169–177.
31 Stearns ME, Garcia FU, Fudge K, Rhim J, Wang M. Role of interleukin 10 and transforming growth factor β1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. *Clin Cancer Res* 1999; **5**: 711–720.
32 Kaklamani V, Pasche B. the role of TGF-β in cancer and the potential for therapy and prevention. *Expert Rev Anticancer Ther* 2004; **4**: 649–661.
33 Tang B, de Castro K, Barnes HE, Parks WT, Stewart L, Böttinger EP *et al.* Loss of responsiveness of to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells. *Cancer Res* 1999; **59**: 4834–4842.
34 Bierie B, Moses H. TGF-β: the molecular jekyll and Hyde of cancer. *Nat Rev* 2006; **6**: 506–520.
35 Zhou W, Park I, Pins M, Kozlowski JM, Jovanovic B, Zhang J *et al.* Dual regulation of proliferation and growth arrest in prostatic stromal cells by transforming growth factor-β1. *Endocrinology* 2003; **144**: 4280–4284.
36 Paterson IC, Davies M, Stone A, Huntley S, Smith E, Pring M *et al.* TGF-b1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G1 arrest. *Oncogene* 2002; **21**: 1616–1624.
37 Bierie B, Moses HL. TGF-beta and cancer. *Cytokine Growth Factor Rev* 2006; **17**: 29–40.
38 Guo Y, Kyprianou N. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. *Cancer Res* 1999; **59**: 1366–1371.
39 Medeiros R, Vasconcelos A, Costa S, Pinto D, Ferreira P, Lobo F *et al.* Metabolic susceptibility genes and prostate cancer risk in a southern European population: the role of glutathione S-transferases GSTM1, GSTM3, And GSTT1 genetic polymorphisms. *Prostate* 2004; **58**: 414–420.
40 Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J *et al.* The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population. *J Hum Genet* 2002; **47**: 413–418.
41 Ribeiro R, Vasconcelos A, Costa S, Pinto D, Morais A, Oliveira J *et al.* Overexpressing leptin genetic polymorphism (−2548G/A) is associated with susceptibility to prostate cancer and risk of advanced disease. *Prostate* 2004; **59**: 268–274.
42 Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G *et al.* Cumulative association of five genetic variants with prostate cancer. *N Engl J Med* 2008; **358**: 910–919.
43 Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR *et al.* A transforming growth factor β1 signal peptide variant increases secretion *in vitro* and is associated with increased incidence of invasive breast cancer. *Cancer Res* 2003; **63**: 2610–2615.
44 Bonaccorsi L, Carloni V, Muratori M, Formigli L, Zecchi S, Forti G *et al.* EGF receptor (EGFR) signalling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). *Int J Cancer* 2004; **112**: 78–86.
45 Angelucci A, Schenone S, Gravina G, Muzi P, Festuccia C, Vicentini C *et al.* Pyrazolo [3,4-d] pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells. *Eur J Cancer* 2006; **42**: 2838–2845.
46 Taille A, Vacherot F, Salomon L, Druel C, Gil Diez De Medina S, Abbou C *et al.* Hormone-refractory prostate cancer: a multi-step and multi-event process. *Prostate Cancer Prostatic Dis* 2001; **4**: 204–212.
47 Zhu M-L, Partin JV, Bruckheimer EM, Strup SE, Kyprianou N. TGF-b signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells. *Prostate* 2008; **68**: 287–295.
48 Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. *Prostate Suppl* 1989; **2**: 33–50.
49 Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. *Blood* 2000; **96**: 2022–2036.
50 Mullenbach R, Lagoda PJ, Welter C. An efficient salt-chloroform extraction of DNA from blood and tissues. *Trends Genet* 1989; **5**: 391.